niacinamide has been researched along with Adenocarcinoma Of Kidney in 789 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to evaluate the safety and feasibility of high-dose interleukin-2 (HD IL-2) followed by sorafenib in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC)." | 9.19 | A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma. ( Bhinder, A; Carson, WE; Clinton, SK; Geyer, S; Kendra, K; Lam, E; Lesinski, GB; Mace, TA; Monk, P; Mortazavi, A; Olencki, T; Tahiri, S, 2014) |
| "To evaluate the safety and efficacy of sorafenib plus cisplatin in the treatment of metastatic renal cell carcinoma (mRCC) with pleural effusion." | 9.16 | [Phase II clinical trial of sorafenib plus local chemotherapy in the treatment of metastatic renal cell carcinoma with pleural effusion]. ( Chi, ZH; Cui, CL; Guo, J; Lian, B; Mao, LL; Sheng, XN; Si, L; Yang, SY, 2012) |
| "To determine the safety, maximum tolerated dose, pharmacokinetics, and efficacy, and to evaluate biomarkers, of the multikinase inhibitor sorafenib plus IFN alpha-2a in advanced renal cell carcinoma (RCC) or melanoma." | 9.12 | Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. ( Angevin, E; Armand, JP; Brendel, E; Chami, L; Escudier, B; Lamuraglia, M; Landreau, V; Lassau, N; Robert, C; Schwartz, B; Soria, JC; Zafarana, E, 2007) |
| "Hypertension is one of the major side effects of sorafenib, and reported incidences vary substantially among clinical trials." | 8.90 | Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. ( Chen, J; Guo, H; Li, S; Li, Y; Liang, X; Meng, H; Shi, B; Zhang, D; Zhu, Y, 2014) |
| "As a group of European nurses familiar with treating patients with renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) using targeted/chemo- therapies, we aimed to review strategies for managing adverse events (AEs) associated with one targeted therapy, sorafenib." | 8.88 | Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. ( Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A, 2012) |
| " Sorafenib concentrations were significantly greater in patients with grade ≥2 HFSR and hypertension than in those not experiencing the adverse events (p = 0." | 7.80 | Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. ( Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T, 2014) |
| "Sorafenib-induced erythema multiforme may not be rare in Japanese patients." | 7.78 | Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma. ( Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S; Satoh, T; Tabata, K; Tanabe, K, 2012) |
| "To evaluate the effect of sorafenib on the glucose tolerance and diabetic status of patients with metastatic renal cell carcinoma (RCC) or advanced hepatocellular carcinoma (HCC)." | 7.78 | The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. ( Caccialanza, R; Ganini, C; Imarisio, I; Magnani, L; Paglino, C; Porta, C, 2012) |
| " Sorafenib has considerable anti-angiogenic effects that lead to tumor starvation and induce tumor hypoxia in the highly vascularized renal cell carcinoma (RCC) xenografts." | 7.78 | Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. ( Chowdhury, NF; Kuge, Y; Murakami, M; Nishijima, K; Takiguchi, M; Tamaki, N; Yu, W; Zhao, S; Zhao, Y, 2012) |
| " Subclinical hypothyroidism was characterized by serum TSH above the upper limit of normal and both total triiodothyronine (T3) and thyroxine (T4) within normal limits." | 7.77 | Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. ( Bierer, S; Herrmann, E; Hertle, L; Hoffmeister, I; Köpke, T; Papavassilis, P; Riesenbeck, LM; Thielen, B, 2011) |
| "Although clinical trials with sunitinib and sorafenib in metastatic renal cell carcinoma (mRCC) have included patients with moderate renal insufficiency (RI), the incidence of renal toxicity induced by their administration as well as the safety of these agents in patients with more severe renal insufficiency has not been extensively reported." | 7.76 | Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. ( Bukowski, R; Elson, P; Garcia, J; Golshayan, A; Khan, G; Rini, B; Wood, L, 2010) |
| "Our patient experienced a diffuse hyperkeratotic rash, hand-foot skin reaction, facial erythema, and stomatitis within three weeks of initiation of sorafenib." | 7.76 | Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib. ( Sahai, S; Swick, BL, 2010) |
| "These data suggest that there could be an association between sorafenib therapy and the development of cutaneous SCC and inflammation of AK." | 7.75 | Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. ( Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM, 2009) |
| " Shortly after chemotherapy with sorafenib [anti-vascular endothelial growth factor (VEGF)] was initiated, progressive renal impairment, hypertension, and nephrotic-range proteinuria developed." | 7.75 | Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. ( Jonkers, IJAM; van Buren, M, 2009) |
| "Hypertension was more frequently observed during treatment with axitinib than sorafenib in patients with RCC, but axitinib-induced hypertension rarely led to treatment discontinuation or cardiovascular sequelae." | 6.80 | Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. ( Arruda, LS; Baum, M; Cisar, L; Kim, S; Motzer, RJ; Quinn, DI; Rini, BI; Roberts, WG; Rosbrook, B; Tarazi, J; Wood, LS, 2015) |
| "Metastatic renal cell cancer (RCC) patients (n = 55) received sorafenib 400 mg b." | 6.75 | Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. ( Antoun, S; Baracos, VE; Birdsell, L; Escudier, B; Sawyer, MB, 2010) |
| "Fatigue is the most common symptom associated with cancer and cancer treatment." | 6.52 | Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. ( Arnaldi, G; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Massari, F; Procopio, G; Rizzo, M; Santoni, M; Tortora, G; Trementino, L, 2015) |
| "She received standard treatment for heart failure, including a beta-blocker, an angiotensin-converting enzyme inhibitor, and diuretics." | 6.45 | Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. ( Jarkowski, A; Wong, MK, 2009) |
| "Tyrosine kinase inhibitors (TKIs) provide more effective targeted treatments for cancer, but are subject to a variety of adverse effects, such as hypothyroidism." | 5.43 | Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses. ( Lin, Z; Shu, M; Wang, R; Zai, X; Zhang, B, 2016) |
| "Treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal cell carcinoma." | 5.42 | [Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report]. ( Deguchi, T; Horie, K; Kato, T; Kawata, K; Kikuchi, M; Miyazaki, T; Mizutani, K; Nakano, M; Seike, K; Takagi, K; Takai, M; Tsuchiya, T; Ushikoshi, H; Yasuda, M; Yokoi, S, 2015) |
| "Sorafenib is an orally administered active multikinase inhibitor for metastatic renal cell carcinoma that is now considered a standard agent." | 5.39 | Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma. ( Amoh, Y; Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S, 2013) |
| "Suddenly, he developed left cardiac failure, and he died 6 days later through a rapid clinical course that included circulatory failure, abnormal glucose tolerance, disseminated intravascular coagulation, and multiple organ failure." | 5.38 | [A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma]. ( Kimura, T; Miyagawa, T; Suetomi, T; Tsutsumi, M, 2012) |
| "Sorafenib is a multikinase inhibitor that is used for the treatment of metastatic renal-cell carcinoma." | 5.37 | Painless acute pancreatitis associated with sorafenib treatment: a case report. ( Fujimoto, T; Itatani, H; Kamoto, A; Kanemitu, T; Kobayashi, Y; Mori, N; Satoh, M; Sekii, K; Yoshioka, T, 2011) |
| "Sorafenib is a chemotherapeutic agent primarily used to treat metastatic renal cell carcinoma." | 5.37 | Chloracne-like drug eruption associated with sorafenib. ( Hughes, M; Pickert, A; Wells, M, 2011) |
| "Clear cell renal cell carcinoma is a hypervascularized solid tumor associated with loss of function of the von Hippel-Lindau (VHL) tumor suppressor gene and increased Raf-1 activity." | 5.36 | Sorafenib-associated remission of psoriasis in hypernephroma: case report. ( Fournier, C; Tisman, G, 2010) |
| "Sorafenib is a new therapeutic agent being used in metastatic renal cell carcinoma, hepatocellular carcinoma, and malignant melanoma." | 5.35 | Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma. ( Bilaç, C; Ermertcan, AT; Kayhan, TC; Müezzinoğlu, T; Oztürkcan, S; Temeltaş, G; Temiz, P, 2009) |
| "Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival." | 5.35 | Sorafenib-induced acute myocardial infarction due to coronary artery spasm. ( Arima, Y; Fukushima, H; Nakamura, S; Noda, K; Ogawa, H; Oshima, S; Shono, M; Taniguchi, I, 2009) |
| "Sorafenib has been approved for use in the treatment of metastatic renal cell carcinoma." | 5.35 | [Sorafenib-induced multiple eruptive keratoacanthomas]. ( Dupre-Goetghebeur, D; Jantzem, H; Merrer, J; Spindler, P, 2009) |
| "Sorafenib was eventually discontinued, and the pancreatitis resolved." | 5.34 | Acute pancreatitis associated with sorafenib. ( Li, M; Srinivas, S, 2007) |
| "This study was designed to evaluate the safety and feasibility of high-dose interleukin-2 (HD IL-2) followed by sorafenib in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC)." | 5.19 | A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma. ( Bhinder, A; Carson, WE; Clinton, SK; Geyer, S; Kendra, K; Lam, E; Lesinski, GB; Mace, TA; Monk, P; Mortazavi, A; Olencki, T; Tahiri, S, 2014) |
| "Twenty-one patients (sorafenib 9, sunitinib 12) developed "hypothyroidism" 95±88 days (range 12-315 days) after the start of treatment." | 5.16 | Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function. ( Fujii, M; Fujisawa, M; Kitajima, K; Maeda, T; Miyake, H; Ohno, Y; Sugimura, K; Takahashi, S; Yoshikawa, T, 2012) |
| "To evaluate the safety and efficacy of sorafenib plus cisplatin in the treatment of metastatic renal cell carcinoma (mRCC) with pleural effusion." | 5.16 | [Phase II clinical trial of sorafenib plus local chemotherapy in the treatment of metastatic renal cell carcinoma with pleural effusion]. ( Chi, ZH; Cui, CL; Guo, J; Lian, B; Mao, LL; Sheng, XN; Si, L; Yang, SY, 2012) |
| "To determine the safety, maximum tolerated dose, pharmacokinetics, and efficacy, and to evaluate biomarkers, of the multikinase inhibitor sorafenib plus IFN alpha-2a in advanced renal cell carcinoma (RCC) or melanoma." | 5.12 | Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. ( Angevin, E; Armand, JP; Brendel, E; Chami, L; Escudier, B; Lamuraglia, M; Landreau, V; Lassau, N; Robert, C; Schwartz, B; Soria, JC; Zafarana, E, 2007) |
| "Hypertension is one of the major side effects of sorafenib, and reported incidences vary substantially among clinical trials." | 4.90 | Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. ( Chen, J; Guo, H; Li, S; Li, Y; Liang, X; Meng, H; Shi, B; Zhang, D; Zhu, Y, 2014) |
| "As a group of European nurses familiar with treating patients with renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) using targeted/chemo- therapies, we aimed to review strategies for managing adverse events (AEs) associated with one targeted therapy, sorafenib." | 4.88 | Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. ( Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A, 2012) |
| "Sorafenib is an oral multikinase inhibitor with regulatory approval in advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and refractory differentiated thyroid carcinoma (DTC)." | 4.12 | Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment. ( Imai, T; Kaneko, S; Okayama, Y; Oya, M; Sunaya, T; Tsujino, T, 2022) |
| "Sorafenib was not statistically different from pazopanib using placebo as the comparator in the indirect comparison (HR = 0." | 3.85 | Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis. ( Chan, AL; Leung, HW, 2011) |
| " Sorafenib concentrations were significantly greater in patients with grade ≥2 HFSR and hypertension than in those not experiencing the adverse events (p = 0." | 3.80 | Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. ( Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T, 2014) |
| "Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of patients with unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC)." | 3.80 | Management of sorafenib-related adverse events: a clinician's perspective. ( Brose, MS; Frenette, CT; Keefe, SM; Stein, SM, 2014) |
| "Sorafenib, a tyrosine kinase inhibitor, is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC)." | 3.80 | Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective. ( Grande, C; Walko, CM, 2014) |
| "To evaluate first-generation rapamycin analogs (everolimus, temsirolimus, and rapamycin) and second-generation drugs inhibiting mTOR kinase (AZD-8055), PI3K (BKM-120) or both (BEZ-235 and GDC-0980) in hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) cells characterized for acquired resistance to sorafenib or sunitinib." | 3.79 | Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. ( de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A, 2013) |
| "Sorafenib is a multi-kinase inhibitor currently approved in Japan for unresectable and/or metastatic renal cell carcinoma and unresectable hepatocellular carcinoma." | 3.79 | Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan. ( Fujimoto, K; Gemma, A; Horiuchi-Yamamoto, Y; Inoue, Y; Johkoh, T; Kudoh, S; Sakai, F; Taniguchi, H, 2013) |
| "Sunitinib and sorafenib can induce serious adverse drug reactions (ADR) such as hypothyroidism." | 3.78 | Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. ( Czeche, S; Feldt, S; Franzmann, A; Ludwig, WD; Quinzler, R; Schulz, M; Schüssel, K, 2012) |
| "The purpose of the present study was to determine the relationship between iatrogenic arterial hypertension or baseline cardiovascular comorbidities and outcomes in metastatic renal cell cancer (mRCC) patients treated with sorafenib." | 3.78 | Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib. ( Filipiak, KJ; Nurzyński, P; Opolski, G; Szczylik, C; Szmit, S; Waśko-Grabowska, A; Zaborowska, M; Żołnierek, J, 2012) |
| "Sorafenib-induced erythema multiforme may not be rare in Japanese patients." | 3.78 | Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma. ( Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S; Satoh, T; Tabata, K; Tanabe, K, 2012) |
| "To evaluate the effect of sorafenib on the glucose tolerance and diabetic status of patients with metastatic renal cell carcinoma (RCC) or advanced hepatocellular carcinoma (HCC)." | 3.78 | The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. ( Caccialanza, R; Ganini, C; Imarisio, I; Magnani, L; Paglino, C; Porta, C, 2012) |
| " Sorafenib has considerable anti-angiogenic effects that lead to tumor starvation and induce tumor hypoxia in the highly vascularized renal cell carcinoma (RCC) xenografts." | 3.78 | Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. ( Chowdhury, NF; Kuge, Y; Murakami, M; Nishijima, K; Takiguchi, M; Tamaki, N; Yu, W; Zhao, S; Zhao, Y, 2012) |
| "The authors postulate that sorafenib could increase the risk of progression from latent to active tuberculosis, and urge vigilance and possible screening for latent tuberculosis in patients who are treated with sorafenib." | 3.78 | Sorafenib-induced tuberculosis reactivation. ( O'Connor, TM; O'Reilly, SP; Power, DG; Teo, M, 2012) |
| "Sunitinib and sorafenib are tyrosine kinase inhibitors used in metastatic renal cell carcinoma and are known to cause hypothyroidism in a subset of patients." | 3.78 | Thyroid dysfunction in patients treated with sunitinib or sorafenib. ( Breaker, K; Clemons, J; Flaig, TW; Gao, D; Garfield, D; Naam, M, 2012) |
| "Retrospective study on all the renal cell carcinoma patients with bone metastases treated with sunitinib or sorafenib between November 2005 and June 2012 at the University Hospitals Leuven and AZ Groeninge in Kortrijk." | 3.78 | Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. ( Berkers, J; Beuselinck, B; Body, JJ; Debruyne, P; Dumez, H; Elaidi, R; Karadimou, A; Lerut, E; Paridaens, R; Rogiers, A; Schöffski, P; Van Cann, T; Van Poppel, H; Willems, L; Wolter, P, 2012) |
| "Sorafenib is recommended for therapy of advanced hepatocellular carcinoma and renal cell carcinoma." | 3.77 | High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. ( Heinz, WJ; Helle-Beyersdorf, A; Kahle, K; Keller, D; Klinker, H; Langmann, P; Lenker, U; Schirmer, D, 2011) |
| " Subclinical hypothyroidism was characterized by serum TSH above the upper limit of normal and both total triiodothyronine (T3) and thyroxine (T4) within normal limits." | 3.77 | Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. ( Bierer, S; Herrmann, E; Hertle, L; Hoffmeister, I; Köpke, T; Papavassilis, P; Riesenbeck, LM; Thielen, B, 2011) |
| "Although clinical trials with sunitinib and sorafenib in metastatic renal cell carcinoma (mRCC) have included patients with moderate renal insufficiency (RI), the incidence of renal toxicity induced by their administration as well as the safety of these agents in patients with more severe renal insufficiency has not been extensively reported." | 3.76 | Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. ( Bukowski, R; Elson, P; Garcia, J; Golshayan, A; Khan, G; Rini, B; Wood, L, 2010) |
| "Our patient experienced a diffuse hyperkeratotic rash, hand-foot skin reaction, facial erythema, and stomatitis within three weeks of initiation of sorafenib." | 3.76 | Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib. ( Sahai, S; Swick, BL, 2010) |
| "We identified 12 cases: 5 CRs with sunitinib, 1 CR with sorafenib, and 6 surgical CRs with sunitinib followed by residual metastasectomy." | 3.75 | Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. ( Bex, A; Cosentino, M; Ficarra, V; Flörcken, A; Grünwald, V; Johannsen, M; Kloeters, C; Miller, K; Rief, M; Rogalla, P; Roigas, J, 2009) |
| "These data suggest that there could be an association between sorafenib therapy and the development of cutaneous SCC and inflammation of AK." | 3.75 | Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. ( Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM, 2009) |
| " Shortly after chemotherapy with sorafenib [anti-vascular endothelial growth factor (VEGF)] was initiated, progressive renal impairment, hypertension, and nephrotic-range proteinuria developed." | 3.75 | Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. ( Jonkers, IJAM; van Buren, M, 2009) |
| "The multitargeted kinase inhibitors sorafenib and sunitinib have improved treatment of solid tumours including renal cell carcinoma and hepatocellular carcinoma by offering better clinical responses." | 3.75 | Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. ( Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC, 2009) |
| "Eight patients (21%) had thyroid dysfunction possibly caused by sorafenib [seven hypothyroidism (18%) and one hyperthyroidism (3%)] and eight additional patients (21%) had findings compatible with nonthyroidal illness." | 3.74 | Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. ( Bukowski, R; Dreicer, R; Elson, P; Garcia, J; Ioachimescu, AG; Mekhail, T; Rini, BI; Tamaskar, I; Wood, L, 2008) |
| " In this study we sought to understand the temporal characteristics of treatment related adverse events (TRAEs) and frequency and timing of the dose modifications." | 3.11 | Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer. ( Atkins, MB; Escudier, B; Hutson, TE; Kasturi, V; McDermott, DF; Pal, SK; Porta, C; Rini, B; Verzoni, E; Zengin, ZB, 2022) |
| "Patients with post-treatment hypoalbuminemia had significantly shorter median PFS (6 months [95% CI 5-7 months]) and OS (11 months [95% CI 9-15 months]) than patients who had normal post-treatment albumin levels (PFS: 12 months [95% CI 11-16 months], P < 0." | 2.84 | Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma. ( Cai, W; Chen, Y; Huang, J; Huang, Y; Kong, W; Zhang, J; Zhou, L, 2017) |
| "The current treatment of metastatic renal cell carcinoma (mRCC) revolves around targeted agents, which have resulted in a median overall survival of 22 to 26 months in registration trials." | 2.84 | Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India. ( Joshi, A; Kannan, RA; Kothari, R; Menon, S; Noronha, V; Patil, VM; Popat, P; Prabhash, K; Ramaswamy, A; Sable, N; Sahu, A, 2017) |
| "The purpose of the present study was to investigate whether genetic variants that influence angiogenesis and sorafenib pharmacokinetics are associated with clinical outcomes and toxic effects in advanced renal cell carcinoma patients treated with this drug." | 2.82 | The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma. ( Cai, H; Cao, Q; Chen, J; Chu, H; Cui, L; Dong, B; Huang, Y; Ji, J; Jiang, M; Ju, X; Li, P; Li, X; Liu, F; Qin, C; Shao, P; Sun, L; Sun, X; Wang, J; Wang, M; Wang, S; Wang, X; Wu, B; Ye, D; Yin, C; Zhang, H; Zhang, Z; Zhao, H; Zhou, H; Zhou, L; Zhu, J; Zou, Q, 2016) |
| " Revised dosing still resulted in high toxicity." | 2.82 | Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. ( Atkins, MB; Carducci, M; Cella, D; Choueiri, TK; Coomes, R; DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Jewett, M; Kane, C; Kohli, M; Kuzel, TM; Manola, J; Matin, S; Pili, R; Pins, M; Puzanov, I; Sexton, WJ; Stadler, W; Uzzo, RG; Wagner, L; Wilding, G; Wong, YN; Wood, CG, 2016) |
| "Hypertension was more frequently observed during treatment with axitinib than sorafenib in patients with RCC, but axitinib-induced hypertension rarely led to treatment discontinuation or cardiovascular sequelae." | 2.80 | Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. ( Arruda, LS; Baum, M; Cisar, L; Kim, S; Motzer, RJ; Quinn, DI; Rini, BI; Roberts, WG; Rosbrook, B; Tarazi, J; Wood, LS, 2015) |
| " We could show variability in plasma levels according to changes in dosage of TKIs or during treatment-free intervals." | 2.80 | [Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib]. ( Götze, L; Hegele, A; Hofmann, R; Keil, C; Nockher, WA; Olbert, P, 2015) |
| "Sorafenib is an orally active multikinase inhibitor, and bortezomib is a proteasome inhibitor that affects multiple signaling pathways." | 2.80 | Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma. ( Lauer, R; Rao, A, 2015) |
| "In sorafenib-treated patients, VEGFR2 rs2071559 (G/G vs." | 2.80 | Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma. ( English, PA; Escudier, B; Huang, X; Kim, S; Loomis, AK; Motzer, RJ; Rini, BI; Rosbrook, B; Tarazi, J; Williams, JA, 2015) |
| " Overall, adverse event rates were generally similar between the treatment arms." | 2.80 | SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. ( Bos, MM; De Santis, M; Eichelberg, C; Fischer von Weikersthal, L; Flörcken, A; Freier, W; Goebell, PJ; Gottstein, D; Hauswald, K; Indorf, M; Lerchenmüller, C; Los, M; Michel, MS; Pahernik, S; Schenck, M; Schirrmacher-Memmel, S; Staehler, M; van Arkel, C; Vervenne, WL; Zimmermann, U, 2015) |
| "A total of 361 patients with metastatic clear cell renal cell carcinoma were randomly assigned equally to arm A (bevacizumab monotherapy 10 mg/kg intravenously [IV] every 2 weeks), B (bevacizumab 10 mg/kg IV every 2 weeks and temsirolimus 25 mg IV every week), C (bevacizumab 5 mg/kg IV every 2 weeks and sorafenib 200 mg orally twice daily on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26), or D (sorafenib 200 mg twice daily and temsirolimus 25 mg IV weekly)." | 2.80 | BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN C ( Atkins, MB; DiPaola, RS; Dutcher, JJ; Flaherty, KT; George, DJ; Manola, JB; Margolin, KA; McDermott, DF; Pins, M, 2015) |
| " We aimed to assess the safety, tolerance, pharmacokinetics and clinical activity of S-1 combined with sorafenib in patients with mRCC." | 2.80 | Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma. ( Akaza, H; Eto, M; Fujisawa, M; Hashine, K; Naito, S; Ozono, S; Sakai, H; Shinohara, N; Tomita, Y, 2015) |
| "In sorafenib-treated but not in everolimus-treated patients (IGR), TGR at PROGRESSION (last cycle) was still lower than TGR BEFORE (washout) (p=0." | 2.79 | Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. ( Albiges, L; Escudier, B; Ferté, C; Fizazi, K; Iacovelli, R; Koscielny, S; Loriot, Y; Rocher, L; Soria, JC, 2014) |
| " The most common adverse event was skin toxicity (67 %), followed by gastrointestinal symptoms (26 %), hypertension (22 %), fatigue (19 %), hematological toxicity (10 %), and hemorrhage (6 %)." | 2.79 | Efficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment. ( Ishizuka, O; Nishizawa, O; Suzuki, H; Suzuki, T; Ueno, M, 2014) |
| "Sorafenib was commenced at 400 mg twice daily continuously." | 2.79 | Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group. ( Boyer, M; Davis, ID; Guo, Y; Liew, MS; Quaggiotto, M; Tafreshi, A; Thientosapol, E, 2014) |
| "Fatigue is a complex and cumulative condition of patients treated for advanced RCC, and it considerably affects patient's quality of life." | 2.79 | A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study. ( A, M; H J, H; L, M; M, K; N, M; P J, G; S, B, 2014) |
| "Treatment with sorafenib resulted in a marked decrease of (111)In-girentuximab uptake in the tumor in clear cell RCC patients, especially in the group treated for 4 wk (mean change in both sorafenib-treated groups, -38." | 2.79 | Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma. ( Boerman, OC; Boers-Sonderen, MJ; de Weijert, MC; Desar, IM; Langenhuijsen, JF; Leenders, WP; Mulders, PF; Muselaers, CH; Oosterwijk, E; Oyen, WJ; Stillebroer, AB; van Herpen, CM, 2014) |
| "metastatic renal cell cancer (mRCC) or GIST patients treated with sunitinib or sorafenib (VEGFR TKI patients n = 30); 2." | 2.79 | Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study. ( Bertens, D; Desar, IM; Kessels, RP; Langenhuijsen, JF; Mulder, SF; Mulders, PF; Punt, CJ; van Herpen, CM; van Spronsen, DJ; Vissers, KC, 2014) |
| "Clear cell renal cell carcinoma (ccRCC) is characterized by high constitutive vascular endothelial growth factor A (VEGF-A) production that induces a specific vascular phenotype." | 2.79 | Neoadjuvant sorafenib treatment of clear cell renal cell carcinoma and release of circulating tumor fragments. ( de Waal, R; de Weijert, M; Desar, I; Hulsbergen-van de Kaa, C; Kats-Ugurlu, G; Leenders, W; Maass, C; Mulders, P; Muselaers, S; Oosterwijk, E; Oosterwijk-Wakka, J; van Herpen, C; van Krieken, H, 2014) |
| "To investigate the role of sorafenib dosage escalation in Asian patients with metastatic renal cell carcinoma that had progressed after routine dosages." | 2.79 | A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma. ( Dai, B; Lin, GW; Ma, CG; Qin, XJ; Shen, YJ; Shi, GH; Wang, HK; Xiao, WJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP, 2014) |
| "Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3." | 2.78 | Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. ( Akaza, H; Chen, C; Kanayama, H; Kim, S; Naito, S; Ozono, S; Shinohara, N; Tarazi, J; Tomita, Y; Tsukamoto, T; Ueda, T; Uemura, H, 2013) |
| "Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3." | 2.78 | Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. ( Alekseev, BY; Alyasova, A; Berkenblit, A; Bondarenko, I; Cella, D; Eisen, T; Esteves, B; Harza, M; Hutson, TE; Ivanescu, C; Kogan, M; Krivoshik, A; Lesovoy, V; Lipatov, O; Lyulko, O; Motzer, RJ; Nosov, D; Sternberg, CN; Strahs, A; Szczylik, C; Tomczak, P, 2013) |
| "Sorafenib has proven efficacy in metastatic renal cell carcinoma (mRCC)." | 2.78 | Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). ( Boni, C; Bracarda, S; Caserta, C; Cinquini, M; Cortesi, E; De Angelis, V; Di Costanzo, F; Falcone, A; Gasparro, D; Labianca, R; Mucciarini, C; Paglino, C; Pazzola, A; Porta, C; Santoro, A, 2013) |
| "Patients with advanced or metastatic renal cell carcinoma (RCC) with predominant clear cell histology were treated with oral dovitinib 500 or 600 mg/day (5-days-on/2-days-off schedule)." | 2.78 | Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. ( Angevin, E; Castellano, D; Chang, J; Escudier, B; Gschwend, JE; Harzstark, A; Kay, A; Lin, CC; Lopez-Martin, JA; Sen, P; Shi, M; Soria, JC, 2013) |
| "After 2 weeks of IFN-alone treatment, eligible patients received 28-day cycles of continuous sorafenib 200 mg (Cohort 1) or 400 mg (Cohorts 2 and 3) twice daily combined with intramuscular IFN 6 (Cohorts 1 and 2) or 9 (Cohort 3) million international units (MIU) three times a week." | 2.77 | Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. ( Fujii, H; Fukino, K; Hamamoto, Y; Hashine, K; Niwakawa, M; Sumiyoshi, Y; Tanigawa, T; Yamaguchi, R, 2012) |
| "Sorafenib is an orally active multikinase inhibitor approved for the treatment of mRCC." | 2.77 | Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. ( Alonso, S; Calabrò, F; Caristo, R; Catalano, A; Cerbone, L; Di Paola, ED; Leone, A; Mancuso, A; Messina, C; Sternberg, CN; Vigna, L; Zivi, A, 2012) |
| "Sorafenib has been demonstrated as second-line therapy, with limited significant adverse events at a dose of 400 mg twice a day (b." | 2.77 | A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma. ( Amato, R; DeFoe, M; Saxena, S; Willis, J; Zhai, J, 2012) |
| "The combination of sorafenib plus gemcitabine and capecitabine is tolerable, but requires attenuation of sorafenib and capecitabine dosing because of the overlapping toxicity of hand-foot syndrome." | 2.76 | A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. ( Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ, 2011) |
| "The European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study provided sorafenib to advanced renal cell carcinoma (RCC) patients in whom previous systemic therapy had failed." | 2.76 | Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. ( Bajetta, E; Beck, J; Bokemeyer, C; Bracarda, S; Burock, K; Escudier, B; Keilholz, U; Mersmann, S; Negrier, S; Procopio, G; Richel, DJ; Staehler, M; Strauss, UP; Szczylik, C, 2011) |
| "Baseline patient-reported kidney cancer symptoms are linked to mPFS and mOS in a clear and interpretable way." | 2.76 | Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. ( Bushmakin, AG; Bycott, P; Cappelleri, JC; Kim, S; Rini, B; Rosbrook, B; Stadler, WM; Tarazi, J; Trask, PC, 2011) |
| "2 months or longer of SD period; (3) lack of either unknown adverse events nor cumulative toxicity in the long-term use of sorafenib." | 2.76 | Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. ( Akaza, H; Fukino, K; Murai, M; Naito, S; Tsukamoto, T, 2011) |
| "We conclude that influenza vaccination should be recommended to cancer patients treated with sunitinib or sorafenib." | 2.76 | Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination. ( de Vries, IJ; Desar, IM; Galama, JM; Jacobs, JF; Mulder, SF; Mulders, PF; Olde Nordkamp, MA; Punt, CJ; Teerenstra, S; Torensma, R; van Herpen, CM; Vissers, KC, 2011) |
| "Treatment of everolimus-resistant disease remains largely undefined in metastatic renal cell carcinoma (mRCC)." | 2.76 | Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. ( Busch, J; Fenner, M; Ganser, A; Grünwald, V; Seidel, C; Weikert, S, 2011) |
| "Axitinib is a treatment option for second-line therapy of advanced renal cell carcinoma." | 2.76 | Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. ( Castellano, D; Cella, D; Chen, C; Escudier, B; Gorbunova, VA; Gore, ME; Hutson, TE; Kaprin, A; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Negrier, S; Ou, YC; Rini, BI; Rosbrook, B; Rusakov, IG; Szczylik, C; Tarazi, J; Tomczak, P; Uemura, H, 2011) |
| "Sorafenib was well tolerated in both subgroups (grade 3/4: 20 and 22%, respectively)." | 2.75 | Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. ( Anderson, S; Bellmunt, J; Bukowski, R; Cihon, F; Escudier, B; Jäger, E; Lewis, J; McDermott, D; Moore, M; Negrier, S; Porta, C, 2010) |
| "The overall incidence of brain metastases in patients receiving sorafenib was 3% (2 of 70 patients) compared with 12% (8 of 69 patients) in patients receiving placebo (P < 0." | 2.75 | Incidence of brain metastases in renal cell carcinoma treated with sorafenib. ( Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Szczylik, C; Zonierek, J, 2010) |
| "Sorafenib-treated patients lost skeletal muscle progressively at 6 months (decrease of 4." | 2.75 | Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. ( Antoun, S; Baracos, VE; Birdsell, L; Escudier, B; Sawyer, MB; Venner, P, 2010) |
| "Metastatic renal cell cancer (RCC) patients (n = 55) received sorafenib 400 mg b." | 2.75 | Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. ( Antoun, S; Baracos, VE; Birdsell, L; Escudier, B; Sawyer, MB, 2010) |
| " The most commonly reported treatment-related adverse events of any grade were diarrhoea (74%), rash/desquamation (51%), hand-foot skin reaction (49%), alopecia (39%), and fatigue (38%)." | 2.75 | Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. ( Anderson, S; Bellmunt, J; Bukowski, R; Eisen, T; Escudier, B; Hutson, TE; Nadel, A; Porta, C; Staehler, M; Szczylik, C, 2010) |
| " Dosing in both treatment phases was generally well tolerated with manageable toxicities and no requirement for dose reduction." | 2.75 | Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. ( Bader, M; Haseke, N; Karl, A; Roosen, A; Siebels, M; Stadler, T; Staehler, M; Stief, CG, 2010) |
| "Sorafenib-treated patients reported fewer symptoms, better quality of life (QOL), and greater treatment satisfaction." | 2.74 | Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. ( Bukowski, RM; Cella, D; Demkow, T; Escudier, B; Hutson, TE; Laferriere, N; Negrier, S; Rolland, F; Scheuring, UJ; Shah, S; Staehler, M; Szczylik, C, 2009) |
| " Adverse events at 16 months after cross over were similar to those previously reported." | 2.74 | Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. ( Anderson, S; Bukowski, RM; Chevreau, C; Demkow, T; Desai, AA; Eisen, T; Escudier, B; Gore, M; Hofilena, G; Hutson, TE; Lathia, C; Negrier, S; Oudard, S; Pena, C; Rolland, F; Shan, M; Stadler, WM; Staehler, M; Szczylik, C, 2009) |
| "Sorafenib was given 400 mg twice daily orally." | 2.74 | Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. ( Boijsen, M; Lundstam, S; Lyrdal, D; Stierner, U; Suurküla, M, 2009) |
| "The axitinib dose was titrated to greater than 5 mg twice daily in 53." | 2.74 | Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. ( Dutcher, JP; Hudes, G; Kim, S; Rini, BI; Rosbrook, B; Stadler, WM; Tarazi, J; Trask, PC; Wilding, G; Wood, L, 2009) |
| "Sorafenib induces frequent cutaneous adverse events, some of which may lead to a dose reduction." | 2.73 | Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. ( Autier, J; Escudier, B; Robert, C; Spatz, A; Wechsler, J, 2008) |
| "Sorafenib is an antiangiogenic agent with activity in renal cancer." | 2.73 | Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. ( Hahn, OM; Karczmar, G; Karrison, T; Kistner, E; Manchen, E; Medved, M; Mitchell, M; Ratain, MJ; Stadler, WM; Yang, C, 2008) |
| "Sorafenib treatment delayed the time to self-reported health status deterioration among both older patients (121 days with sorafenib vs 85 days with placebo; HR = 0." | 2.73 | Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. ( Anderson, S; Bukowski, R; Cihon, F; Eisen, T; Escudier, B; Gravis, G; Heinzer, H; Middleton, R; Oudard, S; Shah, S; Szczylik, C, 2008) |
| "Sorafenib (Nexavar) is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis." | 2.73 | Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. ( Akaza, H; Murai, M; Naito, S; Nakajima, K; Tsukamoto, T, 2007) |
| "Sorafenib is a novel RAF and VEGF receptor tyrosine kinase inhibitor." | 2.73 | Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. ( Flaherty, KT; Gallagher, ML; Heitjan, DF; O'Dwyer, PJ; Rosen, MA; Schnall, MD; Schwartz, B, 2008) |
| "Sorafenib was readministered in 28 patients whose disease progressed on placebo; these patients continued on sorafenib until further progression, for a median of 24 weeks." | 2.72 | Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. ( Abbruzzese, JL; Desai, AA; Eisen, T; Flaherty, KT; Gore, M; Kaye, SB; O'Dwyer, PJ; Patnaik, A; Ratain, MJ; Rosner, GL; Rowinsky, E; Schwartz, B; Simantov, R; Stadler, WM; Xia, C; Xiong, HQ, 2006) |
| "Data from the first 41 patients with renal cell carcinoma showed that 30% of patients had stable disease (defined as between 25% reduction and 25% growth), 40% had responded (defined as >25% reduction), and 30% had progressed." | 2.71 | Kinase inhibition with BAY 43-9006 in renal cell carcinoma. ( Ahmad, T; Eisen, T, 2004) |
| " The most frequently reported adverse events over multiple cycles were gastrointestinal (75%), dermatologic (71%), constitutional (68%), pain (64%), or hepatic (61%) related." | 2.71 | Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. ( Awada, A; Bartholomeus, S; Brendel, E; de Valeriola, D; Gil, T; Haase, CG; Hendlisz, A; Mano, M; Piccart, M; Schwartz, B; Strumberg, D, 2005) |
| "Temsirolimus has proven benefit over interferon-alfa (IFN-α) in patients with non-clear cell RCC (non-ccRCC)." | 2.55 | Systemic therapy in metastatic renal cell carcinoma. ( Bedke, J; Gauler, T; Grünwald, V; Hegele, A; Herrmann, E; Hinz, S; Janssen, J; Miller, K; Schmitz, S; Schostak, M; Tesch, H; Zastrow, S, 2017) |
| "To systematically review relevant literature comparing the oncological outcomes and adverse events of different systemic therapies for patients with metastatic non-ccRCC." | 2.55 | A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. ( Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A, 2017) |
| " Hypertension is an adverse effect of these drugs and the degree of hypertension associates with the anti-tumour effect." | 2.55 | Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma. ( Bauer, J; Grimm, D; Magnusson, NE; Randrup Hansen, C; Wehland, M, 2017) |
| " Outcomes of interest were progression-free survival, objective response rate (ORR), overall survival, discontinuation of treatment due to adverse events (DAE) and occurrence of specific toxicities." | 2.53 | Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials. ( Balar, AV; Bangalore, S; Kang, SK; Ohmann, EL; Volodarskiy, A, 2016) |
| "Sorafenib was the first TA to report a benefit in terms of PFS in this disease, and it has largely been used as a comparator in randomized trials." | 2.53 | Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. ( Aurilio, G; Cossu Rocca, M; Cullurà, D; de Cobelli, O; Iacovelli, R; Nolé, F; Santoni, M; Verri, E, 2016) |
| "Sorafenib treatment was discontinued in 7 patients (19%) because of AEs." | 2.53 | Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review. ( Bersanelli, M; Buti, S; Castagneto, B; Di Meglio, G; Leonetti, A; Masini, C; Pellegrino, B, 2016) |
| "The role of adjuvant therapy for renal cell carcinoma (RCC) after surgical resection has been evaluated in numerous randomized and nonrandomized studies using systemic therapies with distinct mechanisms of action." | 2.53 | Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials? ( Galsky, MD; Mehrazin, R; Sfakianos, J; Tsao, CK, 2016) |
| "Fatigue und hypothyroidism are two common side effects of TKI therapy that can often appear simultaneously." | 2.53 | [Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism]. ( Keck, B; Lieb, V; Lüdecke, G; Sikic, D, 2016) |
| "Survival of patients with metastatic renal cell carcinoma (mRCC) has improved since the advent of targeted therapy." | 2.53 | Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. ( Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M, 2016) |
| "Fatigue is the most common symptom associated with cancer and cancer treatment." | 2.52 | Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. ( Arnaldi, G; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Massari, F; Procopio, G; Rizzo, M; Santoni, M; Tortora, G; Trementino, L, 2015) |
| "Sorafenib was FDA approved in 2005 for treatment of renal cell carcinoma (RCC) based on the results of the pivotal phase 3 clinical trial, TARGET (Treatment Approaches in Renal Cancer Global Evaluation Trial)." | 2.52 | A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting. ( Fishman, MN; Foreman, PK; Fulp, WJ; Tomshine, J, 2015) |
| "Sorafenib is an oral multikinase inhibitor with anticancer activity against a wide spectrum of cancers." | 2.52 | Sorafenib: 10 years after the first pivotal trial. ( Abbate, I; Brandi, M; De Rose, F; Divella, R; Ferraro, E; Filippelli, G; Gadaleta-Caldarola, G; Infusino, S; Mazzocca, A, 2015) |
| " Severe adverse events (AEs) or poor compliance was observed in 64 (36." | 2.52 | Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study. ( Chung, J; Hong, SH; Joo, KJ; Kim, CS; Kim, S; Kim, SH; Kim, TN; Kwak, C; Kwon, TG; Lee, SE; Nam, BH; Seo, IY; Seo, SI; Song, K, 2015) |
| "Diarrhea was the most common GI event." | 2.50 | Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. ( Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M, 2014) |
| "Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2 and 3." | 2.50 | Axitinib for the treatment of advanced renal cell carcinoma. ( Akaza, H; Fukuyama, T, 2014) |
| "Whoever the renal cell carcinoma incidence is low but it seems it is more complicated than the other cancers in terms of pathophysiology and treatments." | 2.50 | Sorafenib in renal cell carcinoma. ( bin-Noordin, MI; Davoudi, ET; Javar, HA; Kadivar, A; Sabeti, B, 2014) |
| " In every case, we recommend to start the selected targeted agents at standard dosage and to pursue therapy as long as possible because the control of disease should be the primary endpoint for the management of mRCC." | 2.50 | Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment. ( Cortesi, E; Iacovelli, R; Mezi, S; Naso, G; Palazzo, A; Pellegrino, D; Trenta, P, 2014) |
| "We observed more cases of skin cancer during sorafenib treatment than during sunitinib treatment for advanced RCC; median MKI treatment duration before the identification of skin cancer was longer than 1 year." | 2.49 | Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma. ( Breaker, K; Flaig, IP; Flaig, TW; La Rosa, FG; Naam, M, 2013) |
| "Axitinib was superior to pazopanib [hazard ratio (HR) 0." | 2.49 | Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy. ( Broom, RJ; Dranitsaris, G; Schmitz, S, 2013) |
| " In conclusion, after using other VEGF inhibitor such as sunitinib, sorafenib is active and safe for the treatment of patients with advanced or metastatic RCC." | 2.49 | Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor. ( Afonso, FJ; Anido, U; Antón-Aparicio, L; Fernández-Calvo, O; Lázaro, M; León, L; Ramos, M; Vázquez-Estévez, S, 2013) |
| "Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs." | 2.48 | Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. ( Bracarda, S; Cortesi, E; D'Angelo, A; Ferraù, F; Merlano, M; Monti, M; Ruggeri, EM; Santoro, A, 2012) |
| " This has raised challenges in the management of adverse events (AEs) associated with the six targeted agents approved in RCC-sorafenib, sunitinib, pazopanib, bevacizumab (in combination with interferon alpha), temsirolimus, and everolimus." | 2.48 | Targeted therapies for renal cell carcinoma: review of adverse event management strategies. ( Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S, 2012) |
| "Sorafenib was the first oral antiangiogenic multikinase inhibitor (Raf kinases, VEGF receptors 1 - 3, PDGF-beta, Flt-3, c-kit) for advanced renal cell carcinoma (RCC) to be approved." | 2.48 | Sorafenib for the treatment of renal cancer. ( Strumberg, D, 2012) |
| "Sorafenib was the first multikinase inhibitor to be approved for use in renal cell cancer (RCC) in the US (2005) and in Europe (2006)." | 2.47 | Experience with sorafenib and adverse event management. ( Bellmunt, J; Eisen, T; Fishman, M; Quinn, D, 2011) |
| " The rapid introduction of novel treatment options into clinical practice within a relatively short time frame has created some new challenges pertaining to adverse event (AE) management in patients with advanced RCC." | 2.47 | Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. ( Ravaud, A, 2011) |
| "Sorafenib is a well tolerated tyrosine kinase inhibitor that initially demonstrated efficacy in the treatment of patients with metastatic RCC who progressed after immunotherapy." | 2.47 | Sorafenib in renal cell carcinoma. ( Arranz, JÁ; Climent, MÁ; González-Larriba, JL; León, L; Maroto, JP, 2011) |
| "Sorafenib was the first oral multikinase inhibitor available for use in RCC, demonstrating a significant clinical benefit for patients living with this disease in the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET)." | 2.47 | Sorafenib for the management of advanced renal cell carcinoma. ( Escudier, B, 2011) |
| "Insights into the biology of clear-cell renal cell carcinoma (CCRCC) have identified multiple pathways associated with the pathogenesis and progression of this cancer." | 2.47 | Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. ( Atkinson, B; Choueiri, TK; Chowdhury, S; Matrana, MR; Tannir, NM; Tsang, C, 2011) |
| " Long-term administration of these drugs, over several months or several years, requires the compliance of patients." | 2.47 | [Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?]. ( Joly, F, 2011) |
| "Renal cell cancer is the most common form of all malignant renal cancers." | 2.47 | [Systemic treatment of renal cell carcinoma - recent update]. ( Grünberger, B, 2011) |
| "Treatment with sorafenib was associated with a significantly increased frequency of hypertension and hand-foot syndrome." | 2.46 | Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. ( Green, C; Hoyle, M; Liu, Z; Moxham, T; Stein, K; Thompson Coon, J; Welch, K, 2010) |
| "Sorafenib was approved by the FDA in fast track for advanced renal cell cancer and hepatocellular cancer and shows good clinical activity in thyroid cancer." | 2.46 | Sorafenib. ( Hasskarl, J, 2010) |
| "Sorafenib is a novel oral bis-aryl urea compound originally developed as an inhibitor of RAF kinase for its anti-proliferative property." | 2.46 | Toxicity of sorafenib: clinical and molecular aspects. ( Barete, S; Billemont, B; Blanchet, B; Cabanes, L; Coriat, R; Francès, C; Garrigue, H; Goldwasser, F; Knebelmann, B, 2010) |
| "Research on angiogenesis in renal carcinoma has brought important advances to understand tumor biology and to allow us development of new antiangiogenic drugs." | 2.46 | [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab]. ( Ayllon, J; Barrascout, E; Cuenod, CA; Elaidi, R; Medioni, J; Mejean, A; Oudard, S; Scotte, F; Tartour, E, 2010) |
| "The incidence of renal cell carcinoma is increasing globally." | 2.46 | Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. ( Bellmunt, J; Eisen, T; Fishman, M; Quinn, D, 2010) |
| "Sorafenib was not statistically different from bevacizumab +IFN-a in this same indirect comparison analysis (HR 0." | 2.45 | Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. ( Mills, EJ; O'Regan, C; Perri, D; Rachlis, B; Thabane, L, 2009) |
| "Advanced renal cell carcinoma (RCC) is resistant to chemotherapy and radiotherapy." | 2.45 | Recent advances in molecular targeted therapy for metastatic renal cell carcinoma. ( Mizutani, Y, 2009) |
| "She received standard treatment for heart failure, including a beta-blocker, an angiotensin-converting enzyme inhibitor, and diuretics." | 2.45 | Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. ( Jarkowski, A; Wong, MK, 2009) |
| "Metastatic renal cell carcinoma (RCC) has traditionally been associated with a poor prognosis with few effective treatments." | 2.45 | Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. ( Abel, EJ; Wood, CG, 2009) |
| "Sorafenib(Nexavar)is a multikinase inhibitor, with disruptive activity at intracellular C-RAF, B-RAF and mutant BRAF receptors, and extracellular C-KIT, FLT-3, VEGFR-2, VEGFR-3 and PDGFRb receptors." | 2.45 | [Sorafenib(Nexavar)]. ( Akaza, H; Miyanaga, N, 2009) |
| "Metastatic renal cell carcinoma is notoriously resistant to chemotherapy and radiotherapy." | 2.45 | [Interferon alpha and half-dose sorafenib is an effective treatment modality for interferon alpha-resistant metastatic renal cell carcinoma: a case report]. ( Abe, H; Fukabori, Y; Furuya, N; Kamai, T; Tokui, N; Yoshida, K, 2009) |
| "Renal cell carcinoma is the most common form of kidney cancer worldwide, and is associated with poor survival." | 2.45 | Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. ( Cella, D, 2009) |
| "Metastatic renal cell carcinoma (mRCC) is a highly vascularized tumor with a generally poor prognosis." | 2.45 | Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. ( Kuczyk, MA; Merseburger, AS; Simon, A; Waalkes, S, 2009) |
| " This article presents a case study to illustrate side-effect management strategies for patients receiving MKIs for the treatment of advanced renal cell carcinoma." | 2.45 | Management of vascular endothelial growth factor and multikinase inhibitor side effects. ( Wood, LS, 2009) |
| "A better understanding of renal cell carcinoma biology has led to a new era of targeted therapy in the management of metastatic renal cell carcinoma." | 2.44 | Targeted therapy in renal cell carcinoma. ( Rini, BI; Vakkalanka, BK, 2008) |
| "Treatment of advanced renal cell carcinoma (RCC) has undergone significant changes over the past 3 years after a long period of relative stagnation." | 2.44 | Novel drugs for renal cell carcinoma. ( Bukowski, RM; Vakkalanka, BK, 2008) |
| "Sorafenib has demonstrated prolonged progression-free survival in a phase III study in comparison with placebo in the second-line setting." | 2.44 | Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. ( Chowdhury, S; Gore, ME; Larkin, JM, 2008) |
| " Congestive heart failure is a less common but serious side effect that warrants treatment discontinuation." | 2.44 | Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. ( Figlin, RA; Hutson, TE; Kuhn, JG; Motzer, RJ, 2008) |
| "Sorafenib is an orally available inhibitor of vascular endothelial growth factor receptors, platelet-derived growth factor receptor-beta, and RAF kinases." | 2.44 | Sorafenib in renal cell carcinoma. ( Flaherty, KT, 2007) |
| "Renal cell carcinoma is a highly vascular tumor associated with expression of vascular endothelial growth factor (VEGF)." | 2.44 | Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. ( Rini, BI, 2007) |
| "Due to the chemoresistance of renal cell cancer, cytokine-based therapeutic approaches were considered the standard treatment for patients with metastatic disease." | 2.44 | [Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot]. ( Kruck, S; Kuczyk, M; Merseburger, AS, 2007) |
| "Approved for the treatment of advanced renal cell carcinoma by the US FDA and other regulatory agencies, sorafenib is an agent with multiple targets that may also prove beneficial in other malignancies." | 2.44 | Sorafenib: delivering a targeted drug to the right targets. ( Flaherty, KT, 2007) |
| "Sorafenib is an orally available multikinase inhibitor active on vascular endothelial growth factor receptor-2 and -3, platelet-derived growth factor receptor-beta, B-RAF, C-RAF, flt3 and C-Kit." | 2.44 | Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. ( Bracarda, S; Caserta, C; Crinò, L; Hamzay, A; Rossi, M; Sordini, L, 2007) |
| "Temsirolimus is an mTOR inhibitor that leads to G1 cell cycle arrest and may affect VEGF production." | 2.44 | The role of targeted therapy in metastatic renal cell carcinoma. ( Rini, BI; Unnithan, J, 2007) |
| "Sporadic renal cell carcinomas are characterized by EGFR (HER-1) and EGFR-2 (HER-2) expression, however, signal transduction inhibitors of this pathway were clinically ineffective." | 2.44 | [Effect of angiogenesis inhibitors on renal cell carcinoma]. ( Bodrogi, I, 2007) |
| "Sorafenib (BAY43-9006) was found to inhibit Raf1, but also VEGFR2 and 3, Flt3, PDGFR-a and b and c-kit, has been tested in a phase III study against placebo after one prior systemic therapy." | 2.44 | [Angiogenesis and renal cell carcinoma]. ( Billemont, B; Izzedine, H; Méric, JB; Rixe, O; Sultan-Amar, V; Taillade, L, 2007) |
| " In the current article, the significance of adverse events and their management in RCC patients is reviewed in order to guide the clinical oncologist through patient surveillance and treatment of adverse events." | 2.44 | Managing side effects of angiogenesis inhibitors in renal cell carcinoma. ( Fiedler, W; Grünwald, V; Heinzer, H, 2007) |
| " The tolerability of an agent is important in long-term treatment, and a predictable and manageable side-effect profile is advantageous." | 2.44 | Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview. ( Hutson, TE, 2007) |
| "Sorafenib is an oral, multikinase inhibitor recently approved by the U." | 2.44 | Sorafenib: a promising new targeted therapy for renal cell carcinoma. ( Manchen, B; Wood, LS, 2007) |
| "Sorafenib has been proven to improve survival in a novel randomized discontinuation trial and a Phase III randomized, placebo-controlled trial." | 2.44 | Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. ( Hiles, JJ; Kolesar, JM, 2008) |
| "Treatment of patients with metastatic renal cell carcinoma is evolving rapidly due to the advent of novel targeted therapies." | 2.44 | [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]. ( de Mulder, PH; Gietema, JA; Groenewegen, G; Haanen, JB; Jansen, RL; Kruit, WH; Mulders, PF; Osanto, S; Richel, DJ; Sleijfer, S; van den Eertwegh, AJ; Voest, EE, 2008) |
| "The recent contributions to renal cell carcinoma in the fields of molecular biology and the expanded use of molecularly targeted agents will be reviewed." | 2.44 | Renal cell carcinoma. ( Godley, P; Rathmell, WK; Rini, BI, 2008) |
| "Metastatic renal cell carcinoma (RCC) has a poor overall survival." | 2.44 | Treatment options for metastatic renal cell carcinoma: a review. ( Athar, U; Gentile, TC, 2008) |
| "In the United States, advanced kidney cancer accounts for over 12,000 deaths each year." | 2.43 | Promising systemic therapy for renal cell carcinoma. ( Cooney, MM; Remick, SC; Vogelzang, NJ, 2005) |
| "Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta." | 2.43 | Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. ( Gollob, JA, 2005) |
| "Metastatic renal cell carcinoma (RCC) has historically been refractory to cytotoxic and hormonal agents; only interleukin 2 and interferon alpha provide response in a minority of patients." | 2.43 | Targeted therapy for metastatic renal cell carcinoma. ( Chaganti, RS; Motzer, RJ; Patel, PH, 2006) |
| "The standard treatment for renal cell carcinoma (RCC) is surgery." | 2.43 | [Progress in therapeutic strategy for renal cell carcinoma]. ( Kanetake, H; Koga, S, 2006) |
| "Sorafenib is a small molecule inhibitor of several kinases involved in tumour proliferation and tumour angiogenesis including Raf, VEGFR and platelet derived growth factor receptor." | 2.43 | Sorafenib. ( Rini, BI, 2006) |
| "Sorafenib (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of tyrosine kinases that are known to be involved in tumor cell proliferation and tumor angiogenesis." | 2.43 | Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma. ( Bukowski, RM; Reddy, GK, 2006) |
| "Metastatic renal cell carcinoma (RCC) is currently one of the most treatment-resistant malignancies." | 2.43 | Molecular targeting therapy for renal cell carcinoma. ( Eto, M; Naito, S, 2006) |
| "The angiogenic phenotype of renal cell carcinoma results from vascular endothelial growth factor pathway activation." | 2.43 | Molecularly targeted therapy in renal cell carcinoma: where do we go from here? ( Rini, BI, 2006) |
| "Metastatic renal cell carcinoma has long been recognized as an aggressive, therapy-refractory epithelial cancer." | 2.43 | Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects. ( Dreicer, R, 2006) |
| " Ultimately, more clinical data is needed to address the chronic use of these agents alone, in combination with other agents, with radiation therapy, and in sequence." | 2.43 | Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. ( Creel, P; George, D; Speca, J; Yenser, S, 2006) |
| "A 60-year-old man with suspected right renal cell carcinoma underwent F-FDG PET/CT and F prostate-specific membrane antigen (PSMA) 1007 PET/CT scan." | 1.56 | 18F-PSMA 1007 in Suspected Renal Cell Carcinoma. ( Al-Terki, A; Alfeeli, M; Marafi, F; Sasikumar, A, 2020) |
| "Prognostic biomarkers for patients with clear cell renal cell carcinoma (ccRCC), particularly those receiving therapy targeting angiogenesis, are not well established." | 1.48 | Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis. ( Cao, YW; Dong, Z; Guo, L; Kang, EH; Liu, Y; Niu, HT; Wang, YH; Zhang, W, 2018) |
| "As the most lethal urological cancers, renal cell carcinoma (RCC) comprises a heterogeneous group of cancer with diverse genetic and molecular alterations." | 1.48 | Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells. ( An, L; Chen, L; Dai, Z; Feng, Y; Gan, H; Gong, C; Haydon, RC; He, F; He, TC; Huang, B; Huang, S; Ji, X; Lei, J; Liu, B; Liu, F; Liu, W; Luu, HH; Shu, Y; Wang, X; Wu, K; Wu, X; Wu, Y; Yan, S; Yang, C; Yu, X; Yuan, C; Zeng, L; Zeng, Z; Zhang, B; Zhang, L; Zhang, R; Zhang, W; Zhao, C, 2018) |
| " We retrospectively analyzed the clinical efficacy between SU/SO combined with DC-CIK and SU/SO monotherapy in treating renal cell carcinoma (RCC) patients with metastasis after radical nephrectomy." | 1.48 | Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy. ( Chen, LJ; Li, BT; Mai, HX; Mei, GH; Tang, YY; Xu, XJ; Zhang, B; Zhao, FL, 2018) |
| " Considering the critical role of VEGF signaling in the homeostasis of the cardiovascular system, we speculated that the long-term use of axitinib and sorafenib directly influenced the initiation of aortic dissection and cardiac dysfunction." | 1.48 | Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma. ( Fujita, M; Kuroda, T; Mukai, M; Nakai, Y; Nishimura, K; Oka, T; Shioyama, W; Takada, M; Yasui, T, 2018) |
| "For patients with metastatic renal cell cancer (mRCC), treatment choice is mainly based on clinical parameters." | 1.46 | Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity. ( Ambert, V; Cambon-Thomsen, A; Castellano, D; Diekstra, MHM; Eisen, T; Fritsch, A; Garcia Donas, J; Guarch Troyas, R; Guchelaar, HJ; Hartmann, A; Hulsbergen-van de Kaa, C; Jaehde, U; Junker, K; Kiemeney, LALM; Martinez-Cardus, A; Masson, G; Maurits, JSF; Oosterwijk, E; Oosterwijk-Wakka, J; Oskarsdottir, A; Radu, MT; Rafnar, T; Rodriguez-Antona, C; Roessler, M; Ruijtenbeek, R; Stefansson, K; van der Zanden, LFM; Vermeulen, SH; Warren, A; Wessels, L, 2017) |
| " Safety and efficacy variables were evaluated using National Cancer Institute-Common Toxicity Criteria for Adverse Events and Response Evaluation Criteria in Solid Tumors criteria." | 1.46 | In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study. ( Chen, L; Huang, J; Liu, J; Mai, H; Mei, GH; Qu, H; Qu, N; Xu, X; Zhang, Y, 2017) |
| " The absence of synergy in vivo highlighted the need to further optimize the dosing schedules of YM155 and sorafenib, as well as their routes of administration." | 1.46 | Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels. ( Go, ML; Huynh, H; Sim, MY; Yuen, JSP, 2017) |
| "Metastatic renal cell carcinoma (MRCC) exhibits primary resistance to both chemotherapy and radiotherapy." | 1.46 | Combination of sorafenib and cytokine-induced killer cells in metastatic renal cell carcinoma: a potential regimen. ( Gao, Q; Lin, H; Song, Y; Yang, Y; Zhao, L, 2017) |
| "Sorafenib has comparable efficacy and lower toxicity profile than sunitinib as first-line therapy for mRCC." | 1.46 | Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma. ( Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhou, L, 2017) |
| "Treatment (sorafenib vs sunitinib), pathology, Eastern Cooperative Oncology Group (ECOG) performance status, MSKCC scores, Heng's criteria of risk, and number of metastases were identified as significant predictors for OS and along with liver metastasis for PFS." | 1.46 | Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors. ( Chi, ZH; Guo, J; He, ZS; Li, XS; Sheng, XN; Wang, HK; Ye, DW; Zhang, HL, 2017) |
| "Metastatic renal cell carcinoma is a largely incurable disease, and existing treatments targeting angiogenesis and tyrosine kinase receptors are only partially effective." | 1.46 | MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance. ( Gobe, GC; He, Y; Hooper, J; Jeffery, PL; Lourie, R; McGuckin, MA; Morais, C; Ng, CP; Oancea, I; Seim, I; Shah, ET; Sheng, Y; Wong, KY, 2017) |
| "Sorafenib was discontinued owing to progressing disease for 15 patients and because of serious adverse events (AE) (≥grade 3) for 4 patients, i." | 1.43 | Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. ( Hashimoto, Y; Iizuka, J; Kennoki, T; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K, 2016) |
| "Several adverse events (AEs) are known to be commonly observed during treatment with different tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma (mRCC) patients." | 1.43 | Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma. ( Fujisawa, M; Harada, K; Imai, S; Miyake, H, 2016) |
| " The incidence of cardiovascular adverse events, including congestive heart failure and cardiomyopathy (CHF/CM), acute myocardial infarction (AMI), stroke, and cardiovascular deaths, was examined through December 2010." | 1.43 | Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. ( Atkins, MB; Barac, A; Freedman, AN; Fu, AZ; Jang, S; Minasian, L; Potosky, AL; Tsai, HT; Zheng, C, 2016) |
| "In metastatic renal cell carcinoma (mRCC), the prognostic role of several tumor tissue biomarkers has been evaluated, but the results were controversial." | 1.43 | Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. ( Ahn, JH; Cho, YM; Lee, DH; Lee, JL; Park, I, 2016) |
| "To describe dosing patterns and to compare the drug costs per month spent in progression-free survival (PFS) among patients with advanced renal cell carcinoma (aRCC) treated with everolimus or axitinib following a first tyrosine kinase inhibitor (TKI)." | 1.43 | Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. ( Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ, 2016) |
| "Tyrosine kinase inhibitors (TKIs) provide more effective targeted treatments for cancer, but are subject to a variety of adverse effects, such as hypothyroidism." | 1.43 | Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses. ( Lin, Z; Shu, M; Wang, R; Zai, X; Zhang, B, 2016) |
| " Most common adverse events were hand-foot skin reaction and thrombocytopenia which were manageable." | 1.43 | Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. ( Chi, Z; Cui, C; Guo, J; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X, 2016) |
| " Baseline characteristics, renal function, survival, safety, and dosage were stratified according to baseline estimated glomerular filtration rate (eGFR): G1 (eGFR≥90), G2 (eGFR≥60-<90), G3a (eGFR≥45-<60), G3b (eGFR≥30-<45), G4 (eGFR≥15-<30), and G5 (eGFR<15)." | 1.43 | Little Impact on Renal Function in Advanced Renal Cell Carcinoma Patients Treated with Sorafenib--Analyses of Postmarketing Surveillance in Japan in over 3,200 Consecutive Cases. ( Adachi, M; Akaza, H; Ito, Y; Kabu, K; Oya, M; Tatsugami, K, 2016) |
| "Sorafenib was started for the lung metastases 1 year after the operation." | 1.43 | Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report. ( Chikui, K; Igawa, T; Matsuo, M; Nakiri, M; Nishihara, K; Ogasawara, N; Suekane, S; Suyama, S; Ueda, K, 2016) |
| "Metastatic renal cell carcinoma (mRCC) has historically been refractory to cytotoxic and hormonal agents." | 1.43 | Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients? ( Aziz, SA; Bhat, GM; Changal, KH; Lone, AR; Mir, MH, 2016) |
| "Targeted drug decisions in metastatic renal cell carcinoma are exclusively made on the basis of clinical criteria." | 1.43 | Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer. ( Gao, Y; Guo, G; Li, H; Liu, K; Ma, X; Meng, Q; Song, Z; Wang, D; Wang, L; Zhang, X; Zhang, Y; Zhao, C, 2016) |
| "Sorafenib is used as first line treatment of renal cell carcinoma (RCC) due to the poor sensitivity to radiotherapy and chemotherapy of this malignancy; however, acquired resistance limits the application of sorafenib and its analogues." | 1.43 | Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism. ( Ding, S; Gao, D; Gao, M; Liu, S; Lv, J; Niu, Z; Wang, X; Wang, Z, 2016) |
| "Late recurrence of renal cell carcinoma is not a rare event." | 1.42 | Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. ( Atzori, F; Basso, U; Bracarda, S; Burattini, L; Buti, S; Cascinu, S; Cerbone, L; Conti, A; De Giorgi, U; De Vivo, R; Derosa, L; Di Lorenzo, G; Falconi, M; Iacovelli, R; Masini, C; Massari, F; Milella, M; Montironi, R; Mosca, A; Muzzonigro, G; Ortega, C; Pagano, M; Paglino, C; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santini, D; Santoni, M; Sternberg, CN; Verzoni, E, 2015) |
| "Sorafenib was the first-line treatment in 15% of patients." | 1.42 | Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry. ( Bortlicek, Z; Buchler, T; Kubackova, K; Linke, Z; Melichar, B; Pavlik, T; Pokorna, P; Prausova, J; Vyzula, R, 2015) |
| "Sorafenib was generally well tolerated and provided clinical benefit in a large, diverse population of patients with advanced RCC treated in routine clinical practice." | 1.42 | Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study. ( Ahn, H; Böckenhoff, A; Escudier, B; Guo, J; Jäger, D; Korbenfeld, E; Leonhartsberger, N; Ma, JH; Mardiak, J; Stauch, K; Ye, DW; Yu, J; Zemanova, M, 2015) |
| " At maximum dosage and time (15 μM and 96 h), Sorafenib-loaded PLGA and HMC-coated liposomes killed 88." | 1.42 | Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma. ( Arora, J; Boonkaew, B; Callaghan, C; Chava, S; Dash, S; He, J; John, VT; Lee, BR; Liu, J; Maddox, MM; Mandava, SH, 2015) |
| "Sorafenib for the treatment of advanced renal cell carcinoma under the labeled dose was feasible in daily medical practice, for its acceptable toxicity profile and favorable clinical benefit that were consistent with those in clinical trials." | 1.42 | A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance. ( Adachi, M; Akaza, H; Gemma, A; Hyodo, I; Iijima, M; Inuyama, L; Itoh, H; Okayama, Y; Oya, M; Sunaya, T, 2015) |
| "Sorafenib was administered at a dose of 400 mg twice daily, and continued until disease progression, at which point the dose was increased to 600 or 800 mg twice daily, or the onset of an intolerable adverse drug event (ADE) that required dose reduction or temporary suspension of treatment." | 1.42 | Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival. ( Fang, D; Guo, G; Huang, L; Li, X; Song, Y; Yu, X; Zhang, C; Zhang, X; Zhou, L, 2015) |
| "To investigate the safety and feasibility of sorafenib neoadjuvant therapy combined with retroperitoneoscopic radical nephrectomy (RRN) in treating T2 large renal cell carcinoma (RCC)." | 1.42 | Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma. ( Gao, ZL; Lin, CH; Liu, QZ; Men, CP; Wang, J; Wang, K; Wu, JT; Yu, SQ; Yuan, HJ, 2015) |
| "Treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal cell carcinoma." | 1.42 | [Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report]. ( Deguchi, T; Horie, K; Kato, T; Kawata, K; Kikuchi, M; Miyazaki, T; Mizutani, K; Nakano, M; Seike, K; Takagi, K; Takai, M; Tsuchiya, T; Ushikoshi, H; Yasuda, M; Yokoi, S, 2015) |
| "The aim of the study is to evaluate the relationship between the adverse events and efficacy of sorafenib in patients with metastatic renal cell carcinoma (mRCC), with a purpose to guide the judgment of efficacy in sorafenib treatment." | 1.42 | The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China. ( Chen, P; Li, P; Lu, J; Lu, X; Wang, F; Wang, J; Wang, Q; Wang, Y; Wang, Z; Wu, G; Yuan, J; Zhang, L; Zheng, Y, 2015) |
| "Sorafenib has good efficacy and safety in Chinese patients with advanced renal cell carcinoma." | 1.42 | [Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma]. ( Chi, Z; Cui, C; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X, 2015) |
| "The primitive tumor size and the thrombus size were defined by computed tomography before TMT." | 1.40 | Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? ( Ammi, M; Azzouzi, AR; Baumert, H; Beauval, JB; Bensalah, K; Berger, J; Bernhard, JC; Bigot, P; Escudier, B; Fardoun, T; Grenier, N; Hétet, JF; Lagabrielle, S; Lebdai, S; Long, JA; Paparel, P; Patard, JJ; Rioux-Leclercq, N; Rouprêt, M; Soulié, M; Xylinas, E, 2014) |
| " Data were collected on all adverse events (AEs) and treatment modifications, including discontinuation, interruption and dose reduction." | 1.40 | Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. ( Ahn, JH; Bellmunt, J; Castellano, D; Chang, YH; Chiang, PH; Chuang, CK; Diaz, JR; Donnellan, P; Duh, MS; Elaidi, R; Feinberg, BA; Hawkins, R; Huang, CY; Korves, C; Levy, A; McCaffrey, J; McDermott, D; McDermott, R; Mehmud, F; Nathan, P; Neary, MP; Oh, WK; Ou, YC; Porta, C; Rha, SY; Scott, J; Scotte, F; Sun, JM; Wagstaff, J, 2014) |
| "Everolimus was associated with significantly longer OS (HR 0." | 1.40 | Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. ( George, DJ; Liu, NS; Liu, Z; Qi, CZ; Signorovitch, JE; Wang, X; Wong, MK; Yang, H, 2014) |
| "Targeted therapies in metastatic renal cell carcinoma (mRCC) have been approved based on registration clinical trials that have strict eligibility criteria." | 1.40 | Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. ( Agarwal, N; Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Lee, J; Mackenzie, M; North, S; Pal, SK; Rha, SY; Rini, BI; Srinivas, S; Tan, MH; Vaishampayan, UN; Wood, LA; Yuasa, T, 2014) |
| "Chemotherapy for collecting duct carcinoma (CDC) has demonstrated only limited efficacy in the advanced setting." | 1.40 | Treatment of collecting duct carcinoma: current status and future perspectives. ( Colecchia, M; De Braud, F; Garanzini, E; Grassi, P; Iacovelli, R; Procopio, G; Testa, I; Torelli, T; Verzoni, E, 2014) |
| "A total of 77 patients had synchronous metastasis (48." | 1.40 | [Systemic treatment of metastatic renal cell carcinoma: change of paradigms after introduction of targeted therapy]. ( Bögemann, M; Herrmann, E; Hertle, L; Hoffmeister, I; Krabbe, LM; Moritz, R; Papavassilis, P; Thielen, B, 2014) |
| "Patients with metastatic renal cell carcinoma (mRCC) in whom first-line therapies have failed might derive clinical benefit with sequential targeted agents." | 1.40 | Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. ( Bellmunt, J; Bracarda, S; Cerbone, L; Choueiri, TK; Fay, AP; Foreshew, A; Hutson, TE; Lampron, ME; Pons, F; Porta, C; Powles, T; Sternberg, CN, 2014) |
| "Clear-cell renal cell carcinoma is a highly treatment-resistant tumor type." | 1.40 | MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1. ( Gao, C; Peng, FH; Peng, LK, 2014) |
| "Sorafenib has a high disease control rate for advanced renal cell carcinoma." | 1.40 | [Five-year therapeutic experience of sorafenib for patients with advanced renal cell carcinoma]. ( Jin, G; Liu, Y; Sun, K; Tian, Y; Wang, Y; Yang, X; Zhang, Q; Zhou, C, 2014) |
| "We retrospectively analyzed metastatic renal cell carcinoma (RCC) patients treated with 3 targeted agents." | 1.39 | Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike? ( Calvani, N; Chiuri, V; Cinieri, S; Fedele, P; Gnoni, A; Lorusso, V; Maiello, E; Morelli, F; Orlando, L; Scavelli, C, 2013) |
| "Forty-seven patients had brain metastases at the start of first-line anti-vascular endothelial growth factor therapy, and the rest developed metastases during follow-up." | 1.39 | Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. ( Al-Harbi, H; Choueiri, TK; Heng, DY; Knox, JJ; Kollmannsberger, C; MacKenzie, M; North, S; Rini, BI; Vickers, MM, 2013) |
| "We report a case of metastatic renal cell carcinoma (RCC) treated with cytoreductive nephrectomy, cytokine therapy, and molecular targeted therapy followed by metastasectomy." | 1.39 | [A case of metastatic renal cell carcinoma with no evidence of disease for a long term after a favorable response to molecular-targeted therapy followed by metastasectomy]. ( Ikehata, Y; Kitamura, H; Masumori, N; Takahashi, S; Tsukamoto, T, 2013) |
| "Thirty-six Japanese metastatic renal cell carcinoma patients treated with sorafenib were enrolled and divided into the groups with or without Hand-Foot skin reaction." | 1.39 | Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib. ( Kobayashi, M; Komatsu, K; Kubo, T; Kurokawa, S; Morita, T; Nakano, K; Natsui, S; Nukui, A, 2013) |
| "Sorafenib is an orally administered active multikinase inhibitor for metastatic renal cell carcinoma that is now considered a standard agent." | 1.39 | Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma. ( Amoh, Y; Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S, 2013) |
| "Sorafenib was administered 7 days after discontinuation of sunitinib ; however, the patient experienced febrile neutropenia and rash, and sorafenib was discontinued." | 1.39 | [Extracorporeal partial nephrectomy and auto-transplantation after presurgical targeted therapy with tyrosine kinase inhibitors for renal cell cancer]. ( Hosoya, N; Iwaba, A; Kanno, H; Kato, T; Kawazoe, H; Mashima, E; Nagaoka, A; Naito, S; Nishida, H; Sakurai, T; Tomita, Y; Yamakawa, M, 2013) |
| "Sorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepatocellular carcinoma." | 1.39 | Sorafenib induced eruptive melanocytic lesions. ( Aronson, P; Uhlenhake, EE; Watson, AC, 2013) |
| "We report two cases of acute pancreatitis associated with tyrosine kinase inhibitors." | 1.39 | Tyrosine kinase inhibitor induced pancreatitis. ( Atkinson, B; Chen, A; Sevin, A, 2013) |
| "Sorafenib is a targeted drug approved for metastatic renal cell carcinoma but it has modest efficacy." | 1.39 | Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma. ( Benitez, A; Bowen, T; Lokeshwar, VB; Shamaldevi, N; Yates, TJ, 2013) |
| "Pituitary metastasis from renal cell carcinoma is rare and has never been reported for renal cell carcinoma primarily treated with sorafenib." | 1.39 | Pituitary metastasis from a renal cell carcinoma progressed after sorafenib treatment. ( Hu, GY; Yang, L; Yu, SY, 2013) |
| "Sorafenib and sunitinib are used for renal cell carcinoma (RCC)." | 1.39 | Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study. ( Ambring, A; Björholt, I; Lesén, E; Odén, A; Stierner, U, 2013) |
| "The incidence of brain metastases per month in patients not treated with TKI therapy was 1." | 1.39 | Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. ( Agarwal, S; Chi, M; Dudek, AZ; Elmquist, WF; Mittapalli, RK; Oberoi, R; Raza, A; Singhal, M, 2013) |
| " The mean starting dose for patients who initiated on sorafenib (n = 16) was 725 mg and for temsirolimus (n = 15) was 25 mg: their study samples were insufficient for further, meaningful dosing analyses." | 1.39 | Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting. ( Borker, R; Fonseca, E; Hess, G, 2013) |
| "Sorafenib was well tolerated regardless of age in a heterogeneous population of RCC patients." | 1.39 | Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. ( Bellmunt, J; Bracarda, S; Brueckner, A; Dutcher, J; Escudier, B; Hutson, TE; Knox, J; Molnar, I; Procopio, G, 2013) |
| "A primary culture of renal cell carcinoma cells (KMRM-S2) was established from an advanced renal cell carcinoma patient with cutaneous metastasis, who had not responded to sorafenib." | 1.39 | Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis. ( Ashida, S; Fukuhara, H; Inoue, K; Kamada, M; Karashima, T; Kuroda, N; Shuin, T; Taguchi, T; Tamura, K, 2013) |
| "Sorafenib was well tolerated, with mostly grade 1/2 adverse events and no treatment-related deaths." | 1.38 | Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. ( Andreadis, C; Bamias, A; Dimopoulos, M; Karadimou, A; Kontovinis, L; Laschos, K; Papazisis, K; Paraskevopoulos, P, 2012) |
| " Rates of adverse events (AEs) and treatment modifications were analyzed; reasons for treatment modifications were examined." | 1.38 | Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. ( Duh, MS; Feinberg, BA; Fortner, B; Gilmore, J; Jolly, P; Neary, MP; Scott, J; Wang, ST, 2012) |
| "Data from patients with metastatic renal cell carcinoma (mRCC) treated with anti-VEGF therapy were collected through the International mRCC Database Consortium from 12 centers." | 1.38 | Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. ( Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Mackenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wang, Y; Wood, L, 2012) |
| " Their baseline characteristics, radiologic response, adverse events, and survival status were assessed." | 1.38 | Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. ( Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C, 2012) |
| "Though uncommon, the collecting duct carcinoma (CDC) of Bellini is a very aggressive primary renal tumour occurring in less than 1% of all renal cell carcinoma (RCC) cases." | 1.38 | Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. ( Colecchia, M; Iacovelli, R; Mariani, L; Procopio, G; Torelli, T; Verzoni, E, 2012) |
| "This report describes a positive experience of adverse event (AE) management of a multidisciplinary clinical team and 18 patients with late-stage renal cell carcinoma and hepatocellular carcinoma attending the Day Hospital Unit of the 'Centro Catanese di Oncologia Humanitas' (Italy) over a 2-year period." | 1.38 | Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience. ( Aiello, RA; Alì, M; Caruso, M; La Rocca, R; Licciardello, P; Sanò, MV; Scandurra, G; Taibi, E; Todaro, FM, 2012) |
| "everolimus was observed for both temsirolimus (hazard ratio [HR] 2." | 1.38 | Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma. ( Agarwala, SS; Chen, CC; Garay, CC; Gesme, DH; Guo, A; Hess, GP; Hill, JW; Liu, Z, 2012) |
| "Sorafenib is a multikinase inhibitor approved for the systemic treatment of renal cell carcinoma (RCC)." | 1.38 | GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC). ( Bilim, VN; Kato, T; Kawazoe, H; Nagaoka, A; Naito, S; Tomita, Y; Ugolkov, AV; Yuuki, K, 2012) |
| "A retrospective, registry-based analysis to assess the outcomes of metastatic renal cell cancer (mRCC) patients treated with sunitinib and sorafenib who developed dermatologic adverse events was performed." | 1.38 | Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. ( Abrahamova, J; Bortlicek, Z; Buchler, T; Dusek, L; Melichar, B; Pavlik, T; Poprach, A; Puzanov, I; Vyzula, R, 2012) |
| "Patients with metastatic renal cell carcinoma (mRCC) are often treated sequentially with targeted agents, although the optimal strategy is not known." | 1.38 | Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. ( Abrahamova, J; Bortlicek, Z; Buchler, T; Melichar, B; Pavlik, T; Poprach, A; Vyzula, R, 2012) |
| "Hyponatremia is reported to be associated with poor survival in localized renal cell carcinoma and metastatic renal cell carcinoma treated with immunotherapy." | 1.38 | Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy. ( Arai, Y; Kawashima, A; Nakai, Y; Nin, M; Nishimura, K; Nonomura, N; Takayama, H; Tanigawa, G; Tsujimura, A; Uemura, M, 2012) |
| "Suddenly, he developed left cardiac failure, and he died 6 days later through a rapid clinical course that included circulatory failure, abnormal glucose tolerance, disseminated intravascular coagulation, and multiple organ failure." | 1.38 | [A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma]. ( Kimura, T; Miyagawa, T; Suetomi, T; Tsutsumi, M, 2012) |
| "We analyzed renal cell carcinoma (RCC) brain metastasis (BM) risk factors and compared BM occurrence in metastatic RCC (mRCC) treated with or without anti-angiogenic agents (AA)." | 1.38 | Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma? ( Adenis, A; Alt, M; Caty, A; Fumagalli, I; Penel, N; Vanhuyse, M; Zini, L, 2012) |
| "Sorafenib is an orally available kinase inhibitor with activity at Raf, PDGFβ and VEGF receptors that is licensed for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC)." | 1.38 | Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma. ( Collier, J; Eisen, T; Fairfax, BP; Kaplan, R; Macaulay, VM; Meade, AM; Pratap, S; Protheroe, A; Ritchie, AW; Roberts, IS, 2012) |
| " It should be remembered that caution is required for long-term use or combined radiation therapy and NSAIDs with molecular target drug." | 1.38 | [Two cases of bowel perforation in patients with metastatic renal cancer treated with a molecularly targeted drug]. ( Ashikari, A; Kobayashi, H; Kohno, Y; Namitome, R; Nishiyama, T; Saito, S; Yagi, Y, 2012) |
| "Sorafenib is a multikinase inhibitor that is used for the treatment of metastatic renal-cell carcinoma." | 1.37 | Painless acute pancreatitis associated with sorafenib treatment: a case report. ( Fujimoto, T; Itatani, H; Kamoto, A; Kanemitu, T; Kobayashi, Y; Mori, N; Satoh, M; Sekii, K; Yoshioka, T, 2011) |
| "Sorafenib is an orally administered multikinase inhibitor that blocks intracellular kinases in the Raf/MEK/ERK pathway involved in tumor proliferation, and also kinases responsible for angiogenesis, including VEGFr-2, VEGFr-3, Flt-3, PDGFr-β and c-KIT." | 1.37 | Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report. ( Bigatti, GL; Castagneto, B; Cosimi, MF; Giorcelli, L; Montefiore, F; Pisacco, P; Stevani, I, 2011) |
| "Long-term stabilization of advanced renal cell carcinoma (RCC) by the sequence of sorafenib monotherapy followed by sunitinib and everolimus treatments in a man with multiple metastases is reported." | 1.37 | Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study. ( Beck, J; Bellmunt, J; Escudier, B, 2011) |
| "Laboratory data showed marked leukocytosis with increased serum and urinary G-CSF." | 1.37 | Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor. ( Baba, S; Kinoshita, M; Kurita, Y; Kyono, Y; Mugiya, S; Ozono, S; Takayama, T, 2011) |
| "• A Markov model simulated disease progression, adverse events and survival with sunitinib vs sorafenib in the US and bevacizumab plus interferon-α (IFN-α) in both countries." | 1.37 | Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. ( Benedict, A; Charbonneau, C; Figlin, RA; Hariharan, S; Harmenberg, U; Négrier, S; Remák, E; Sandin, R; Sandström, P; Ullén, A, 2011) |
| "Chromophobe renal cell carcinoma (chRCC) is a common subtype of renal cell carcinoma (RCC), occurring in 6-11% of renal carcinoma patients." | 1.37 | Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy. ( Brion, N; Paule, B, 2011) |
| "Sorafenib is a multikinase inhibitor approved for the treatment of renal cell carcinoma and hepatocellular carcinoma." | 1.37 | [Squamous cell carcinoma in a patient receiving sorafenib]. ( Adnot-Desanlis, L; Bernard, P; Reguiaï, Z, 2011) |
| "Treatment with sorafenib of patients with metastatic renal cell carcinoma undergoing hemodialysis appears to be feasible, but we express some concern about the higher incidence of serious adverse events even with the reduced dose." | 1.37 | Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. ( Hashimoto, Y; Iizuka, J; Ishimori, I; Kennoki, T; Kimata, N; Kobayashi, H; Kondo, T; Murakami, J; Nakazawa, H; Takagi, T; Tanabe, K; Yoshida, K, 2011) |
| "Sorafenib and sunitinib is a small molecule inhibitor of certain receptor tyrosine kinases, and have improved outcomes for patients with advanced renal cell carcinoma." | 1.37 | Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. ( Ikeda, R; Iseki, K; Maeda, H; Nakano, K; Shibayama, Y; Sugawara, M; Taguchi, M; Takeda, Y; Yamada, K, 2011) |
| "Sorafenib is a multikinase inhibitor with activity against B-raf, C-raf, VEGFR2, PDGFRβ and FGFR1." | 1.37 | Population pharmacokinetic analysis of sorafenib in patients with solid tumours. ( Dahut, WL; Figg, WD; Gardner, ER; Giaccone, G; Jain, L; Kohn, EC; Kummar, S; Mould, DR; Venitz, J; Woo, S; Yarchoan, R, 2011) |
| "Sorafenib was given to 83 patients with clear cell mRCC." | 1.37 | Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib. ( Dai, B; Shen, YJ; Shi, GH; Wang, CF; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP, 2011) |
| "Sorafenib is a multikinase inhibitor used as a second-line treatment for metastatic renal cell carcinoma (mRCC)." | 1.37 | One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients. ( Arai, Y; Imazu, T; Inoue, H; Kajikawa, J; Kawashima, A; Kinoshita, T; Nin, M; Nishimura, K; Nonomura, N; Takada, S; Takayama, H; Tanigawa, G; Tsujimura, A; Yasunaga, Y, 2011) |
| "A 14-year-old girl with metastatic renal cell carcinoma was treated with nephrectomy, interferon, and several lines of the targeted agents sorafenib, bevacizumab, sunitinib, and everolimus, either alone or in combination." | 1.37 | Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma. ( Boldrini, R; Cortesi, E; De Pasquale, MD; Donfrancesco, A; Ilari, I; Jenkner, A; Pessolano, R, 2011) |
| "Sorafenib was then again administered to both sets of mice." | 1.37 | Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. ( Alsop, DC; Atkins, MB; Bhasin, M; Bhatt, RS; Collins, MP; Goldberg, SN; Libermann, T; Mier, JW; Panka, D; Putheti, P; Schor-Bardach, R; Signoretti, S; Wang, X; Zhang, L, 2011) |
| "Temsirolimus appears to be an effective and well-tolerated substance in the treatment of patients with a good performance status, low MSKCC score and stable disease under previous antiangiogenic treatment in advanced renal cell cancer." | 1.37 | Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer. ( Greil, R; Grundbichler, M; Kappacher, A; Mlineritsch, B; Moik, M; Ressler, S; Rosenlechner, S, 2011) |
| " Here, we evaluated the effect of the dual PI3K/mTOR inhibitor NVP-BEZ235, in combination with the multikinase inhibitor sorafenib on renal cancer cell proliferation and survival in vitro as well as on tumor growth in vivo." | 1.37 | Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. ( Demartines, N; Dormond, O; Dormond-Meuwly, A; Dufour, M; Roulin, D; Waselle, L, 2011) |
| "Sorafenib was effective in Japanese patients with advanced renal cell carcinoma in general clinical practice and was tolerated although most patients required dose reduction or interruption of therapy." | 1.37 | Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice. ( Hara, T; Kajikawa, J; Kawashima, A; Meguro, N; Miyoshi, S; Nishimura, K; Nonomura, N; Oka, T; Takayama, H; Tanigawa, G; Yamaguchi, S; Yosioka, T, 2011) |
| "Sorafenib is a chemotherapeutic agent primarily used to treat metastatic renal cell carcinoma." | 1.37 | Chloracne-like drug eruption associated with sorafenib. ( Hughes, M; Pickert, A; Wells, M, 2011) |
| "In advanced renal cell carcinoma (RCC), sunitinib and sorafenib tyrosine kinase inhibitors (TKI) are associated with several clinical side effects, with no definitive established data concerning their clinical impact." | 1.37 | Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. ( Di Fiore, F; Ménager, C; Michel, P; Pfister, C; Rigal, O, 2011) |
| "A modification of the sorafenib dosing schedule involving higher dose intermittent treatment appeared to improve its efficacy in this xenograft model relative to conventional dosing." | 1.37 | High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. ( Alsop, DC; Atkins, MB; Bhasin, M; Bhatt, RS; Brown, V; Goldberg, SN; Mier, JW; Signoretti, S; Wang, X; Zhang, L, 2011) |
| "Spontaneous pyopneumothorax is a very rare occurrence, even in cancer treated patients." | 1.36 | Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases. ( Beynat, C; Coudert, B; Diaz, P; Favier, L; Ghiringhelli, F; Ladoire, S, 2010) |
| "Approximately half of all new renal cell carcinoma diagnoses are made in persons 65 years of age or older." | 1.36 | Experience with sorafenib and the elderly patient. ( Bellmunt, J; Dutcher, JP; Escudier, B; Tannir, N, 2010) |
| "Sorafenib was approved for RCC 6 months after study initiation, at which time patients with no prior therapy or with nonclear cell RCC could enroll in an extension protocol for continued assessment for a period of 6 months." | 1.36 | Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. ( Bukowski, RM; Chu, L; Cupit, L; Curti, BD; Drabkin, HA; Dutcher, JP; Ernstoff, MS; Figlin, RA; George, JR; Hainsworth, JD; Hajdenberg, J; Henderson, CA; Hotte, SJ; Kindwall-Keller, TL; Knox, JJ; McDermott, DF; Miller, WH; Ryan, CW; Stadler, WM; Xia, C, 2010) |
| "Lung-metastasized renal cell carcinoma mice were treated with various combinations of recombinant human interleukin-2 and sorafenib." | 1.36 | Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models. ( Abe, K; Amagai, Y; Hojo, K; Ide, N; Iguchi, M; Kato, A; Matsumoto, M; Shichijo, M; Tanaka, H; Wada, T, 2010) |
| "Xp11 translocation renal cell carcinoma (RCC) is an RCC subtype affecting 15% of RCC patients <45 years." | 1.36 | Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. ( Billemont, B; Boccon-Gibod, L; Bompas, E; Camparo, P; Couturier, J; Dutcher, J; Escudier, B; Guillot, A; Malouf, GG; Molinié, V; Oudard, S; Rixe, O; Rustine, A; Schleiermacher, G; Theodore, C, 2010) |
| "Clear cell renal cell carcinoma is a hypervascularized solid tumor associated with loss of function of the von Hippel-Lindau (VHL) tumor suppressor gene and increased Raf-1 activity." | 1.36 | Sorafenib-associated remission of psoriasis in hypernephroma: case report. ( Fournier, C; Tisman, G, 2010) |
| "Sorafenib (Nexavar(®)) has been approved for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma." | 1.36 | Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. ( Inui, K; Kamba, T; Mizuno, T; Nakamura, E; Ogawa, O; Shinsako, K; Terada, T; Watanabe, J, 2010) |
| "We present the case of a patient with renal cell carcinoma treated preoperatively with sorafenib." | 1.36 | Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report. ( Hara, T; Hatano, K; Inoue, H; Kinoshita, T; Kinouchi, T; Kobayashi, M; Nonomura, N; Takada, T, 2010) |
| "Advanced renal cell carcinoma is associated with a poor prognosis and is refractory to standard chemotherapy." | 1.36 | [Renal cell carcinoma management and therapies in 2010]. ( Albouy, B; Escudier, B; Gross Goupil, M; Massard, C, 2010) |
| " Clinicians have changed their practice and are faced with a number of new adverse events." | 1.36 | [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma]. ( Boyle, H; Fléchon, A; Négrier, S, 2010) |
| "Advanced or metastatic renal carcinoma represents a frequent disease in oncologic practice." | 1.36 | [Advanced renal carcinomas with special situations. How to treat them?]. ( Culine, S; Patard, JJ; Pouessel, D, 2010) |
| "Treatment continued until disease progression or treatment intolerance occurred." | 1.36 | Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients. ( Fukasawa, S; Ichikawa, T; Imamura, Y; Komaru, A; Maruoka, M; Naya, Y; Nihei, N; Sazuka, T; Suyama, T; Ueda, T, 2010) |
| " The most common grade ≥3 adverse events included rash/desquamation (5% in both groups), hand-foot skin reaction (8% in those aged ≥70 years vs." | 1.36 | Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. ( Bukowski, RM; Chu, L; Cupit, L; Curti, BD; Drabkin, HA; Dutcher, JP; Ernstoff, MS; Figlin, RA; Hainsworth, JD; Hajdenberg, J; Henderson, CA; Hotte, SJ; Kindwall-Keller, TL; Knox, JJ; McDermott, DF; Miller, WH; Ryan, CW; Stadler, WM; Xia, C, 2010) |
| " The most common adverse events were rash and diarrhoea." | 1.36 | Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. ( Breaker, K; Costa, LJ; Crighton, F; Drabkin, H; Flaig, TW; Gustafson, DL; Kim, FJ; Schultz, MK, 2010) |
| "The pathological diagnosis was renal cell carcinoma, clear cell type, grade 1, pT3bNxMx stage III." | 1.36 | [Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2]. ( Homma, Y; Kaneko, T; Matsushima, H; Morimoto, H; Tsuzaka, Y, 2010) |
| "Treatment with sorafenib resulted in a significant decrease of (111)In-bevacizumab uptake in the tumor in the patients with ccRCC (mean change, -60." | 1.36 | 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. ( Boerman, OC; Desar, IM; Leenders, WP; Mulders, PF; Oosterwijk, E; Oyen, WJ; Stillebroer, AB; van der Graaf, WT; van Herpen, CM, 2010) |
| "We used murine and human renal cell carcinoma cell lines for in vitro cell proliferation assay." | 1.36 | Mechanism of synergistic antitumor effect of sorafenib and interferon-α on treatment of renal cell carcinoma. ( Eto, M; Kiyoshima, K; Naito, S; Oki, T; Takeuchi, A; Tatsugami, K; Yamada, H; Yoshikai, Y, 2010) |
| "She had no history of skin cancer." | 1.35 | Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. ( Cohen, PR; Diwan, AH; Evans, HL; Hong, DS; Kurzrock, R; Prieto, VG; Reddy, SB; Tannir, NM; Wright, JJ, 2008) |
| "Sorafenib is an oral multikinase inhibitor used in the treatment of renal cell carcinoma." | 1.35 | Sorafenib-induced palmoplantar hyperkeratosis. ( Lountzis, NI; Maroon, MS, 2008) |
| "A 71-year-old man with advanced left renal cell carcinoma (lymph node involvement and vena cava thrombus) was submitted to 6 months of neoadjuvant treatment with sorafenib before open radical nephrectomy." | 1.35 | Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. ( Andrea, A; Di Silverio, F; Panebianco, V; Parente, U; Passariello, R; Sciarra, A; Von Heland, M, 2008) |
| "Ten percent of patients with kidney cancer have associated vena cava thrombus, which is associated with a high operative morbidity." | 1.35 | [Regression of vena cava tumour thrombus in response to sorafenib]. ( Bart, S; Billemont, B; Bitker, MO; Izzedine, H; Rixe, O; Sultan, V; Thibault, F, 2008) |
| "Patients with metastatic clear cell renal cell carcinoma with available baseline tumor samples who received vascular endothelial growth factor targeted therapy were included in analysis." | 1.35 | von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. ( Bhalla, IP; Bukowski, RM; Choueiri, TK; Elson, P; Ganapathi, R; Golshayan, AR; Jaeger, E; Rini, BI; Sein, N; Sercia, L; Simko, J; Small, EJ; Vaziri, SA; Waldman, FM; Weinberg, V; Wood, L; Zhou, M, 2008) |
| "sorafenib)." | 1.35 | Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. ( Rey, PM; Villavicencio, H, 2008) |
| "Although medical treatment for advanced renal cell carcinoma has included cytokine therapies such as interferon and interleukin-2, the treatment system has been revolutionized with the emergence of molecular target medicine." | 1.35 | [Renal cell carcinoma]. ( Fujioka, T; Obara, W, 2008) |
| "Since the majority of clear cell renal cell carcinomas are well vascularised, angiogenetic inhibition offered an alternative therapy goal." | 1.35 | [Systemic therapy of metastasizing renal cell carcinoma]. ( Haseke, N; Karl, A; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K, 2008) |
| "Sorafenib seems to be a safe treatment option for patients with ESRD and mRCC, but further studies are required." | 1.35 | Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure. ( Hakenberg, OW; Klebingat, KJ; Protzel, C; Ruppin, S, 2009) |
| "Metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation is an aggressive disease that is associated with poor outcomes to chemotherapy or immunotherapy." | 1.35 | Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. ( Aydin, H; Bukowski, RM; Elson, P; Garcia, JA; George, S; Golshayan, AR; Heng, DY; Mekhail, TM; Rini, BI; Wood, LS; Zhou, M, 2009) |
| "Sorafenib treatment was initiated a 400 mg orally twice a day." | 1.35 | Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome. ( Borrás-Blasco, J; Casterá, ME; Galán Brotons, A; Rosique-Robles, JD; Vicent Verge, JM, 2008) |
| "Patients with renal cell and breast carcinoma metastases to the brain were identified from the prospective database at the Penn State Hershey Medical Center and Penn State Cancer Institute." | 1.35 | Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. ( Hill, KL; Lipson, AC; Sheehan, JM, 2009) |
| "In this study, VEGF and supernatants of renal carcinoma cell lines cultured under hypoxia were found to alter the differentiation of human monocytes to DC." | 1.35 | Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. ( Alfaro, C; Dubrot, J; Erro, L; Gonzalez, A; Grande-Pulido, E; Gurpide, A; Hervas-Stubbs, S; Lopez-Picazo, JM; Melero, I; Palazon, A; Perez-Gracia, JL; Solano, S; Suarez, N, 2009) |
| "Sorafenib did not inhibit rhIL-2-induced natural killer cell expansion and rhIL-2 had no effect on the anti-angiogenic activity of sorafenib." | 1.35 | Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma. ( Abe, K; Arimura, A; Hojo, K; Iguchi, M; Matsumoto, M; Matsuo, Y; Wada, T, 2009) |
| "In this renal cell carcinoma population sorafenib followed by sunitinib was associated with longer survival than sunitinib followed by sorafenib." | 1.35 | Sequential sorafenib and sunitinib for renal cell carcinoma. ( Balleyguier, C; Celier, C; Escudier, B; Gautier, J; Medioni, J; Negrier, S; Oudard, S; Ravaud, A; Sablin, MP, 2009) |
| "Caki-1, A498, and 786-0 human renal cell carcinoma (RCC) xenografts were implanted in 39 nude mice." | 1.35 | Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? ( Alsop, DC; Atkins, MB; Goldberg, SN; Lenkinski, RE; Marquis, RP; Pedrosa, I; Regan, M; Schor-Bardach, R; Signoretti, S; Solazzo, SA; Wang, X, 2009) |
| "Sorafenib is a new therapeutic agent being used in metastatic renal cell carcinoma, hepatocellular carcinoma, and malignant melanoma." | 1.35 | Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma. ( Bilaç, C; Ermertcan, AT; Kayhan, TC; Müezzinoğlu, T; Oztürkcan, S; Temeltaş, G; Temiz, P, 2009) |
| "The development of targeted agents for renal cell carcinoma has renewed interest in consolidative surgery due to the robust clinical responses seen with these agents." | 1.35 | Surgical resection of renal cell carcinoma after targeted therapy. ( Campbell, SC; Fergany, A; Garcia, JA; Gill, IS; Klein, EA; Krishnamurthi, V; Novick, AC; Rini, BI; Stephenson, AJ; Thomas, AA; Zhou, M, 2009) |
| " The medication dosed at 400 mg twice daily is both efficacious and safe in the treatment of metastatic renal cell carcinoma in Chinese patients." | 1.35 | Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. ( Dai, B; Dong, B; Huang, Y; Lu, JJ; Shen, Y; Yao, X; Ye, D; Zhang, H; Zhang, S; Zhu, Y, 2009) |
| "Sorafenib is a multikinase inhibitor newly approved for the treatment of renal cell carcinoma and hepatocellular carcinoma." | 1.35 | The histologic spectrum of epithelial neoplasms induced by sorafenib. ( Jaworsky, C; Kish, LS; Kwon, EJ, 2009) |
| "Everolimus is an orally administered, targeted therapy indicated for the treatment of advanced renal cell carcinoma." | 1.35 | Everolimus: in advanced renal cell carcinoma. ( Garnock-Jones, KP; Keating, GM, 2009) |
| "We report a case of metastatic renal cell carcinoma in the native kidney of a renal transplant recipient." | 1.35 | Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient. ( Hasegawa, Y; Matsubara, A; Mita, K; Ohdan, H, 2009) |
| "Sorafenib is a tyrosine kinase inhibitor prescribed primarily for the management of metastatic kidney cancer." | 1.35 | Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon? ( Chevreau, C; Delord, JP; Sibaud, V, 2009) |
| "Renal cell carcinoma is an uncommon type of cancer that rarely metastasizes to the brain." | 1.35 | Successful treatment of a brain-metastasized renal cell carcinoma. ( Johnston, KW; Walid, MS, 2009) |
| "Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival." | 1.35 | Sorafenib-induced acute myocardial infarction due to coronary artery spasm. ( Arima, Y; Fukushima, H; Nakamura, S; Noda, K; Ogawa, H; Oshima, S; Shono, M; Taniguchi, I, 2009) |
| "Sorafenib has been approved for use in the treatment of metastatic renal cell carcinoma." | 1.35 | [Sorafenib-induced multiple eruptive keratoacanthomas]. ( Dupre-Goetghebeur, D; Jantzem, H; Merrer, J; Spindler, P, 2009) |
| "Four of them had known brain metastases." | 1.35 | High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. ( Culine, S; Pouessel, D, 2008) |
| "Patients with advanced renal cell carcinoma currently being treated with either sunitinib or sorafenib after receiving 1 or more prior antiangiogenic agent(s) were investigated in a retrospective analysis." | 1.35 | Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. ( Bukowski, RM; Dreicer, R; Elson, P; Garcia, JA; Mekhail, T; Rini, BI; Tamaskar, I; Wood, L, 2008) |
| "Due to the long-lasting course of CLL second cancers can occur in these patients." | 1.34 | [Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination]. ( Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P, 2007) |
| "Sorafenib has been approved in the U." | 1.34 | Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib. ( Distelrath, A; Hoeffkes, HG; Hofmann, E; Ranze, O, 2007) |
| "Sorafenib was eventually discontinued, and the pancreatitis resolved." | 1.34 | Acute pancreatitis associated with sorafenib. ( Li, M; Srinivas, S, 2007) |
| " We report the development of localized palmar-plantar epidermal hyperplasia, a rare but significant cutaneous adverse event from sorafenib therapy." | 1.34 | Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. ( Beldner, M; Burges, GE; Chaudhary, UB; Dewaay, D; Jacobson, M; Maize, JC, 2007) |
| "Cutaneous metastases from renal cell carcinoma (RCC) are uncommon, but may be painful and deforming." | 1.34 | Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy. ( Allison, RR; Cavalieri, R; Finley, J; Gay, HA; Quan, WD, 2007) |
| " Safety was acceptable, with the most common adverse events consisting of hand-foot skin reaction, cutaneous rash, diarrhoea, fatigue and hypertension." | 1.34 | Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. ( Bajetta, E; Catena, L; Gevorgyan, A; Guadalupi, V; Mancin, M; Martinetti, A; Platania, M; Procopio, G; Pusceddu, S; Verzoni, E, 2007) |
| "Thirty patients with a metastatic renal cell carcinoma (RCC) already enrolled in a double-blind randomised study were evaluated." | 1.33 | To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. ( Chami, L; Escudier, B; Lamuraglia, M; Lassau, N; Leclère, J; Roche, A; Schwartz, B, 2006) |
| "Isolated renal cell carcinoma feeder vessels were perfused in an organ bath with the alpha(1)-adrenoceptor agonist phenylephrine (PE)." | 1.31 | Contractile properties of human renal cell carcinoma recruited arteries and their response to nicotinamide. ( Burns, DM; Hirst, DG; Keane, PF; McKeown, SR; Murphy, L; Ruddock, MW; Walsh, IK, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 224 (28.39) | 29.6817 |
| 2010's | 557 (70.60) | 24.3611 |
| 2020's | 8 (1.01) | 2.80 |
| Authors | Studies |
|---|---|
| Oya, M | 5 |
| Kaneko, S | 1 |
| Imai, T | 1 |
| Tsujino, T | 1 |
| Sunaya, T | 2 |
| Okayama, Y | 2 |
| Sadeq, A | 1 |
| Usmani, S | 1 |
| Esmail, AA | 1 |
| Fathallah, W | 1 |
| Alfeeli, MA | 1 |
| Marafi, F | 3 |
| Reustle, A | 1 |
| Menig, LS | 1 |
| Leuthold, P | 1 |
| Hofmann, U | 1 |
| Stühler, V | 1 |
| Schmees, C | 1 |
| Becker, M | 1 |
| Haag, M | 1 |
| Klumpp, V | 1 |
| Winter, S | 1 |
| Büttner, FA | 1 |
| Rausch, S | 1 |
| Hennenlotter, J | 1 |
| Fend, F | 1 |
| Scharpf, M | 1 |
| Stenzl, A | 3 |
| Bedke, J | 3 |
| Schwab, M | 1 |
| Schaeffeler, E | 1 |
| Zengin, ZB | 1 |
| Pal, SK | 8 |
| McDermott, DF | 7 |
| Escudier, B | 49 |
| Hutson, TE | 19 |
| Porta, C | 20 |
| Verzoni, E | 12 |
| Atkins, MB | 14 |
| Kasturi, V | 1 |
| Rini, B | 8 |
| Sasikumar, A | 2 |
| Al-Terki, A | 1 |
| Alfeeli, M | 1 |
| Miranda-Gonçalves, V | 1 |
| Lameirinhas, A | 1 |
| Macedo-Silva, C | 1 |
| Lobo, J | 1 |
| C Dias, P | 1 |
| Ferreira, V | 1 |
| Henrique, R | 1 |
| Jerónimo, C | 1 |
| Aldaas, M | 1 |
| Esmail, A | 1 |
| Zeng, Y | 1 |
| Luo, J | 1 |
| Liao, H | 1 |
| Chen, P | 2 |
| van der Zanden, LFM | 1 |
| Vermeulen, SH | 1 |
| Oskarsdottir, A | 1 |
| Maurits, JSF | 1 |
| Diekstra, MHM | 1 |
| Ambert, V | 1 |
| Cambon-Thomsen, A | 1 |
| Castellano, D | 5 |
| Fritsch, A | 1 |
| Garcia Donas, J | 1 |
| Guarch Troyas, R | 1 |
| Guchelaar, HJ | 2 |
| Hartmann, A | 1 |
| Hulsbergen-van de Kaa, C | 3 |
| Jaehde, U | 1 |
| Junker, K | 1 |
| Martinez-Cardus, A | 1 |
| Masson, G | 1 |
| Oosterwijk-Wakka, J | 2 |
| Radu, MT | 1 |
| Rafnar, T | 1 |
| Rodriguez-Antona, C | 2 |
| Roessler, M | 1 |
| Ruijtenbeek, R | 1 |
| Stefansson, K | 1 |
| Warren, A | 1 |
| Wessels, L | 1 |
| Eisen, T | 14 |
| Kiemeney, LALM | 1 |
| Oosterwijk, E | 6 |
| Mai, H | 1 |
| Huang, J | 5 |
| Zhang, Y | 4 |
| Qu, N | 1 |
| Qu, H | 1 |
| Mei, GH | 2 |
| Liu, J | 4 |
| Xu, X | 1 |
| Chen, L | 2 |
| Cai, W | 5 |
| Zhang, J | 6 |
| Chen, Y | 5 |
| Kong, W | 6 |
| Huang, Y | 7 |
| Zhou, L | 7 |
| Kim, C | 2 |
| Lee, JH | 3 |
| Baek, SH | 2 |
| Ko, JH | 1 |
| Nam, D | 1 |
| Ahn, KS | 2 |
| Gill, DM | 1 |
| Agarwal, N | 3 |
| Vaishampayan, U | 2 |
| Sim, MY | 3 |
| Huynh, H | 3 |
| Go, ML | 1 |
| Yuen, JSP | 1 |
| Ishihara, H | 3 |
| Kondo, T | 8 |
| Tanabe, K | 8 |
| Yano, H | 2 |
| Motoshima, T | 1 |
| Ma, C | 1 |
| Pan, C | 1 |
| Yamada, S | 2 |
| Nakayama, T | 1 |
| Kitada, S | 1 |
| Fujimoto, N | 1 |
| Kamba, T | 3 |
| Takeya, M | 1 |
| Komohara, Y | 1 |
| Lalani, AA | 1 |
| McKay, RR | 3 |
| Lin, X | 3 |
| Simantov, R | 6 |
| Kaymakcalan, MD | 2 |
| Choueiri, TK | 23 |
| Yang, Y | 2 |
| Lin, H | 1 |
| Zhao, L | 1 |
| Song, Y | 3 |
| Gao, Q | 1 |
| Buchler, T | 9 |
| Poprach, A | 5 |
| Bortlicek, Z | 6 |
| Lakomy, R | 2 |
| Chloupková, R | 1 |
| Vyzula, R | 7 |
| Zemanova, M | 3 |
| Kopeckova, K | 1 |
| Svoboda, M | 3 |
| Slaby, O | 2 |
| Kiss, I | 2 |
| Studentova, H | 1 |
| Hornova, J | 1 |
| Fiala, O | 2 |
| Kopecky, J | 1 |
| Finek, J | 1 |
| Dusek, L | 5 |
| Melichar, B | 8 |
| Yasuda, Y | 2 |
| Saito, K | 4 |
| Yuasa, T | 6 |
| Uehara, S | 1 |
| Kawamura, N | 1 |
| Yokoyama, M | 2 |
| Ishioka, J | 1 |
| Matsuoka, Y | 1 |
| Yamamoto, S | 4 |
| Okuno, T | 1 |
| Yonese, J | 5 |
| Kihara, K | 1 |
| Fujii, Y | 2 |
| Maroun, R | 1 |
| Fleury, L | 1 |
| Nachbaur, G | 1 |
| Maunoury, F | 1 |
| Vanhille, JL | 1 |
| Durand-Zaleski, I | 1 |
| Dong, B | 5 |
| Xue, W | 4 |
| Amzal, B | 1 |
| Fu, S | 1 |
| Meng, J | 1 |
| Lister, J | 1 |
| Karcher, H | 1 |
| Jain, RK | 1 |
| Gandhi, S | 1 |
| George, S | 2 |
| Zhong, H | 1 |
| Buti, S | 3 |
| Puligandla, M | 1 |
| Bersanelli, M | 2 |
| DiPaola, RS | 5 |
| Manola, J | 5 |
| Taguchi, S | 1 |
| Haas, NB | 4 |
| He, HL | 1 |
| Yao, WX | 1 |
| Hioki, T | 1 |
| Takama, H | 1 |
| Makita, S | 1 |
| Chen, KR | 1 |
| Watanabe, D | 1 |
| Akiyama, M | 1 |
| Fukuda, H | 1 |
| Yoshida, K | 6 |
| Omae, K | 3 |
| Takagi, T | 4 |
| Iizuka, J | 5 |
| Kobayashi, H | 6 |
| Li, Z | 1 |
| Tang, Y | 1 |
| Zhu, S | 1 |
| Li, D | 1 |
| Han, X | 1 |
| Gu, G | 1 |
| Xing, N | 1 |
| Ren, J | 1 |
| Guo, Z | 1 |
| Jiao, W | 1 |
| Yan, L | 1 |
| Xu, Z | 2 |
| Zhang, W | 3 |
| Chen, X | 3 |
| Liu, L | 3 |
| Wang, J | 8 |
| Lin, Z | 3 |
| Xiong, Y | 3 |
| Qu, Y | 3 |
| Wang, Z | 3 |
| Guo, J | 8 |
| Xu, J | 4 |
| Golinelli, G | 1 |
| Toso, A | 1 |
| Rosa, MS | 1 |
| Valletti, PA | 1 |
| Pia, F | 1 |
| Cao, YW | 1 |
| Liu, Y | 2 |
| Dong, Z | 1 |
| Guo, L | 1 |
| Kang, EH | 1 |
| Wang, YH | 1 |
| Niu, HT | 1 |
| Yu, X | 2 |
| Liu, F | 3 |
| Zeng, L | 1 |
| He, F | 1 |
| Zhang, R | 1 |
| Yan, S | 2 |
| Zeng, Z | 1 |
| Shu, Y | 1 |
| Zhao, C | 2 |
| Wu, X | 1 |
| Lei, J | 1 |
| Yang, C | 4 |
| Wu, K | 2 |
| Wu, Y | 3 |
| An, L | 1 |
| Huang, S | 1 |
| Ji, X | 1 |
| Gong, C | 1 |
| Yuan, C | 1 |
| Zhang, L | 4 |
| Feng, Y | 1 |
| Huang, B | 1 |
| Liu, W | 1 |
| Zhang, B | 3 |
| Dai, Z | 1 |
| Wang, X | 12 |
| Liu, B | 2 |
| Haydon, RC | 1 |
| Luu, HH | 1 |
| Gan, H | 2 |
| He, TC | 1 |
| Yuan, YC | 1 |
| Li, MY | 1 |
| Dong, BJ | 1 |
| Chen, YH | 1 |
| Huang, YR | 1 |
| Zhou, LX | 1 |
| Huang, JW | 1 |
| Mai, HX | 1 |
| Zhao, FL | 1 |
| Li, BT | 1 |
| Tang, YY | 1 |
| Xu, XJ | 1 |
| Chen, LJ | 1 |
| Takada, M | 1 |
| Yasui, T | 1 |
| Oka, T | 2 |
| Shioyama, W | 1 |
| Kuroda, T | 1 |
| Nakai, Y | 3 |
| Nishimura, K | 6 |
| Mukai, M | 1 |
| Fujita, M | 1 |
| Procopio, G | 16 |
| Pignata, S | 2 |
| Altavilla, A | 1 |
| Attademo, L | 1 |
| De Lisi, D | 1 |
| De Giorgi, U | 6 |
| Santini, D | 3 |
| Maitland, ML | 1 |
| Sharma, MR | 1 |
| Jin, Y | 1 |
| Kang, SP | 1 |
| Stadler, WM | 11 |
| Karrison, TG | 1 |
| Ratain, MJ | 3 |
| Bies, RR | 1 |
| Latteux, G | 1 |
| Lebdai, S | 2 |
| Hoarau, N | 1 |
| Abadie-Lacourtoisie, S | 1 |
| Delva, R | 1 |
| Chautard, D | 1 |
| Azzouzi, AR | 2 |
| Bigot, P | 2 |
| Breaker, K | 4 |
| Naam, M | 2 |
| La Rosa, FG | 1 |
| Flaig, IP | 1 |
| Flaig, TW | 5 |
| Serova, M | 1 |
| de Gramont, A | 1 |
| Tijeras-Raballand, A | 1 |
| Dos Santos, C | 1 |
| Riveiro, ME | 1 |
| Slimane, K | 1 |
| Faivre, S | 1 |
| Raymond, E | 1 |
| Levy, A | 2 |
| Menard, J | 1 |
| Albiges, L | 9 |
| Loriot, Y | 4 |
| Di Palma, M | 2 |
| Fizazi, K | 4 |
| Vrdoljak, E | 1 |
| Schmidinger, M | 7 |
| Omrčen, T | 1 |
| Torday, L | 1 |
| Szczylik, C | 19 |
| Sella, A | 1 |
| Bruno, R | 2 |
| Mercier, F | 2 |
| Claret, L | 2 |
| Shah, CH | 1 |
| Viktorsson, K | 1 |
| Sherif, A | 1 |
| Kanter, L | 1 |
| Grybäck, P | 1 |
| Lewensohn, R | 1 |
| Sandström, P | 2 |
| Nilsson, S | 1 |
| Ullén, A | 2 |
| Park, SJ | 1 |
| Lee, JL | 9 |
| Park, I | 5 |
| Park, K | 3 |
| Ahn, Y | 3 |
| Ahn, JH | 6 |
| Lee, DH | 3 |
| Ahn, S | 3 |
| Song, C | 5 |
| Hong, JH | 5 |
| Kim, CS | 7 |
| Ahn, H | 6 |
| Cella, D | 8 |
| Chen, C | 8 |
| Bhattacharyya, H | 1 |
| Tarazi, J | 9 |
| Rosbrook, B | 11 |
| Kim, S | 13 |
| Motzer, R | 3 |
| Bex, A | 5 |
| Motzer, RJ | 15 |
| Tomczak, P | 4 |
| Michaelson, MD | 4 |
| Negrier, S | 14 |
| Oudard, S | 14 |
| Gore, ME | 6 |
| Hariharan, S | 4 |
| Rini, BI | 36 |
| Haraldsdottir, S | 1 |
| Li, Q | 1 |
| Villalona-Calero, MA | 1 |
| Olencki, TE | 1 |
| Kendra, K | 2 |
| Ing, SW | 1 |
| Calvani, N | 3 |
| Morelli, F | 3 |
| Chiuri, V | 1 |
| Gnoni, A | 2 |
| Scavelli, C | 1 |
| Fedele, P | 1 |
| Orlando, L | 2 |
| Maiello, E | 2 |
| Lorusso, V | 2 |
| Cinieri, S | 2 |
| Hainsworth, JD | 3 |
| Waterhouse, DM | 1 |
| Penley, WC | 1 |
| Shipley, DL | 1 |
| Thompson, DS | 1 |
| Webb, CD | 1 |
| Anthony Greco, F | 1 |
| Fardoun, T | 1 |
| Bernhard, JC | 1 |
| Xylinas, E | 1 |
| Berger, J | 1 |
| Rouprêt, M | 1 |
| Beauval, JB | 1 |
| Lagabrielle, S | 1 |
| Ammi, M | 1 |
| Baumert, H | 1 |
| Grenier, N | 2 |
| Hétet, JF | 1 |
| Long, JA | 1 |
| Paparel, P | 1 |
| Rioux-Leclercq, N | 2 |
| Soulié, M | 1 |
| Bensalah, K | 3 |
| Patard, JJ | 7 |
| Marchesi, V | 1 |
| Ueda, T | 2 |
| Uemura, H | 3 |
| Tomita, Y | 6 |
| Tsukamoto, T | 6 |
| Kanayama, H | 1 |
| Shinohara, N | 4 |
| Ozono, S | 3 |
| Naito, S | 12 |
| Akaza, H | 8 |
| Smidt-Hansen, T | 1 |
| Folkmar, TB | 1 |
| Fode, K | 2 |
| Agerbaek, M | 1 |
| Donskov, F | 5 |
| Payton, S | 4 |
| El Tal, AK | 1 |
| Remichofsky, CJ | 1 |
| Mehregan, DA | 1 |
| Ganger, LK | 1 |
| Vickers, MM | 1 |
| Al-Harbi, H | 1 |
| Kollmannsberger, C | 6 |
| North, S | 6 |
| MacKenzie, M | 2 |
| Knox, JJ | 9 |
| Heng, DY | 13 |
| Zhao, RN | 1 |
| Nie, LH | 1 |
| Gong, R | 1 |
| Wang, JZ | 1 |
| Wazir, R | 1 |
| Liu, LR | 1 |
| Song, TR | 1 |
| Wei, Q | 1 |
| Helft, PR | 1 |
| Antoun, S | 3 |
| Lanoy, E | 2 |
| Iacovelli, R | 13 |
| Albiges-Sauvin, L | 1 |
| Merad-Taoufik, M | 1 |
| Baracos, VE | 3 |
| Matsubara, N | 1 |
| Mukai, H | 1 |
| Naito, Y | 1 |
| Itoh, K | 1 |
| Komai, Y | 2 |
| Sakai, Y | 1 |
| Ikehata, Y | 1 |
| Takahashi, S | 7 |
| Kitamura, H | 1 |
| Masumori, N | 2 |
| Rosa, R | 1 |
| Damiano, V | 1 |
| Nappi, L | 1 |
| Formisano, L | 1 |
| Massari, F | 3 |
| Scarpa, A | 1 |
| Martignoni, G | 1 |
| Bianco, R | 1 |
| Tortora, G | 2 |
| Harrison, MR | 2 |
| George, DJ | 5 |
| Walker, MS | 2 |
| Korytowsky, B | 1 |
| Kirkendall, DT | 1 |
| Stepanski, EJ | 1 |
| Abernethy, AP | 2 |
| Nakano, K | 4 |
| Komatsu, K | 1 |
| Kubo, T | 1 |
| Natsui, S | 1 |
| Nukui, A | 1 |
| Kurokawa, S | 1 |
| Kobayashi, M | 2 |
| Morita, T | 1 |
| Ikeda, M | 2 |
| Fujita, T | 4 |
| Amoh, Y | 2 |
| Mii, S | 3 |
| Matsumoto, K | 3 |
| Iwamura, M | 5 |
| Kato, S | 1 |
| Shibamori, K | 1 |
| Hiyama, Y | 1 |
| Tabata, H | 1 |
| Matsuda, Y | 1 |
| Takei, F | 1 |
| Yanase, M | 1 |
| Yoshinaga, A | 1 |
| Ichiyanagi, N | 1 |
| Kamata, S | 1 |
| Garcia-Donas, J | 1 |
| Jonasch, E | 10 |
| Ferté, C | 1 |
| Koscielny, S | 1 |
| Rocher, L | 1 |
| Soria, JC | 3 |
| Nakamura, M | 1 |
| Yao, M | 2 |
| Sano, F | 2 |
| Sakata, R | 1 |
| Tatenuma, T | 1 |
| Makiyama, K | 2 |
| Nakaigawa, N | 2 |
| Kubota, Y | 2 |
| Nishida, H | 1 |
| Kanno, H | 1 |
| Hosoya, N | 1 |
| Sakurai, T | 1 |
| Mashima, E | 1 |
| Kawazoe, H | 2 |
| Kato, T | 5 |
| Nagaoka, A | 2 |
| Iwaba, A | 1 |
| Yamakawa, M | 1 |
| Clyne, M | 1 |
| Vercelli, A | 1 |
| Paglino, C | 8 |
| Uhlenhake, EE | 1 |
| Watson, AC | 1 |
| Aronson, P | 1 |
| Garnick, MB | 1 |
| Nosov, D | 1 |
| Bondarenko, I | 1 |
| Lesovoy, V | 2 |
| Lipatov, O | 1 |
| Lyulko, O | 1 |
| Alyasova, A | 1 |
| Harza, M | 1 |
| Kogan, M | 1 |
| Alekseev, BY | 1 |
| Sternberg, CN | 8 |
| Ivanescu, C | 1 |
| Krivoshik, A | 1 |
| Strahs, A | 1 |
| Esteves, B | 1 |
| Berkenblit, A | 1 |
| Dranitsaris, G | 2 |
| Schmitz, S | 2 |
| Broom, RJ | 1 |
| Bracarda, S | 11 |
| Ricci, S | 2 |
| Sacco, C | 2 |
| Ridolfi, L | 2 |
| Miceli, R | 2 |
| Zilembo, N | 2 |
| Bajetta, E | 5 |
| Derbel Miled, O | 1 |
| Dionne, C | 1 |
| Terret, C | 1 |
| Segura-Ferlay, C | 1 |
| Flechon, A | 2 |
| Neidhart, EM | 1 |
| Droz, JP | 1 |
| Alesini, D | 1 |
| Palazzo, A | 2 |
| Trenta, P | 2 |
| Santoni, M | 5 |
| De Marchis, L | 1 |
| Cascinu, S | 4 |
| Naso, G | 2 |
| Cortesi, E | 5 |
| Guerin, M | 1 |
| Salem, N | 1 |
| Walz, J | 1 |
| Dermeche, S | 1 |
| Gravis, G | 3 |
| Suzuki, H | 1 |
| Suzuki, T | 1 |
| Ishizuka, O | 1 |
| Nishizawa, O | 1 |
| Ueno, M | 1 |
| Conti, A | 3 |
| Pantano, F | 1 |
| Burattini, L | 3 |
| Muzzonigro, G | 2 |
| Berardi, R | 1 |
| Fukudo, M | 1 |
| Ito, T | 1 |
| Mizuno, T | 3 |
| Shinsako, K | 2 |
| Hatano, E | 1 |
| Uemoto, S | 1 |
| Yamasaki, T | 2 |
| Ogawa, O | 2 |
| Seno, H | 1 |
| Chiba, T | 1 |
| Matsubara, K | 1 |
| Tafreshi, A | 1 |
| Thientosapol, E | 1 |
| Liew, MS | 1 |
| Guo, Y | 1 |
| Quaggiotto, M | 1 |
| Boyer, M | 1 |
| Davis, ID | 2 |
| Guy, L | 1 |
| Bay, JO | 1 |
| Bastide, C | 1 |
| Mahammedi, H | 1 |
| Bruyere, F | 2 |
| Karsenty, G | 1 |
| Yousaf, N | 1 |
| Larkin, J | 4 |
| Al-Shukri, S | 2 |
| Stus, VP | 2 |
| Lipatov, ON | 2 |
| Bair, AH | 2 |
| Vogelzang, NJ | 10 |
| Zustovich, F | 3 |
| Novara, G | 1 |
| Oh, WK | 3 |
| McDermott, D | 3 |
| Elaidi, R | 3 |
| Scotte, F | 3 |
| Hawkins, R | 1 |
| Bellmunt, J | 13 |
| Rha, SY | 5 |
| Sun, JM | 1 |
| Nathan, P | 1 |
| Feinberg, BA | 2 |
| Scott, J | 2 |
| McDermott, R | 1 |
| Wagstaff, J | 1 |
| Chang, YH | 1 |
| Ou, YC | 3 |
| Donnellan, P | 1 |
| Huang, CY | 1 |
| McCaffrey, J | 1 |
| Chiang, PH | 1 |
| Chuang, CK | 3 |
| Korves, C | 1 |
| Neary, MP | 2 |
| Diaz, JR | 1 |
| Mehmud, F | 1 |
| Duh, MS | 2 |
| Tsuzuki, T | 2 |
| Sassa, N | 2 |
| Shimoyama, Y | 1 |
| Morikawa, T | 1 |
| Shiroki, R | 1 |
| Kuroda, M | 1 |
| Fukatsu, A | 1 |
| Kuwahara, K | 1 |
| Yoshino, Y | 3 |
| Hattori, R | 2 |
| Gotoh, M | 3 |
| Esteban, E | 3 |
| Bjarnason, GA | 5 |
| Lim, HY | 3 |
| Pittman, KB | 1 |
| Senico, P | 1 |
| Niethammer, A | 1 |
| Lu, DR | 1 |
| Cetin, B | 1 |
| Afsar, B | 1 |
| Deger, SM | 1 |
| Gonul, II | 1 |
| Gumusay, O | 1 |
| Ozet, A | 1 |
| Benekli, M | 1 |
| Coskun, U | 2 |
| Buyukberber, S | 1 |
| P J, G | 1 |
| A, M | 1 |
| L, M | 1 |
| H J, H | 1 |
| M, K | 1 |
| S, B | 1 |
| N, M | 1 |
| Pavlik, T | 5 |
| Kubackova, K | 3 |
| Fukuyama, T | 1 |
| Wong, MK | 2 |
| Yang, H | 1 |
| Signorovitch, JE | 4 |
| Liu, Z | 7 |
| Liu, NS | 1 |
| Qi, CZ | 1 |
| Garcia-Roig, M | 1 |
| Ortiz, N | 1 |
| Lokeshwar, V | 1 |
| Hutchinson, L | 1 |
| Nonomura, N | 5 |
| Eto, M | 7 |
| Kimura, G | 3 |
| Minami, H | 1 |
| Tokunaga, S | 1 |
| Lee, J | 1 |
| Srinivas, S | 3 |
| Vaishampayan, UN | 3 |
| Tan, MH | 3 |
| Wood, LA | 1 |
| Harada, K | 4 |
| Miyake, H | 11 |
| Kusuda, Y | 4 |
| Fujisawa, M | 12 |
| Hong, DS | 2 |
| Gordon, MS | 1 |
| Samlowski, WE | 1 |
| Kurzrock, R | 2 |
| Tannir, N | 4 |
| Friedland, D | 1 |
| Mendelson, DS | 1 |
| Rasmussen, E | 1 |
| Wu, BM | 1 |
| Bass, MB | 2 |
| Zhong, ZD | 1 |
| Friberg, G | 1 |
| Appleman, LJ | 1 |
| Davoudi, ET | 1 |
| bin-Noordin, MI | 1 |
| Javar, HA | 1 |
| Kadivar, A | 1 |
| Sabeti, B | 1 |
| Muselaers, CH | 1 |
| Stillebroer, AB | 3 |
| Desar, IM | 7 |
| Boers-Sonderen, MJ | 2 |
| van Herpen, CM | 7 |
| de Weijert, MC | 1 |
| Langenhuijsen, JF | 2 |
| Leenders, WP | 3 |
| Boerman, OC | 2 |
| Mulders, PF | 9 |
| Oyen, WJ | 4 |
| Petrou, PK | 1 |
| Talias, MA | 1 |
| Arnaldi, G | 1 |
| Rizzo, M | 5 |
| Trementino, L | 1 |
| Testa, I | 2 |
| Grassi, P | 2 |
| Garanzini, E | 1 |
| Colecchia, M | 2 |
| Torelli, T | 2 |
| De Braud, F | 2 |
| De Lichtenberg, TH | 1 |
| Hermann, GG | 2 |
| Rørth, M | 1 |
| Højer Larsen, MJ | 1 |
| Mansourvar, Z | 1 |
| Holm, ML | 1 |
| Scheike, T | 1 |
| Papavassilis, P | 2 |
| Krabbe, LM | 1 |
| Thielen, B | 2 |
| Bögemann, M | 1 |
| Moritz, R | 1 |
| Hoffmeister, I | 2 |
| Hertle, L | 5 |
| Herrmann, E | 8 |
| Zolnierek, J | 2 |
| Grünwald, V | 12 |
| Urbanowitz, G | 1 |
| Cai, C | 1 |
| Squires, M | 1 |
| Marker, M | 1 |
| Shi, MM | 1 |
| Maute, L | 1 |
| Weikert, S | 5 |
| Kube, U | 1 |
| Gauler, T | 2 |
| Kahl, C | 1 |
| Burkholder, I | 1 |
| Bergmann, L | 5 |
| De Braud, FM | 1 |
| Shetty, AV | 1 |
| Matrana, MR | 2 |
| Atkinson, BJ | 1 |
| Flaherty, AL | 2 |
| Tannir, NM | 7 |
| Karashima, T | 2 |
| Komatsu, T | 1 |
| Niimura, M | 1 |
| Kawada, C | 1 |
| Kamada, M | 2 |
| Inoue, K | 2 |
| Udaka, K | 1 |
| Kuroda, N | 2 |
| Shuin, T | 2 |
| Brose, MS | 1 |
| Frenette, CT | 1 |
| Keefe, SM | 2 |
| Stein, SM | 1 |
| Walko, CM | 1 |
| Grande, C | 1 |
| Quinn, DI | 1 |
| Baum, M | 1 |
| Wood, LS | 5 |
| Arruda, LS | 1 |
| Cisar, L | 2 |
| Roberts, WG | 1 |
| Monk, P | 1 |
| Lam, E | 1 |
| Mortazavi, A | 1 |
| Lesinski, GB | 1 |
| Mace, TA | 1 |
| Geyer, S | 1 |
| Carson, WE | 1 |
| Tahiri, S | 1 |
| Bhinder, A | 1 |
| Clinton, SK | 1 |
| Olencki, T | 1 |
| Perkins, JJ | 1 |
| Li, Y | 4 |
| Li, S | 3 |
| Zhu, Y | 8 |
| Liang, X | 1 |
| Meng, H | 1 |
| Chen, J | 2 |
| Zhang, D | 1 |
| Guo, H | 1 |
| Shi, B | 1 |
| Derosa, L | 2 |
| Gernone, A | 1 |
| Sava, T | 1 |
| Ferrari, V | 2 |
| Sabbatini, R | 2 |
| Gasparro, D | 2 |
| Felici, A | 2 |
| Lo Re, G | 1 |
| Banna, G | 1 |
| Pia Brizzi, M | 1 |
| Ciuffreda, L | 1 |
| Ferraù, F | 2 |
| Taibi, E | 2 |
| Galligioni, E | 1 |
| Contu, A | 1 |
| Mulder, SF | 5 |
| Bertens, D | 1 |
| Vissers, KC | 2 |
| Punt, CJ | 2 |
| van Spronsen, DJ | 3 |
| Kessels, RP | 1 |
| Grépin, R | 1 |
| Ambrosetti, D | 1 |
| Marsaud, A | 1 |
| Gastaud, L | 1 |
| Amiel, J | 1 |
| Pedeutour, F | 1 |
| Pagès, G | 1 |
| Kwon, T | 1 |
| You, D | 2 |
| Jeong, IG | 3 |
| Kats-Ugurlu, G | 3 |
| Muselaers, S | 1 |
| de Weijert, M | 1 |
| van Krieken, H | 1 |
| Desar, I | 1 |
| van Herpen, C | 2 |
| Maass, C | 2 |
| de Waal, R | 2 |
| Mulders, P | 4 |
| Leenders, W | 2 |
| Rexer, H | 3 |
| Biondani, P | 1 |
| Torri, V | 1 |
| Porcu, L | 1 |
| Pons, F | 1 |
| Foreshew, A | 1 |
| Fay, AP | 2 |
| Powles, T | 4 |
| Lampron, ME | 1 |
| Cerbone, L | 3 |
| Bhatt, VR | 1 |
| Ganti, AK | 1 |
| Schwarz, JK | 1 |
| Khambati, HK | 1 |
| Kollmannsberger, CK | 2 |
| Wood, L | 10 |
| MacKenzie, MJ | 2 |
| Clark, JI | 1 |
| Porfiri, E | 2 |
| Zalewski, P | 1 |
| Kannourakis, G | 1 |
| Staehler, M | 12 |
| Elledge, R | 1 |
| Elledge, RO | 1 |
| Raskauskiene, D | 1 |
| Beuselinck, B | 3 |
| Lerut, E | 2 |
| Wolter, P | 2 |
| Dumez, H | 2 |
| Berkers, J | 2 |
| Van Poppel, H | 2 |
| Joniau, S | 1 |
| Oyen, R | 1 |
| De Wever, L | 1 |
| Strijbos, M | 1 |
| Paridaens, R | 2 |
| Schöffski, P | 2 |
| Gunduz, S | 1 |
| Mutlu, H | 1 |
| Uysal, M | 1 |
| Coskun, HS | 1 |
| Bozcuk, H | 1 |
| Furukawa, J | 1 |
| Czarnecka, AM | 2 |
| Oborska, S | 2 |
| Rzepecki, P | 1 |
| Nouhaud, FX | 3 |
| Rebibo, JD | 2 |
| Blanchard, F | 1 |
| Sabourin, JC | 2 |
| Di Fiore, F | 4 |
| Pfister, C | 4 |
| Basso, U | 1 |
| Ortega, C | 2 |
| Masini, C | 2 |
| Milella, M | 2 |
| Di Lorenzo, G | 7 |
| Atzori, F | 1 |
| Pagano, M | 1 |
| De Vivo, R | 1 |
| Mosca, A | 1 |
| Rossi, M | 2 |
| Falconi, M | 1 |
| Montironi, R | 1 |
| Batalla, A | 1 |
| Menéndez, L | 1 |
| Blay, P | 2 |
| Curto, JR | 1 |
| Shah, BK | 1 |
| Ghimire, KB | 1 |
| Gao, C | 1 |
| Peng, FH | 1 |
| Peng, LK | 1 |
| Linke, Z | 1 |
| Pokorna, P | 1 |
| Prausova, J | 1 |
| Sisani, M | 1 |
| Marrocolo, F | 1 |
| Hamzaj, A | 1 |
| D Buono, S | 1 |
| Wang, HK | 4 |
| Zhang, HL | 6 |
| Yao, XD | 3 |
| Zhang, SL | 3 |
| Dai, B | 5 |
| Shen, YJ | 2 |
| Zhu, YP | 3 |
| Shi, GH | 5 |
| Qin, XJ | 3 |
| Ma, CG | 2 |
| Lin, GW | 1 |
| Xiao, WJ | 1 |
| Ye, DW | 7 |
| Nakazawa, H | 2 |
| Hatano, T | 1 |
| Kawata, N | 1 |
| Kume, H | 1 |
| Morita, M | 1 |
| Nakajima, K | 2 |
| Ohno, Y | 3 |
| Okegawa, T | 1 |
| Wakumoto, Y | 1 |
| Horie, S | 1 |
| Yamaguchi, R | 2 |
| Murakami, M | 2 |
| Juengel, E | 1 |
| Kim, D | 1 |
| Makarević, J | 1 |
| Reiter, M | 1 |
| Tsaur, I | 1 |
| Bartsch, G | 1 |
| Haferkamp, A | 1 |
| Blaheta, RA | 1 |
| Jäger, D | 1 |
| Ma, JH | 1 |
| Mardiak, J | 2 |
| Korbenfeld, E | 1 |
| Leonhartsberger, N | 1 |
| Stauch, K | 1 |
| Böckenhoff, A | 1 |
| Yu, J | 2 |
| Keil, C | 1 |
| Götze, L | 1 |
| Olbert, P | 2 |
| Hofmann, R | 2 |
| Nockher, WA | 1 |
| Hegele, A | 5 |
| Soerensen, AV | 1 |
| Kjellberg, J | 1 |
| Ibsen, R | 1 |
| Jensen, NV | 1 |
| Geertsen, PF | 1 |
| Boonkaew, B | 1 |
| Arora, J | 1 |
| Mandava, SH | 2 |
| Maddox, MM | 1 |
| Chava, S | 1 |
| Callaghan, C | 2 |
| He, J | 1 |
| Dash, S | 2 |
| John, VT | 1 |
| Lee, BR | 2 |
| Hu, W | 1 |
| Yuan, Q | 1 |
| Liu, XH | 1 |
| Zhu, HC | 1 |
| Lv, SQ | 1 |
| Wang, XH | 1 |
| Zhou, C | 1 |
| Zhang, Q | 1 |
| Jin, G | 1 |
| Tian, Y | 1 |
| Wang, Y | 4 |
| Sun, K | 1 |
| Yang, X | 1 |
| Deng, J | 1 |
| Ji, Z | 1 |
| Yu, H | 1 |
| Li, H | 3 |
| Zheng, B | 1 |
| Zhu, H | 1 |
| Gu, D | 1 |
| Pan, X | 1 |
| Qian, L | 1 |
| Xue, B | 1 |
| Yang, D | 1 |
| Zhou, J | 1 |
| Shan, Y | 1 |
| Rao, A | 1 |
| Lauer, R | 1 |
| Dicken, V | 2 |
| Bornemann, L | 1 |
| Moltz, JH | 1 |
| Peitgen, HO | 1 |
| Zaim, S | 2 |
| Scheuring, U | 1 |
| Araki, H | 1 |
| Kimura, T | 2 |
| Tanaka, K | 1 |
| Huang, X | 1 |
| English, PA | 1 |
| Loomis, AK | 1 |
| Williams, JA | 1 |
| Fishman, MN | 1 |
| Tomshine, J | 1 |
| Fulp, WJ | 1 |
| Foreman, PK | 1 |
| Qin, S | 1 |
| Zhang, S | 2 |
| Tei, H | 1 |
| Ho, TH | 1 |
| Liu, XD | 1 |
| Warneke, CL | 2 |
| Johnson, MM | 2 |
| Hoang, A | 1 |
| Tamboli, P | 3 |
| Wang, F | 2 |
| Eichelberg, C | 2 |
| Vervenne, WL | 1 |
| De Santis, M | 1 |
| Fischer von Weikersthal, L | 1 |
| Goebell, PJ | 1 |
| Lerchenmüller, C | 1 |
| Zimmermann, U | 1 |
| Bos, MM | 1 |
| Freier, W | 1 |
| Schirrmacher-Memmel, S | 1 |
| Pahernik, S | 2 |
| Los, M | 1 |
| Schenck, M | 1 |
| Flörcken, A | 4 |
| van Arkel, C | 1 |
| Hauswald, K | 1 |
| Indorf, M | 1 |
| Gottstein, D | 1 |
| Michel, MS | 2 |
| Petrou, P | 1 |
| Ky, B | 1 |
| Flaherty, KT | 11 |
| Uzzo, RG | 3 |
| Kane, CJ | 1 |
| Jewett, M | 2 |
| Wood, CG | 4 |
| Dutcher, JJ | 2 |
| Wilding, G | 3 |
| Thoma, C | 1 |
| Ouzaid, I | 1 |
| Defortescu, G | 2 |
| Giwerc, A | 2 |
| Charbit, D | 1 |
| Gouerant, S | 2 |
| Moreo, A | 1 |
| Vallerio, P | 1 |
| Ricotta, R | 2 |
| Stucchi, M | 1 |
| Pozzi, M | 1 |
| Musca, F | 1 |
| Meani, P | 1 |
| Maloberti, A | 1 |
| Facchetti, R | 1 |
| Di Bella, S | 1 |
| Giganti, MO | 1 |
| Sartore-Bianchi, A | 1 |
| Siena, S | 1 |
| Mancia, G | 1 |
| Giannattasio, C | 1 |
| Ninomiya, N | 1 |
| Tamada, S | 1 |
| Kato, M | 1 |
| Iguchi, T | 1 |
| Nakatani, T | 1 |
| Manola, JB | 1 |
| Pins, M | 2 |
| Margolin, KA | 1 |
| Sakai, H | 2 |
| Hashine, K | 3 |
| Jeon, TY | 1 |
| Kim, CK | 1 |
| Kim, JH | 1 |
| Im, GH | 1 |
| Park, BK | 1 |
| Gadaleta-Caldarola, G | 1 |
| Infusino, S | 1 |
| Divella, R | 1 |
| Ferraro, E | 1 |
| Mazzocca, A | 1 |
| De Rose, F | 1 |
| Filippelli, G | 1 |
| Abbate, I | 1 |
| Brandi, M | 1 |
| Kennoki, T | 2 |
| Hashimoto, Y | 3 |
| Iijima, M | 1 |
| Hyodo, I | 1 |
| Gemma, A | 2 |
| Itoh, H | 1 |
| Adachi, M | 2 |
| Inuyama, L | 1 |
| Kim, SH | 3 |
| Nam, BH | 2 |
| Lee, SE | 2 |
| Seo, IY | 2 |
| Kim, TN | 2 |
| Hong, SH | 2 |
| Kwon, TG | 2 |
| Seo, SI | 2 |
| Joo, KJ | 2 |
| Song, K | 2 |
| Kwak, C | 2 |
| Chung, J | 3 |
| Guo, G | 2 |
| Li, X | 3 |
| Zhang, C | 2 |
| Huang, L | 3 |
| Fang, D | 1 |
| Zhang, X | 2 |
| Mitchell, AP | 1 |
| Hirsch, BR | 1 |
| Miyazaki, A | 1 |
| Imai, S | 2 |
| Fütterer, JJ | 1 |
| De Geus-Oei, LF | 1 |
| Van Der Graaf, WT | 4 |
| Lin, CH | 1 |
| Yuan, HJ | 1 |
| Wang, K | 2 |
| Wu, JT | 1 |
| Liu, QZ | 1 |
| Yu, SQ | 1 |
| Men, CP | 1 |
| Gao, ZL | 1 |
| Jang, S | 2 |
| Zheng, C | 1 |
| Tsai, HT | 1 |
| Fu, AZ | 1 |
| Barac, A | 1 |
| Freedman, AN | 1 |
| Minasian, L | 1 |
| Potosky, AL | 1 |
| Kawano, Y | 1 |
| Hirao, Y | 1 |
| Mita, K | 2 |
| Arai, Y | 4 |
| Matsubara, A | 2 |
| Fujioka, T | 2 |
| Tatsugami, K | 5 |
| Hinotsu, S | 1 |
| Gu, WJ | 2 |
| Zhou, LP | 1 |
| Ueda, K | 2 |
| Akiba, J | 1 |
| Ogasawara, S | 1 |
| Todoroki, K | 1 |
| Nakayama, M | 2 |
| Sumi, A | 1 |
| Kusano, H | 1 |
| Sanada, S | 1 |
| Suekane, S | 2 |
| Xu, K | 1 |
| Bae, KH | 1 |
| Kurisawa, M | 1 |
| Igawa, T | 2 |
| Takagi, K | 1 |
| Takai, M | 1 |
| Kawata, K | 1 |
| Horie, K | 1 |
| Kikuchi, M | 1 |
| Mizutani, K | 1 |
| Seike, K | 1 |
| Tsuchiya, T | 1 |
| Yasuda, M | 1 |
| Yokoi, S | 1 |
| Nakano, M | 2 |
| Ushikoshi, H | 1 |
| Miyazaki, T | 1 |
| Deguchi, T | 1 |
| Fenner, A | 1 |
| Cho, YM | 1 |
| Xie, W | 3 |
| North, SA | 1 |
| Smoragiewicz, M | 1 |
| Kroeger, N | 2 |
| Wells, JC | 1 |
| De Velasco, G | 1 |
| Ivanyi, P | 1 |
| Cai, Y | 1 |
| Vitale, MG | 1 |
| Cartenì, G | 4 |
| Reichmann, WM | 3 |
| Li, N | 4 |
| Perez, JR | 4 |
| Zheng, Y | 1 |
| Wu, G | 2 |
| Wang, Q | 1 |
| Lu, J | 1 |
| Li, P | 2 |
| Lu, X | 1 |
| Yuan, J | 1 |
| Koo, DH | 1 |
| Hong, B | 1 |
| Koo, V | 1 |
| Solarek, W | 1 |
| Kornakiewicz, A | 1 |
| Tang, B | 2 |
| Chi, Z | 2 |
| Sheng, X | 2 |
| Cui, C | 2 |
| Si, L | 3 |
| Kong, Y | 1 |
| Mao, L | 2 |
| Lian, B | 3 |
| Yan, X | 2 |
| Kang, SK | 1 |
| Volodarskiy, A | 1 |
| Ohmann, EL | 1 |
| Balar, AV | 1 |
| Bangalore, S | 1 |
| Kitamura, Y | 1 |
| Yoshii, H | 1 |
| Nishimoto, K | 1 |
| Shinchi, Y | 1 |
| Tokonabe, S | 1 |
| Takao, M | 1 |
| Daido, Y | 1 |
| Veskrnova, V | 1 |
| Honzirkova, M | 1 |
| Shu, M | 1 |
| Zai, X | 1 |
| Wang, R | 1 |
| Verri, E | 1 |
| Cossu Rocca, M | 1 |
| Aurilio, G | 1 |
| Cullurà, D | 1 |
| de Cobelli, O | 1 |
| Nolé, F | 1 |
| Zhang, P | 1 |
| Xing, Z | 1 |
| Zhao, J | 2 |
| Xiao, Y | 1 |
| Xing, Y | 1 |
| Qin, C | 1 |
| Cao, Q | 1 |
| Wang, S | 1 |
| Wang, M | 1 |
| Chu, H | 1 |
| Ye, D | 3 |
| Zhang, H | 3 |
| Sun, X | 1 |
| Zou, Q | 1 |
| Cai, H | 1 |
| Sun, L | 1 |
| Zhu, J | 1 |
| Ji, J | 1 |
| Cui, L | 1 |
| Zhou, H | 1 |
| Zhao, H | 1 |
| Wu, B | 1 |
| Jiang, M | 1 |
| Zhang, Z | 1 |
| Shao, P | 1 |
| Ju, X | 1 |
| Yin, C | 1 |
| Diekstra, MH | 1 |
| Swen, JJ | 1 |
| Gelderblom, H | 1 |
| Peralta, D | 1 |
| Maddox, M | 1 |
| Tarr, MA | 1 |
| Takyar, S | 1 |
| Diaz, J | 1 |
| Sehgal, M | 1 |
| Sapunar, F | 1 |
| Pandha, H | 1 |
| Leonetti, A | 1 |
| Castagneto, B | 2 |
| Di Meglio, G | 1 |
| Pellegrino, B | 1 |
| Marschner, N | 3 |
| Müller, L | 1 |
| Münch, A | 1 |
| Blumenstengel, K | 2 |
| Hutzschenreuter, U | 2 |
| Busies, S | 1 |
| Um, JY | 1 |
| Shim, BS | 1 |
| Kane, C | 1 |
| Dutcher, JP | 6 |
| Wagner, L | 1 |
| Matin, S | 1 |
| Kuzel, TM | 1 |
| Sexton, WJ | 1 |
| Wong, YN | 1 |
| Pili, R | 1 |
| Puzanov, I | 2 |
| Kohli, M | 2 |
| Stadler, W | 2 |
| Carducci, M | 1 |
| Coomes, R | 1 |
| Duensing, S | 2 |
| Hohenfellner, M | 2 |
| Chrom, P | 1 |
| Stec, R | 1 |
| Semeniuk-Wojtas, A | 1 |
| Bodnar, L | 1 |
| Spencer, NJ | 1 |
| Mehrazin, R | 1 |
| Tsao, CK | 1 |
| Sfakianos, J | 1 |
| Galsky, MD | 2 |
| Stone, L | 1 |
| Felsch, M | 1 |
| Lehmacher, W | 1 |
| Scheuring, UJ | 2 |
| Sikic, D | 1 |
| Lüdecke, G | 1 |
| Lieb, V | 1 |
| Keck, B | 1 |
| Gu, W | 1 |
| Wang, B | 1 |
| Wang, H | 2 |
| Shi, G | 1 |
| Li, ZY | 1 |
| Fan, XX | 1 |
| Wang, YJ | 1 |
| Yao, K | 1 |
| Liu, ZW | 1 |
| Pan, WT | 1 |
| Ye, YL | 1 |
| Yang, P | 1 |
| Huang, YC | 1 |
| Wu, ZM | 1 |
| Zhou, FJ | 1 |
| Kabu, K | 1 |
| Ito, Y | 1 |
| Kalanovic, D | 1 |
| Hinz, S | 3 |
| Janssen, J | 1 |
| Schostak, M | 1 |
| Tesch, H | 1 |
| Zastrow, S | 1 |
| Miller, K | 13 |
| Xi, W | 2 |
| Xia, Y | 1 |
| Bai, Q | 1 |
| Long, Q | 1 |
| Ogasawara, N | 1 |
| Chikui, K | 1 |
| Suyama, S | 1 |
| Nakiri, M | 1 |
| Nishihara, K | 1 |
| Matsuo, M | 1 |
| Shantakumar, S | 1 |
| Nordstrom, BL | 1 |
| Djousse, L | 1 |
| Hall, SA | 1 |
| Gagnon, DR | 1 |
| Fraeman, KH | 1 |
| van Herk-Sukel, M | 1 |
| Chagin, K | 1 |
| Nelson, J | 1 |
| Mir, MH | 1 |
| Changal, KH | 1 |
| Aziz, SA | 1 |
| Bhat, GM | 1 |
| Lone, AR | 1 |
| Zheng, J | 1 |
| Chanu, P | 1 |
| Yazdi, P | 1 |
| Milligan, PA | 1 |
| Joo, J | 1 |
| Seo, HK | 1 |
| Joung, JY | 1 |
| Lee, KH | 1 |
| Ma, X | 1 |
| Wang, L | 2 |
| Gao, Y | 1 |
| Liu, K | 1 |
| Meng, Q | 1 |
| Wang, D | 1 |
| Song, Z | 1 |
| Shparyk, Y | 1 |
| Andrews, GI | 1 |
| Nishi, M | 1 |
| Tabata, K | 3 |
| Yagisawa, T | 1 |
| Wan, FN | 1 |
| Calvo, E | 2 |
| Bourlon, MT | 1 |
| Gao, D | 3 |
| Trigero, S | 1 |
| Clemons, JE | 1 |
| Lam, ET | 1 |
| Liu, S | 1 |
| Gao, M | 1 |
| Ding, S | 1 |
| Lv, J | 1 |
| Niu, Z | 1 |
| Miyake, M | 1 |
| Morizawa, Y | 1 |
| Hori, S | 1 |
| Tatsumi, Y | 1 |
| Anai, S | 1 |
| Onishi, S | 1 |
| Tanaka, N | 1 |
| Fujimoto, K | 2 |
| Yang, F | 1 |
| Wei, D | 1 |
| Bao, Y | 1 |
| Wu, Z | 1 |
| Wu, D | 1 |
| Tan, H | 1 |
| Li, J | 1 |
| Sun, S | 1 |
| Qu, L | 1 |
| Fernández-Pello, S | 1 |
| Hofmann, F | 1 |
| Tahbaz, R | 1 |
| Marconi, L | 1 |
| Lam, TB | 1 |
| Canfield, SE | 1 |
| Dabestani, S | 1 |
| Giles, RH | 1 |
| Hora, M | 1 |
| Kuczyk, MA | 6 |
| Merseburger, AS | 6 |
| Volpe, A | 1 |
| Ljungberg, B | 1 |
| Jones, RJ | 1 |
| Ravaud, A | 10 |
| Kuczyk, M | 2 |
| Demkow, T | 4 |
| Bearz, A | 2 |
| Shapiro, J | 1 |
| Strauss, UP | 2 |
| Hatiboglu, G | 1 |
| Arslan, A | 1 |
| Hadaschik, B | 1 |
| Teber, D | 1 |
| Radtke, JP | 1 |
| Hallscheidt, P | 1 |
| Tolstov, Y | 1 |
| Roth, W | 1 |
| Grüllich, C | 1 |
| Huesing, J | 1 |
| Wendel, C | 1 |
| Campitiello, M | 1 |
| Plastino, F | 1 |
| Eid, N | 1 |
| Hennequin, L | 1 |
| Quétin, P | 1 |
| Longo, R | 1 |
| Sheng, XN | 2 |
| Li, XS | 1 |
| Chi, ZH | 2 |
| He, ZS | 1 |
| Dos Santos, M | 1 |
| Brachet, PE | 1 |
| Chevreau, C | 7 |
| Joly, F | 3 |
| Ramaswamy, A | 1 |
| Joshi, A | 1 |
| Noronha, V | 1 |
| Patil, VM | 1 |
| Kothari, R | 1 |
| Sahu, A | 1 |
| Kannan, RA | 1 |
| Sable, N | 1 |
| Popat, P | 1 |
| Menon, S | 1 |
| Prabhash, K | 1 |
| Burchardt, M | 1 |
| Wen, T | 1 |
| Xiao, H | 1 |
| Luo, C | 1 |
| Xiong, M | 1 |
| Yao, J | 1 |
| Liu, G | 1 |
| Qu, J | 1 |
| Suo, S | 1 |
| Liu, X | 1 |
| Ghate, SR | 1 |
| Swallow, E | 1 |
| Peeples, M | 1 |
| Zichlin, ML | 1 |
| Afriansyah, A | 1 |
| Hamid, AR | 1 |
| Mochtar, CA | 1 |
| Umbas, R | 1 |
| Gillissen, B | 1 |
| Richter, A | 2 |
| Preissner, R | 1 |
| Schulze-Osthoff, K | 1 |
| Essmann, F | 1 |
| Daniel, PT | 1 |
| Kakoki, K | 1 |
| Miyata, Y | 1 |
| Mochizuki, Y | 1 |
| Iwata, T | 1 |
| Obatake, M | 1 |
| Abe, K | 3 |
| Nagayasu, T | 1 |
| Sheng, Y | 1 |
| Ng, CP | 1 |
| Lourie, R | 1 |
| Shah, ET | 1 |
| He, Y | 1 |
| Wong, KY | 1 |
| Seim, I | 1 |
| Oancea, I | 1 |
| Morais, C | 1 |
| Jeffery, PL | 1 |
| Hooper, J | 1 |
| Gobe, GC | 1 |
| McGuckin, MA | 1 |
| Randrup Hansen, C | 1 |
| Grimm, D | 1 |
| Bauer, J | 1 |
| Wehland, M | 1 |
| Magnusson, NE | 1 |
| Niinivirta, M | 1 |
| Enblad, G | 1 |
| Edqvist, PH | 1 |
| Pontén, F | 1 |
| Dragomir, A | 1 |
| Ullenhag, GJ | 1 |
| Hsieh, JJ | 3 |
| Purdue, MP | 1 |
| Signoretti, S | 7 |
| Swanton, C | 1 |
| Ficarra, V | 2 |
| Hwang, SH | 1 |
| Cho, A | 1 |
| Yun, M | 1 |
| Choi, YD | 1 |
| Kang, WJ | 1 |
| Lacouture, ME | 4 |
| Reilly, LM | 1 |
| Gerami, P | 1 |
| Guitart, J | 1 |
| Reddy, SB | 1 |
| Prieto, VG | 2 |
| Wright, JJ | 4 |
| Cohen, PR | 1 |
| Diwan, AH | 1 |
| Evans, HL | 1 |
| Kong, HH | 1 |
| Sibaud, V | 2 |
| Chanco Turner, ML | 1 |
| Fojo, T | 1 |
| Hornyak, TJ | 1 |
| Lountzis, NI | 1 |
| Maroon, MS | 1 |
| Di Silverio, F | 2 |
| Sciarra, A | 2 |
| Parente, U | 2 |
| Andrea, A | 1 |
| Von Heland, M | 1 |
| Panebianco, V | 1 |
| Passariello, R | 1 |
| Hakenberg, OW | 2 |
| Moldawer, NP | 1 |
| Figlin, R | 1 |
| Gerss, J | 2 |
| Bierer, S | 5 |
| Köpke, T | 3 |
| Bolenz, C | 2 |
| Wülfing, C | 3 |
| Thibault, F | 1 |
| Izzedine, H | 4 |
| Sultan, V | 1 |
| Bart, S | 1 |
| Billemont, B | 5 |
| Rixe, O | 4 |
| Bitker, MO | 1 |
| Strumberg, D | 4 |
| Kruck, S | 2 |
| Gakis, G | 1 |
| Kramer, MW | 1 |
| Elson, P | 11 |
| Khasawneh, MK | 1 |
| Cotta, C | 1 |
| Unnithan, J | 2 |
| Mekhail, T | 3 |
| Garcia, J | 3 |
| Dreicer, R | 6 |
| Bukowski, RM | 21 |
| Vaziri, SA | 1 |
| Jaeger, E | 1 |
| Bhalla, IP | 1 |
| Small, EJ | 2 |
| Weinberg, V | 1 |
| Sein, N | 1 |
| Simko, J | 1 |
| Golshayan, AR | 4 |
| Sercia, L | 1 |
| Zhou, M | 4 |
| Waldman, FM | 1 |
| Ganapathi, R | 1 |
| Autier, J | 1 |
| Wechsler, J | 1 |
| Spatz, A | 1 |
| Robert, C | 4 |
| Ardavanis, A | 1 |
| Doufexis, D | 1 |
| Kountourakis, P | 1 |
| Rigatos, G | 1 |
| Vakkalanka, BK | 2 |
| Rübben, H | 1 |
| Amin, C | 2 |
| Wallen, E | 1 |
| Pruthi, RS | 2 |
| Calvo, BF | 1 |
| Godley, PA | 2 |
| Rathmell, WK | 6 |
| Pouessel, D | 5 |
| Culine, S | 6 |
| Heuer, R | 1 |
| Chun, FK | 1 |
| Hinrichs, K | 1 |
| Zacharias, M | 1 |
| Huland, H | 1 |
| Heinzer, H | 5 |
| Nitschmann, S | 1 |
| Alexandrescu, DT | 2 |
| McClure, R | 1 |
| Farzanmehr, H | 1 |
| Dasanu, CA | 2 |
| Valcamonico, F | 1 |
| Amoroso, V | 1 |
| Rangoni, G | 1 |
| Simoncini, E | 1 |
| Marpicati, P | 1 |
| Vassalli, L | 1 |
| Grisanti, S | 1 |
| Marini, G | 1 |
| Rey, PM | 1 |
| Villavicencio, H | 1 |
| Boudou-Rouquette, P | 1 |
| Ropert, S | 1 |
| Goldwasser, F | 3 |
| Tuma, RS | 1 |
| Moch, H | 1 |
| Obara, W | 1 |
| Kakehi, Y | 1 |
| Maluf, FC | 1 |
| Fernandes, Gdos S | 1 |
| Kann, AG | 1 |
| Aguilar-Ponce, JL | 1 |
| de la Garza, J | 1 |
| Buzaid, AC | 1 |
| Hahn, OM | 1 |
| Medved, M | 1 |
| Karczmar, G | 1 |
| Kistner, E | 1 |
| Karrison, T | 1 |
| Manchen, E | 1 |
| Mitchell, M | 1 |
| Haseke, N | 3 |
| Zilinberg, K | 1 |
| Stadler, T | 3 |
| Karl, A | 2 |
| Stief, CG | 3 |
| Chowdhury, S | 3 |
| Larkin, JM | 2 |
| Sire, M | 2 |
| Wallerand, H | 1 |
| Kilkoski, F | 1 |
| Ferrière, JM | 1 |
| Figlin, RA | 6 |
| Kuhn, JG | 1 |
| Zielinski, CC | 3 |
| Vogl, UM | 3 |
| Bojic, A | 1 |
| Bojic, M | 2 |
| Schukro, C | 1 |
| Ruhsam, M | 1 |
| Hejna, M | 1 |
| Schmidinger, H | 1 |
| Middleton, R | 1 |
| Cihon, F | 2 |
| Anderson, S | 4 |
| Shah, S | 2 |
| Bukowski, R | 7 |
| Bamias, A | 2 |
| Johannsen, M | 3 |
| Roigas, J | 1 |
| Cosentino, M | 1 |
| Kloeters, C | 1 |
| Rief, M | 1 |
| Rogalla, P | 1 |
| Cicek, D | 1 |
| Kandi, B | 1 |
| Dagli, FA | 1 |
| Karaoglu, A | 1 |
| Haligur, BD | 1 |
| Kroog, GS | 1 |
| Ruppin, S | 1 |
| Protzel, C | 1 |
| Klebingat, KJ | 1 |
| Dudek, AZ | 3 |
| Dham, A | 1 |
| Lindgren, BR | 1 |
| Mekhail, TM | 1 |
| Garcia, JA | 6 |
| Aydin, H | 1 |
| Galán Brotons, A | 1 |
| Borrás-Blasco, J | 1 |
| Rosique-Robles, JD | 1 |
| Vicent Verge, JM | 1 |
| Casterá, ME | 1 |
| Tochizawa, S | 1 |
| Yanai, Y | 2 |
| Ohmoto, Y | 1 |
| Yabuuchi, Y | 1 |
| Berger, W | 1 |
| Micksche, M | 1 |
| Pirker, C | 1 |
| Lamm, W | 2 |
| Pichelmeyer, O | 1 |
| Rolland, F | 5 |
| Laferriere, N | 1 |
| Mills, EJ | 1 |
| Rachlis, B | 1 |
| O'Regan, C | 1 |
| Thabane, L | 1 |
| Perri, D | 1 |
| Trojan, L | 1 |
| Honeck, P | 1 |
| Schöppler, G | 2 |
| Alken, P | 1 |
| Häcker, A | 1 |
| Jäger, E | 4 |
| Jakse, G | 2 |
| Wirth, M | 1 |
| Keilholz, U | 8 |
| Hill, KL | 1 |
| Lipson, AC | 1 |
| Sheehan, JM | 1 |
| Ansari, J | 1 |
| Fatima, A | 1 |
| Chaudhri, S | 1 |
| Bhatt, RI | 1 |
| Wallace, M | 1 |
| James, ND | 1 |
| Dubauskas, Z | 1 |
| Kunishige, J | 1 |
| Hwu, P | 1 |
| Alfaro, C | 1 |
| Suarez, N | 1 |
| Gonzalez, A | 1 |
| Solano, S | 1 |
| Erro, L | 1 |
| Dubrot, J | 1 |
| Palazon, A | 1 |
| Hervas-Stubbs, S | 1 |
| Gurpide, A | 1 |
| Lopez-Picazo, JM | 1 |
| Grande-Pulido, E | 1 |
| Melero, I | 1 |
| Perez-Gracia, JL | 3 |
| Mizutani, Y | 2 |
| Zimmermann, K | 2 |
| Schmittel, A | 3 |
| Steiner, U | 1 |
| Asemissen, AM | 2 |
| Knoedler, M | 1 |
| Thiel, E | 3 |
| Jarkowski, A | 1 |
| Iguchi, M | 2 |
| Matsumoto, M | 2 |
| Hojo, K | 2 |
| Wada, T | 2 |
| Matsuo, Y | 1 |
| Arimura, A | 1 |
| Bastien, L | 1 |
| Paule, B | 2 |
| Ledbai, S | 1 |
| de la Taille, A | 1 |
| Richards, TM | 1 |
| Plowman, PN | 1 |
| Reznek, R | 1 |
| Ball, SA | 1 |
| Jonkers, IJAM | 1 |
| van Buren, M | 1 |
| Secasan, CC | 1 |
| Drummond, M | 1 |
| Evans, B | 1 |
| LeLorier, J | 1 |
| Karakiewicz, P | 1 |
| Martin, D | 1 |
| Tugwell, P | 1 |
| MacLeod, S | 1 |
| Sablin, MP | 1 |
| Balleyguier, C | 1 |
| Gautier, J | 1 |
| Celier, C | 1 |
| Medioni, J | 4 |
| Molina, AM | 1 |
| Desai, AA | 4 |
| Gore, M | 4 |
| Hofilena, G | 1 |
| Shan, M | 3 |
| Pena, C | 2 |
| Lathia, C | 2 |
| Schor-Bardach, R | 2 |
| Alsop, DC | 3 |
| Pedrosa, I | 2 |
| Solazzo, SA | 1 |
| Marquis, RP | 1 |
| Regan, M | 2 |
| Lenkinski, RE | 1 |
| Goldberg, SN | 4 |
| Feltes, RA | 1 |
| Feito Rodríguez, M | 1 |
| González-Beato, MJ | 1 |
| Berchem, G | 1 |
| Dewilde, S | 1 |
| Mahassen, P | 1 |
| Bilaç, C | 1 |
| Müezzinoğlu, T | 2 |
| Ermertcan, AT | 1 |
| Kayhan, TC | 1 |
| Temeltaş, G | 2 |
| Oztürkcan, S | 1 |
| Temiz, P | 1 |
| Lyrdal, D | 1 |
| Boijsen, M | 1 |
| Suurküla, M | 1 |
| Lundstam, S | 1 |
| Stierner, U | 2 |
| Guevremont, C | 1 |
| Alasker, A | 2 |
| Karakiewicz, PI | 6 |
| Abel, EJ | 1 |
| Miyanaga, N | 1 |
| Lee, WJ | 1 |
| Chang, SE | 1 |
| Lee, MW | 1 |
| Kang, YK | 1 |
| Choi, JH | 1 |
| Moon, KC | 1 |
| Koh, JK | 1 |
| Furuya, N | 2 |
| Kamai, T | 2 |
| Tokui, N | 1 |
| Abe, H | 2 |
| Fukabori, Y | 1 |
| Thomas, AA | 1 |
| Stephenson, AJ | 1 |
| Fergany, A | 1 |
| Krishnamurthi, V | 1 |
| Novick, AC | 1 |
| Gill, IS | 1 |
| Klein, EA | 1 |
| Campbell, SC | 2 |
| Lu, JJ | 1 |
| Yao, X | 1 |
| Shen, Y | 1 |
| Autorino, R | 2 |
| Bruni, G | 1 |
| Tudini, M | 1 |
| Aieta, M | 2 |
| Gonnella, A | 1 |
| Rescigno, P | 2 |
| Perdonà, S | 1 |
| Giannarini, G | 1 |
| Longo, N | 2 |
| Palmieri, G | 2 |
| Imbimbo, C | 2 |
| De Laurentiis, M | 1 |
| Mirone, V | 2 |
| Ficorella, C | 1 |
| De Placido, S | 3 |
| Hudes, G | 1 |
| Trask, PC | 2 |
| James, N | 1 |
| Pascoe, J | 1 |
| Zachariah, A | 1 |
| Ray, D | 1 |
| Oldroyd, A | 1 |
| Parry, H | 1 |
| Benghiat, H | 1 |
| Karina, M | 1 |
| Collins, S | 1 |
| Kwon, EJ | 1 |
| Kish, LS | 1 |
| Jaworsky, C | 1 |
| Zołnierek, J | 2 |
| Nurzyński, P | 2 |
| Langiewicz, P | 1 |
| Waśko-Grabowska, A | 2 |
| Kuszatal, E | 1 |
| Obrocka, B | 1 |
| La Vine, DB | 1 |
| Coleman, TA | 1 |
| Davis, CH | 1 |
| Carbonell, CE | 1 |
| Davis, WB | 1 |
| Moore, M | 1 |
| Lewis, J | 1 |
| Ladoire, S | 1 |
| Beynat, C | 1 |
| Diaz, P | 1 |
| Coudert, B | 1 |
| Favier, L | 1 |
| Ghiringhelli, F | 1 |
| Garnock-Jones, KP | 1 |
| Keating, GM | 1 |
| Regan, MM | 2 |
| Warren, MA | 1 |
| Sahi, C | 1 |
| Eigl, BJ | 1 |
| Ruether, JD | 1 |
| Cheng, T | 1 |
| Venner, P | 2 |
| Chi, KN | 1 |
| Simon, A | 1 |
| Waalkes, S | 2 |
| Massard, C | 2 |
| Zonierek, J | 1 |
| Gross-Goupil, M | 1 |
| Hasegawa, Y | 1 |
| Ohdan, H | 1 |
| Serrano, C | 1 |
| Suárez, C | 1 |
| Andreu, J | 1 |
| Carles, J | 3 |
| Corn, P | 1 |
| Pagliaro, LC | 1 |
| Ng, C | 1 |
| Aparicio, A | 1 |
| Ashe, RG | 1 |
| Overkleeft, EN | 1 |
| Goldschmeding, R | 1 |
| van Reekum, F | 1 |
| Voest, EE | 2 |
| Verheul, HM | 2 |
| Breau, RH | 1 |
| Leibovich, BC | 1 |
| Delord, JP | 1 |
| Ide, S | 1 |
| Soda, H | 1 |
| Hakariya, T | 1 |
| Takemoto, S | 1 |
| Ishimoto, H | 1 |
| Tomari, S | 1 |
| Sawai, T | 1 |
| Nagashima, S | 1 |
| Furukawa, M | 1 |
| Nakamura, Y | 1 |
| Kohno, S | 1 |
| Walid, MS | 1 |
| Johnston, KW | 1 |
| Wang, SS | 1 |
| Cheng, CL | 1 |
| Dahm, P | 1 |
| Tai, CJ | 1 |
| Cowey, CL | 4 |
| Fielding, JR | 2 |
| Siebels, M | 4 |
| Varga, Z | 2 |
| Oberneder, R | 2 |
| Doehn, C | 2 |
| Arima, Y | 1 |
| Oshima, S | 1 |
| Noda, K | 1 |
| Fukushima, H | 1 |
| Taniguchi, I | 1 |
| Nakamura, S | 1 |
| Shono, M | 1 |
| Ogawa, H | 1 |
| Digue, L | 1 |
| Trufflandier, N | 1 |
| Smith, D | 1 |
| Thompson, JA | 1 |
| Chung, C | 1 |
| Dawson, LA | 1 |
| Joshua, AM | 1 |
| Brade, AM | 1 |
| Jantzem, H | 1 |
| Dupre-Goetghebeur, D | 1 |
| Spindler, P | 1 |
| Merrer, J | 1 |
| Kamada, P | 1 |
| Wang, ZY | 1 |
| Xie, XD | 1 |
| Piao, Y | 1 |
| Liu, ZZ | 1 |
| Thompson Coon, J | 1 |
| Hoyle, M | 1 |
| Green, C | 1 |
| Welch, K | 1 |
| Moxham, T | 1 |
| Stein, K | 1 |
| Maksimovic, O | 1 |
| Schraml, C | 1 |
| Hartmann, JT | 1 |
| Bitzer, M | 1 |
| Claussen, CD | 1 |
| Pintoffl, J | 1 |
| Horger, M | 1 |
| Smith, AD | 3 |
| Lieber, ML | 3 |
| Shah, SN | 4 |
| Hasskarl, J | 1 |
| Blanchet, B | 1 |
| Barete, S | 1 |
| Garrigue, H | 1 |
| Cabanes, L | 1 |
| Coriat, R | 1 |
| Francès, C | 1 |
| Knebelmann, B | 1 |
| Miller, WH | 2 |
| Henderson, CA | 2 |
| George, JR | 1 |
| Hajdenberg, J | 2 |
| Kindwall-Keller, TL | 2 |
| Ernstoff, MS | 3 |
| Drabkin, HA | 4 |
| Curti, BD | 2 |
| Chu, L | 2 |
| Ryan, CW | 3 |
| Hotte, SJ | 2 |
| Xia, C | 3 |
| Cupit, L | 2 |
| Birdsell, L | 2 |
| Sawyer, MB | 2 |
| Khan, G | 1 |
| Golshayan, A | 1 |
| Tong, TQ | 1 |
| Rohde, D | 1 |
| Peter, S | 1 |
| Amagai, Y | 1 |
| Tanaka, H | 1 |
| Ide, N | 1 |
| Kato, A | 1 |
| Shichijo, M | 1 |
| Kurashige, Y | 1 |
| Otani, A | 1 |
| Yoshimura, N | 1 |
| Malouf, GG | 1 |
| Camparo, P | 1 |
| Schleiermacher, G | 1 |
| Theodore, C | 1 |
| Rustine, A | 1 |
| Dutcher, J | 4 |
| Bompas, E | 1 |
| Guillot, A | 2 |
| Boccon-Gibod, L | 1 |
| Couturier, J | 1 |
| Molinié, V | 1 |
| Wallen, EM | 1 |
| Nielsen, ME | 1 |
| Grigson, G | 2 |
| Watkins, C | 2 |
| Nance, KV | 1 |
| Crane, J | 1 |
| Jalkut, M | 1 |
| Moore, DT | 2 |
| Kim, WY | 1 |
| Whang, YE | 1 |
| Trigo, JM | 2 |
| Rubió, J | 1 |
| Virizuela, JA | 1 |
| López, R | 1 |
| Lázaro, M | 2 |
| Albanell, J | 2 |
| Gschwend, JE | 2 |
| Fournier, C | 1 |
| Tisman, G | 1 |
| Rosmorduc, O | 1 |
| Dielenseger, P | 1 |
| Ederhy, S | 1 |
| Grange, JD | 1 |
| Mortier, L | 1 |
| Neidhardt-Berard, ME | 1 |
| Seitz, JF | 1 |
| Rosenberg, JE | 2 |
| Clement, J | 1 |
| Amato, AM | 1 |
| Cho, DC | 1 |
| Kobayashi, Y | 1 |
| Kanemitu, T | 1 |
| Kamoto, A | 1 |
| Satoh, M | 1 |
| Mori, N | 1 |
| Sekii, K | 1 |
| Yoshioka, T | 1 |
| Itatani, H | 1 |
| Fujimoto, T | 1 |
| Hutson, T | 1 |
| Terada, T | 1 |
| Watanabe, J | 1 |
| Nakamura, E | 1 |
| Inui, K | 1 |
| Barbastefano, J | 1 |
| Lane, BR | 1 |
| Oosterwijk-Wakka, JC | 1 |
| Kiemeney, LA | 1 |
| Old, LJ | 1 |
| Grossgoupil, M | 1 |
| Fishman, M | 3 |
| Quinn, D | 2 |
| Sánchez Zalabardo, D | 1 |
| Millán Serrano, JA | 1 |
| De Pablo Cárdenas, A | 1 |
| Cuesta Alcalá, JA | 1 |
| Kinoshita, T | 2 |
| Inoue, H | 2 |
| Kinouchi, T | 1 |
| Takada, T | 1 |
| Hara, T | 2 |
| Hatano, K | 1 |
| Albouy, B | 1 |
| Gross Goupil, M | 1 |
| Barrascout, E | 1 |
| Ayllon, J | 1 |
| Mejean, A | 1 |
| Cuenod, CA | 2 |
| Tartour, E | 1 |
| Boyle, H | 1 |
| Shiota, M | 2 |
| Yokomizo, A | 2 |
| Tada, Y | 1 |
| Takeuchi, A | 3 |
| Masubuchi, D | 1 |
| Inokuchi, J | 2 |
| Kuroiwa, K | 2 |
| Uchiumi, T | 1 |
| Seki, N | 1 |
| Norum, J | 1 |
| Nieder, C | 1 |
| Kondo, M | 1 |
| Sun, M | 4 |
| Lughezzani, G | 1 |
| Perrotte, P | 4 |
| Albers, P | 2 |
| Gschwend, J | 2 |
| Remer, EM | 2 |
| Eto, H | 1 |
| Katsuoka, K | 1 |
| Fournier, LS | 1 |
| Thiam, R | 1 |
| Trinquart, L | 1 |
| Banu, E | 1 |
| Balvay, D | 1 |
| Chatellier, G | 1 |
| Frija, G | 1 |
| Stevani, I | 1 |
| Giorcelli, L | 1 |
| Montefiore, F | 1 |
| Bigatti, GL | 1 |
| Pisacco, P | 1 |
| Cosimi, MF | 1 |
| Kurahashi, T | 1 |
| Yamanaka, K | 1 |
| Kondo, Y | 1 |
| Takenaka, A | 1 |
| Inoue, TA | 2 |
| Kodaira, M | 2 |
| Takeuchi, K | 1 |
| Saotome, T | 1 |
| Fukui, I | 4 |
| Hatake, K | 3 |
| Beck, J | 2 |
| Maroto-Rey, P | 1 |
| Guillem, V | 1 |
| López-Martín, JA | 2 |
| Antón-Torres, A | 1 |
| Urruticoechea, L | 2 |
| Hou, MM | 1 |
| Chang, NJ | 1 |
| Huang, HY | 1 |
| Wang, HM | 1 |
| Hsu, T | 1 |
| Chang, JW | 2 |
| Kramer, M | 1 |
| Herrmann, TR | 1 |
| Schrader, AJ | 3 |
| Imamura, Y | 1 |
| Komaru, A | 1 |
| Fukasawa, S | 1 |
| Sazuka, T | 1 |
| Suyama, T | 1 |
| Naya, Y | 1 |
| Nihei, N | 1 |
| Ichikawa, T | 1 |
| Maruoka, M | 1 |
| Nadel, A | 1 |
| Lekili, M | 1 |
| Nese, N | 1 |
| Roosen, A | 1 |
| Bader, M | 1 |
| Nishikawa, T | 1 |
| Muriel, C | 1 |
| Corral, N | 1 |
| Fonseca, PJ | 1 |
| Luque, M | 1 |
| Berros, JP | 1 |
| Fernández, Y | 1 |
| Fra, J | 1 |
| Villanueva, N | 1 |
| Sanmamed, M | 1 |
| Pardo, P | 1 |
| Izquierdo, M | 1 |
| Vieitez, JM | 1 |
| Estrada, E | 1 |
| Lacave, ÁJ | 1 |
| Degen, A | 1 |
| Satzger, I | 1 |
| Voelker, B | 1 |
| Kapp, A | 1 |
| Hauschild, A | 1 |
| Gutzmer, R | 1 |
| Gilligan, T | 1 |
| Nemec, C | 1 |
| Costa, LJ | 1 |
| Gustafson, DL | 1 |
| Schultz, MK | 1 |
| Crighton, F | 1 |
| Kim, FJ | 1 |
| Drabkin, H | 1 |
| Jacobs, JH | 1 |
| Hulsbergen-vandeKaa, CA | 1 |
| Adema, GJ | 1 |
| de Vries, IJ | 2 |
| Ferguson, TR | 1 |
| Pickering, LM | 1 |
| Edmonds, K | 2 |
| James, MG | 1 |
| Thomas, K | 1 |
| Banerji, U | 1 |
| Berns, B | 1 |
| de Boer, C | 1 |
| Kyono, Y | 1 |
| Takayama, T | 1 |
| Kinoshita, M | 1 |
| Kurita, Y | 1 |
| Mugiya, S | 1 |
| Baba, S | 2 |
| Heinzl, H | 1 |
| Haitel, A | 1 |
| Clodi, M | 1 |
| Kramer, G | 1 |
| Tagawa, ST | 1 |
| Milowsky, MI | 1 |
| Jeske, S | 1 |
| Mazumdar, M | 2 |
| Kung, S | 1 |
| Sung, M | 1 |
| Lehrer, D | 1 |
| Matulich, D | 1 |
| Selzer, J | 1 |
| Nanus, DM | 1 |
| Minami-Hori, M | 1 |
| Ishida-Yamamoto, A | 1 |
| Komatsu, S | 1 |
| Iiduka, H | 1 |
| Sahai, S | 1 |
| Swick, BL | 1 |
| Buonerba, C | 3 |
| Federico, P | 1 |
| D'Aniello, C | 1 |
| Ruggeri, EM | 3 |
| Aglietta, M | 1 |
| Heinz, WJ | 1 |
| Kahle, K | 1 |
| Helle-Beyersdorf, A | 1 |
| Schirmer, D | 1 |
| Lenker, U | 1 |
| Keller, D | 1 |
| Langmann, P | 1 |
| Klinker, H | 1 |
| Yokoyama, H | 1 |
| Lundqvist, A | 1 |
| Su, S | 1 |
| Childs, R | 1 |
| Morimoto, H | 1 |
| Tsuzaka, Y | 1 |
| Kaneko, T | 1 |
| Matsushima, H | 1 |
| Homma, Y | 1 |
| Eulitt, PJ | 1 |
| Park, MA | 1 |
| Hossein, H | 1 |
| Cruikshanks, N | 1 |
| Dmitriev, IP | 1 |
| Yacoub, A | 1 |
| Curiel, DT | 1 |
| Fisher, PB | 1 |
| Dent, P | 1 |
| Yamada, H | 1 |
| Oki, T | 1 |
| Kiyoshima, K | 2 |
| Yoshikai, Y | 1 |
| Lampard, JG | 1 |
| Biglietto, M | 1 |
| Scognamiglio, F | 1 |
| Chiurazzi, B | 1 |
| Riccardi, F | 1 |
| Busse, A | 2 |
| Asemissen, A | 1 |
| Nonnenmacher, A | 2 |
| Ochsenreither, S | 2 |
| Fusi, A | 2 |
| Braun, F | 2 |
| Stather, D | 2 |
| Riesenbeck, LM | 1 |
| Ruangkanchanasetr, P | 1 |
| Kanjanapayak, B | 1 |
| Jungmeechoke, K | 1 |
| Niwakawa, M | 1 |
| Fujii, H | 1 |
| Hamamoto, Y | 1 |
| Fukino, K | 2 |
| Tanigawa, T | 1 |
| Sumiyoshi, Y | 1 |
| Filson, CP | 1 |
| Redman, BG | 1 |
| Dunn, RL | 1 |
| Miller, DC | 1 |
| Benedict, A | 1 |
| Harmenberg, U | 1 |
| Charbonneau, C | 1 |
| Sandin, R | 1 |
| Remák, E | 1 |
| Brion, N | 1 |
| Kontovinis, L | 1 |
| Laschos, K | 1 |
| Karadimou, A | 2 |
| Andreadis, C | 1 |
| Paraskevopoulos, P | 1 |
| Dimopoulos, M | 1 |
| Papazisis, K | 1 |
| Krajewski, KM | 1 |
| Guo, M | 1 |
| Van den Abbeele, AD | 1 |
| Yap, J | 1 |
| Ramaiya, N | 1 |
| Jagannathan, J | 1 |
| Schutz, FA | 1 |
| Urakami, S | 3 |
| Inamura, K | 1 |
| Ishikwa, Y | 1 |
| Bokemeyer, C | 1 |
| Richel, DJ | 3 |
| Mersmann, S | 1 |
| Burock, K | 1 |
| Pérez López, G | 1 |
| Carrasco De La Fuente, M | 1 |
| Menacho Román, M | 1 |
| González Albarrán, O | 1 |
| Cano Megías, M | 1 |
| Adnot-Desanlis, L | 1 |
| Bernard, P | 1 |
| Reguiaï, Z | 1 |
| Shirataki, H | 1 |
| Fukuda, T | 1 |
| Nakamura, F | 1 |
| Kambara, T | 1 |
| Nakanishi, K | 1 |
| Ondrácková, B | 1 |
| Demlová, R | 1 |
| Komínek, J | 1 |
| Harshman, LC | 1 |
| Yu, RJ | 1 |
| Allen, GI | 1 |
| Gill, HS | 1 |
| Chung, BI | 1 |
| Kimata, N | 1 |
| Murakami, J | 1 |
| Ishimori, I | 1 |
| Shibayama, Y | 1 |
| Maeda, H | 1 |
| Taguchi, M | 1 |
| Ikeda, R | 1 |
| Sugawara, M | 1 |
| Iseki, K | 1 |
| Takeda, Y | 1 |
| Yamada, K | 1 |
| Harzstark, AL | 1 |
| Weinberg, VK | 1 |
| Sun, J | 1 |
| Ryan, CJ | 1 |
| Lin, AM | 1 |
| Fong, L | 1 |
| Brocks, DR | 1 |
| Jain, L | 2 |
| Woo, S | 1 |
| Gardner, ER | 1 |
| Dahut, WL | 1 |
| Kohn, EC | 1 |
| Kummar, S | 1 |
| Mould, DR | 1 |
| Giaccone, G | 1 |
| Yarchoan, R | 1 |
| Venitz, J | 2 |
| Figg, WD | 2 |
| Behnsawy, HM | 1 |
| Fukuhara, T | 1 |
| Yuen, JS | 2 |
| Siml, HG | 1 |
| Chong, TW | 2 |
| Lau, WK | 2 |
| Cheng, CW | 2 |
| Arranz, JÁ | 2 |
| Climent, MÁ | 2 |
| González-Larriba, JL | 2 |
| León, L | 2 |
| Maroto, JP | 2 |
| Grimm, MO | 1 |
| Ohlmann, CH | 1 |
| Overkamp, F | 1 |
| Groschek, M | 1 |
| Pühse, G | 1 |
| Steiner, T | 1 |
| Maráz, A | 1 |
| Zurita, AJ | 1 |
| Khajavi, M | 1 |
| Du, DZ | 1 |
| Xu, L | 1 |
| Herynk, MH | 1 |
| McKee, KS | 1 |
| Tran, HT | 1 |
| Logothetis, CJ | 1 |
| Heymach, JV | 1 |
| Bushmakin, AG | 1 |
| Cappelleri, JC | 2 |
| Bycott, P | 1 |
| Jolly, P | 1 |
| Wang, ST | 1 |
| Fortner, B | 1 |
| Gilmore, J | 1 |
| Tanji, N | 1 |
| Wang, CF | 2 |
| Murai, M | 2 |
| Thuret, R | 1 |
| Maurin, C | 1 |
| Verma, J | 1 |
| Allen, P | 1 |
| Mahajan, A | 1 |
| Kempkensteffen, C | 3 |
| Busch, J | 4 |
| Westermann, J | 2 |
| Weinkauf, L | 2 |
| Klapka, R | 1 |
| Brabec, P | 1 |
| Abrahamova, J | 3 |
| Kawashima, A | 3 |
| Takayama, H | 3 |
| Tanigawa, G | 3 |
| Nin, M | 2 |
| Kajikawa, J | 2 |
| Imazu, T | 1 |
| Yasunaga, Y | 1 |
| Takada, S | 1 |
| Tsujimura, A | 2 |
| De Pasquale, MD | 1 |
| Pessolano, R | 1 |
| Boldrini, R | 1 |
| Ilari, I | 1 |
| Donfrancesco, A | 1 |
| Jenkner, A | 1 |
| Block, MS | 1 |
| Bhasin, M | 2 |
| Collins, MP | 1 |
| Panka, D | 1 |
| Putheti, P | 1 |
| Libermann, T | 1 |
| Mier, JW | 2 |
| Bhatt, RS | 2 |
| Casciano, R | 1 |
| Malangone, E | 1 |
| Sherman, S | 1 |
| Willet, J | 1 |
| Zhao, Y | 2 |
| Chiappino, I | 1 |
| Re, GL | 1 |
| Landi, L | 1 |
| Calcagno, A | 1 |
| Imarisio, I | 4 |
| Guadalupi, V | 2 |
| Grundbichler, M | 1 |
| Mlineritsch, B | 1 |
| Ressler, S | 1 |
| Moik, M | 1 |
| Kappacher, A | 1 |
| Rosenlechner, S | 1 |
| Greil, R | 1 |
| Hull, D | 1 |
| Spencer-Shaw, A | 1 |
| Koldenhof, J | 1 |
| Chrysou, M | 1 |
| Boers-Doets, C | 1 |
| Molassiotis, A | 1 |
| Cohen, JD | 1 |
| Tham, KY | 1 |
| Mastrandrea, NJ | 1 |
| Gallegos, AC | 1 |
| Monks, TJ | 1 |
| Lau, SS | 1 |
| Leung, HW | 1 |
| Chan, AL | 1 |
| Jacobs, JF | 1 |
| Olde Nordkamp, MA | 1 |
| Galama, JM | 1 |
| Torensma, R | 1 |
| Teerenstra, S | 1 |
| Kitajima, K | 1 |
| Maeda, T | 1 |
| Yoshikawa, T | 1 |
| Fujii, M | 1 |
| Sugimura, K | 1 |
| Seidel, C | 3 |
| Wolff, I | 2 |
| Magheli, A | 2 |
| Salem, M | 1 |
| Tsang, C | 1 |
| Atkinson, B | 2 |
| Roulin, D | 1 |
| Waselle, L | 1 |
| Dormond-Meuwly, A | 1 |
| Dufour, M | 1 |
| Demartines, N | 1 |
| Dormond, O | 1 |
| Royston, P | 1 |
| McCormack, JB | 1 |
| Atkins, M | 1 |
| Leo, S | 1 |
| Lombardi, L | 1 |
| Cinefra, M | 1 |
| Hittinger, M | 1 |
| Schramm, N | 1 |
| Ubleis, C | 1 |
| Becker, C | 1 |
| Reiser, M | 1 |
| Berger, F | 1 |
| Tsuchiya, N | 2 |
| Horikawa, Y | 2 |
| Narita, S | 2 |
| Inoue, T | 4 |
| Saito, M | 1 |
| Habuchi, T | 2 |
| Monti, M | 1 |
| Merlano, M | 1 |
| D'Angelo, A | 1 |
| Santoro, A | 2 |
| Grünberger, B | 1 |
| Salinas-Sánchez, AS | 1 |
| Giménez-Bachs, JM | 1 |
| Serrano-Oviedo, L | 1 |
| Nam Cha, S | 1 |
| Sánchez-Prieto, R | 1 |
| Yamaguchi, S | 1 |
| Miyoshi, S | 1 |
| Meguro, N | 1 |
| Yosioka, T | 1 |
| Vatsyayan, R | 1 |
| Singhal, J | 1 |
| Nagaprashantha, LD | 1 |
| Awasthi, S | 1 |
| Singhal, SS | 1 |
| Fenner, M | 1 |
| Ganser, A | 1 |
| Pickert, A | 1 |
| Hughes, M | 1 |
| Wells, M | 1 |
| Haanen, J | 1 |
| Kaprin, A | 1 |
| Gorbunova, VA | 1 |
| Rusakov, IG | 1 |
| Tokuyama, Y | 1 |
| Sugita, A | 1 |
| Maeyama, R | 1 |
| Bessho, H | 1 |
| Ishikawa, W | 1 |
| Rigal, O | 1 |
| Ménager, C | 1 |
| Michel, P | 1 |
| Sakai, I | 1 |
| Calvo Aller, E | 1 |
| Maroto, P | 1 |
| Kreif, N | 1 |
| González Larriba, JL | 1 |
| López-Brea, M | 1 |
| Martí, B | 1 |
| Díaz Cerezo, S | 1 |
| Takvorian, A | 1 |
| Van Lessen, A | 1 |
| Singh, A | 1 |
| Hopfenmüller, W | 1 |
| Dörken, B | 1 |
| Pezzutto, A | 1 |
| Amato, RJ | 1 |
| Stepankiw, M | 1 |
| Peng, E | 1 |
| Guan, W | 1 |
| Hu, Z | 1 |
| Ye, Z | 1 |
| Zhuang, Q | 1 |
| Takeda, H | 1 |
| Nakano, Y | 1 |
| Kashiwagi, Y | 1 |
| Brown, V | 1 |
| Mancuso, A | 2 |
| Di Paola, ED | 1 |
| Leone, A | 1 |
| Catalano, A | 1 |
| Calabrò, F | 1 |
| Zivi, A | 1 |
| Messina, C | 1 |
| Alonso, S | 1 |
| Vigna, L | 1 |
| Caristo, R | 1 |
| Lanocita, R | 1 |
| Vincent, MD | 1 |
| Fang, F | 2 |
| Caty, A | 2 |
| Duclos, B | 1 |
| Geoffrois, L | 1 |
| Laguerre, B | 1 |
| Legouffe, E | 1 |
| Kohser, F | 1 |
| Dietrich, PY | 1 |
| Theodore, CA | 1 |
| Pyle, L | 1 |
| Zbinden, S | 1 |
| Park, S | 2 |
| Kim, TW | 1 |
| Mariani, L | 1 |
| Linassier, C | 1 |
| Carmier, D | 1 |
| Combe, P | 1 |
| D'Arcier, BF | 1 |
| Narciso, B | 1 |
| Martin, B | 1 |
| Edeline, J | 1 |
| Oger, E | 1 |
| Jouan, F | 1 |
| Boulanger, G | 1 |
| Zerrouki, S | 1 |
| Vigneau, C | 1 |
| Nozawa, M | 1 |
| Yamamoto, Y | 1 |
| Minami, T | 1 |
| Shimizu, N | 1 |
| Hatanaka, Y | 1 |
| Tsuji, H | 1 |
| Singer, EA | 1 |
| Gupta, GN | 1 |
| Srinivasan, R | 1 |
| Feldt, S | 1 |
| Schüssel, K | 1 |
| Quinzler, R | 1 |
| Franzmann, A | 1 |
| Czeche, S | 1 |
| Ludwig, WD | 1 |
| Schulz, M | 1 |
| Dasari, A | 1 |
| Gore, L | 1 |
| Messersmith, WA | 1 |
| Diab, S | 1 |
| Jimeno, A | 1 |
| Weekes, CD | 1 |
| Lewis, KD | 1 |
| Camidge, DR | 1 |
| Ueno, D | 1 |
| Tateishi, U | 1 |
| Minamimoto, R | 1 |
| Hayashi, N | 1 |
| Murakami, T | 1 |
| Kishida, T | 1 |
| Miura, T | 1 |
| Kobayashi, K | 1 |
| Noguchi, S | 1 |
| Ikeda, I | 1 |
| Ohgo, Y | 1 |
| Amato, R | 1 |
| Zhai, J | 1 |
| Willis, J | 1 |
| Saxena, S | 1 |
| DeFoe, M | 1 |
| Konca Degertekin, C | 1 |
| Baloş Törüner, F | 1 |
| Aktürk, M | 1 |
| Demirci, U | 1 |
| Lucas, LM | 1 |
| Kususda, Y | 1 |
| Gleave, ME | 1 |
| Daimon, M | 1 |
| Kaino, W | 1 |
| Takase, K | 1 |
| Karasawa, S | 1 |
| Wada, K | 1 |
| Kameda, W | 1 |
| Susa, S | 1 |
| Oizumi, T | 1 |
| Steffens, S | 1 |
| Schnoeller, TJ | 1 |
| Schrader, M | 1 |
| Sim, HG | 1 |
| Ong, RW | 1 |
| Scandurra, G | 1 |
| Aiello, RA | 1 |
| Alì, M | 1 |
| Sanò, MV | 1 |
| Todaro, FM | 1 |
| La Rocca, R | 1 |
| Licciardello, P | 1 |
| Caruso, M | 1 |
| He, H | 1 |
| Zhou, W | 1 |
| Shen, Z | 1 |
| Stenner, F | 1 |
| Chastonay, R | 1 |
| Liewen, H | 1 |
| Haile, SR | 1 |
| Cathomas, R | 1 |
| Rothermundt, C | 1 |
| Siciliano, RD | 1 |
| Stoll, S | 1 |
| Knuth, A | 1 |
| Renner, C | 1 |
| Samaras, P | 1 |
| Chen, CC | 1 |
| Hess, GP | 1 |
| Gesme, DH | 1 |
| Agarwala, SS | 1 |
| Garay, CC | 1 |
| Hill, JW | 1 |
| Guo, A | 1 |
| Bilim, VN | 1 |
| Ugolkov, AV | 1 |
| Yuuki, K | 1 |
| Pantaleo, MA | 1 |
| Mandrioli, A | 1 |
| Saponara, M | 1 |
| Nannini, M | 1 |
| Erente, G | 1 |
| Lolli, C | 1 |
| Biasco, G | 1 |
| Szmit, S | 1 |
| Zaborowska, M | 1 |
| Filipiak, KJ | 1 |
| Opolski, G | 1 |
| Koralewski, P | 1 |
| Deptala, A | 1 |
| Dirix, LY | 1 |
| Ramlau, R | 1 |
| Rogowski, W | 1 |
| Kracht, K | 1 |
| Sun, YN | 1 |
| Puhlmann, M | 1 |
| Khandani, AH | 1 |
| Gohil, H | 1 |
| Horiuchi-Yamamoto, Y | 1 |
| Taniguchi, H | 1 |
| Inoue, Y | 1 |
| Sakai, F | 1 |
| Johkoh, T | 1 |
| Kudoh, S | 1 |
| Satoh, T | 1 |
| Kashima, T | 1 |
| Tachibana, M | 1 |
| Kim, MJ | 1 |
| Kim, DE | 1 |
| Choi, J | 1 |
| Ro, S | 1 |
| Hwang, JJ | 1 |
| Uemura, M | 1 |
| Kitsukawa, S | 1 |
| Ganini, C | 1 |
| Magnani, L | 1 |
| Caccialanza, R | 1 |
| Kinoshita, H | 1 |
| Kawabata, T | 1 |
| Kawa, G | 1 |
| Uemura, Y | 1 |
| Matsuda, T | 1 |
| Zygulska, AL | 1 |
| Krzemieniecki, K | 1 |
| Sowa-Staszczak, A | 1 |
| Boni, C | 1 |
| Mucciarini, C | 1 |
| Pazzola, A | 1 |
| Labianca, R | 1 |
| Di Costanzo, F | 1 |
| Falcone, A | 1 |
| Cinquini, M | 1 |
| Caserta, C | 2 |
| De Angelis, V | 1 |
| Zhao, S | 1 |
| Chowdhury, NF | 1 |
| Yu, W | 1 |
| Nishijima, K | 1 |
| Takiguchi, M | 1 |
| Tamaki, N | 1 |
| Kuge, Y | 1 |
| Vázquez-Alonso, F | 1 |
| Puche-Sanz, I | 1 |
| Teo, M | 1 |
| O'Connor, TM | 1 |
| O'Reilly, SP | 1 |
| Power, DG | 1 |
| Clemons, J | 1 |
| Garfield, D | 1 |
| Sevin, A | 1 |
| Chen, A | 1 |
| Suetomi, T | 1 |
| Miyagawa, T | 1 |
| Tsutsumi, M | 1 |
| von Falck, C | 1 |
| Wacker, F | 1 |
| Rosenthal, H | 1 |
| Trinh, QD | 1 |
| Rogiers, A | 1 |
| Van Cann, T | 1 |
| Willems, L | 1 |
| Body, JJ | 1 |
| Debruyne, P | 1 |
| Cheng, S | 1 |
| Qu, AQ | 1 |
| Pastorek, J | 1 |
| Kroon, BK | 1 |
| de Bruijn, R | 1 |
| Prevoo, W | 1 |
| Horenblas, S | 1 |
| Westgeest, HM | 1 |
| van Erp, NP | 1 |
| Honeywell, RJ | 1 |
| Hoekstra, R | 1 |
| Peters, GJ | 1 |
| Hegde, U | 1 |
| Patel, V | 1 |
| Kaloudis, E | 1 |
| Vanhuyse, M | 1 |
| Penel, N | 1 |
| Fumagalli, I | 1 |
| Alt, M | 1 |
| Zini, L | 1 |
| Adenis, A | 1 |
| Benitez, A | 1 |
| Yates, TJ | 1 |
| Shamaldevi, N | 1 |
| Bowen, T | 1 |
| Lokeshwar, VB | 1 |
| Fairfax, BP | 1 |
| Pratap, S | 1 |
| Roberts, IS | 1 |
| Collier, J | 1 |
| Kaplan, R | 1 |
| Meade, AM | 1 |
| Ritchie, AW | 1 |
| Macaulay, VM | 1 |
| Protheroe, A | 1 |
| Yang, L | 1 |
| Yu, SY | 1 |
| Hu, GY | 1 |
| Hasunuma, N | 1 |
| Numakura, K | 1 |
| Satoh, S | 1 |
| Notoya, T | 1 |
| Fujishima, N | 1 |
| Hatakeyama, S | 1 |
| Ohyama, C | 1 |
| Ambring, A | 1 |
| Björholt, I | 1 |
| Lesén, E | 1 |
| Odén, A | 1 |
| Kang, HC | 1 |
| Tan, KS | 1 |
| Heitjan, DF | 2 |
| Siegelman, ES | 1 |
| O'Dwyer, PJ | 3 |
| Rosen, MA | 2 |
| Paine, A | 1 |
| Tumur, I | 1 |
| Healey, PJ | 1 |
| Foley, G | 1 |
| Mitchell, S | 1 |
| Kroes, M | 1 |
| Raza, A | 1 |
| Chi, M | 1 |
| Singhal, M | 1 |
| Oberoi, R | 1 |
| Mittapalli, RK | 1 |
| Agarwal, S | 1 |
| Elmquist, WF | 1 |
| Grenader, T | 1 |
| Rosenbaum, E | 1 |
| Zilber, S | 1 |
| Bogot, N | 1 |
| Shavit, L | 1 |
| Hess, G | 1 |
| Borker, R | 1 |
| Fonseca, E | 1 |
| Meskawi, M | 1 |
| Ismail, S | 1 |
| Hanna, N | 1 |
| Hansen, J | 1 |
| Tian, Z | 1 |
| Bianchi, M | 1 |
| Knox, J | 1 |
| Brueckner, A | 1 |
| Molnar, I | 1 |
| Feng, G | 1 |
| Ye, X | 1 |
| Pu, C | 1 |
| Huang, H | 1 |
| Li, G | 1 |
| Yang, SY | 1 |
| Cui, CL | 1 |
| Mao, LL | 1 |
| Blesius, A | 1 |
| Angevin, E | 2 |
| Lin, CC | 1 |
| Harzstark, A | 1 |
| Sen, P | 1 |
| Chang, J | 1 |
| Shi, M | 1 |
| Kay, A | 1 |
| Ashikari, A | 1 |
| Namitome, R | 1 |
| Yagi, Y | 1 |
| Kohno, Y | 1 |
| Nishiyama, T | 1 |
| Saito, S | 1 |
| del Muro, XG | 1 |
| Mellado, B | 2 |
| Andrés, R | 1 |
| Cruz, J | 1 |
| Gallardo, E | 1 |
| Domenech, M | 1 |
| Meana, JA | 1 |
| Fukuhara, H | 1 |
| Tamura, K | 1 |
| Ashida, S | 1 |
| Taguchi, T | 1 |
| Mezi, S | 1 |
| Pellegrino, D | 1 |
| Afonso, FJ | 1 |
| Anido, U | 1 |
| Fernández-Calvo, O | 1 |
| Vázquez-Estévez, S | 1 |
| Ramos, M | 1 |
| Antón-Aparicio, L | 1 |
| Ahmad, T | 1 |
| Sridhar, SS | 1 |
| Hedley, D | 1 |
| Siu, LL | 1 |
| Awada, A | 1 |
| Hendlisz, A | 1 |
| Gil, T | 1 |
| Bartholomeus, S | 1 |
| Mano, M | 1 |
| de Valeriola, D | 1 |
| Brendel, E | 2 |
| Haase, CG | 1 |
| Schwartz, B | 7 |
| Piccart, M | 1 |
| Sosman, JA | 1 |
| Cooney, MM | 1 |
| Remick, SC | 1 |
| Gollob, JA | 3 |
| Patel, PH | 2 |
| Chaganti, RS | 2 |
| Koga, S | 1 |
| Kanetake, H | 1 |
| Kaye, SB | 1 |
| Rosner, GL | 1 |
| Patnaik, A | 1 |
| Xiong, HQ | 1 |
| Rowinsky, E | 1 |
| Abbruzzese, JL | 1 |
| Reddy, GK | 1 |
| Hampton, T | 1 |
| Shaheen, PE | 1 |
| Wilhelm, S | 2 |
| Carter, C | 3 |
| Kelley, SL | 1 |
| Biedrzycki, BA | 1 |
| King, CR | 1 |
| Lamuraglia, M | 2 |
| Chami, L | 2 |
| Leclère, J | 1 |
| Roche, A | 1 |
| Lassau, N | 2 |
| Sonpavde, G | 1 |
| Berry, WR | 1 |
| Lynch, M | 1 |
| Lowinger, T | 1 |
| Dumas, J | 1 |
| Smith, RA | 1 |
| Kelley, S | 1 |
| Heinemann, G | 1 |
| Burton, A | 1 |
| Murphy, DA | 1 |
| Makonnen, S | 1 |
| Lassoued, W | 1 |
| Feldman, MD | 1 |
| Lee, WM | 1 |
| Gascón, P | 1 |
| Wetherbee, SL | 1 |
| Chadalavada, RS | 1 |
| Kane, RC | 1 |
| Farrell, AT | 1 |
| Saber, H | 1 |
| Tang, S | 1 |
| Williams, G | 1 |
| Jee, JM | 1 |
| Liang, C | 1 |
| Booth, B | 1 |
| Chidambaram, N | 1 |
| Morse, D | 1 |
| Sridhara, R | 1 |
| Garvey, P | 1 |
| Justice, R | 1 |
| Pazdur, R | 1 |
| Solska, E | 1 |
| Freeman, S | 1 |
| Brugarolas, J | 1 |
| Lai, SE | 1 |
| Kuzel, T | 1 |
| Speca, J | 1 |
| Yenser, S | 1 |
| Creel, P | 1 |
| George, D | 2 |
| McKeage, K | 1 |
| Wagstaff, AJ | 1 |
| Zafarana, E | 1 |
| Landreau, V | 1 |
| Armand, JP | 1 |
| Amar, S | 1 |
| Wu, KJ | 1 |
| Tan, WW | 1 |
| Autran Gomez, AM | 1 |
| Gentilucci, A | 1 |
| Salciccia, S | 1 |
| Gentile, V | 1 |
| Vira, MA | 1 |
| Novakovic, KR | 1 |
| Pinto, PA | 1 |
| Linehan, WM | 1 |
| De Mulder, PH | 2 |
| Brocheriou, I | 1 |
| Deray, G | 1 |
| Sendi, P | 1 |
| Puric, E | 1 |
| Schönenberger, A | 1 |
| Bargetzi, M | 1 |
| Gondek, K | 1 |
| Kasibhatla, M | 1 |
| Steinberg, P | 1 |
| Meyer, J | 1 |
| Khasawneh, M | 1 |
| Usman, S | 1 |
| Baz, RC | 1 |
| Sordini, L | 1 |
| Hamzay, A | 1 |
| Crinò, L | 1 |
| Stein, MN | 1 |
| Hakimé, A | 1 |
| Hines-Peralta, A | 1 |
| Peddi, H | 1 |
| Sukhatme, VP | 1 |
| Geschwend, JE | 1 |
| Grandinetti, CA | 1 |
| Goldspiel, BR | 1 |
| Bodrogi, I | 1 |
| Richmond, TM | 1 |
| Marino, CB | 1 |
| Miller, EK | 1 |
| Gu, L | 1 |
| Peterson, BL | 1 |
| Goldman, BH | 1 |
| Lara, PN | 1 |
| Mack, PC | 1 |
| Beer, TM | 1 |
| Tangen, CM | 1 |
| Lemmon, D | 1 |
| Pan, CX | 1 |
| Crawford, ED | 1 |
| Kibble, A | 1 |
| Shumoogam, J | 1 |
| Buer, J | 1 |
| Jeron, A | 1 |
| Raspollini, MR | 1 |
| Méric, JB | 1 |
| Taillade, L | 1 |
| Sultan-Amar, V | 1 |
| Ranze, O | 1 |
| Hofmann, E | 1 |
| Distelrath, A | 1 |
| Hoeffkes, HG | 1 |
| Fiedler, W | 1 |
| Li, M | 1 |
| Radulovic, S | 1 |
| Bjelogrlic, SK | 1 |
| Manchen, B | 1 |
| Tamaskar, I | 2 |
| Ioachimescu, AG | 1 |
| Beldner, M | 1 |
| Jacobson, M | 1 |
| Burges, GE | 1 |
| Dewaay, D | 1 |
| Maize, JC | 1 |
| Chaudhary, UB | 1 |
| López-Vivanco, G | 1 |
| Eng, FC | 1 |
| Easson, AM | 1 |
| Szentgyorgyi, E | 1 |
| Mego, M | 1 |
| Reckova, M | 1 |
| Obertova, J | 1 |
| Sycova-Mila, Z | 1 |
| Brozmanova, K | 1 |
| Bhojani, N | 1 |
| Jeldres, C | 1 |
| Suardi, N | 1 |
| Hutterer, G | 1 |
| Patenaude, F | 1 |
| Yang, CH | 1 |
| Lin, WC | 1 |
| Chang, YC | 1 |
| Pang, ST | 1 |
| Lin, YC | 1 |
| Kuo, TT | 1 |
| Plantade, A | 1 |
| Hiles, JJ | 1 |
| Kolesar, JM | 1 |
| Chu, D | 1 |
| Fillos, T | 1 |
| Wu, S | 1 |
| Gallagher, ML | 1 |
| Schnall, MD | 1 |
| van Bronswijk, H | 1 |
| Dubois, EA | 1 |
| Osanto, S | 2 |
| Cohen, AF | 1 |
| Nakanishi, H | 1 |
| Mizuno, M | 1 |
| Yoshida, J | 1 |
| Miki, T | 1 |
| Gay, HA | 1 |
| Cavalieri, R | 1 |
| Allison, RR | 1 |
| Finley, J | 1 |
| Quan, WD | 1 |
| Haanen, JB | 1 |
| Sleijfer, S | 1 |
| Kruit, WH | 1 |
| Gietema, JA | 1 |
| Groenewegen, G | 1 |
| van den Eertwegh, AJ | 1 |
| Jansen, RL | 1 |
| Godley, P | 1 |
| Athar, U | 1 |
| Gentile, TC | 1 |
| Shuch, B | 1 |
| Riggs, SB | 1 |
| LaRochelle, JC | 1 |
| Kabbinavar, FF | 1 |
| Avakian, R | 1 |
| Pantuck, AJ | 1 |
| Belldegrun, AS | 1 |
| Gevorgyan, A | 1 |
| Mancin, M | 1 |
| Pusceddu, S | 1 |
| Catena, L | 1 |
| Platania, M | 1 |
| Martinetti, A | 1 |
| Peters, NA | 1 |
| Verhoeff, JJ | 1 |
| Stalpers, LJ | 1 |
| Margulis, V | 1 |
| Matin, SF | 1 |
| Swanson, DA | 1 |
| Ruddock, MW | 1 |
| Burns, DM | 1 |
| McKeown, SR | 1 |
| Murphy, L | 1 |
| Walsh, IK | 1 |
| Keane, PF | 1 |
| Hirst, DG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma[NCT00326898] | Phase 3 | 1,943 participants (Actual) | Interventional | 2006-04-24 | Completed | ||
| A Randomised, Double-blind, Placebo Controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients With Locally Advanced and/or Metastatic Renal Cell Carcinoma[NCT00334282] | Phase 3 | 435 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL[NCT00678392] | Phase 3 | 723 participants (Actual) | Interventional | 2008-09-03 | Completed | ||
| Phase 2 Randomized Study of Efficacy and Safety of Testosterone in Metastatic Renal Cell Carcinoma Patients With Fatigue[NCT03379012] | Phase 2 | 60 participants (Actual) | Interventional | 2016-02-08 | Completed | ||
| A Randomized Open Label Multicenter Phase II Study of First Line Therapy With Sorafenib in Association With IL-2 vs Sorafenib Alone in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma[NCT00609401] | Phase 2 | 90 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Pembrolizumab With Axitinib in Recurrent Endometrial Cancer With Deficient Mismatch Repair System Post PD1 Exposure: Phase II Trial[NCT04197219] | Phase 2 | 0 participants (Actual) | Interventional | 2021-02-01 | Withdrawn (stopped due to PI is leaving institution) | ||
| AG-013736 (AXITINIB) FOR THE TREATMENT OF METASTATIC RENAL CELL CANCER[NCT00920816] | Phase 3 | 492 participants (Actual) | Interventional | 2009-08-25 | Completed | ||
| A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy[NCT00474786] | Phase 3 | 512 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Clinical Registry Describing Treatment Reality and Therapy Modality of Patients With Metastatic or Locally Advanced Renal Cell Carcinoma Requiring Therapy[NCT00610012] | 1,500 participants (Actual) | Observational [Patient Registry] | 2007-12-31 | Completed | |||
| Re-validating Prophylactic Efficacy of Urea-based Cream on Sorafenib-induced Hand-foot Skin Reaction in Patients With Advanced Hepatocellular Carcinoma[NCT04568330] | 129 participants (Actual) | Interventional | 2014-03-21 | Completed | |||
| An Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 With AMG 706, AMG 386 With Bevacizumab, AMG 386 With Sorafenib, and AMG 386 With Sunitinib in Adult Patients With Advanced Solid Tumors[NCT00861419] | Phase 1 | 88 participants (Anticipated) | Interventional | 2005-12-31 | Completed | ||
| Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE)[NCT05372302] | 100 participants (Anticipated) | Observational | 2021-07-08 | Recruiting | |||
| caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI)[NCT03354884] | Phase 2 | 23 participants (Actual) | Interventional | 2018-01-12 | Completed | ||
| An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies[NCT01223027] | Phase 3 | 564 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus Sorafenib Versus Sorafenib for the Third-line Treatment of Patients With Metastatic Renal Cell Carcinoma[NCT02330783] | Phase 2 | 106 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| A Phase I Study of Bolus High Dose Interleukin-2 With Sorafenib (BAY 43-9006) in Patients With Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma[NCT00418496] | Phase 1 | 17 participants (Actual) | Interventional | 2006-11-08 | Completed | ||
| Evaluation of Cognitive Function of Patients Treated With Sunitinib or Sorafenib[NCT01246843] | 50 participants (Anticipated) | Observational | 2009-07-31 | Completed | |||
| Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma[NCT01100242] | Phase 2 | 17 participants (Actual) | Interventional | 2010-04-30 | Terminated (stopped due to Low accrual) | ||
| A Phase II Clinical Trial to Evaluate the Efficacy of BAY 43-9006 With or Without Low Dose Interferon in Metastatic Renal Cell Carcinoma[NCT00126594] | Phase 2 | 80 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced / Metastatic Renal Cell Carcinoma[NCT00732914] | Phase 3 | 272 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma[NCT00378703] | Phase 2 | 361 participants (Actual) | Interventional | 2007-09-14 | Completed | ||
| Role of Immunohistochemical Markers , Geminin and Mcm2 in Prognosis of Renal Cell Carcinoma, and Its Clinicopathological Correlation. A Prospective Controlled Study[NCT03692533] | 80 participants (Anticipated) | Interventional | 2018-10-01 | Not yet recruiting | |||
| Randomized, Double-blind Phase 2 Study Of Axitinib (Ag-013736) With Or Without Dose Titration In Patients With Metastatic Renal Cell Carcinoma[NCT00835978] | Phase 2 | 213 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Phase II Study Of Single-Agent SU011248 In The Second-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma[NCT00054886] | Phase 2 | 63 participants | Interventional | 2003-01-31 | Completed | ||
| A Phase 2 Efficacy And Safety Study Of SU011248 Administered In A Continuous Daily Regimen In Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma[NCT00137423] | Phase 2 | 107 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma[NCT00631371] | Phase 3 | 791 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A Phase II Efficacy And Safety Study Of Sunitinib Malate (SU011248) Administered In A Continuous Daily Regimen In Patients With Advanced (First-Line) Renal Cell Cancer[NCT00338884] | Phase 2 | 120 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Randomized Phase II Study Of The Efficacy And Safety Of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (Renal EFFECT Trial)[NCT00267748] | Phase 2 | 317 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma[NCT00077974] | Phase 2 | 106 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma[NCT00083889] | Phase 3 | 750 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.[NCT00065468] | Phase 3 | 626 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| An Open-label, Prospective Study of Tumor Response Time of Palbociclib in Combination With AI in Real-world First-line Treatment of Postmenopausal Chinese Patients With ER (+) HER2 (-) Metastatic Breast Cancer[NCT04858997] | Phase 2 | 150 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| Phase1/2 Study of Vaccination With DNP Modified Autologous Renal Cell Carcinoma in Combination With Sunitinib in Stage 4 RCC[NCT00890110] | Phase 1/Phase 2 | 13 participants (Anticipated) | Interventional | 2009-06-30 | Not yet recruiting | ||
| A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.[NCT00073307] | Phase 3 | 903 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| A Randomised, Open-label, Multi-centre Phase II Study of BAY43-9006 (Sorafenib) Versus Standard Treatment With Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma.[NCT00117637] | Phase 2 | 189 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC)[NCT01649180] | Phase 2 | 3 participants (Actual) | Interventional | 2012-07-31 | Terminated (stopped due to Closed due to prolonged enrollment timelines) | ||
| Mind-Body Health in Uro-Oncology: A Randomized Controlled Trial[NCT03852030] | 120 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Dovitinib In 1st-Line Renal Cell Carcinoma, an Investigation Into Tumour GENe Status and Correlation With Efficacy - 1st Exploratory Study[NCT01791387] | Phase 2 | 30 participants (Anticipated) | Interventional | 2012-03-31 | Active, not recruiting | ||
| Vessels Encapsulating Tumor Clusters (VETC), Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal Gland Carcinoma[NCT04666220] | 180 participants (Anticipated) | Observational | 2021-01-02 | Recruiting | |||
| Clinical Evaluation of Neoadjuvant Chemotherapy for Primary Malignant Sarcomas That Originate in Bone: a Multi-center Retrospective Study for Standardization and Modification of Response Evaluation Criteria[NCT03742063] | 190 participants (Actual) | Observational | 2017-06-01 | Completed | |||
| Open Label, Non-Comparative Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma[NCT00111020] | Phase 3 | 2,567 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| A Phase II Double Blind Randomized Trial Comparing Standard Dosing Based on Body Surface Area Versus Dosing Based on Personalized Lean Body Mass in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Receiving First Line Cisplatin Based Chemotherapy[NCT01624051] | Phase 2 | 144 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| Development of a Prospective Clinico-biological Database in Cachexia in Patients With Colon Cancer[NCT05257135] | 150 participants (Anticipated) | Interventional | 2021-12-23 | Recruiting | |||
| "PADRES (Prior Axitinib as a Determinant of Outcome of REnal Surgery)"[NCT03438708] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-03-05 | Recruiting | ||
| Phase II Clinical Trial, Non-Randomized, Multicentre, on the Combination of Gemcitabine, Capecitabine and Sorafenib (Bay 43-9006) in Treatment of Patients With Unresectable and/or Metastatic Renal Cell Carcinoma (RCC)[NCT00496301] | Phase 2 | 40 participants (Anticipated) | Interventional | 2006-11-30 | Completed | ||
| Multiomics Approach for Patients Stratification and Novel Target Identification in Metastatic Clear Renal Cell Carcnoma[NCT05782400] | 100 participants (Anticipated) | Observational | 2023-02-28 | Recruiting | |||
| Rapalogues for Autism Phenotype in TSC: A Feasibility Study[NCT01929642] | Phase 2 | 3 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| The Effect of Sorafenib (Nexavar®) on 111-Indium Labeled Chimeric Monoclonal Antibody G250 or 111-Indium Labeled Bevacizumab (Avastin®) Uptake in Patients With Clear Cell RCC (ccRCC)[NCT00602862] | 26 participants (Actual) | Interventional | 2007-07-31 | Completed | |||
| Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery[NCT02535351] | Phase 3 | 13 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to low enrolment) | ||
| Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb in Metastatic reNal Cell Carcinoma[NCT04462445] | Phase 2 | 25 participants (Actual) | Interventional | 2015-06-25 | Completed | ||
| A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer[NCT00090545] | Phase 2 | 46 participants (Actual) | Interventional | 2004-09-01 | Completed | ||
| Extension Study for BAY43-9006 in Japanese Patients With Renal Cell Carcinoma[NCT00586495] | Phase 2 | 95 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Phase II Study of BAY 43-9006 in Japanese Patients With Renal Cell Carcinoma[NCT00661375] | Phase 2 | 131 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)[NCT03061955] | 28 participants (Actual) | Observational | 2016-10-01 | Completed | |||
| A Phase Ib,Open,Mono-center,Dose-escalation,Tolerability and Pharmacokinetic Study of Recombinant Humanized Anti-PD-1 mAb for Injection in Combination With Axitinib in Patients With Advanced Kidney Cancer and Melanoma[NCT03086174] | Phase 1 | 24 participants (Anticipated) | Interventional | 2017-03-31 | Active, not recruiting | ||
| A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus[NCT01798446] | Phase 2 | 41 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| A Study of Anti-PD-1( Pembrolizumab) Combinations of D-CIK (Cytokine-induced Killer Cells Are Stimulated Using Mature Dendritic Cells) Immunotherapy and Axitinib in Advanced Ranal Carcinoma[NCT03736330] | Phase 2 | 24 participants (Anticipated) | Interventional | 2018-09-08 | Recruiting | ||
| Sorafenib Administered Using a High-dose, Pulsatile Regimen in Patients With Advanced Solid Malignancies: a Phase I Exposure Escalation Study[NCT02636426] | Phase 1 | 17 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney[NCT00467025] | Phase 2 | 152 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse[NCT00492258] | Phase 3 | 1,656 participants (Anticipated) | Interventional | 2007-06-30 | Completed | ||
| A Phase II, Single Arm, Prospective Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma[NCT00480935] | Phase 2 | 3 participants (Actual) | Interventional | 2007-10-31 | Terminated (stopped due to poor recruitment) | ||
| Randomized Phase II Trial Assessing the Combination of Nexavar® (Sorafenib), and Gemcitabine/Oxaliplatin in Patients Treated for Advanced (Unresectable/Metastatic) Hepatocellular Carcinoma.[NCT00941967] | Phase 2 | 78 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer[NCT02363647] | 10 participants (Actual) | Interventional | 2015-01-31 | Terminated (stopped due to No Current Funding) | |||
| A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients With an Unmethylated MGMT Gene Promoter[NCT02928575] | Phase 2 | 45 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel® (Temsirolimus) and Avastin® (Bevacizumab) Versus Sutent® (Sunitinib) and Versus a Combination of Avastin® (Bevacizumab) and Roféron® (Interferon Alpha-2a) in First-line Treatm[NCT00619268] | Phase 2 | 160 participants (Anticipated) | Interventional | 2008-02-29 | Completed | ||
| SORAVE-Sorafenib and Everolimus in Solid Tumors. A Phase I Clinical Trial to Evaluate the Safety of Combined Sorafenib and Everolimus Treatment in Patients With Relapsed Solid Tumors[NCT00933777] | Phase 1 | 36 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma[NCT01339975] | 310 participants (Anticipated) | Observational | 2011-06-06 | Completed | |||
| Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors[NCT01202032] | Phase 1 | 36 participants (Anticipated) | Interventional | 2010-07-31 | Completed | ||
| Sorafenib Combined With Cisplatin and Gemcitabine for the Treatment of Patients With Advanced Renal Collecting Duct Carcinoma:A Pilot, Open Study[NCT01762150] | Phase 2 | 26 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma[NCT02733809] | Phase 4 | 40 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| Randomized, Double-Blind, Placebo-Controlled, Phase II Trial Of Short Course Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized (3.5 to 7cm) Hepatocellular Cancer[NCT00813293] | Phase 2 | 20 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| An Open Single-center Phase II Clinical Study of Fruquintinib Combined With Chemotherapy in Patients With Liver Metastases From Pancreatic Cancer[NCT05168527] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-09-03 | Recruiting | ||
| The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study[NCT03212625] | Phase 4 | 288 participants (Actual) | Interventional | 2016-01-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Disease-free survival (DFS) is defined as time from randomization to recurrence, development of second primary cancer (except localized breast or prostate cancer or nonmelanoma skin cancer), or death from any cause. Patients who were alive without recurrence or qualifying second primary cancer were censored at the date of last disease evaluation. 5-year DFS rate is the proportion of patients who are alive and disease-free at 5 years based on the Kaplan-Meier estimate. (NCT00326898)
Timeframe: Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry; then annually if patient is 5 - 10 years from study entry
| Intervention | proportion of participants (Number) |
|---|---|
| Arm A (Sunitinib + Sorafenib Placebo) | 0.534 |
| Arm B (Sorafenib + Sunitinib Placebo) | 0.527 |
| Arm C (Sunitinib Placebo + Sorafenib Placebo) | 0.560 |
Overall survival is defined as the time from randomization to death from any cause. Patients without a date of death were censored at the date of last contact. Kaplan-Meier method was used to estimate 5-year survival rate. (NCT00326898)
Timeframe: Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry
| Intervention | proportion of participants (Number) |
|---|---|
| Arm A (Sunitinib + Sorafenib Placebo) | 0.779 |
| Arm B (Sorafenib + Sunitinib Placebo) | 0.805 |
| Arm C (Sunitinib Placebo + Sorafenib Placebo) | 0.803 |
Disease-free survival (DFS) is defined as time from randomization to recurrence, development of second primary cancer (except localized breast or prostate cancer or nonmelanoma skin cancer), or death from any cause. Patients who were alive without recurrence or qualifying second primary cancer were censored at the date of last disease evaluation. (NCT00326898)
Timeframe: Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry; then annually if patient is 5 - 10 years from study entry
| Intervention | years (Median) |
|---|---|
| Arm A (Sunitinib + Sorafenib Placebo) | 5.8 |
| Arm B (Sorafenib + Sunitinib Placebo) | 6.1 |
| Arm C (Sunitinib Placebo + Sorafenib Placebo) | 6.6 |
Cardiac event is defined as left ventricular ejection fraction (LVEF) below the institutional lower limit of normal, where the decrease was >15% absolute percentage points from baseline within 6 months. (NCT00326898)
Timeframe: Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A (Sunitinib + Sorafenib Placebo) | 0.017 |
| Arm B (Sorafenib + Sunitinib Placebo) | 0.013 |
| Arm C (Sunitinib Placebo + Sorafenib Placebo) | 0.008 |
Duration of response is defined as the time from first observation of response until progression of disease or death. (NCT00334282)
Timeframe: Time from response until progression (up to 2 years)
| Intervention | weeks (Median) |
|---|---|
| Pazopanib 800 mg | 58.7 |
Overall survival is defined as the time from randomization until death. The length of this interval was estimated as the date of death minus the date of randomization plus 1 day. Participants who were still alive at the time of analysis were censored. (NCT00334282)
Timeframe: Randomization until death (up to 2 years)
| Intervention | months (Median) |
|---|---|
| Pazopanib 800 mg | 22.9 |
| Placebo | 20.5 |
Progression-free survival (PFS) is defined as the interval between the date of randomization and the earliest date of disease progression or death due to any cause. Assessments of progression and non-progression were made by an independent imaging review committee (IRC) for the primary analysis. (NCT00334282)
Timeframe: Randomization until progression (up to 2 years)
| Intervention | months (Median) |
|---|---|
| Pazopanib 800 mg | 9.2 |
| Placebo | 4.2 |
The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer participants. The analyses for EORTC QLQ-C30 were focused on global health status/Health-Related Quality of Life (HRQOL) scores on the questionnaire. The scores (from 1 [very poor quality of life] to 7 [excellent quality of life]) for these two questions were averaged and then transformed to a 0 - 100 scale (based on published methods) prior to analysis of change from Baseline. (NCT00334282)
Timeframe: Baseline and Weeks 6, 12, 18, 24, and 48
| Intervention | points on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 6, n=243, 110 | Week 12, n=219, 81 | Week 18, n=191, 61 | Week 24, n=164, 49 | Week 48, n=96, 24 | |
| Pazopanib | -3.2 | -3.6 | -2.5 | 0.1 | -0.3 |
| Placebo | -2.6 | -0.5 | -0.3 | -0.5 | 0.3 |
The EQ-5D is comprised of a 5-item health status measure and a visual analogue rating scale, and measures mobility, self-care, usual activities, pain, discomfort, and anxiety/depression. Responses to each of the 5 health states are measured on a 3-point scale (no, moderate, and extreme problems). Scoring of the EQ-5D yields an index-based summary score (Index), through application of societal weights, and a VAS score (VAS). Index is interpreted on a continuum from 1.0 (best possible health) to 0 (represents dead), to some health sates being worse than dead (<0). (NCT00334282)
Timeframe: Baseline and Weeks 6, 12, 18, 24, and 48
| Intervention | points on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 6, n=253, 125 | Week 12, n=219, 86 | Week 18, n=196, 62 | Week 24, n=166, 51 | Week 36, n=98, 24 | |
| Pazopanib 800 mg | -0.014 | -0.040 | -0.023 | -0.025 | 0.030 |
| Placebo | -0.029 | 0.007 | -0.006 | -0.001 | -0.005 |
The EQ-5D is comprised of a 5-item health status measure and a visual analogue rating scale, and measures mobility, self-care, usual activities, pain, discomfort, and anxiety/depression. Responses to each of the 5 health states are measured on a 3-point scale (no, moderate, and extreme problems). Scoring of the EQ-5D yields an index-based summary score (Index) and a VAS score (VAS), obtained from participant's self-reports of their health on a VAS thermometer scale. The EQ-5D VAS ranges from 0% (worst imaginable health state) to 100% (best imaginable health state). (NCT00334282)
Timeframe: Baseline and Weeks 6, 12, 18, 24, and 48
| Intervention | points on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 12, n=212, 80 | Week 6, n=239, 111 | Week 18, n=189, 60 | Week 24, n=161, 49 | Week 36, n=95, 23 | |
| Pazopanib 800 mg | -0.9 | 0.4 | 0.1 | 2.6 | 2.4 |
| Placebo | -3.6 | 0.2 | 0.1 | 5.4 | 8.8 |
Baseline plasma samples were obtained from participants and were tested for the indicated cytokine and angiogenesis factors. Protein levels were determined using the Searchlight multiplex system based on chemiluminescence. (NCT00334282)
Timeframe: Baseline
| Intervention | picograms per milliliter (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Interleukin-6 | Interleukin-8 | Vascular endothelial growth factor | Hepatocyte growth factor | Tissue inhibitor of metalloproteinase 1 | e-Selectin | Osteopotin | |
| Pazopanib 800 mg | 31.003 | 35.429 | 308.61 | 383.55 | 847464 | 41649.28 | 444343 |
| Placebo | 24.145 | 27.755 | 273.15 | 522.94 | 735915 | 41231.45 | 369317 |
Overall response is the number of participants who had a complete response (CR) or a partial response (PR). Per RECIST: CR, all detectable tumor has disappeared; PR, a >=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the Baseline sum, no worsening of non-TLs, and no new lesions; Progressive disease (PD), a >=20% increase in TLs, clearly worsening of non-TLs, or emergence of new lesions; Stable Disease, small changes that do not meet previously given criteria. IRC, independent review committee. (NCT00334282)
Timeframe: Baseline until either response or progression (up to 2 years)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Complete Response, IRC assessed | Partial Response, IRC assessed | Stable Disease, IRC assessed | Progressive Disease, IRC assessed | Unknown, IRC assessed | Complete Response, Investigator assessed | Partial Response, Investigator assessed | Stable Disease, Investigator assessed | Progressive Disease, Investigator assessed | Unknown, Investigator assessed | |
| Pazopanib 800 mg | 1 | 87 | 110 | 51 | 41 | 4 | 99 | 118 | 46 | 23 |
| Placebo | 0 | 5 | 59 | 58 | 23 | 0 | 9 | 62 | 65 | 9 |
This is similar to overall response rate, but also includes participants who had stable disease for at least 6 months. Per Response Evaluation Criteria In Solid Tumors (RECIST): CR, all detectable tumor has disappeared; PR, a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the Baseline sum; Stable Disease, small changes that do not meet previously given criteria; Progressive Disease, a >=20% increase in target lesions. IRC, independent review committee. (NCT00334282)
Timeframe: Baseline until 6 months post-Baseline or progressive disease
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response, IRC assessed | Partial Response, IRC assessed | 6 Months Stable Disease, IRC assessed | Progressive Disease, IRC assessed | Unknown | |
| Pazopanib 800 mg | 1 | 87 | 48 | 92 | 62 |
| Placebo | 0 | 5 | 17 | 84 | 39 |
The concentration of pazopanib in the plasma was measured. (NCT00334282)
Timeframe: Day 1 and Week 3
| Intervention | nanograms per milliliter (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 1, before dosing, n=57 | Week 3, before dosing, n=48 | Day 1, 2 hours after dosing, n=57 | Week 3, 2 hours after dosing, n=49 | Day 1, 4 hours after dosing, n=57 | Week 3, 4 hours after dosing, n=49 | Day 1, 8 hours after dosing, n=57 | Week 3, 8 hours after dosing, n=48 | |
| Pazopanib 800 mg | 0 | 31851 | 17270 | 42205 | 24360 | 42637 | 19925 | 40177.5 |
Time to response is defined as the time from randomization until the first documented evidence of complete response (all detectable tumor has disappeared) or partial response (a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the Baseline sum) (whichever status was recorded first). (NCT00334282)
Timeframe: Randomization until CR or PR (assessed for up to 2 years)
| Intervention | weeks (Median) | |
|---|---|---|
| IRC assessed, n=88 | Investigator assessed, n=103 | |
| Pazopanib 800 mg | 11.9 | 12.0 |
DR: time from first documentation of objective tumor response (CR or PR), that was subsequently confirmed, to the first documentation of PD or to death due to any cause, whichever occurred first as per RECIST version 1.0, a) CR: disappearance of all target, non target lesions and no appearance of new lesions, documented on 2 occasions separated by at least 4 weeks, b) PR: at least 30 % decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non target lesions, no appearance of new lesions, c) PD: >=20% increase in sum of LD of the target lesions taking as a reference smallest sum of LD recorded since the start of treatment or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Occurrence of pleural effusion or ascites if demonstrated by cytological investigation, not previously documented. New bone lesions not previously documented if confirmed by computed tomography/magnetic resonance imaging or X-ray. (NCT00678392)
Timeframe: From initiation of treatment up to follow-up period (up to 3 years)
| Intervention | Months (Median) |
|---|---|
| Axitinib 5 mg | 11.0 |
| Sorafenib 400 mg | 10.6 |
ORR = percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.0 recorded from first dose of study treatment until PD or death due to any cause. CR: disappearance of all target, non target lesions and no appearance of new lesions, documented on 2 occasions separated by at least 4 weeks. PR: at least 30 % decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non target lesions, no appearance of new lesions. PD: >=20% increase in sum of LD of the target lesions taking as a reference smallest sum of LD recorded since the start of treatment or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Occurrence of pleural effusion or ascites if demonstrated by cytological investigation, not previously documented. New bone lesions not previously documented if confirmed by computed tomography/magnetic resonance imaging or X-ray. (NCT00678392)
Timeframe: From initiation of treatment up to follow-up period (up to 3 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Axitinib 5 mg | 19.4 |
| Sorafenib 400 mg | 9.4 |
OS was defined as the duration from start of study treatment to date of death due to any cause. OS was calculated as (months) = (date of death minus the date of first dose of study medication plus 1) divided by 30.4. For participants who were alive, overall survival was censored on last date the participants were known to be alive. (NCT00678392)
Timeframe: From initiation of treatment up to follow-up period (up to 3 years)
| Intervention | Months (Median) |
|---|---|
| Axitinib 5 mg | 20.1 |
| Sorafenib 400 mg | 19.2 |
PFS was defined as the time in months from start of study treatment to the first documentation of objective tumor progression of disease (PD) or to death due to any cause, whichever occurs first. PD was assessed by response evaluation criteria in solid tumors (RECIST) version 1.0. PD: >=20 percent (%) increase in the sum of the longest dimensions (LD) of the target lesions taking as a reference the smallest sum of the LD recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. Occurrence of a pleural effusion or ascites was also considered PD if demonstrated by cytological investigation and it was not previously documented. New bone lesions not previously documented were considered PD if confirmed by computed tomography/magnetic resonance imaging or X-ray. (NCT00678392)
Timeframe: From initiation of treatment up to follow-up period (up to 3 years)
| Intervention | Months (Median) |
|---|---|
| Axitinib 5 mg | 6.7 |
| Sorafenib 400 mg | 4.7 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility or index score. Health state profile component assesses level of health for 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain was rated on a 3-point response scale (1= no problems, 2= some/moderate problems and 3= extreme problems). Scoring formula developed by EuroQol Group assigned a utility value for each domain in the profile. Score were transformed and resulted in a total score range of 0 to 1, with higher scores indicating better health. (NCT00678392)
Timeframe: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
| Intervention | Units on a scale (Mean) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n =347, 341) | Cycle 2/Day1 (n =326, 307) | Cycle 3/Day1 (n =287, 248) | Cycle 4/Day1 (n =262, 226) | Cycle 5/Day1 (n =244, 207) | Cycle 6/Day1 (n =221, 178) | Cycle 7/Day1 (n =213, 163) | Cycle 8/Day1 (n =181, 136) | Cycle 9/Day1 (n =169, 120) | Cycle 10/Day1 (n =151, 98) | Cycle 11/Day1 (n =126, 87) | Cycle 12/Day1 (n =110, 73) | Cycle 13/Day1 (n =96, 61) | Cycle 14/Day1 (n =80, 57) | Cycle 15/Day1 (n =63, 41) | Cycle 16/Day1 (n =54, 37) | Cycle 17/Day1 (n =48, 29) | Cycle 18/Day1 (n =37, 20) | Cycle 19/Day1 (n =29, 14) | Cycle 20/Day1 (n =21, 12) | Cycle 21/Day1 (n =16, 7) | End of Treatment (n =169, 196) | Follow up (n =76, 106) | |
| Axitinib 5 mg | 0.732 | 0.716 | 0.722 | 0.730 | 0.730 | 0.734 | 0.718 | 0.756 | 0.760 | 0.734 | 0.764 | 0.744 | 0.760 | 0.723 | 0.730 | 0.749 | 0.779 | 0.755 | 0.734 | 0.794 | 0.700 | 0.608 | 0.682 |
| Sorafenib 400 mg | 0.731 | 0.696 | 0.709 | 0.716 | 0.711 | 0.704 | 0.728 | 0.702 | 0.730 | 0.730 | 0.724 | 0.734 | 0.753 | 0.752 | 0.758 | 0.785 | 0.764 | 0.755 | 0.804 | 0.771 | 0.771 | 0.612 | 0.666 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. VAS component: participants rated their current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health. (NCT00678392)
Timeframe: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
| Intervention | Units on a scale (Mean) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n =341, 339) | Cycle 2/Day1 (n =317, 302) | Cycle 3/Day1 (n =280, 250) | Cycle 4/Day1 (n =261, 224) | Cycle 5/Day1 (n =244, 205) | Cycle 6/Day1 (n =220, 178) | Cycle 7/Day1 (n =209, 163) | Cycle 8/Day1 (n =180, 139) | Cycle 9/Day1 (n =168, 121) | Cycle 10/Day1 (n =151, 98) | Cycle 11/Day1 (n =126, 87) | Cycle 12/Day1 (n =111, 73) | Cycle 13/Day1 (n =94, 61) | Cycle 14/Day1 (n =81, 58) | Cycle 15/Day1 (n =62, 42) | Cycle 16/Day1 (n =52, 37) | Cycle 17/Day1 (n =48, 30) | Cycle 18/Day1 (n =37, 23) | Cycle 19/Day1 (n =29, 14) | Cycle 20/Day1 (n =21, 12) | Cycle 21/Day1 (n =16, 7) | End of Treatment (n =166, 197) | Follow up (n =76, 109) | |
| Axitinib 5 mg | 70.560 | 69.003 | 69.843 | 69.180 | 69.705 | 69.900 | 69.919 | 70.756 | 70.667 | 70.629 | 72.103 | 71.730 | 70.723 | 69.420 | 73.016 | 70.269 | 71.375 | 70.459 | 71.034 | 73.143 | 74.563 | 61.759 | 64.382 |
| Sorafenib 400 mg | 70.351 | 67.606 | 69.712 | 70.759 | 71.888 | 71.365 | 72.282 | 71.475 | 73.380 | 75.102 | 74.586 | 73.959 | 75.693 | 75.362 | 75.357 | 73.676 | 73.767 | 73.870 | 70.571 | 66.917 | 64.714 | 61.690 | 66.037 |
FKSI was used to assess quality of life (QoL) for those diagnosed with renal cell cancer and consisted of 15 items (lack of energy, side effects, pain, losing weight, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria and sleep). Each of the 15 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score = sum of the 15 item scores; total range: 0 - 60; 0 (no symptoms) to 60 (very much); higher scores indicate greater presence of symptoms. (NCT00678392)
Timeframe: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
| Intervention | Units on a scale (Mean) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n =346, 342) | Cycle 2/Day1 (n =319, 296) | Cycle 3/Day1 (n =279, 246) | Cycle 4/Day1 (n =257, 221) | Cycle 5/Day1 (n =238, 203) | Cycle 6/Day1 (n =213, 179) | Cycle 7/Day1 (n =206, 158) | Cycle 8/Day1 (n =177, 136) | Cycle 9/Day1 (n =163, 118) | Cycle 10/Day1 (n =146, 96) | Cycle 11/Day1 (n =122, 85) | Cycle 12/Day1 (n =110, 70) | Cycle 13/Day1 (n =92, 58) | Cycle 14/Day1 (n =81, 54) | Cycle 15/Day1 (n =61, 38) | Cycle 16/Day1 (n =52, 34) | Cycle 17/Day1 (n =47, 28) | Cycle 18/Day1 (n =36, 22) | Cycle 19/Day1 (n =29, 14) | Cycle 20/Day1 (n =20, 12) | Cycle 21/Day1 (n =15, 7) | End of treatment (n=163, 191) | Follow up (n =80, 110) | |
| Axitinib 5 mg | 43.199 | 42.351 | 42.590 | 42.791 | 42.968 | 42.949 | 42.747 | 43.580 | 43.191 | 43.312 | 44.119 | 44.517 | 44.492 | 44.485 | 45.291 | 45.217 | 45.242 | 44.861 | 45.379 | 47.050 | 45.850 | 38.328 | 41.919 |
| Sorafenib 400 mg | 43.339 | 41.668 | 42.424 | 43.424 | 42.907 | 43.057 | 43.578 | 44.074 | 44.518 | 44.771 | 44.438 | 44.357 | 45.261 | 44.898 | 45.053 | 44.445 | 44.438 | 44.182 | 45.026 | 44.780 | 44.494 | 38.457 | 40.028 |
FKSI-DRS was used to assess quality of life for those diagnosed with renal cell cancer and consisted of 9 items (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, and hematuria). Each of the 9 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI-DRS score = sum of the 9 item scores; total range: 0 - 36; 0 (no symptoms) to 36 (very much); higher scores indicate greater presence of symptoms. (NCT00678392)
Timeframe: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
| Intervention | Units on a scale (Mean) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n =346, 341) | Cycle 2/Day1 (n =319, 295) | Cycle 3/Day1 (n =279, 244) | Cycle 4/Day1 (n =257, 220) | Cycle 5/Day1 (n =238, 202) | Cycle 6/Day1 (n =213, 178) | Cycle 7/Day1 (n =206, 157) | Cycle 8/Day1 (n =177, 135) | Cycle 9/Day1 (n =163, 117) | Cycle 10/Day1 (n =146, 96) | Cycle 11/Day1 (n =122, 85) | Cycle 12/Day1 (n =110, 70) | Cycle 13/Day1 (n =92, 58) | Cycle 14/Day1 (n =81, 54) | Cycle 15/Day1 (n =61, 38) | Cycle 16/Day1 (n =52, 34) | Cycle 17/Day1 (n =47, 28) | Cycle 18/Day1 (n =36, 22) | Cycle 19/Day1 (n =29, 14) | Cycle 20/Day1 (n =20, 12) | Cycle 21/Day1 (n =15, 7) | End of Treatment (n =163, 191) | Follow up (n =80, 110) | |
| Axitinib 5 mg | 28.874 | 28.211 | 28.640 | 28.822 | 28.869 | 29.159 | 29.042 | 29.520 | 29.194 | 29.343 | 29.762 | 29.764 | 29.594 | 29.711 | 30.324 | 30.430 | 30.551 | 30.194 | 30.130 | 31.300 | 31.067 | 26.288 | 28.263 |
| Sorafenib 400 mg | 28.975 | 28.399 | 28.640 | 29.130 | 29.007 | 29.098 | 29.361 | 29.619 | 29.884 | 29.604 | 29.366 | 29.257 | 29.666 | 29.820 | 29.500 | 29.474 | 28.737 | 29.045 | 29.286 | 29.250 | 30.143 | 26.517 | 27.516 |
Biochemistry laboratory test included parameters: alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin, creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, hypophosphatemia and lipase. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. (NCT00678392)
Timeframe: From initiation of treatment up to follow-up period (up to 3 years)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alanine aminotransferase: Grade 1 (n =331, 313) | Alanine aminotransferase: Grade 2 (n =331, 313) | Alanine aminotransferase: Grade 3 (n =331, 313) | Alanine aminotransferase: Grade 4 (n =331, 313) | Alkaline phosphatase: Grade 1 (n =336, 319) | Alkaline phosphatase: Grade 2 (n =336, 319) | Alkaline phosphatase: Grade 3 (n =336, 319) | Alkaline phosphatase: Grade 4 (n =336, 319) | Amylase: Grade 1 (n =338, 319) | Amylase: Grade 2 (n =338, 319) | Amylase: Grade 3 (n =338, 319) | Amylase: Grade 4 (n =338, 319) | Aspartate aminotransferase: Grade 1 (n =331, 311) | Aspartate aminotransferase: Grade 2 (n =331, 311) | Aspartate aminotransferase: Grade 3 (n =331, 311) | Aspartate aminotransferase: Grade 4 (n =331, 311) | Bicarbonate: Grade 1 (n =314, 291) | Bicarbonate: Grade 2 (n =314, 291) | Bicarbonate: Grade 3 (n =314, 291) | Bicarbonate: Grade 4 (n =314, 291) | Bilirubin: Grade 1 (n =336, 318) | Bilirubin: Grade 2 (n =336, 318) | Bilirubin: Grade 3 (n =336, 318) | Bilirubin: Grade 4 (n =336, 318) | Creatinine: Grade 1 (n =336, 318) | Creatinine: Grade 2 (n =336, 318) | Creatinine: Grade 3 (n =336, 318) | Creatinine: Grade 4 (n =336, 318) | Hypercalcemia: Grade 1 (n =336, 319) | Hypercalcemia: Grade 2 (n =336, 319) | Hypercalcemia: Grade 3 (n =336, 319) | Hypercalcemia: Grade 4 (n =336, 319) | Hyperglycemia: Grade 1 (n =336, 319) | Hyperglycemia: Grade 2 (n =336, 319) | Hyperglycemia: Grade 3 (n =336, 319) | Hyperglycemia: Grade 4 (n =336, 319) | Hyperkalemia: Grade 1 (n =333, 314) | Hyperkalemia: Grade 2 (n =333, 314) | Hyperkalemia: Grade 3 (n =333, 314) | Hyperkalemia: Grade 4 (n =333, 314) | Hypernatremia: Grade 1 (n =338, 319) | Hypernatremia: Grade 2 (n =338, 319) | Hypernatremia: Grade 3 (n =338, 319) | Hypernatremia: Grade 4 (n =338, 319) | Hypoalbuminemia: Grade 1 (n =337, 319) | Hypoalbuminemia: Grade 2 (n =337, 319) | Hypoalbuminemia: Grade 3 (n =337, 319) | Hypoalbuminemia: Grade 4 (n =337, 319) | Hypocalcemia: Grade 1 (n =336, 319) | Hypocalcemia: Grade 2 (n =336, 319) | Hypocalcemia: Grade 3 (n =336, 319) | Hypocalcemia: Grade 4 (n =336, 319) | Hypoglycemia: Grade 1 (n =336, 319) | Hypoglycemia: Grade 2 (n =336, 319) | Hypoglycemia: Grade 3 (n =336, 319) | Hypoglycemia: Grade 4 (n =336, 319) | Hypokalemia: Grade 1 (n =333, 314) | Hypokalemia: Grade 2 (n =333, 314) | Hypokalemia: Grade 3 (n =333, 314) | Hypokalemia: Grade 4 (n =333, 314) | Hyponatremia: Grade 1 (n =338, 319) | Hyponatremia: Grade 2 (n =338, 319) | Hyponatremia: Grade 3 (n =338, 319) | Hyponatremia: Grade 4 (n =338, 319) | Hypophosphatemia: Grade 1 (n =336, 318) | Hypophosphatemia: Grade 2 (n =336, 318) | Hypophosphatemia: Grade 3 (n =336, 318) | Hypophosphatemia: Grade 4 (n =336, 318) | Lipase: Grade 1 (n =338, 319) | Lipase: Grade 2 (n =338, 319) | Lipase: Grade 3 (n =338, 319) | Lipase: Grade 4 (n =338, 319) | |
| Axitinib 5 mg | 65 | 8 | 1 | 0 | 88 | 8 | 4 | 0 | 64 | 12 | 7 | 0 | 59 | 5 | 1 | 0 | 127 | 11 | 0 | 1 | 16 | 8 | 1 | 0 | 155 | 30 | 0 | 0 | 92 | 8 | 1 | 0 | 41 | 45 | 7 | 0 | 0 | 42 | 9 | 0 | 34 | 19 | 3 | 0 | 37 | 11 | 1 | 0 | 25 | 4 | 2 | 1 | 23 | 12 | 1 | 0 | 22 | 0 | 0 | 0 | 33 | 0 | 11 | 1 | 4 | 33 | 6 | 0 | 53 | 22 | 14 | 2 |
| Sorafenib 400 mg | 57 | 6 | 2 | 3 | 92 | 15 | 3 | 0 | 76 | 21 | 6 | 1 | 67 | 7 | 4 | 0 | 115 | 10 | 0 | 0 | 12 | 2 | 1 | 0 | 121 | 9 | 1 | 0 | 22 | 1 | 0 | 0 | 28 | 37 | 7 | 0 | 0 | 22 | 8 | 0 | 23 | 14 | 1 | 2 | 25 | 31 | 2 | 0 | 67 | 18 | 2 | 2 | 9 | 16 | 1 | 0 | 21 | 0 | 5 | 0 | 27 | 0 | 6 | 1 | 8 | 99 | 51 | 0 | 76 | 25 | 40 | 7 |
Hematology laboratory test included hemoglobin, platelet count, white blood cells count, neutrophils and lymphocytes. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. (NCT00678392)
Timeframe: From initiation of treatment up to follow-up period (up to 3 years)
| Intervention | Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin: Grade 1 (n =320, 316) | Hemoglobin: Grade 2 (n =320, 316) | Hemoglobin: Grade 3 (n =320, 316) | Hemoglobin: Grade 4 (n =320, 316) | Lymphocytes: Grade 1 (n =317, 309) | Lymphocytes: Grade 2 (n =317, 309) | Lymphocytes: Grade 3 (n =317, 309) | Lymphocytes: Grade 4 (n =317, 309) | Neutrophils: Grade 1 (n =316, 308) | Neutrophils: Grade 2 (n =316, 308) | Neutrophils: Grade 3 (n =316, 308) | Neutrophils: Grade 4 (n =316, 308) | Platelets: Grade 1 (n =312, 310) | Platelets: Grade 2 (n =312, 310) | Platelets: Grade 3 (n =312, 310) | Platelets: Grade 4 (n =312, 310) | White Blood Cells: Grade 1 (n =320, 315) | White Blood Cells: Grade 2 (n =320, 315) | White Blood Cells: Grade 3 (n =320, 315) | White Blood Cells: Grade 4 (n =320, 315) | |
| Axitinib 5 mg | 93 | 19 | 1 | 0 | 7 | 89 | 10 | 0 | 13 | 4 | 2 | 0 | 47 | 0 | 1 | 0 | 32 | 4 | 0 | 0 |
| Sorafenib 400 mg | 112 | 41 | 11 | 1 | 7 | 93 | 11 | 0 | 20 | 4 | 2 | 0 | 41 | 3 | 0 | 0 | 36 | 12 | 1 | 0 |
Urinalysis included urine blood/ hemoglobin, glucose and protein. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. (NCT00678392)
Timeframe: From initiation of treatment up to follow-up period (up to 3 years)
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Urine blood/ hemoglobin: Grade 1 (n =304, 272) | Urine blood/ hemoglobin: Grade 2 (n =304, 272) | Urine blood/ hemoglobin: Grade 3 (n =304, 272) | Urine blood/ hemoglobin: Grade 4 (n =304, 272) | Urine glucose: Grade 1 (n =322, 286) | Urine glucose: Grade 2 (n =322, 286) | Urine glucose: Grade 3 (n =322, 286) | Urine glucose: Grade 4 (n =322, 286) | Urine protein: Grade 1 (n =326, 289) | Urine protein: Grade 2 (n =326, 289) | Urine protein: Grade 3 (n =326, 289) | Urine protein: Grade 4 (n =326, 289) | |
| Axitinib 5 mg | 45 | 1 | 0 | 0 | 12 | 0 | 0 | 1 | 105 | 31 | 27 | 9 |
| Sorafenib 400 mg | 35 | 0 | 0 | 0 | 13 | 3 | 0 | 1 | 91 | 27 | 21 | 7 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Grade 1= mild; Grade 2= moderate; Grade 3= severe; Grade 4= life-threatening or disabling; Grade 5= death related to AE. (NCT00678392)
Timeframe: From initiation of treatment up to follow-up period (up to 3 years)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Axitinib 5 mg | 3.9 | 20.1 | 47.6 | 10.6 | 13.9 |
| Sorafenib 400 mg | 3.1 | 21.7 | 52.4 | 11.5 | 9.3 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life- threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious AEs. (NCT00678392)
Timeframe: From initiation of treatment up to follow-up period (up to 3 years)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| AEs | SAEs | |
| Axitinib 5 mg | 96.1 | 40.7 |
| Sorafenib 400 mg | 98.0 | 35.8 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life -threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both serious and non -serious AEs. (NCT00678392)
Timeframe: From initiation of treatment up to follow-up period (up to 3 years)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| AEs | SAEs | |
| Axitinib 5 mg | 92.2 | 15.3 |
| Sorafenib 400 mg | 95.2 | 13.8 |
Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response. (NCT00920816)
Timeframe: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)
| Intervention | months (Median) |
|---|---|
| Axitinib (First-line Participants) | 14.7 |
| Sorafenib (First-line Participants) | 14.3 |
Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response. (NCT00920816)
Timeframe: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)
| Intervention | months (Median) |
|---|---|
| Axitinib (Second-line Participants) | NA |
| Sorafenib (Second-line Participants) | 8.7 |
Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). (NCT00920816)
Timeframe: Baseline until death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)
| Intervention | months (Median) |
|---|---|
| Axitinib (First-line Participants) | NA |
| Sorafenib (First-line Participants) | NA |
Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). (NCT00920816)
Timeframe: Baseline until death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)
| Intervention | months (Median) |
|---|---|
| Axitinib (Second-line Participants) | 17.2 |
| Sorafenib (Second-line Participants) | 18.1 |
Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent. (NCT00920816)
Timeframe: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)
| Intervention | percentage of participants (Number) |
|---|---|
| Axitinib (First-line Participants) | 32.3 |
| Sorafenib (First-line Participants) | 14.6 |
Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent. (NCT00920816)
Timeframe: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)
| Intervention | percentage of participants (Number) |
|---|---|
| Axitinib (Second-line Participants) | 23.7 |
| Sorafenib (Second-line Participants) | 10.1 |
"Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease [PD]), or from adverse event (AE) data (where outcome was Death). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is >= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions." (NCT00920816)
Timeframe: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)
| Intervention | months (Median) |
|---|---|
| Axitinib (First-line Participants) | 10.1 |
| Sorafenib (First-line Participants) | 6.5 |
"Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease [PD]), or from adverse event (AE) data (where outcome was Death). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is >= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions." (NCT00920816)
Timeframe: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)
| Intervention | months (Median) |
|---|---|
| Axitinib (Second-line Participants) | 6.5 |
| Sorafenib (Second-line Participants) | 4.8 |
"EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state." (NCT00920816)
Timeframe: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1 D1 | C2 D1 | C3 D1 | C4 D1 | C5 D1 | C6 D1 | C7 D1 | C8 D1 | C9 D1 | C10 D1 | C11 D1 | C12 D1 | C13 D1 | C14 D1 | C15 D1 | C16 D1 | C17 D1 | C18 D1 | C19 D1 | C20 D1 | C21 D1 | C22 D1 | C23 D1 | End of treatment | Follow-up | |
| Axitinib (First-line Participants) | 0.710 | 0.709 | 0.694 | 0.696 | 0.708 | 0.683 | 0.685 | 0.678 | 0.704 | 0.682 | 0.698 | 0.708 | 0.708 | 0.703 | 0.689 | 0.702 | 0.706 | 0.699 | 0.713 | 0.699 | 0.712 | 0.737 | 0.736 | 0.635 | 0.545 |
| Sorafenib (First-line Participants) | 0.712 | 0.693 | 0.687 | 0.668 | 0.673 | 0.641 | 0.676 | 0.717 | 0.729 | 0.723 | 0.748 | 0.742 | 0.761 | 0.731 | 0.755 | 0.775 | 0.738 | 0.777 | 0.762 | 0.710 | 0.702 | 0.774 | 0.789 | 0.588 | 0.618 |
"EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state." (NCT00920816)
Timeframe: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1 D1 | C2 D1 | C3 D1 | C4 D1 | C5 D1 | C6 D1 | C7 D1 | C8 D1 | C9 D1 | C10 D1 | C11 D1 | C12 D1 | C13 D1 | C14 D1 | C15 D1 | C16 D1 | C17 D1 | C18 D1 | C19 D1 | C20 D1 | C21 D1 | End of treatment | Follow-up | |
| Axitinib (Second-line Participants) | 0.812 | 0.769 | 0.772 | 0.737 | 0.780 | 0.767 | 0.762 | 0.758 | 0.796 | 0.768 | 0.792 | 0.797 | 0.786 | 0.833 | 0.819 | 0.811 | 0.834 | 0.830 | 0.830 | 0.832 | 0.859 | 0.582 | 0.429 |
| Sorafenib (Second-line Participants) | 0.831 | 0.754 | 0.755 | 0.759 | 0.768 | 0.753 | 0.768 | 0.733 | 0.794 | 0.820 | 0.848 | 0.837 | 0.814 | 0.871 | 0.829 | 0.828 | 0.865 | 0.829 | 0.861 | 0.923 | 0.852 | 0.623 | 0.418 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state. (NCT00920816)
Timeframe: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1 D1 | C2 D1 | C3 D1 | C4 D1 | C5 D1 | C6 D1 | C7 D1 | C8 D1 | C9 D1 | C10 D1 | C11 D1 | C12 D1 | C13 D1 | C14 D1 | C15 D1 | C16 D1 | C17 D1 | C18 D1 | C19 D1 | C20 D1 | C21 D1 | C22 D1 | C23 D1 | End of treatment | Follow-up | |
| Axitinib (First-line Participants) | 71.181 | 71.714 | 72.006 | 72.179 | 72.451 | 71.574 | 71.050 | 71.031 | 72.690 | 72.910 | 72.763 | 73.610 | 73.030 | 73.147 | 74.494 | 73.878 | 73.090 | 73.817 | 72.089 | 74.244 | 75.694 | 78.000 | 77.143 | 67.254 | 69.195 |
| Sorafenib (First-line Participants) | 72.362 | 72.422 | 71.241 | 72.086 | 73.615 | 69.944 | 73.923 | 73.183 | 73.780 | 72.400 | 72.271 | 75.295 | 75.432 | 75.108 | 74.405 | 75.818 | 74.333 | 75.571 | 75.125 | 74.190 | 70.500 | 73.917 | 72.571 | 67.048 | 64.885 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state. (NCT00920816)
Timeframe: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1 D1 | C2 D1 | C3 D1 | C4 D1 | C5 D1 | C6 D1 | C7 D1 | C8 D1 | C9 D1 | C10 D1 | C11 D1 | C12 D1 | C13 D1 | C14 D1 | C15 D1 | C16 D1 | C17 D1 | C18 D1 | C19 D1 | C20 D1 | C21 D1 | End of treatment | Follow-up | |
| Axitinib (Second-line Participants) | 82.799 | 81.102 | 80.895 | 81.138 | 83.018 | 82.222 | 82.900 | 83.382 | 84.171 | 83.041 | 84.136 | 84.305 | 82.927 | 86.520 | 85.841 | 87.579 | 88.424 | 86.586 | 89.500 | 90.333 | 90.313 | 75.568 | 58.154 |
| Sorafenib (Second-line Participants) | 82.058 | 78.231 | 80.534 | 81.245 | 80.250 | 80.829 | 80.868 | 81.000 | 83.788 | 82.778 | 83.000 | 83.500 | 83.300 | 86.667 | 86.462 | 86.083 | 84.300 | 83.125 | 82.143 | 86.000 | 84.167 | 74.741 | 64.333 |
FKSI-DRS: subset of FKSI which is FACT-Kidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate). (NCT00920816)
Timeframe: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1 D1 | C2 D1 | C3 D1 ( | C4 D1 | C5 D1 | C6 D1 | C7 D1 | C8 D1 | C9 D1 | C10 D1 | C11 D1 | C12 D1 | C13 D1 | C14 D1 | C15 D1 | C16 D1 | C17 D1 | C18 D1 | C19 D1 | C20 D1 | C21 D1 | C22 D1 | C23 D1 | End of treatment | Follow-up | |
| Axitinib (First-line Participants) | 28.691 | 28.728 | 29.171 | 28.577 | 29.020 | 28.574 | 28.568 | 28.557 | 28.817 | 29.057 | 29.146 | 29.648 | 29.545 | 29.579 | 29.859 | 29.683 | 29.564 | 29.380 | 29.737 | 29.844 | 30.889 | 31.696 | 31.357 | 26.556 | 26.805 |
| Sorafenib (First-line Participants) | 29.653 | 29.963 | 29.750 | 29.642 | 30.255 | 29.153 | 29.523 | 30.296 | 30.186 | 30.364 | 30.688 | 30.727 | 31.483 | 31.027 | 30.730 | 31.515 | 31.567 | 31.107 | 31.417 | 30.762 | 30.056 | 31.000 | 31.143 | 26.786 | 26.769 |
FKSI-DRS: subset of FKSI which is FACT-Kidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate). (NCT00920816)
Timeframe: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1 D1 | C2 D1 | C3 D1 | C4 D1 | C5 D1 | C6 D1 | C7 D1 | C8 D1 | C9 D1 | C10 D1 | C11 D1 | C12 D1 | C13 D1 | C14 D1 | C15 D1 | C16 D1 | C17 D1 | C18 D1 | C19 D1 | C20 D1 | C21 D1 | End of treatment | Follow-up | |
| Axitinib (Second-line Participants) | 31.020 | 30.600 | 30.645 | 30.103 | 30.676 | 30.731 | 30.920 | 30.966 | 31.012 | 30.986 | 31.212 | 31.356 | 31.418 | 32.100 | 32.000 | 31.921 | 32.061 | 31.931 | 32.364 | 31.905 | 33.125 | 28.216 | 24.692 |
| Sorafenib (Second-line Participants) | 31.489 | 30.682 | 30.965 | 30.679 | 31.063 | 31.439 | 30.632 | 30.703 | 30.667 | 30.926 | 32.045 | 32.000 | 32.100 | 32.800 | 32.769 | 33.167 | 32.800 | 32.625 | 32.429 | 33.500 | 33.500 | 29.519 | 27.500 |
FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate). (NCT00920816)
Timeframe: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1 D1 | C2 D1 | C3 D1 | C4 D1 | C5 D1 | C6 D1 | C7 D1 | C8 D1 | C9 D1 | C10 D1 | C11 D1 | C12 D1 | C13 D1 | C14 D1 | C15 D1 | C16 D1 | C17 D1 | C18 D1 | C19 D1 | C20 D1 | C21 D1 | C22 D1 | C23 D1 | End of treatment | Follow-up | |
| Axitinib (First-line Participants) | 43.869 | 43.328 | 43.366 | 42.932 | 43.211 | 42.787 | 42.474 | 42.534 | 42.778 | 43.120 | 43.264 | 43.962 | 44.141 | 43.789 | 44.176 | 44.232 | 43.897 | 43.761 | 43.737 | 43.733 | 45.417 | 47.000 | 47.571 | 39.052 | 39.683 |
| Sorafenib (First-line Participants) | 43.865 | 43.969 | 43.345 | 42.926 | 44.022 | 42.344 | 43.446 | 44.077 | 44.051 | 44.018 | 45.000 | 45.318 | 45.787 | 45.459 | 45.514 | 46.000 | 46.400 | 45.357 | 45.583 | 44.333 | 43.500 | 45.833 | 45.714 | 39.524 | 40.038 |
FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate). (NCT00920816)
Timeframe: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1 D1 | C2 D1 | C3 D1 | C4 D1 | C5 D1 | C6 D1 | C7 D1 | C8 D1 | C9 D1 | C10 D1 | C11 D1 | C12 D1 | C13 D1 | C14 D1 | C15 D1 | C16 D1 | C17 D1 | C18 D1 | C19 D1 | C20 D1 | C21 D1 | End of treatment | Follow-up | |
| Axitinib (Second-line Participants) | 46.753 | 46.217 | 45.968 | 45.060 | 45.775 | 45.407 | 45.709 | 45.169 | 45.829 | 45.608 | 45.833 | 45.797 | 46.727 | 47.740 | 48.023 | 48.184 | 47.909 | 48.138 | 48.636 | 48.810 | 50.188 | 41.432 | 35.385 |
| Sorafenib (Second-line Participants) | 47.470 | 45.045 | 45.684 | 45.792 | 46.125 | 46.341 | 45.053 | 45.676 | 45.970 | 46.148 | 47.227 | 48.091 | 47.600 | 49.133 | 49.308 | 50.500 | 49.000 | 49.125 | 48.571 | 50.500 | 50.000 | 42.889 | 38.583 |
Duration of response as defined by the time from CR or PR (whichever status recorded first) until the date of death or PD was objectively documented. Median and its 95 percent confidence interval (95% CI) were estimated using Kaplan-Meier method. (NCT00474786)
Timeframe: Baseline up to 24 Months
| Intervention | months (Median) |
|---|---|
| Temsirolimus | 8.26 |
| Sorafenib | 6.96 |
Overall survival was the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact. (NCT00474786)
Timeframe: Baseline to date of death from any cause (up to 24 months)
| Intervention | months (Median) |
|---|---|
| Temsirolimus | 12.27 |
| Sorafenib | 16.64 |
Percentage of participants with tumor response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST and evaluated by independent central review. CR/PR persisted on repeat imaging study at least 4 weeks after initial documentation of response. PR had at least 30 percent decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. (NCT00474786)
Timeframe: Baseline up to 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Temsirolimus | 7.7 |
| Sorafenib | 7.9 |
Interval from date of randomization until documentation of PD by an investigator tumor assessment, symptomatic deterioration, or death for any reason whichever occurred first. (NCT00474786)
Timeframe: Baseline up to 24 Months
| Intervention | months (Median) |
|---|---|
| Temsirolimus | 5.43 |
| Sorafenib | 4.14 |
Interval from date of randomization until documentation of progressive disease (PD) by an independent tumor assessment according to Response Evaluation Criteria in Solid Tumor (RECIST) or death for any reason whichever occurred first. (NCT00474786)
Timeframe: Baseline up to 24 Months
| Intervention | months (Median) |
|---|---|
| Temsirolimus | 4.28 |
| Sorafenib | 3.91 |
Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to [study drug] was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. (NCT00474786)
Timeframe: Baseline up to 24 months
| Intervention | participants (Number) | |
|---|---|---|
| Serious AE | Any AE | |
| Sorafenib | 86 | 251 |
| Temsirolimus | 103 | 248 |
PFS: Interval from date of randomization until documentation of PD by an independent tumor assessment according to RECIST or death for any reason whichever occurred first. PFS calculated as (Weeks)=(randomization date minus first dose date plus 1) divided by 7. (NCT00474786)
Timeframe: Weeks 12, 24, and 36
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Baseline to Week 12 | Week 13 to Week 24 | Week 25 to Week 36 | |
| Sorafenib | 36.7 | 20.1 | 11.2 |
| Temsirolimus | 31.2 | 20.9 | 12.3 |
Overall survival (OS) was the key secondary endpoint and was defined as the time from date of randomization to the date of death due to any cause. If a patient was not known to have died, survival was censored on the date of last contact. (NCT01223027)
Timeframe: until at least 386 deaths are documented in the clinical database.
| Intervention | Months (Median) |
|---|---|
| Dovitinib + Best Supportive Care (BSC) | 11.1 |
| Sorafenib + BSC | 11.0 |
The EORTC QLQ-C30 contains 30 items and is composed of both multi-item scales and single-item measures. These include five functional scales (physical, role, emotional, social and cognitive functioning), three symptom scales (fatigue, pain, nausea, and vomiting), a global health status/QoL scale, and six single items (dyspnea, diarrhea, constipation, anorexia, insomnia and financial impact). Each of the multiitem scales includes a different set of items - no item occurs in more than one scale. Each item in the EORTC QLQ-C30 has 4 response categories (1=Not at all, 2= A little, 3= Quite a bit, 4= Very much) with the higher number representing a worse outcome. (NCT01223027)
Timeframe: from date of randomization
| Intervention | Months (Median) |
|---|---|
| Dovitinib + Best Supportive Care (BSC) | 3.8 |
| Sorafenib + BSC | 5.6 |
The EORTC QLQ-C30 contains 30 items and is composed of both multi-item scales and single-item measures. These include five functional scales (physical, role, emotional, social and cognitive functioning), three symptom scales (fatigue, pain, nausea, and vomiting), a global health status/QoL scale, and six single items (dyspnea, diarrhea, constipation, anorexia, insomnia and financial impact). Each of the multiitem scales includes a different set of items - no item occurs in more than one scale. Each item in the EORTC QLQ-C30 has 4 response categories (1=Not at all, 2= A little, 3= Quite a bit, 4= Very much) with the higher number representing a worse outcome. (NCT01223027)
Timeframe: from date of randomization
| Intervention | Months (Median) |
|---|---|
| Dovitinib + Best Supportive Care (BSC) | 3.7 |
| Sorafenib + BSC | 4.5 |
The Kidney Cancer Symptom Index - Disease Related Symptoms (FKSI-DRS) is a validated symptom scale used in studies of patients with kidney cancer. It includes 9-items that assess pain, bone pain, fatigue, lack of energy, shortness of breath, fevers, weight loss, coughing, and blood in urine and responses to each question are answered on a 5-point Likert-type scale ranging from 0 to 4 (e.g., 0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). FKSI-DRS scores range from 0 to 36, where higher scores correspond to better outcomes (eg, fewer symptoms). (NCT01223027)
Timeframe: from date of randomization, at least 2 score units
| Intervention | Months (Median) |
|---|---|
| Dovitinib + Best Supportive Care (BSC) | 4.9 |
| Sorafenib + BSC | 6.4 |
Overall response rate (ORR) was defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR). Best overall esponse (BOR) for each patient was determined from the sequence of overall (lesion) responses according to the following rules: CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required. CR = at least two determinations of CR at least 4 weeks apart before progression where confirmation required or one determination of CR prior to progression where confirmation not required. SD = at least one SD assessment (or better) > 6 weeks after randomization (and not qualifying for CR or PR). PD = progression ≤ 17 weeks after randomization (and not qualifying for CR, PR or SD). (NCT01223027)
Timeframe: Until disease progression or discontinuation of treatment due to unacceptable toxicity
| Intervention | Percentage of Participants (Number) |
|---|---|
| Dovitinib + Best Supportive Care (BSC) | 3.9 |
| Sorafenib + BSC | 3.8 |
Assessed according to RECIST 1.1. PFS was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause. If a patient had not progressed or died, on the date of the analysis cut-off or when he/she received any further anti-neoplastic therapy, PFS was censored on the date of last tumor assessment before the cutoff date or the anti-neoplastic therapy date. The distribution of PFS was estimated using the Kaplan-Meier method. The median PFS along with 95% confidence intervals was presented by treatment group. (NCT01223027)
Timeframe: Until disease progression or discontinuation of treatment due to unacceptable toxicity up to 30-Jun-2014 (discontinuation)
| Intervention | Months (Median) |
|---|---|
| Dovitinib + Best Supportive Care (BSC) | 3.7 |
| Sorafenib + BSC | 3.6 |
PFS was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause. The primary analysis for PFS (based on central review) was also to be repeated on FAS considering the Investigator assessments and using the same analytical conventions as the primary analysis. (NCT01223027)
Timeframe: Until disease progression or discontinuation of treatment due to unacceptable toxicity
| Intervention | Months (Median) |
|---|---|
| Dovitinib + Best Supportive Care (BSC) | 3.9 |
| Sorafenib + BSC | 3.9 |
Time to definitive worsening of Karnofsky performance status (KPS) was defined as the time from date of randomization to the date of definitive worsening of KPS or to the date of death whichever occurred earlier. Definitive worsening was defined as a definitive decrease in performance status by at least one Karnofsky category (i.e. at least 10 points less) compared to Baseline. Worsening was considered definitive if no later increase above the defined threshold was observed within the course of the study. A single measure reporting a decrease in Karnofsky performance status was sufficient to consider it as definitive only if it was the last one available for this patient. Time to definitive worsening of KPS was analyzed at the time of the final analysis for PFS. (NCT01223027)
Timeframe: from date of randomization to the date of definitive worsening of KPS or to the date of death whichever occurred earlier
| Intervention | Months (Median) |
|---|---|
| Dovitinib + Best Supportive Care (BSC) | 5.1 |
| Sorafenib + BSC | 5.7 |
Predose concentrations of dovitinib were summarized by visit using PAS. All concentration data was listed by patient and time point using FAS. Mean pre-dose concentrations along with standard deviation (SD) was plotted over time if appropriate. (NCT01223027)
Timeframe: Week 2 Day 5, Week 4 Day 5, Week 6 Day 5
| Intervention | ng/ml (Mean) | ||
|---|---|---|---|
| Week 2 Day 5 (n: 205) | Week 4 Day 5 (n: 202) | Week 6 Day 5 (n: 170) | |
| Dovitinib + Best Supportive Care (BSC) | 128.06 | 114.08 | 118.27 |
Progression free survival will be measured from the beginning of treatment until there is evidence of progressive disease or death from any cause. Progression is evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.0). Target lesions are assessed by computerized tomography (CT) or magnetic resonance imaging (MRI): Progressive Disease (PD), 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01100242)
Timeframe: 36 weeks
| Intervention | weeks (Median) |
|---|---|
| VELCADE and Sorafenib | 13.71 |
Tumor response is evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.0). Target lesions are assessed by computerized tomography (CT) or magnetic resonance imaging (MRI:) Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. Overall response rate (ORR) is the percentage of patients who achieve a CR or PR (NCT01100242)
Timeframe: 42 days
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete response (CR) | Partial response (PR) | Overall response rate (CR + PR) | |
| VELCADE and Sorafenib | 0 | 5.9 | 5.9 |
Toxicity is assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Toxicity profile is reported as the number of patients who received at least one dose of on-study treatment and experienced a grade 3 or grade 4 adverse event (AE). For a more complete listing of all AEs experienced by patients on study, please see the Adverse Event section. (NCT01100242)
Timeframe: 42 days
| Intervention | participants (Number) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal pain | Anorexia (loss of appetite) | Dehydration | Fatigue | Hand and foot syndrome | Hemoglobin | Hyperglycemia | Hypertension | Hypoalbuminemia | Hypokalemia | Hyponatremia | Hypophosphatemia | Lymphopenia | Pain - Other (All over body) | Pain in extremity | Decreased platelets | Weight loss | |
| VELCADE and Sorafenib | 2 | 2 | 1 | 2 | 1 | 2 | 1 | 1 | 3 | 1 | 5 | 4 | 4 | 1 | 1 | 1 | 2 |
Duration of response for participants with disease stabilization following treatment as measured from the date response is confirmed to the date of disease progression, first assessed up to 8 weeks (2 cycles) following start of treatment. The duration of a Stable Disease (SD) response is measured from the time measurement criteria are met for that specific SD response until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Repeat radiologic studies (CT, MRI, Chest x-ray and bone scan as indicated) to evaluate disease progression or response every 8 weeks. (NCT00126594)
Timeframe: From the date response is confirmed to the date of disease progression, up to 12 months
| Intervention | Months (Median) |
|---|---|
| Sorafenib Tosylate or Sorafenib Plus Interferon | 5.7 |
Overall survival defined as the time interval from the start of protocol therapy to death or date of last follow-up if alive. (NCT00126594)
Timeframe: From the start of protocol therapy to death or date of last follow-up, up to 36 months
| Intervention | Months (Median) |
|---|---|
| Sorafenib Tosylate | NA |
| Sorafenib Tosylate, Recombinant Interferon Alfa-2b | 27.04 |
ORR defined as participants with Complete Response (CR) and Partial Response (PR) as defined by RECIST criteria: Complete Response (CR): Disappearance all target lesions. Partial Response (PR): >30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD. Progressive Disease (PD): >20% increase in sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of one or more new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, reference smallest sum LD since treatment started. Radiologic testing for progressive disease repeated every 8 weeks. (NCT00126594)
Timeframe: Tumor restaging performed at 8 weeks following baseline, responding or stable participants restaged at 8 week intervals, up to 12 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Sorafenib Tosylate | 30 |
| Sorafenib Tosylate, Recombinant Interferon Alfa-2b | 25 |
Progression free survival (PFS) is defined as the time interval from the start of protocol therapy to death or disease progression. (NCT00126594)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
| Intervention | Months (Median) |
|---|---|
| Sorafenib Tosylate | 7.39 |
| Sorafenib Tosylate, Recombinant Interferon Alfa-2b | 7.56 |
Best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The participant's best response assignment will depend on the achievement of both measurement and confirmation criteria as defined by RECIST: Complete Response (CR): Disappearance all target lesions. Partial Response (PR): >30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD. Progressive Disease (PD): >20% increase in sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of one or more new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, reference smallest sum LD since treatment started. Radiologic testing for progressive disease repeated every 8 weeks. (NCT00126594)
Timeframe: From the date response is confirmed to the date of disease progression, first assessed 2 months (8 weeks) following start of treatment and reassessed up to 36 months (on average reassessed 12 months or less).
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | Inevaluable | |
| Sorafenib Tosylate | 1 | 11 | 17 | 6 | 5 |
| Sorafenib Tosylate, Recombinant Interferon Alfa-2b | 0 | 10 | 20 | 7 | 3 |
Adverse events graded using the CTCAE version 4.0 tabulated by treatment arm within either toxicity grade for the treatment period. Treatment-related toxicity (acute and cumulative) performed every 8 weeks during the first year. (NCT00126594)
Timeframe: Up to 12 months of treatment
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fatigue | Diarrhea | Hand-Foot Syndrome | Hyperuricemia | Hyperamylasemia or Lipasemia | Dyspnea | Hypophosphatemia | Neutropenia | Hypertension | Nausea and vomiting | Rash/Desquamation | Proteinuria | Syncope (Fainting) | Weight Loss | Transaminitis | Hyponatremia | Nonneutropenic Infection | Sensory Neuropathy | Cardiac Ischemia/Infarction | Appendicitis | Pancreatitis | Adrenal Insufficiency | Reversible Posterior Leukonencephalopathy | Small Bowel Obstruction | Pneumonitis | |
| Sorafenib Tosylate | 10 | 13 | 10 | 12 | 5 | 4 | 3 | 0 | 2 | 1 | 2 | 1 | 0 | 0 | 0 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| Sorafenib Tosylate, Recombinant Interferon Alfa-2b | 13 | 8 | 7 | 3 | 4 | 4 | 5 | 6 | 3 | 3 | 2 | 2 | 3 | 3 | 3 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
Response was assessed using Solid Tumor Response Criteria (RECIST). Patients with complete responses or partial responses are considered having an objective response. (NCT00378703)
Timeframe: Assessed every 2 cycles for the first 12 cycles, then every 3 cycles until treatment discontinuation, then every 8 weeks until disease progression or up to 5 years
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm A (Bevacizumab) | 0.133 |
| Arm B (Bevacizumab and Temsirolimus) | 0.316 |
| Arm C (Bevacizumab and Sorafenib) | 0.305 |
| Arm D (Sorafenib and Temsirolimus) | 0.202 |
Overall survival was defined as the time from randomization to death. Patients alive at last contact were censored on the date of last contact. (NCT00378703)
Timeframe: Assessed every 2 cycles for the first 12 cycles, then every 3 cycles until treatment discontinuation, then every 8 weeks until disease progression or up to 5 years
| Intervention | Months (Median) |
|---|---|
| Arm A (Bevacizumab) | 28.6 |
| Arm B (Bevacizumab and Temsirolimus) | 24.7 |
| Arm C (Bevacizumab and Sorafenib) | 27.5 |
| Arm D (Sorafenib and Temsirolimus) | 24.3 |
Progression-free survival is defined as time from randomization to clinical evidence of disease progression or death from any cause without progression. Patients alive without progression were censored at the date of last disease assessment. (NCT00378703)
Timeframe: Assessed every 2 cycles for the first 12 cycles, then every 3 cycles until treatment discontinuation, then every 8 weeks until disease progression or up to 5 years
| Intervention | Months (Median) |
|---|---|
| Arm A (Bevacizumab) | 7.5 |
| Arm B (Bevacizumab and Temsirolimus) | 7.6 |
| Arm C (Bevacizumab and Sorafenib) | 9.2 |
| Arm D (Sorafenib and Temsirolimus) | 7.4 |
Patients whose date of progression was after 6 months or who were disease-free at last follow-up beyond 6 months were considered to be stable at 6 months and all other patients were not. (NCT00378703)
Timeframe: Assessed every 2 cycles for the first 12 cycles, then every 3 cycles until treatment discontinuation, then every 8 weeks until disease progression or up to 5 years
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm A (Bevacizumab) | 0.548 |
| Arm B (Bevacizumab and Temsirolimus) | 0.562 |
| Arm C (Bevacizumab and Sorafenib) | 0.590 |
| Arm D (Sorafenib and Temsirolimus) | 0.524 |
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Clearance is defined as the volume of blood from which drug can be completely removed per unit of time. CL/F for steady-state axitinib was evaluated on Cycle 2 Day 15. (NCT00835978)
Timeframe: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
| Intervention | L/hr (Geometric Mean) |
|---|---|
| Active Titration Arm | 54.15 |
| Placebo Titration Arm | 61.93 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz/F is influenced by the fraction absorbed. Vz/F for steady-state axitinb was evaluated on Cycle 2 Day 15. (NCT00835978)
Timeframe: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
| Intervention | L (Geometric Mean) |
|---|---|
| Active Titration Arm | 158.18 |
| Placebo Titration Arm | 216.62 |
Area under the plasma concentration time-curve from zero 24 hours[AUC(0-24). AUC(0-24) for steady-state axitinib was evaluated on Cycle 2 Day 15. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm. (NCT00835978)
Timeframe: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
| Intervention | ng.hr/mL (Geometric Mean) |
|---|---|
| Active Titration Arm | 258.68 |
| Placebo Titration Arm | 161.38 |
Area under the plasma concentration time-curve from zero to the last measurable concentration (AUClast). AUClast for steady-state axitinib was evaluated on Cycle 2 Day 15. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm. (NCT00835978)
Timeframe: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
| Intervention | ng.hr/mL (Geometric Mean) |
|---|---|
| Active Titration Arm | 105.33 |
| Placebo Titration Arm | 78.44 |
DR was defined as the time from the first documentation of objective tumor response (complete response - CR or Partial response - PR) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. The median values were estimated based on Kaplan-Meier method. 95% confidence interval was based on the Brookmeyer and Crowley method. (NCT00835978)
Timeframe: Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks
| Intervention | Months (Median) |
|---|---|
| Active Titration Arm | NA |
| Placebo Titration Arm | 21.2 |
| Non-randomized Arm | 23.3 |
Cmax for steady-state axitinib was evaluated on Cycle 2 Day 15. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm. (NCT00835978)
Timeframe: Cycle 2 Day 15 (C2D15): pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Active Titration Arm | 31.74 |
| Placebo Titration Arm | 23.05 |
ORR was defined as the proportion of participants with objective response based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as complete disappearance of all target lesions and non-target disease. No new lesions. PR was defined as >=30% decrease on study under baseline of the sum of longest diameters of all target lesions. No unequivocal progression of non-target disease. No new lesions. (NCT00835978)
Timeframe: Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks.
| Intervention | Percentage of Participants (Number) |
|---|---|
| Active Titration Arm | 53.6 |
| Placebo Titration Arm | 33.9 |
| Non-randomized Arm | 59.3 |
| All Participants | 48.4 |
OS was defined as the time from date of the first dose of the study medication to date of death due to any cause. For participants who did not die, their survival times were to be censored at the last date they were known to be alive. (NCT00835978)
Timeframe: Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks.
| Intervention | Months (Median) |
|---|---|
| Active Titration Arm (FA Population) | 42.7 |
| Placebo Titration Arm (FA Population) | 30.4 |
| Non-randomized Arm (SA Population) | 41.6 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Plasma decay half life for steady-state axitinib was evaluated on Cycle 2 Day 15. (NCT00835978)
Timeframe: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
| Intervention | hr (Mean) |
|---|---|
| Active Titration Arm | 2.48 |
| Placebo Titration Arm | 2.81 |
The time from first dose administration to first documentation of objective tumor progression or to death due to any cause. PFS in each arm was assessed using the Kaplan-Meier method and estimates of the PFS curves from the Kaplan-Meier method were presented. (NCT00835978)
Timeframe: Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks.
| Intervention | Months (Median) |
|---|---|
| Active Titration Arm | 14.5 |
| Placebo Titration Arm | 15.7 |
| Non-randomized Arm | 16.6 |
| All Participants | 14.6 |
Tmax for steady-state axitinib was evaluated on Cycle 2 Day 15. (NCT00835978)
Timeframe: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
| Intervention | hrs (Median) |
|---|---|
| Active Titration Arm | 2.04 |
| Placebo Titration Arm | 2.00 |
Value at respective visit minus value at baseline. (NCT00835978)
Timeframe: At screening (D-14 to D-1); lead-in period: Cycle 1 - Day 1 and Day 15; Cycle 2 - Day 1 and Day 15; Cycle 3 & subsequent cycles Day 1; end of study and follow-up 28 days after last dose.
| Intervention | mmHg (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=52,51,73) | Cycle 1 Day 15 (n=56,56,91) | Cycle 2 Day 1 (n=56,56,91) | Cycle 2 Day 15 (n=55,55,86) | Cycle 3 Day 1 (n=48,49,84) | Cycle 4 Day 1 (n=45,48,79) | End of treatment (n=35,44,51) | Follow-up (n=16,25,36) | |
| Active Titration Arm | -1.6 | 4.8 | 4.2 | 5.5 | 6.6 | 7.4 | 0.6 | -4.5 |
| Non-randomized Arm | 0.5 | 11.5 | 10.5 | 9.7 | 9.1 | 8.7 | 3.0 | 1.8 |
| Placebo Titration Arm | -2.6 | 3.0 | 3.5 | 4.4 | 5.9 | 4.6 | 3.5 | -1.3 |
Value at respective visit minus value at baseline (NCT00835978)
Timeframe: At screening (D-14 to D-1); lead-in period: Cycle 1 - Day 1 and Day 15; Cycle 2 - Day 1 and Day 15; Cycle 3 & subsequent cycles Day 1; end of study and follow-up 28 days after last dose.
| Intervention | mmHg (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=52,51,73) | Cycle 1 Day 15 (n=56,56,91) | Cycle 2 Day 1 (n=56,56,91) | Cycle 2 Day 15 (n=55,55,86) | Cycle 3 Day 1 (n=48,49,84) | Cycle 4 Day 1 (n=45,48,79) | End of treatment (n=35,44,51) | Follow-up (n=16,25,36) | |
| Active Titration Arm | -4.3 | 3.8 | 1.9 | 3.6 | 3.5 | 4.3 | 2.4 | -3.6 |
| Non-randomized Arm | -1.8 | 11.5 | 9.9 | 5.9 | 5.2 | 5.5 | -2.8 | -0.6 |
| Placebo Titration Arm | -2.9 | 4.1 | 0.9 | 2.7 | 8.4 | 3.5 | 1.7 | -0.4 |
CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD31+/CD146+ CECs, CD31+/CD146+ MFI PDGFR-beta, CD31+/CD146+ MFI pPDGFR-beta, CD31+/CD146+ pVEGFR, CD31+/CD146+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported. (NCT00835978)
Timeframe: At baseline - Beginning of the lead-in period (Cycle 1 Day 1)
| Intervention | Fluorescent Intensity Unit (FIU) (Mean) | ||||
|---|---|---|---|---|---|
| Baseline CECs Count (n=17,22,20) | Baseline MFI PDGFR-BETA (n=17,21,20) | Baseline MFI pPDGFR-BETA (n=17,21,20) | Baseline MFI pVEGFR (n=17,22,20) | Baseline MFI VEGFR (n=17,22,20) | |
| Active Titration Arm | 74668 | 333760 | 380139 | 385617 | 330333 |
| Non-randomized Arm | 77437 | 442642 | 383202 | 380184 | 359097 |
| Placebo Titration Arm | 76258 | 380886 | 355441 | 352644 | 401909 |
CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD146+/CD105+ CECs, CD146+/CD105+ mean fluorescence intensity (MFI) platelet derived growth factor receptor (PDGFR)-beta, CD146+/CD105+ MFI phospho-PDGFR (pPDGFR)-beta, CD146+/CD105+ phospho-Vascular endothelial growth factor receptor (pVEGFR), CD146+/CD105+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported. (NCT00835978)
Timeframe: At baseline - Beginning of the lead-in period (Cycle 1 Day 1)
| Intervention | Fluorescent Intensity Unit (FIU) (Mean) | ||||
|---|---|---|---|---|---|
| Baseline CECs Count (n=17,22,20) | Baseline MFI PDGFR-BETA (n=17,22,20) | Baseline MFI pPDGFR-BETA (n=17,22,20) | Baseline MFI pVEGFR (n=16,22,20) | Baseline MFI VEGFR (n=16,22,20) | |
| Active Titration Arm | 23584 | 346815 | 401226 | 456086 | 367799 |
| Non-randomized Arm | 29663 | 327567 | 397672 | 398754 | 359092 |
| Placebo Titration Arm | 28544 | 455238 | 395509 | 436197 | 473290 |
CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD31+/CD146+ CECs, CD31+/CD146+ MFI PDGFR-beta, CD31+/CD146+ MFI pPDGFR-beta, CD31+/CD146+ pVEGFR, CD31+/CD146+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported. (NCT00835978)
Timeframe: At end of the lead-in period (Cycle 1 Day 15), Cycle 2 Day 15 and End of therapy (EOT)
| Intervention | Ratio (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D15:C1D1 CECs Count (n=11,18,14) | C2D15:C1D1 CECs Count (n=13,16,11) | EOT:C1D1 CECs COUNT (n=7,9,4) | C1D15:C1D1 MFI PDGFRBETA (n=11,15,13) | C2D15:C1D1 MFI PDGFRBETA (n=13,14,11) | EOT:C1D1 MFI PDGFRBETA (n=6,8,4) | C1D15:C1D1 MFI pPDGFR-BETA (n=11,15,13) | C2D15:C1D1 MFI pPDGFR-BETA (n=13,14,11) | EOT:C1D1 MFI pPDGFRBETA (n=6,8,4) | C1D15:C1D1 MFI pVEGFR (n=11,18,14) | C2D15:C1D1 MFI pVEGFR (n=13,16,10) | EOT:C1D1 MFI pVEGFR (n=7,9,4) | C1D15:C1D1 MFI VEGFR (n=11,18,14) | C2D15:C1D1 MFI VEGFR n=13,16,10) | EOT:C1D1 MFI VEGFR (n=7,9,4) | |
| Active Titration Arm | 2.7 | 1.4 | 1.5 | 1.2 | 1.4 | 1.2 | 1.2 | 1.2 | 0.7 | 1.1 | 1.2 | 0.7 | 1.3 | 1.5 | 1.2 |
| Non-randomized Arm | 1.5 | 2.5 | 0.6 | 0.8 | 2.2 | 1.7 | 1.0 | 1.1 | 3.0 | 1.2 | 1.3 | 3.1 | 1.0 | 2.1 | 1.5 |
| Placebo Titration Arm | 1.6 | 2.2 | 1.4 | 1.3 | 1.1 | 0.6 | 1.4 | 0.8 | 0.8 | 1.4 | 0.9 | 1.1 | 1.3 | 1.2 | 1.1 |
CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD146+/CD105+ CECs, CD146+/CD105+ MFI platelet derived growth factor receptor (PDGFR)-beta, CD146+/CD105+ MFI phospho-PDGFR (pPDGFR)-beta, CD146+/CD105+ phospho-VEGFR (pVEGFR), CD146+/CD105+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported. (NCT00835978)
Timeframe: At end of the lead-in period (Cycle 1 Day 15), Cycle 2 Day 15 and End of therapy (EOT)
| Intervention | Ratio (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D15:C1D1 CECs Count (n=11,18,14) | C2D15:C1D1 CECs Count (n=13,16,11) | EOT:C1D1 CECs Count (n=7,9,4) | C1D15:C1D1 MFI PDGFRBETA (n=11,17,13) | C2D15:C1D1 MFI PDGFRBETA (n=13,16,11) | EOT:C1D1 MFI PDGFRBETA (n=7,9,4) | C1D15:C1D1 MFI pPDGFR-BETA (n=11,17,13) | C2D15:C1D1 MFI pPDGFR-BETA (n=13,16,11) | EOT:C1D1 MFI pPDGFRBETA (n=7,9,4) | C1D15:C1D1 MFI pVEGFR (n=10,18,14) | C2D15:C1D1 MFI pVEGFR (n=12,16,11) | EOT:C1D1 MFI pVEGFR (n=7,9,4) | C1D15:C1D1 MFI VEGFR (n=10,18,14) | C2D15:C1D1 MFI VEGFR (n=12,16,11) | EOT:C1D1 MFI VEGFR (n=7,9,4) | |
| Active Titration Arm | 2.3 | 1.3 | 2.8 | 1.3 | 1.4 | 1.5 | 1.1 | 1.0 | 0.8 | 1.0 | 1.0 | 0.8 | 1.4 | 1.5 | 1.1 |
| Non-randomized Arm | 2.2 | 1.3 | 1.2 | 1.1 | 2.2 | 1.2 | 1.0 | 1.2 | 1.9 | 1.2 | 1.2 | 3.0 | 1.0 | 2.1 | 1.9 |
| Placebo Titration Arm | 3.7 | 4.4 | 8.9 | 1.5 | 1.1 | 0.6 | 1.2 | 0.8 | 0.8 | 1.2 | 0.9 | 1.3 | 1.3 | 1.3 | 0.7 |
ORR, defined as proportion of participants with CR or PR according to RECIST, in subgroups that were defined by VEGFA or VEGFR3 polymorphisms. (NCT00835978)
Timeframe: At baseline - Beginning of the lead-in period (Cycle 1 Day 1)
| Intervention | Percentage of participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VEGFA/rs699947 Genotype: A/A (n = 7, 9, 14) | VEGFA/rs699947 Genotype: A/C (n = 22, 20, 41) | VEGFA/rs699947 Genotype: C/C (n = 14, 14, 24) | VEGFA/rs1570360 Genotype: G/G (n = 22, 23, 43) | VEGFA/rs1570360 Genotype: G/A (n = 19, 16, 29) | VEGFA/rs1570360 Genotype: A/A (n = 2, 4, 7) | VEGFR3/rs448012 Genotype: G/G (n = 16, 15, 28) | VEGFR3/rs448012 Genotype: G/C (n = 22, 22, 35) | VEGFR3/rs448012 Genotype: C/C (n = 5, 6, 16) | VEGFR3/rs307826 Genotype: A/A (n = 36, 39, 79) | VEGFR3/rs307826 Genotype: A/G (n = 6, 4, 9) | VEGFR3/rs307826 Genotype: G/G (n = 1, 0, 0) | VEGFR3/rs307821 Genotype: G/G (n = 36, 38, 79) | VEGFR3/rs307821 Genotype: G/T (n = 6, 5, 10) | VEGFR3/rs307821 Genotype: T/T (n = 1, 0, 0) | |
| Active Titration Arm | 85.7 | 54.5 | 50.0 | 59.1 | 57.9 | 50.0 | 81.3 | 45.5 | 40.0 | 58.3 | 50.0 | 100.0 | 55.6 | 66.7 | 100.0 |
| Non-randomized Arm | 42.9 | 65.9 | 66.7 | 67.4 | 58.6 | 42.9 | 60.7 | 57.1 | 75.0 | 64.3 | 44.4 | 0 | 65.2 | 40.0 | 0 |
| Placebo Titration Arm | 22.2 | 35.0 | 35.7 | 39.1 | 18.8 | 50.0 | 53.3 | 18.2 | 33.3 | 30.8 | 50.0 | 0 | 28.9 | 60.0 | 0 |
PFS, defined as the time from randomization to first documentation of objective tumor progression or to death due to any cause, in subgroups that were defined by VEGFA or VEGFR3 polymorphisms. Estimates of the PFS curves from the Kaplan-Meier method were presented. (NCT00835978)
Timeframe: At baseline - Beginning of the lead-in period (Cycle 1 Day 1)
| Intervention | Months (Median) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VEGFA/rs699947 Genotype: A/A (n = 7, 9, 14) | VEGFA/rs699947 Genotype: A/C (n = 22, 20, 41) | VEGFA/rs699947 Genotype: C/C (n = 14, 14, 41) | VEGFA/rs1570360 Genotype: G/G (n = 22, 23, 43) | VEGFA/rs1570360 Genotype: G/A (n = 19, 16, 29) | VEGFA/rs1570360 Genotype: A/A (n = 2, 4, 29) | VEGFR3/rs448012 Genotype: G/G (n = 16, 15, 28) | VEGFR3/rs448012 Genotype: G/C (n = 22, 22, 35) | VEGFR3/rs448012 Genotype: C/C (n = 5, 6, 16) | VEGFR3/rs307826 Genotype: A/A (n = 36, 39, 70) | VEGFR3/rs307826 Genotype: A/G (n = 6, 4, 9) | VEGFR3/rs307826 Genotype: G/G (n = 0, 0, 0) | VEGFR3/rs307821 Genotype: G/G (n = 36, 38, 69) | VEGFR3/rs307821 Genotype: G/T (n = 36, 38, 10) | VEGFR3/rs307821 Genotype: T/T (n = 1, 0, 0) | |
| Active Titration Arm | NA | 11.07 | 18.74 | 14.62 | 12.78 | NA | 17.44 | 9.18 | 11.07 | 13.73 | 16.52 | NA | 12.78 | 24.80 | NA |
| Non-randomized Arm | 7.33 | 16.59 | 25.13 | 25.13 | 13.90 | 8.57 | 22.54 | 13.83 | NA | 16.56 | 16.26 | NA | 16.59 | 13.86 | NA |
| Placebo Titration Arm | 11.50 | 9.67 | 24.64 | 19.42 | 8.34 | 10.04 | 19.42 | 8.31 | 15.67 | 15.67 | 7.93 | NA | 15.67 | 8.34 | NA |
Using RECIST criteria: date of 1st objective tumor response (CR or PR) subsequently confirmed to date of 1st objective tumor progression or to death due to any cause within 28 days after last dose of study medication, whichever was first. Censored on day after the date of the last oncologic assessment documenting no tumor progression. (NCT00137423)
Timeframe: 4 week treatment cycles up to 1 year in absence of withdrawal criteria requiring discontinuation includes 28 day post study follow up
| Intervention | weeks (Median) |
|---|---|
| AM Dose Sunitinib Malate (SU011248) | 24.0 |
| PM Dose Sunitinib Malate (SU011248) | 32.0 |
Confirmed objective responses using RECIST criteria defined as responses persisting on repeat imaging study for 2 assessments with at least 4 weeks between, and evaluating all target and non-target sites followed since baseline. Two PRs separated by an SD or NE visit in between was considered a confirmed response if the 2 PRs were > 4 weeks apart. CR=disappearance of all target lesions. PR is a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. (NCT00137423)
Timeframe: 4 week treatment cycles up to 1 year in absence of withdrawal criteria requiring discontinuation includes 28 day post study follow up
| Intervention | participants (Number) |
|---|---|
| AM Dose Sunitinib Malate (SU011248) | 15 |
| PM Dose Sunitinib Malate (SU011248) | 6 |
Overall survival is time from the date of first dose of medication to the date of death due to any cause (NCT00137423)
Timeframe: 4 week treatment cycles up to 1 year in absence of withdrawal criteria requiring discontinuation includes 28 day post study follow up
| Intervention | weeks (Median) |
|---|---|
| AM Dose Sunitinib Malate (SU011248) | 91.4 |
| PM Dose Sunitinib Malate (SU011248) | 76.4 |
Using RECIST criteria: Time from date 1st dose study medication to date 1st documentation of objective tumor progression or death due to any cause occurring on treatment including within 28 days after last dose, whichever occurred 1st. Censored on day following the date of last oncologic assessment documenting absence of tumor progression. PFS based on the number of subjects with measurable disease at baseline, the correct histological cancer type, and had disease that was refractory to prior cytokine-based therapy(105 in total group). (NCT00137423)
Timeframe: 4 week treatment cycles up to 1 year in absence of withdrawal criteria requiring discontinuation includes 28 day post study follow up
| Intervention | weeks (Median) |
|---|---|
| AM Dose Sunitinib Malate (SU011248) | 35.7 |
| PM Dose Sunitinib Malate (SU011248) | 35.3 |
Time from date of first dose of study medication to date of first documentation of objective tumor progression using RECIST criteria that occurred on treatment including within 28 days after the last dose of study medication. TTP censored on the day following the date of last oncologic assessment documenting absence of tumor progression. TTP based on the number of subjects with measurable disease at baseline, the correct histological cancer type, and had disease that was refractory to prior cytokine-based therapy(105 in total group). (NCT00137423)
Timeframe: 4 week treatment cycles up to 1 year in absence of withdrawal criteria requiring discontinuation includes 28 day post study follow up
| Intervention | weeks (Median) |
|---|---|
| AM Dose Sunitinib Malate (SU011248) | 35.7 |
| PM Dose Sunitinib Malate (SU011248) | 35.9 |
EQ-5D health status in 5 dimensions (mobility, self-care, pain / discomfort, anxiety / depression, usual activities) with a weighted health index based on general population values where 0.0=death and 1.0 = perfect health. Change: median index score at observation minus median index score at baseline. (NCT00137423)
Timeframe: Day 1 and day 15 of each treatment cycle from cycle 1 to cycle 4; day 1 of each treatment cycle after cycle 4 up to one year.
| Intervention | score on scale (Median) | |
|---|---|---|
| Maximum Increase | Maximum Decrease | |
| AM Dose Sunitinib Malate (SU011248) | 0.0 | 0.0 |
| PM Dose Sunitinib Malate (SU011248) | 0.0 | -0.1 |
"EQ-VAS score on the self-rated thermometer indicated the patient's own assessment of their health status from 0 (worst) to 100 (best) imaginable health state. Change: median score at observation minus median score at baseline. Maximum changes (increase or decrease from baseline)." (NCT00137423)
Timeframe: Day 1 and day 15 of each treatment cycle from cycle 1 to cycle 4; day 1 of each treatment cycle after cycle 4 up to one year.
| Intervention | score on scale (Median) | |
|---|---|---|
| Maximum Increase | Maximum Decrease | |
| AM Dose Sunitinib Malate (SU011248) | 0.0 | -10.0 |
| PM Dose Sunitinib Malate (SU011248) | 0.0 | -9.0 |
FACIT Fatigue Scale: Overall score from 13-questionnaire, which measures fatigue / asthenia for patients with chronic, life-threatening illnesses. For each question, a patient rates his / her condition for the past week on a 5-point Likert scale ranging from 0 (not at all) to 4 (very much). Higher scores always represent less fatigue / asthenia. Outcome based on completed questionnaires. (NCT00137423)
Timeframe: Day 1 and day 15 of each treatment cycle from cycle 1 to cycle 4; day 1 of each treatment cycle after cycle 4 up to one year.
| Intervention | score on scale (Mean) | ||
|---|---|---|---|
| Baseline Score n=52,52 | Maximum Post-Baseline Score n=53,52 | Minimum Post-Baseline Score n=53,52 | |
| AM Dose Sunitinib Malate | 39.5 | 43.4 | 28.0 |
| PM Dose Sunitinib Malate | 39.6 | 42.7 | 29.4 |
OS was defined as the time from randomization to death due to any cause, censored at the last date known alive. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). (NCT00631371)
Timeframe: Baseline until death due to any cause, assessed every 8 weeks (up to cut-off date: 19 April 2012)
| Intervention | months (Median) |
|---|---|
| Bevacizumab+Temsirolimus | 25.8 |
| Bevacizumab+ Interferon-Alfa | 25.5 |
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30% decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent. (NCT00631371)
Timeframe: Baseline until disease progression, initiation of new anticancer treatment, or death, assessed every 8 weeks (up to cut-off date: 19 April 2012)
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab+Temsirolimus | 27.0 |
| Bevacizumab+ Interferon-Alfa | 27.4 |
PFS was defined as the interval from the date of randomization until the earlier date of progression or death. Progression was assessed by independent imaging reviewers using Response Evaluation Criteria in Solid Tumors (RECIST) criteria which is 20% increase in sum of longest diameter of target lesions from nadir (the lowest blood counts); measurable increase in non-target lesion; appearance of new lesions. (NCT00631371)
Timeframe: Baseline until disease progression, initiation of new anticancer treatment, or death, assessed every 8 weeks (up to cut-off date: 19 April 2012)
| Intervention | months (Median) |
|---|---|
| Bevacizumab+Temsirolimus | 9.1 |
| Bevacizumab+ Interferon-Alfa | 9.3 |
PFS was defined as the interval from the date of randomization until the earlier date of progression or death. Progression was assessed by investigator imaging reviewers using RECIST criteria which is 20% increase in sum of longest diameter of target lesions from nadir (the lowest blood counts); measurable increase in non-target lesion; appearance of new lesions. (NCT00631371)
Timeframe: Baseline until disease progression, initiation of new anticancer treatment, or death, assessed every 8 weeks (up to cut-off date: 19 April 2012)
| Intervention | months (Median) |
|---|---|
| Bevacizumab+Temsirolimus | 9.1 |
| Bevacizumab+ Interferon-Alfa | 10.8 |
One year survival rate defined as the probability that a subject was alive 1 year after the date of first study treatment. (NCT00338884)
Timeframe: From start of treatment through Day 1 of Weeks 5, 9, and every 8 weeks thereafter up until 1 year
| Intervention | percent chance of survival (Median) |
|---|---|
| Sunitinib | 67.8 |
Time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or to death due to to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. DR was calculated as [the end date for DR minus first CR or PR that was subsequently confirmed +1]/7. (NCT00338884)
Timeframe: From start of treatment through Day 1 of Weeks 5, 9, and every 8 weeks thereafter or death due to any cause
| Intervention | months (Mean) |
|---|---|
| Sunitinib | 7.14 |
OR = subjects with confirmed complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) persisting > = 4 weeks after initial documentation of response. A CR was defined as the disappearance of all target lesions. A PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. (NCT00338884)
Timeframe: From start of treatment through Day 1 of Weeks 5, 9, and every 8 weeks thereafter
| Intervention | participants (Number) |
|---|---|
| Sunitinib | 41 |
Time from start of study medication to first documentation of objective tumor progression or to death due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. PFS (in months) was calculated as (first event date minus first dose date +1)/7. (NCT00338884)
Timeframe: From start of treatment through Day 1 of Weeks 5, 9, and every 8 weeks thereafter or death
| Intervention | months (Median) |
|---|---|
| Sunitinib | 9.0 |
(NCT00338884)
Timeframe: Baseline
| Intervention | pg/mL (Mean) |
|---|---|
| Sunitinib | 9163.4 |
Time from date of first dose of study medication to first documentation of objective tumor progression. The 50% quartile point estimate is provided. The criteria for tumor progression was according to RECIST. (NCT00338884)
Timeframe: From start of treatment through Day 1 of Weeks 5, 9, and every 8 weeks thereafter
| Intervention | months (Median) |
|---|---|
| Sunitinib | 10.0 |
(NCT00338884)
Timeframe: Baseline
| Intervention | picograms (pg)/mL (Mean) |
|---|---|
| Sunitinib | 154.8 |
FACT-Advanced Kidney Cancer Symptom Index (FKSI) Questionnaire: subscale designed to be a stand-alone instrument to measure symptoms and quality of life in patients with advanced kidney cancer. Contains 15 questions. Each question was answered on a 5-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Total FKSI score = sum score of the 15 item scores; total range: 0 - 60; 0 (most severe symptoms and concerns) to 60 (no symptoms or concerns). End of treatment assessment was for subjects who completed the study only. (NCT00338884)
Timeframe: Baseline (Day 1, Week 1), Day 1 of Weeks 3, 5, 7, 9, 11, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, Week 53 (End of Treatment)
| Intervention | scores on a scale (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=109) | Week 3 (n=104) | Week 5 (n=101) | Week 7 (n=97) | Week 9 (n=88) | Week 11 (n=84) | Week 13 (n=81) | Week 17 (n=72) | Week 21 (n=63) | Week 25 (n=55) | Week 29 (n=55) | Week 33 (n=50) | Week 37 (n=47) | Week 41 (n=45) | Week 45 (n=37) | Week 49 (n=36) | Week 53 (End of Treatment) (n=35) | |
| Sunitinib | 44.68 | 43.69 | 42.71 | 43.69 | 44.11 | 43.26 | 43.49 | 44.21 | 45.51 | 45.42 | 44.64 | 44.06 | 45.23 | 44.71 | 46.73 | 45.92 | 45.94 |
Ctrough = the concentration prior to study drug administration. (NCT00338884)
Timeframe: Predose on Day 1 of Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53
| Intervention | ng/mL (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, Week 1 (n=111) | Day 1, Week 3 (n=108) | Day 1, Week 5 (n=106) | Day 1, Week 7 (n=104) | Day 1, Week 9 (n=97) | Day 1, Week 13 (n=93) | Day 1, Week 17 (n=82) | Day 1, Week 21 (n=73) | Day 1, Week 25 (n=70) | Day 1, Week 29 (n=58) | Day 1, Week 33 (n=58) | Day 1, Week 37 (n=50) | Day 1, Week 41 (n=49) | Day 1, Week 45 (n=44) | Day 1, Week 49 (n=40) | Day 1, Week 53 (n=33) | |
| Sunitinib | 2.62 | 20.27 | 20.25 | 20.41 | 21.18 | 20.01 | 19.76 | 17.13 | 17.30 | 17.38 | 16.55 | 15.71 | 16.50 | 15.61 | 16.57 | 13.81 |
Ctrough = the concentration prior to study drug administration. (NCT00338884)
Timeframe: Predose on Day 1 of Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53
| Intervention | ng/mL (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, Week 1 (n=111) | Day 1, Week 3 (n=108) | Day 1, Week 5 (n=106) | Day 1, Week 7 (n=104) | Day 1, Week 9 (n=97) | Day 1, Week 13 (n=93) | Day 1, Week 17 (n=82) | Day 1, Week 21 (n=73) | Day 1, Week 25 (n=70) | Day 1, Week 29 (n=58) | Day 1, Week 33 (n=58) | Day 1, Week 37 (n=50) | Day 1, Week 41 (n=49) | Day 1, Week 45 (n=44) | Day 1, Week 49 (n=40) | Day 1, Week 53 (n=33) | |
| Sunitinib | 9.77 | 75.04 | 65.89 | 66.76 | 68.72 | 61.31 | 61.41 | 53.09 | 53.69 | 55.39 | 50.27 | 51.74 | 49.83 | 51.82 | 53.07 | 46.91 |
Summary statistics of ctrough at each time point by group (CR or PR versus PD) are presented. (NCT00338884)
Timeframe: Predose on Day 1 of Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53
| Intervention | ng/mL (Median) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, Week 1 (CR or PR, n=39) | Day 1, Week 3 (CR or PR, n=40) | Day 1, Week 5 (CR or PR, n=38) | Day 1, Week 7 (CR or PR, n=40) | Day 1, Week 9 (CR or PR, n=38) | Day 1, Week 13 (CR or PR, n=41) | Day 1, Week 17 (CR or PR, n=38) | Day 1, Week 21 (CR or PR, n=38) | Day 1, Week 25 (CR or PR, n=37) | Day 1, Week 29 (CR or PR, n=32) | Day 1, Week 33 (CR or PR, n=33) | Day 1, Week 37 (CR or PR, n=28) | Day 1, Week 41 (CR or PR, n=28) | Day 1, Week 45 (CR or PR, n=29) | Day 1, Week 49 (CR or PR, n=26) | Day 1, Week 53 (CR or PR, n=21) | Day 1, Week 1 (PD, n=16) | Day 1, Week 3 (PD, n=15) | Day 1, Week 5 (PD, n=15) | Day 1, Week 7 (PD, n=13) | Day 1, Week 9 (PD, n=8) | Day 1, Week 13 (PD, n=1) | Day 1, Week 17 (PD, n=1) | Day 1, Week 21 (PD, n=1) | Day 1, Week 25 (PD, n=1) | Day 1, Week 29 (PD, n=1) | Day 1, Week 33 (PD, n=1) | |
| Sunitinib | 0.000 | 18.250 | 16.650 | 17.300 | 15.100 | 15.900 | 14.300 | 12.600 | 14.500 | 12.850 | 12.800 | 14.350 | 14.000 | 13.400 | 14.700 | 11.600 | 0.000 | 20.000 | 18.800 | 14.300 | 16.550 | 9.710 | 12.600 | 23.400 | 29.400 | 13.700 | 4.360 |
Summary statistics of ctrough at each time point by group (CR or PR versus PD) are presented. (NCT00338884)
Timeframe: Predose on Day 1 of Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53
| Intervention | ng/mL (Median) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, Week 1 (CR or PR, n=39) | Day 1, Week 3 (CR or PR, n=40) | Day 1, Week 5 (CR or PR, n=38) | Day 1, Week 7 (CR or PR, n=40) | Day 1, Week 9 (CR or PR, n=38) | Day 1, Week 13 (CR or PR, n=41) | Day 1, Week 17 (CR or PR, n=38) | Day 1, Week 21 (CR or PR, n=38) | Day 1, Week 25 (CR or PR, n=37) | Day 1, Week 29 (CR or PR, n=32) | Day 1, Week 33 (CR or PR, n=33) | Day 1, Week 37 (CR or PR, n=28) | Day 1, Week 41 (CR or PR, n=28) | Day 1, Week 45 (CR or PR, n=29) | Day 1, Week 49 (CR or PR, n=26) | Day 1, Week 53 (CR or PR, n=21) | Day 1, Week 1 (PD, n=16) | Day 1, Week 3 (PD, n=15) | Day 1, Week 5 (PD, n=15) | Day 1, Week 7 (PD, n=13) | Day 1, Week 9 (PD, n=8) | Day 1, Week 13 (PD, n=1) | Day 1, Week 17 (PD, n=1) | Day 1, Week 21 (PD, n=1) | Day 1, Week 25 (PD, n=1) | Day 1, Week 29 (PD, n=1) | Day 1, Week 33 (PD, n=1) | |
| Sunitinib | 0.000 | 76.950 | 65.900 | 66.100 | 65.150 | 57.600 | 55.660 | 47.370 | 50.700 | 50.650 | 46.000 | 49.750 | 43.365 | 45.200 | 49.975 | 41.000 | 0.000 | 69.000 | 64.700 | 50.200 | 55.850 | 34.810 | 40.800 | 71.100 | 52.100 | 37.400 | 13.880 |
Summary statistics of ctrough at each time point by group (CR or PR versus PD) are presented. (NCT00338884)
Timeframe: Predose on Day 1 of Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53
| Intervention | ng/mL (Median) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, Week 1 (CR or PR, n=39) | Day 1, Week 3 (CR or PR, n=40) | Day 1, Week 5 (CR or PR, n=38) | Day 1, Week 7 (CR or PR, n=40) | Day 1, Week 9 (CR or PR, n=38) | Day 1, Week 13 (CR or PR, n=41) | Day 1, Week 17 (CR or PR, n=38) | Day 1, Week 21 (CR or PR, n=38) | Day 1, Week 25 (CR or PR, n=37) | Day 1, Week 29 (CR or PR, n=32) | Day 1, Week 33 (CR or PR, n=33) | Day 1, Week 37 (CR or PR, n=28) | Day 1, Week 41 (CR or PR, n=28) | Day 1, Week 45 (CR or PR, n=29) | Day 1, Week 49 (CR or PR, n=26) | Day 1, Week 53 (CR or PR, n=21) | Day 1, Week 1 (PD, n=16) | Day 1, Week 3 (PD, n=15) | Day 1, Week 5 (PD, n=15) | Day 1, Week 7 (PD, n=13) | Day 1, Week 9 (PD, n=8) | Day 1, Week 13 (PD, n=1) | Day 1, Week 17 (PD, n=1) | Day 1, Week 21 (PD, n=1) | Day 1, Week 25 (PD, n=1) | Day 1, Week 29 (PD, n=1) | Day 1, Week 33 (PD, n=1) | |
| Sunitinib | 0.000 | 57.900 | 45.000 | 45.400 | 46.250 | 40.000 | 41.350 | 34.400 | 34.200 | 34.450 | 33.000 | 35.350 | 30.900 | 34.000 | 36.250 | 28.600 | 0.000 | 50.200 | 45.600 | 35.600 | 39.050 | 25.100 | 28.200 | 47.700 | 22.700 | 23.700 | 9.520 |
Summary statistics of ctrough at each time point by group (CR or PR or SD versus PD) are presented. (NCT00338884)
Timeframe: Predose on Day 1 of Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53
| Intervention | ng/mL (Median) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, Week 1 (CR or PR or SD, n=83) | Day 1, Week 3 (CR or PR or SD, n=83) | Day 1, Week 5 (CR or PR or SD, n=83) | Day 1, Week 7 (CR or PR or SD, n=86) | Day 1, Week 9 (CR or PR or SD, n=85) | Day 1, Week 13 (CR or PR or SD, n=88) | Day 1, Week 17 (CR or PR or SD, n=79) | Day 1, Week 21 (CR or PR or SD, n=71) | Day 1, Week 25 (CR or PR or SD, n=68) | Day 1, Week 29 (CR or PR or SD, n=56) | Day 1, Week 33 (CR or PR or SD, n=56) | Day 1, Week 37 (CR or PR or SD, n=49) | Day 1, Week 41 (CR or PR or SD, n=49) | Day 1, Week 45 (CR or PR or SD, n=44) | Day 1, Week 49 (CR or PR or SD, n=40) | Day 1, Week 53 (CR or PR or SD, n=32) | Day 1, Week 1 (PD, n=16) | Day 1, Week 3 (PD, n=15) | Day 1, Week 5 (PD, n=15) | Day 1, Week 7 (PD, n=13) | Day 1, Week 9 (PD, n=8) | Day 1, Week 13 (PD, n=1) | Day 1, Week 17 (PD, n=1) | Day 1, Week 21 (PD, n=1) | Day 1, Week 25 (PD, n=1) | Day 1, Week 29 (PD, n=1) | Day 1, Week 33 (PD, n=1) | |
| Sunitinib | 0.000 | 18.800 | 17.300 | 17.900 | 18.700 | 16.350 | 14.600 | 14.100 | 14.950 | 14.900 | 14.050 | 15.500 | 15.400 | 13.700 | 14.700 | 11.450 | 0.000 | 20.000 | 18.800 | 14.300 | 16.550 | 9.710 | 12.600 | 23.400 | 29.400 | 13.700 | 4.360 |
Summary statistics of ctrough at each time point by group (CR or PR or SD versus PD) are presented. (NCT00338884)
Timeframe: Predose on Day 1 of Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53
| Intervention | ng/mL (Median) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, Week 1 (CR or PR or SD, n=83) | Day 1, Week 3 (CR or PR or SD, n=83) | Day 1, Week 5 (CR or PR or SD, n=83) | Day 1, Week 7 (CR or PR or SD, n=86) | Day 1, Week 9 (CR or PR or SD, n=85) | Day 1, Week 13 (CR or PR or SD, n=88) | Day 1, Week 17 (CR or PR or SD, n=79) | Day 1, Week 21 (CR or PR or SD, n=71) | Day 1, Week 25 (CR or PR or SD, n=68) | Day 1, Week 29 (CR or PR or SD, n=56) | Day 1, Week 33 (CR or PR or SD, n=56) | Day 1, Week 37 (CR or PR or SD, n=49) | Day 1, Week 41 (CR or PR or SD, n=49) | Day 1, Week 45 (CR or PR or SD, n=44) | Day 1, Week 49 (CR or PR or SD, n=40) | Day 1, Week 53 (CR or PR or SD, n=32) | Day 1, Week 1 (PD, n=16) | Day 1, Week 3 (PD, n=15) | Day 1, Week 5 (PD, n=15) | Day 1, Week 7 (PD, n=13) | Day 1, Week 9 (PD, n=8) | Day 1, Week 13 (PD, n=1) | Day 1, Week 17 (PD, n=1) | Day 1, Week 21 (PD, n=1) | Day 1, Week 25 (PD, n=1) | Day 1, Week 29 (PD, n=1) | Day 1, Week 33 (PD, n=1) | |
| Sunitinib | 0.000 | 75.000 | 63.300 | 66.400 | 70.600 | 57.600 | 58.100 | 49.860 | 51.150 | 53.500 | 50.050 | 50.800 | 48.000 | 50.500 | 54.885 | 42.160 | 0.000 | 69.000 | 64.700 | 50.200 | 55.850 | 34.810 | 40.800 | 71.100 | 52.100 | 37.400 | 13.880 |
Summary statistics of ctrough at each time point by group (CR or PR or SD versus PD) are presented. (NCT00338884)
Timeframe: Predose on Day 1 of Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53
| Intervention | ng/mL (Median) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, Week 1 (CR or PR or SD, n=83) | Day 1, Week 3 (CR or PR or SD, n=83) | Day 1, Week 5 (CR or PR or SD, n=83) | Day 1, Week 7 (CR or PR or SD, n=86) | Day 1, Week 9 (CR or PR or SD, n=85) | Day 1, Week 13 (CR or PR or SD, n=88) | Day 1, Week 17 (CR or PR or SD, n=79) | Day 1, Week 21 (CR or PR or SD, n=71) | Day 1, Week 25 (CR or PR or SD, n=68) | Day 1, Week 29 (CR or PR or SD, n=56) | Day 1, Week 33 (CR or PR or SD, n=56) | Day 1, Week 37 (CR or PR or SD, n=49) | Day 1, Week 41 (CR or PR or SD, n=49) | Day 1, Week 45 (CR or PR or SD, n=44) | Day 1, Week 49 (CR or PR or SD, n=40) | Day 1, Week 53 (CR or PR or SD, n=32) | Day 1, Week 1 (PD, n=16) | Day 1, Week 3 (PD, n=15) | Day 1, Week 5 (PD, n=15) | Day 1, Week 7 (PD, n=13) | Day 1, Week 9 (PD, n=8) | Day 1, Week 13 (PD, n=1) | Day 1, Week 17 (PD, n=1) | Day 1, Week 21 (PD, n=1) | Day 1, Week 25 (PD, n=1) | Day 1, Week 29 (PD, n=1) | Day 1, Week 33 (PD, n=1) | |
| Sunitinib | 0.000 | 55.300 | 44.600 | 46.750 | 49.500 | 39.550 | 42.300 | 36.500 | 35.500 | 37.250 | 34.400 | 35.300 | 33.200 | 35.950 | 37.250 | 31.100 | 0.000 | 50.200 | 45.600 | 35.600 | 39.050 | 25.100 | 28.200 | 47.700 | 22.700 | 23.700 | 9.520 |
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Scale: Overall score from 13-question questionnaire (measures fatigue/asthenia for patients with chronic, life-threatening illnesses). For each question, patient rates condition for the past week on a 5-point Likert scale ranging from 0 (not at all) to 4 (very much). Total FACIT-Fatigue score = sum score of the 13 question scores; total range: 0 - 52; higher total score represents less fatigue. End of treatment assessment was for subjects who completed the study only. (NCT00338884)
Timeframe: Baseline (Day 1, Week 1), Day 1 of Weeks 3, 5, 7, 9, 11, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, Week 53 (End of Treatment)
| Intervention | scores on a scale (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=118) | Week 3 (n=113) | Week 5 (n=110) | Week 7 (n=106) | Week 9 (n=97) | Week 11 (n=93) | Week 13 (n=90) | Week 17 (n=80) | Week 21 (n=71) | Week 25 (n=62) | Week 29 (n=60) | Week 33 (n=55) | Week 37 (n=52) | Week 41 (n=50) | Week 45 (n=42) | Week 49 (n=41) | Week 53 (End of Treatment) (n=40) | |
| Sunitinib | 39.29 | 36.98 | 35.44 | 36.54 | 36.82 | 35.94 | 36.58 | 37.44 | 38.42 | 38.05 | 36.77 | 36.00 | 37.88 | 36.96 | 38.71 | 39.32 | 39.05 |
Summary statistics of sVEGFR2 at baseline by group (CR or PR or SD versus PD) are presented. (NCT00338884)
Timeframe: Baseline (Cycle 1, Day 1)
| Intervention | pg/mL (Median) | |
|---|---|---|
| Cycle 1, Day 1 (CR or PR or SD, n=85) | Cycle 1, Day 1 (PD, n=16) | |
| Sunitinib | 9772.500 | 8342.750 |
Summary statistics of sVEGFR2 at baseline by group (CR or PR versus PD) are presented. (NCT00338884)
Timeframe: Baseline (Cycle 1, Day 1)
| Intervention | pg/mL (Median) | |
|---|---|---|
| Cycle 1, Day 1 (CR or PR, n=40) | Cycle 1, Day 1 (PD, n=16) | |
| Sunitinib | 9968.000 | 8342.750 |
sVEGFR2 concentration at each time point divided by sVEGFR2 concentration at baseline (ratio to baseline). (NCT00338884)
Timeframe: Baseline to Day 1 of Weeks 3 through 53
| Intervention | ratio (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, Week 3 (n=106) | Day 1, Week 5 (n=104) | Day 1, Week 7 (n=101) | Day 1, Week 9 (n=95) | Day 1, Week 13 (n=91) | Day 1, Week 17 (n=79) | Day 1, Week 21 (n=69) | Day 1, Week 25 (n=68) | Day 1, Week 29 (n=55) | Day 1, Week 33 (n=55) | Day 1, Week 37 (n=50) | Day 1, Week 41 (n=48) | Day 1, Week 45 (n=42) | Day 1, Week 49 (n=38) | Day 1, Week 53 (n=31) | |
| Sunitinib | 0.7 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.7 |
Median sVEGFR2 concentration at each time point divided by sVEGFR2 concentration at baseline (ratio to baseline) for subjects with tumor response (CR or PR or [SD > = 12 weeks] versus PD). (NCT00338884)
Timeframe: Baseline to Day 1 of Weeks 3 through 53
| Intervention | ratio (Median) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, Week 3 (CR or PR or SD, n=81) | Day 1, Week 3 (PD, n=15) | Day 1, Week 5 (CR or PR or SD, n=81) | Day 1, Week 5 (PD, n=15) | Day 1, Week 7 (CR or PR or SD, n=84) | Day 1, Week 7 (PD, n=13) | Day 1, Week 9 (CR or PR or SD, n=83) | Day 1, Week 9 (PD, n=8) | Day 1, Week 13 (CR or PR or SD, n=85) | Day 1, Week 13 (PD, n=2) | Day 1, Week 17 (CR or PR or SD, n=77) | Day 1, Week 17 (PD, n=1) | Day 1, Week 21 (CR or PR or SD, n=67) | Day 1, Week 21 (PD, n=1) | Day 1, Week 25 (CR or PR or SD, n=66) | Day 1, Week 25 (PD, n=1) | Day 1, Week 29 (CR or PR or SD, n=53) | Day 1, Week 29 (PD, n=1) | Day 1, Week 33 (CR or PR or SD, n=54) | Day 1, Week 33 (PD, n=1) | Day 1, Week 37 (CR or PR or SD, n=49) | Day 1, Week 41 (CR or PR or SD, n=48) | Day 1, Week 45 (CR or PR or SD, n=42) | Day 1, Week 49 (CR or PR or SD, n=38) | Day 1, Week 53 (CR or PR or SD, n=30) | |
| Sunitinib | 0.691 | 0.653 | 0.625 | 0.531 | 0.599 | 0.574 | 0.563 | 0.603 | 0.534 | 0.529 | 0.524 | 0.687 | 0.548 | 0.540 | 0.570 | 0.509 | 0.556 | 0.671 | 0.569 | 0.610 | 0.559 | 0.572 | 0.538 | 0.569 | 0.638 |
Median sVEGFR2 concentration at each time point divided by sVEGFR2 concentration at baseline (ratio to baseline) for subjects with tumor response (CR or PR versus PD). (NCT00338884)
Timeframe: Baseline to Day 1 of Weeks 3 through 53
| Intervention | ratio (Median) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, Week 3 (CR or PR, n=39) | Day 1, Week 3 (PD, n=15) | Day 1, Week 5 (CR or PR, n=38) | Day 1, Week 5 (PD, n=15) | Day 1, Week 7 (CR or PR, n=40) | Day 1, Week 7 (PD, n=13) | Day 1, Week 9 (CR or PR, n=38) | Day 1, Week 9 (PD, n=8) | Day 1, Week 13 (CR or PR, n=40) | Day 1, Week 13 (PD, n=2) | Day 1, Week 17 (CR or PR, n=37) | Day 1, Week 17 (PD, n=1) | Day 1, Week 21 (CR or PR, n=36) | Day 1, Week 21 (PD, n=1) | Day 1, Week 25 (CR or PR, n=36) | Day 1, Week 25 (PD, n=1) | Day 1, Week 29 (CR or PR, n=30) | Day 1, Week 29 (PD, n=1) | Day 1, Week 33 (CR or PR, n=32) | Day 1, Week 33 (PD, n=1) | Day 1, Week 37 (CR or PR, n=29) | Day 1, Week 41 (CR or PR, n=29) | Day 1, Week 45 (CR or PR, n=28) | Day 1, Week 49 (CR or PR, n=25) | Day 1, Week 53 (CR or PR, n=20) | |
| Sunitinib | 0.704 | 0.653 | 0.638 | 0.531 | 0.596 | 0.574 | 0.562 | 0.603 | 0.555 | 0.529 | 0.545 | 0.687 | 0.566 | 0.540 | 0.564 | 0.509 | 0.564 | 0.671 | 0.547 | 0.610 | 0.554 | 0.561 | 0.535 | 0.555 | 0.630 |
Ctrough = the concentration prior to study drug administration. (NCT00338884)
Timeframe: Predose on Day 1 of Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53
| Intervention | nanograms (ng)/milliliter (mL) (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, Week 1 (n=111) | Day 1, Week 3 (n=108) | Day 1, Week 5 (n=106) | Day 1, Week 7 (n=104) | Day 1, Week 9 (n=97) | Day 1, Week 13 (n=93) | Day 1, Week 17 (n=82) | Day 1, Week 21 (n=73) | Day 1, Week 25 (n=70) | Day 1, Week 29 (n=58) | Day 1, Week 33 (n=58) | Day 1, Week 37 (n=50) | Day 1, Week 41 (n=49) | Day 1, Week 45 (n=44) | Day 1, Week 49 (n=40) | Day 1, Week 53 (n=33) | |
| Sunitinib | 7.15 | 54.78 | 45.64 | 46.35 | 47.54 | 41.29 | 41.65 | 35.95 | 36.39 | 38.01 | 33.72 | 36.04 | 33.33 | 36.20 | 36.49 | 33.10 |
Summary statistics of VEGF at baseline by group (CR or PR or SD versus PD) are presented. (NCT00338884)
Timeframe: Baseline (Cycle 1, Day 1)
| Intervention | pg/mL (Median) | |
|---|---|---|
| Cycle 1, Day 1 (CR or PR or SD, n=85) | Cycle 1, Day 1 (PD, n=16) | |
| Sunitinib | 86.400 | 109.300 |
Summary statistics of VEGF at baseline by group (CR or PR versus PD) are presented. (NCT00338884)
Timeframe: Baseline (Cycle 1, Day 1)
| Intervention | pg/mL (Median) | |
|---|---|---|
| Cycle 1, Day 1 (CR or PR, n=39) | Cycle 1, Day 1 (PD, n=16) | |
| Sunitinib | 73.600 | 109.300 |
VEGF concentration at each time point divided by VEGF concentration at baseline (ratio to baseline). (NCT00338884)
Timeframe: Baseline to Day 1 of Weeks 3 through 53
| Intervention | ratio (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, Week 3 (n=108) | Day 1, Week 5 (n=104) | Day 1, Week 7 (n=101) | Day 1, Week 9 (n=95) | Day 1, Week 13 (n=91) | Day 1, Week 17 (n=78) | Day 1, Week 21 (n=70) | Day 1, Week 25 (n=67) | Day 1, Week 29 (n=55) | Day 1, Week 33 (n=54) | Day 1, Week 37 (n=49) | Day 1, Week 41 (n=48) | Day 1, Week 45 (n=41) | Day 1, Week 49 (n=37) | Day 1, Week 53 (n=30) | |
| Sunitinib | 2.9 | 2.6 | 2.6 | 3.4 | 3.2 | 2.8 | 2.6 | 3 | 2.5 | 2.3 | 2.7 | 5.5 | 2.9 | 2.8 | 3.2 |
Median VEGF concentration at each time point divided by VEGF concentration at baseline (ratio to baseline) for subjects with tumor response (CR or PR or [SD > = 12 weeks] versus PD). (NCT00338884)
Timeframe: Baseline to Day 1 of Weeks 3 through 53
| Intervention | ratio (Median) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, Week 3 (CR or PR or SD, n=83) | Day 1, Week 3 (PD, n=15) | Day 1, Week 5 (CR or PR or SD, n=81) | Day 1, Week 5 (PD, n=15) | Day 1, Week 7 (CR or PR or SD, n=84) | Day 1, Week 7 (PD, n=13) | Day 1, Week 9 (CR or PR or SD, n=83) | Day 1, Week 9 (PD, n=8) | Day 1, Week 13 (CR or PR or SD, n=85) | Day 1, Week 13 (PD, n=2) | Day 1, Week 17 (CR or PR or SD, n=76) | Day 1, Week 17 (PD, n=1) | Day 1, Week 21 (CR or PR or SD, n=68) | Day 1, Week 21 (PD, n=1) | Day 1, Week 25 (CR or PR or SD, n=65) | Day 1, Week 25 (PD, n=1) | Day 1, Week 29 (CR or PR or SD, n=53) | Day 1, Week 29 (PD, n=1) | Day 1, Week 33 (CR or PR or SD, n=53) | Day 1, Week 33 (PD, n=1) | Day 1, Week 37 (CR or PR or SD, n=48) | Day 1, Week 41 (CR or PR or SD, n=48) | Day 1, Week 45 (CR or PR or SD, n=41) | Day 1, Week 49 (CR or PR or SD, n=37) | Day 1, Week 53 (CR or PR or SD, n=29) | |
| Sunitinib | 2.127 | 1.948 | 1.574 | 2.471 | 1.798 | 1.405 | 2.481 | 1.176 | 1.890 | 3.921 | 2.070 | 0.988 | 1.972 | 1.510 | 1.906 | 1.433 | 1.831 | 1.929 | 2.200 | 1.063 | 2.201 | 1.859 | 2.484 | 2.329 | 2.431 |
Median VEGF concentration at each time point divided by VEGF concentration at baseline (ratio to baseline) for subjects with tumor response (CR or PR versus PD). (NCT00338884)
Timeframe: Baseline to Day 1 of Weeks 3 through 53
| Intervention | ratio (Median) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, Week 3 (CR or PR, n=38) | Day 1, Week 3 (PD, n=15) | Day 1, Week 5 (CR or PR, n=37) | Day 1, Week 5 (PD, n=15) | Day 1, Week 7 (CR or PR, n=39) | Day 1, Week 7 (PD, n=13) | Day 1, Week 9 (CR or PR, n=37) | Day 1, Week 9 (PD, n=8) | Day 1, Week 13 (CR or PR, n=39) | Day 1, Week 13 (PD, n=2) | Day 1, Week 17 (CR or PR, n=36) | Day 1, Week 17 (PD, n=1) | Day 1, Week 21 (CR or PR, n=36) | Day 1, Week 21 (PD, n=1) | Day 1, Week 25 (CR or PR, n=35) | Day 1, Week 25 (PD, n=1) | Day 1, Week 29 (CR or PR, n=30) | Day 1, Week 29 (PD, n=1) | Day 1, Week 33 (CR or PR, n=31) | Day 1, Week 33 (PD, n=1) | Day 1, Week 37 (CR or PR, n=28) | Day 1, Week 41 (CR or PR, n=28) | Day 1, Week 45 (CR or PR, n=27) | Day 1, Week 49 (CR or PR, n=24) | Day 1, Week 53 (CR or PR, n=19) | |
| Sunitinib | 1.999 | 1.948 | 1.383 | 2.471 | 1.761 | 1.405 | 2.215 | 1.176 | 1.753 | 3.921 | 2.012 | 0.988 | 1.523 | 1.510 | 1.809 | 1.433 | 1.805 | 1.929 | 2.248 | 1.063 | 2.179 | 1.864 | 2.240 | 2.707 | 2.863 |
Time from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.44. DR was calculated for the subgroup of participants with a confirmed objective tumor response. (NCT00267748)
Timeframe: From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years
| Intervention | Months (Median) |
|---|---|
| Sunitinib 50 mg (Schedule 4/2) | 12.5 |
| Sunitinib 37.5 mg | 8.7 |
"FKSI-DRS is a subset of FKSI which is a questionnaire for Functional Assessment of Cancer Therapy -Kidney Symptom Index used to assess QoL/participant-reported outcomes for participants diagnosed with renal cell cancer.~The FKSI contained 15 questions and the FKSI-DRS consisted of 9 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI-DRS ranged between 0-36. Since the questions could be reversed coded, as appropriate, before calculating FKSI-DRS, 0 and 36 could be considered the worst and best health states based on the 9 questions comprising FKSI-DRS." (NCT00267748)
Timeframe: From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years
| Intervention | Units on scale (Mean) |
|---|---|
| Sunitinib 50 mg (Schedule 4/2) | 28.3 |
| Sunitinib 37.5 mg | 27.2 |
FACT-G is core questionnaire of Functional Assessment of Chronic Illness Therapy (FACIT) measurement system to evaluate quality of life (QoL) in cancer population.FACT-G consisted of 27 questions grouped in 4 domains of general Health-Related QoL(HRQoL):Physical Well-being(PWB),Social/Family Well-Being (SWB),Emotional Well-Being (EWB) and Functional Well-Being (FWB);each ranging from 0 (not at all) to 4 (very much) so that FACT-G ranged between 0-108.Since questions could be reversed coded, as appropriate, before calculating FACT-G,0 and 108 could be considered worst and best health states. (NCT00267748)
Timeframe: From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years
| Intervention | Units on a scale (Mean) |
|---|---|
| Sunitinib 50 mg (Schedule 4/2) | 78.0 |
| Sunitinib 37.5 mg | 77.0 |
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with atleast 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. (NCT00267748)
Timeframe: From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sunitinib 50 mg (Schedule 4/2) | 32.2 |
| Sunitinib 37.5 mg | 28.1 |
MSKCC Prognostic Factor Model assessed as low (0), intermediate (1-2) or high (=>3) based upon number of criteria present. Criteria as follows: Karnofsky performance status < 80 %, Lactate dehydrogenase > 1.5 * Upper limit of Normal, Hemoglobin < lower limit of normal for local lab, Corrected serum calcium > 10 mg/dL; Time from first diagnosis of renal cell carcinoma to start of systemic therapy of < 1 year. OS was defined as time from date of start of treatment to date of death due to any cause. OS, in months, was calculated as (event date -start of treatment date + 1)/30.44. (NCT00267748)
Timeframe: From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years
| Intervention | Months (Median) | ||
|---|---|---|---|
| High Risk (equal or more than 3) | Intermediate Risk (1-2) | Low Risk (0) | |
| Sunitinib 37.5 mg | 6.1 | 21.8 | 28.9 |
| Sunitinib 50 mg (Schedule 4/2) | 3.5 | 19.3 | NA |
MSKCC Prognostic Factor Model assessed as low(0),intermediate(1-2) or high(=>3) based on number of criteria present such as Karnofsky performance status < 80 %, Lactate dehydrogenase > 1.5 * Upper limit of Normal,Hemoglobin < lower limit of normal, serum calcium > 10 mg/dL;Time from first diagnosis of renal cell carcinoma to start of systemic therapy of < 1 year.TTP was time from start of study treatment to first documentation of objective tumor progression or death due to cancer.TTP was calculated as (first event date minus date of first dose of study medication plus 1) divided by 30.44. (NCT00267748)
Timeframe: From date of randomization until the date of first documented progression or date of death due to any cause, assessed up to a maximum of 2 years
| Intervention | Months (Median) | |||
|---|---|---|---|---|
| Stratified analysis : High Risk (=>3) | Stratified analysis : Intermediate Risk (1-2) | Stratified analysis : Low Risk (0) | Overall unstratified analysis | |
| Sunitinib 37.5 mg | 4.4 | 7.1 | 8.4 | 7.1 |
| Sunitinib 50 mg (Schedule 4/2) | 3.1 | 8.0 | 20.7 | 9.9 |
"Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.~DR was calculated for the subgroup of patients with a confirmed objective tumor response." (NCT00077974)
Timeframe: Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter or death due to cancer
| Intervention | weeks (Median) |
|---|---|
| Sunitinib Malate | 60.4 |
Overall confirmed objective response = confirmed Complete Response (CR) or confirmed Partial Response (PR) according to RECIST. CR defined as disappearance of all target lesions. PR defined as >= 30 percent decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. (NCT00077974)
Timeframe: From start of study treatment until Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter
| Intervention | participants (Number) |
|---|---|
| Sunitinib Malate | 35 |
Time in weeks from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 7. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the subject current status was death). (NCT00077974)
Timeframe: From start of study treatment until death
| Intervention | weeks (Median) |
|---|---|
| Sunitinib Malate | 104.1 |
"Time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was Death)." (NCT00077974)
Timeframe: From start of study treatment until Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter or death
| Intervention | weeks (Median) |
|---|---|
| Sunitinib Malate | 38.0 |
Time in weeks from start of study treatment to first documentation of objective tumor progression or death due to cancer, whichever comes first. TTP was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]). (NCT00077974)
Timeframe: From start of study treatment until Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter
| Intervention | weeks (Median) |
|---|---|
| Sunitinib Malate | 46.3 |
Dose corrected plasma trough (predose) (Cmin) concentrations of sunitinib. Dose-corrected trough concentrations were set to missing for trough samples collected outside acceptable times from dose administration, samples not collected within scheduled day range, samples with missing collection or administration dates or times, samples collected with dose interruption, and samples collected with inconsistent dose level within 10 days of last dose date. (NCT00077974)
Timeframe: Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
| Intervention | nanograms per milliliter (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 28 (n = 33) | Cycle 2 Day 28 (n = 26) | Cycle 3 Day 28 (n = 20) | Cycle 4 Day 28 (n = 25) | Cycle 5 Day 1 (n = 28) | Cycle 6 Day 1 (n = 41) | Cycle 7 Day 1 (n = 35) | Cycle 8 Day 1 (n = 32) | Cycle 9 Day 1 (n = 32) | Cycle 10 Day 1 (n = 32) | Cycle 11 Day 1 (n = 25) | Cycle 12 Day 1 (n = 28) | Cycle 13 Day 1 (n = 23) | Cycle 14 Day 1 (n = 24) | Cycle 15 Day 1 (n = 16) | Cycle 16 Day 1 (n = 18) | Cycle 17 Day 1 (n = 17) | Cycle 18 Day 1 (n = 14) | Cycle 19 Day 1 (n = 11) | Cycle 20 Day 1 (n = 11) | Cycle 21 Day 1 (n = 8) | Cycle 22 Day 1 (n = 9) | Cycle 23 Day 1 (n = 6) | Cycle 24 Day 1 (n = 6) | Cycle 25 Day 1 (n = 5) | Cycle 26 Day 1 (n = 5) | Cycle 27 Day 1 (n = 5) | Cycle 28 Day 1 (n = 4) | Cycle 29 Day 1 (n = 4) | Cycle 30 Day 1 (n = 3) | |
| Sunitinib Malate | 53.64 | 55.94 | 69.44 | 64.33 | 1.94 | 2.15 | 2.04 | 2.32 | 2.07 | 2.68 | 3.42 | 1.94 | 2.23 | 2.41 | 1.58 | 2.42 | 2.23 | 3.05 | 1.92 | 5.09 | 3.41 | 3.91 | 4.53 | 3.82 | 3.14 | 4.09 | 2.12 | 2.97 | 4.02 | 1.36 |
Dose corrected plasma trough (predose) (Cmin) concentrations of sunitinib metabolite (SU012662). Dose-corrected trough concentrations were set to missing for trough samples collected outside acceptable times from dose administration, samples not collected within scheduled day range, samples with missing collection or administration dates or times, samples collected with dose interruption, and samples collected with inconsistent dose level within 10 days of last dose date. (NCT00077974)
Timeframe: Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
| Intervention | nanograms per milliliter (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 28 (n = 33) | Cycle 2 Day 28 (n = 26) | Cycle 3 Day 28 (n = 20) | Cycle 4 Day 28 (n = 25) | Cycle 5 Day 1 (n = 28) | Cycle 6 Day 1 (n = 41) | Cycle 7 Day 1 (n = 35) | Cycle 8 Day 1 (n = 32) | Cycle 9 Day 1 (n = 32) | Cycle 10 Day 1 (n = 32) | Cycle 11 Day 1 (n = 25) | Cycle 12 Day 1 (n = 28) | Cycle 13 Day 1 (n = 23) | Cycle 14 Day 1 (n = 24) | Cycle 15 Day 1 (n = 16) | Cycle 16 Day 1 (n = 18) | Cycle 17 Day 1 (n = 17) | Cycle 18 Day 1 (n = 14) | Cycle 19 Day 1 (n = 11) | Cycle 20 Day 1 (n = 11) | Cycle 21 Day 1 (n = 8) | Cycle 22 Day 1 (n = 9) | Cycle 23 Day 1 (n = 6) | Cycle 24 Day 1 (n = 6) | Cycle 25 Day 1 (n = 5) | Cycle 26 Day 1 (n = 5) | Cycle 27 Day 1 (n = 5) | Cycle 28 Day 1 (n = 4) | Cycle 29 Day 1 (n = 4) | Cycle 30 Day 1 (n = 3) | |
| Sunitinib Malate | 31.85 | 28.15 | 40.53 | 38.04 | 2.99 | 3.35 | 3.11 | 3.37 | 3.45 | 3.61 | 4.37 | 3.24 | 3.68 | 3.54 | 2.80 | 3.40 | 2.55 | 2.59 | 2.93 | 4.53 | 3.97 | 5.31 | 4.26 | 3.62 | 3.00 | 4.49 | 2.36 | 2.94 | 3.32 | 1.18 |
Dose corrected plasma trough (predose) (Cmin) concentrations of sunitinib plus its metabolite (SU012662). Dose-corrected trough concentrations were set to missing for trough samples collected outside acceptable times from dose administration, samples not collected within scheduled day range, samples with missing collection or administration dates or times, samples collected with dose interruption, and samples collected with inconsistent dose level within 10 days of last dose date. (NCT00077974)
Timeframe: Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
| Intervention | nanograms per milliliter (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 28 (n = 33) | Cycle 2 Day 28 (n = 26) | Cycle 3 Day 28 (n = 20) | Cycle 4 Day 28 (n = 25) | Cycle 5 Day 1 (n = 28) | Cycle 6 Day 1 (n = 41) | Cycle 7 Day 1 (n = 35) | Cycle 8 Day 1 (n = 32) | Cycle 9 Day 1 (n = 32) | Cycle 10 Day 1 (n = 32) | Cycle 11 Day 1 (n = 25) | Cycle 12 Day 1 (n = 28) | Cycle 13 Day 1 (n = 23) | Cycle 14 Day 1 (n = 24) | Cycle 15 Day 1 (n = 16) | Cycle 16 Day 1 (n = 18) | Cycle 17 Day 1 (n = 17) | Cycle 18 Day 1 (n = 14) | Cycle 19 Day 1 (n = 11) | Cycle 20 Day 1 (n = 11) | Cycle 21 Day 1 (n = 8) | Cycle 22 Day 1 (n = 9) | Cycle 23 Day 1 (n = 6) | Cycle 24 Day 1 (n = 6) | Cycle 25 Day 1 (n = 5) | Cycle 26 Day 1 (n = 5) | Cycle 27 Day 1 (n = 5) | Cycle 28 Day 1 (n = 4) | Cycle 29 Day 1 (n = 4) | Cycle 30 Day 1 (n = 3) | |
| Sunitinib Malate | 85.49 | 84.09 | 109.97 | 102.37 | 4.93 | 5.50 | 5.15 | 5.69 | 5.52 | 6.29 | 7.78 | 5.19 | 5.91 | 5.95 | 4.39 | 5.82 | 4.78 | 5.64 | 4.85 | 9.63 | 7.38 | 9.23 | 8.79 | 7.44 | 6.13 | 8.58 | 4.48 | 5.90 | 7.34 | 2.54 |
Observed plasma trough (predose) (Cmin) concentrations of sunitinib (NCT00077974)
Timeframe: Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
| Intervention | nanograms per milliliter (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 28 (n = 103) | Cycle 2 Day 28 (n = 81) | Cycle 3 Day 28 (n = 73) | Cycle 4 Day 28 (n = 66) | Cycle 5 Day 1 (n = 63) | Cycle 6 Day 1 (n = 59) | Cycle 7 Day 1 (n = 52) | Cycle 8 Day 1 (n = 48) | Cycle 9 Day 1 (n = 46) | Cycle 10 Day 1 (n = 41) | Cycle 11 Day 1 (n = 38) | Cycle 12 Day 1 (n = 34) | Cycle 13 Day 1 (n = 30) | Cycle 14 Day 1 (n = 30) | Cycle 15 Day 1 (n = 24) | Cycle 16 Day 1 (n = 24) | Cycle 17 Day 1 (n = 19) | Cycle 18 Day 1 (n = 16) | Cycle 19 Day 1 (n = 14) | Cycle 20 Day 1 (n = 12) | Cycle 21 Day 1 (n = 11) | Cycle 22 Day 1 (n = 11) | Cycle 23 Day 1 (n = 7) | Cycle 24 Day 1 (n = 7) | Cycle 25 Day 1 (n = 6) | Cycle 26 Day 1 (n = 6) | Cycle 27 Day 1 (n = 6) | Cycle 28 Day 1 (n = 4) | Cycle 29 Day 1 (n = 5) | Cycle 30 Day 1 (n = 4) | |
| Sunitinib Malate | 46.82 | 50.13 | 49.36 | 53.18 | 1.55 | 1.44 | 1.51 | 1.60 | 1.60 | 1.69 | 2.05 | 1.72 | 1.74 | 1.60 | 1.56 | 1.46 | 1.42 | 2.20 | 1.34 | 2.96 | 2.53 | 2.18 | 3.14 | 2.75 | 1.99 | 2.46 | 1.20 | 1.75 | 2.93 | 1.02 |
Observed plasma trough (predose) (Cmin) concentrations of sunitinib metabolite (SU012662) (NCT00077974)
Timeframe: Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
| Intervention | nanograms per milliliter (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 28 (n = 103) | Cycle 2 Day 28 (n = 81) | Cycle 3 Day 28 (n = 73) | Cycle 4 Day 28 (n = 66) | Cycle 5 Day 1 (n = 63) | Cycle 6 Day 1 (n = 59) | Cycle 7 Day 1 (n = 52) | Cycle 8 Day 1 (n = 48) | Cycle 9 Day 1 (n = 46) | Cycle 10 Day 1 (n = 41) | Cycle 11 Day 1 (n = 38) | Cycle 12 Day 1 (n = 34) | Cycle 13 Day 1 (n = 30) | Cycle 14 Day 1 (n = 30) | Cycle 15 Day 1 (n = 24) | Cycle 16 Day 1 (n = 24) | Cycle 17 Day 1 (n = 19) | Cycle 18 Day 1 (n = 16) | Cycle 19 Day 1 (n = 14) | Cycle 20 Day 1 (n = 12) | Cycle 21 Day 1 (n = 11) | Cycle 22 Day 1 (n = 11) | Cycle 23 Day 1 (n = 7) | Cycle 24 Day 1 (n = 7) | Cycle 25 Day 1 (n = 6) | Cycle 26 Day 1 (n = 6) | Cycle 27 Day 1 (n = 6) | Cycle 28 Day 1 (n = 4) | Cycle 29 Day 1 (n = 5) | Cycle 30 Day 1 (n = 4) | |
| Sunitinib Malate | 26.44 | 28.21 | 28.32 | 28.54 | 2.50 | 2.64 | 2.64 | 2.66 | 2.81 | 2.54 | 2.78 | 2.67 | 2.77 | 2.49 | 2.51 | 2.30 | 1.83 | 2.16 | 2.06 | 2.92 | 3.13 | 3.24 | 3.10 | 2.64 | 1.99 | 2.60 | 1.36 | 1.81 | 2.43 | 1.10 |
Observed plasma trough (predose) concentrations of sunitinib plus its metabolite (SU012662) (NCT00077974)
Timeframe: Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
| Intervention | nanograms per milliliter (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 28 (n = 103) | Cycle 2 Day 28 (n = 81) | Cycle 3 Day 28 (n = 73) | Cycle 4 Day 28 (n = 66) | Cycle 5 Day 1 (n = 63) | Cycle 6 Day 1 (n = 59) | Cycle 7 Day 1 (n = 52) | Cycle 8 Day 1 (n = 48) | Cycle 9 Day 1 (n = 46) | Cycle 10 Day 1 (n = 41) | Cycle 11 Day 1 (n = 38) | Cycle 12 Day 1 (n = 34) | Cycle 13 Day 1 (n = 30) | Cycle 14 Day 1 (n = 30) | Cycle 15 Day 1 (n = 24) | Cycle 16 Day 1 (n = 24) | Cycle 17 Day 1 (n = 19) | Cycle 18 Day 1 (n = 16) | Cycle 19 Day 1 (n = 14) | Cycle 20 Day 1 (n = 12) | Cycle 21 Day 1 (n = 11) | Cycle 22 Day 1 (n = 11) | Cycle 23 Day 1 (n = 7) | Cycle 24 Day 1 (n = 7) | Cycle 25 Day 1 (n = 6) | Cycle 26 Day 1 (n = 6) | Cycle 27 Day 1 (n = 6) | Cycle 28 Day 1 (n = 4) | Cycle 29 Day 1 (n = 5) | Cycle 30 Day 1 (n = 4) | |
| Sunitinib Malate | 73.26 | 78.34 | 77.68 | 81.71 | 4.04 | 4.08 | 4.15 | 4.26 | 4.41 | 4.23 | 4.83 | 4.39 | 4.52 | 4.09 | 4.07 | 3.75 | 3.25 | 4.35 | 3.40 | 5.88 | 5.66 | 5.43 | 6.24 | 5.39 | 3.97 | 5.06 | 2.55 | 3.56 | 5.36 | 2.13 |
Probability of survival 1 year and 2 years after the first dose of study treatment (NCT00077974)
Timeframe: From start of study treatment until death
| Intervention | percent chance of survival (Number) | |
|---|---|---|
| 1 year | 2 years | |
| Sunitinib Malate | 67.2 | 50.2 |
Duration of response (DR) = time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause. DR data were censored on the day following the date of the last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects without objective tumor progression who did not die due to any cause while on treatment or who were given anti-tumor treatment other than study treatment prior to observing tumor progression. (NCT00083889)
Timeframe: Day 28 of each cycle: duraton of treatment phase
| Intervention | weeks (Median) |
|---|---|
| SU011248 | 52.9 |
| IFN-α | 64.9 |
Duration of response (DR) = time from the first documentation of objective tumor response to the first documentaion of objective tumor progression or to death due to any cause. DR data were censored on the day following the date of the last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects without objective tumor progression who did not die due to any cause while on treatment or who were given anti-tumor treatment other than study treatment prior to observing tumor progression. (NCT00083889)
Timeframe: Day 28 of each cycle: duration of treatment phase
| Intervention | weeks (Median) |
|---|---|
| SU011248 | 56.3 |
| IFN-α | 48.1 |
Incremental cost effectiveness ratio (ICER) of sunitinib compared to IFN-a as first-line treatment for MRCC, defined as the ratio of the incremental cost of treatment over the incremental effectiveness; effectiveness measured as quality adjusted life year (QALY) gain. This objective was not addressed in the clinical study report, but an interim analysis of cost-effectiveness was presented separately. These results were not available for inclusion at the time of this posting. (NCT00083889)
Timeframe: post study measurement
| Intervention | ratio (Number) |
|---|---|
| SU011248 | 0 |
| IFN-α | 0 |
Objective response (OR) = the number of patients with confirmed complete response (CR) and confirmed partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, relative to all randomized patients. CR was defined as the disappearance of all target lesions. PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses (CR or PR) = those that persisted on repeat imaging study >= 4 weeks after initial documentation of response. (NCT00083889)
Timeframe: Day 28 of each 6-week cycle: duration of treatment phase
| Intervention | participants (Number) |
|---|---|
| SU011248 | 145 |
| IFN-α | 29 |
Objective response (OR) = the number of patients with confirmed complete response (CR) and confirmed partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, relative to all randomized patients. CR was defined as the disappearance of all target lesions. PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses = those that persist on repeat imaging study >= 4 weeks after initial documentation of response. (NCT00083889)
Timeframe: Day 28 of each 6-week cycle: duration of treatment phase
| Intervention | participants (Number) |
|---|---|
| SU011248 | 171 |
| IFN-α | 45 |
Overall survival (OS) = time from date of randomization to date of death due to any cause. For patients not expiring, survival time was censored at the last date they were known to be alive. Patients lacking data beyond randomization had their survival times censored at the date of randomization with a duration of 1 day. (NCT00083889)
Timeframe: Clinic visit or telephone contact every 2 months until death
| Intervention | weeks (Median) |
|---|---|
| SU011248 | 114.6 |
| IFN-α | 94.9 |
Progression-free survival (PFS) = time from randomization to first documentation of objective tumor progression or to death due to any cause, whichever occured first. If tumor progression data included more than 1 date, the first date was used. PFS = first event date minus the date of randomization + 1. On study included treatment plus 28-day follow-up periods. (NCT00083889)
Timeframe: Day 28 of each 6-week cycle: duration of treatment phase
| Intervention | weeks (Median) |
|---|---|
| SU011248 | 48.3 |
| IFN-α | 22.1 |
Progression-free survival = time from randomization to first documentation of objective tumor progression or to death due to any cause, whichever occured first. PFS = first event date minus the date of randomization + 1). On study included treatment plus 28-day follow-up periods. (NCT00083889)
Timeframe: Day 28 of each 6-week cycle: duration of treatment phase
| Intervention | weeks (Median) |
|---|---|
| SU011248 | 47.7 |
| IFN-α | 22.1 |
TTP = time from randomization to first documentation of objective tumor progression. TTP data were censored on the day following the date of last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects who did not have objective tumor progression while on treatment or who were given anti-tumor treatment other than study treatment prior to documentation of objective tumor progression. Subjects with no tumor assessments after randomization had TTP censored on the date of randomization with a duration of 1 day. (NCT00083889)
Timeframe: Randomization to first documentation of tumor progression: duration of treatment phase
| Intervention | weeks (Median) |
|---|---|
| SU011248 | 49.1 |
| IFN-α | 22.4 |
TTP = time from randomization to first documentation of objective tumor progression. TTP data were censored on the day following the date of last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects who did not have objective tumor progression while on treatment or who were given anti-tumor treatment other than the study treatment prior to documentation of objective tumor progression. Subjects with no tumor assessments after randomization had TTP censored on the date of randomization with a duration of 1 day. (NCT00083889)
Timeframe: Randomization to first documentation of tumor progression: duration of treatment phase
| Intervention | weeks (Median) |
|---|---|
| SU011248 | 49.0 |
| IFN-α | 22.3 |
Subject observed Ctrough (trough drug) concentrations of active metabolite SU012662 per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter [ng/mL]). (NCT00083889)
Timeframe: Day 28 of Cycle 1 to Cycle 4
| Intervention | ng/mL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 28 (n=31) | Cycle 2, Day 28 (n=36) | Cycle 3, Day 28 (n=36) | Cycle 4, Day 28 (n=32) | Dose-Corrected: Cycle 1, Day 28 (n=24) | Dose-Corrected: Cycle 2, Day 28 (n=28) | Dose-Corrected: Cycle 3, Day 28 (n=27) | Dose-Corrected: Cycle 4, Day 28 (n=26) | |
| SU012662 | 27.10 | 27.35 | 26.11 | 22.11 | 28.21 | 28.32 | 29.04 | 25.99 |
Subject observed Ctrough (trough drug) concentrations of SU011248 per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter [ng/mL]). (NCT00083889)
Timeframe: Day 28 of Cycle 1 to Cycle 4
| Intervention | ng/mL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 28 (n=31) | Cycle 2, Day 28 (n=36) | Cycle 3, Day 28 (n=36) | Cycle 4, Day 28 (n=32) | Dose-Corrected: Cycle 1, Day 28 (n=24) | Dose-Corrected: Cycle 2, Day 28 (n=28) | Dose-Corrected: Cycle 3, Day 28 (n=27) | Dose-Corrected: Cycle 4, Day 28 (n=26) | |
| SU011248 | 57.26 | 57.59 | 50.26 | 45.05 | 64.22 | 59.90 | 58.45 | 54.31 |
Subject observed Ctrough (trough drug) concentrations of total drug (SU011248 and its active metabolite SU012662) per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter [ng/mL]). (NCT00083889)
Timeframe: Day 28 of Cycle 1 to Cycle 4
| Intervention | ng/mL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 28 (n=31) | Cycle 2, Day 28 (n=36) | Cycle 3, Day 28 (n=36) | Cycle 4, Day 28 (n=32) | Dose-Corrected: Cycle 1, Day 28 (n=24) | Dose-Corrected: Cycle 2, Day 28 (n=28) | Dose-Corrected: Cycle 3, Day 28 (n=27) | Dose-Corrected: Cycle 4, Day 28 (n=27) | |
| Total Drug: SU011248 and SU012662 | 84.36 | 84.94 | 76.37 | 67.15 | 92.43 | 88.22 | 87.49 | 80.30 |
EQ-VAS: overall self-rating rating of the patient's current health state using a 20 cm Visual Analog Scale (EQ-VAS), also called the health state thermometer) is a metric measurement (in 2 mm interval) from the visual analog scale which ranges between 0 (worse imaginable health state) and 100 (best imaginable health state). (NCT00083889)
Timeframe: Day 1 & 28 of each cycle: duration of treatment phase
| Intervention | scores on scale (Mean) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=365, 352) | Cycle 1 Day 28 (n=347, 315) | Cycle 2 Day 1 (n=323, 247) | Cycle 2 Day 28 (n=314, 237) | Cycle 3 Day 1 (n=293, 198) | Cycle 3 Day 28 (n=287, 193) | Cycle 4 Day 1 (n=270, 152) | Cycle 4 Day 28 (n=264, 139) | Cycle 5 Day 1 (n=248, 118) | Cycle 5 Day 28 (n=240, 104) | Cycle 6 Day 1 (n=237, 99) | Cycle 6 Day 28 (n=223, 98) | Cycle 7 Day 1 (n=209, 77) | Cycle 7 Day 28 (n=201, 74) | Cycle 8 Day 1 (n=192, 67) | Cycle 8 Day 28 (n=191, 60) | Cycle 9 Day 1 (n=172, 50) | Cycle 9 Day 28 (n=168, 46) | Cycle 10 Day 1 (n=160, 50) | Cycle 10 Day 28 (n=154, 45) | Cycle 11 Day 1 (n=138, 34) | Cycle 11 Day 28 (n=141, 33) | Cycle 12 Day 1 (n=130, 31) | Cycle 12 Day 28 (n=128, 31) | Cycle 13 Day 1 (n=114, 27) | Cycle 13 Day 28 (n=115, 27) | Cycle 14 Day 1 (n=114, 26) | Cycle 14 Day 28 (n=107, 25) | Cycle 15 Day 1 (n=101, 21) | Cycle 15 Day 28 (n=96, 20) | Cycle 16 Day 1 (n=96, 19) | Cycle 16 Day 28 (n=92, 18) | Cycle 17 Day 1 (n=84, 17) | Cycle 17 Day 28 (n=82, 14) | Cycle 18 Day 1 (n=78, 12) | Cycle 18 Day 28 (n=70, 11) | Cycle 19 Day 1 (n=70, 11) | Cycle 19 Day 28 (n=62, 11) | Cycle 20 Day 1 (n=65, 9) | Cycle 20 Day 28 (n=54, 9) | |
| IFN-α | 71.43 | 67.66 | 70.45 | 70.70 | 72.68 | 71.45 | 72.74 | 72.20 | 73.44 | 72.57 | 73.68 | 72.26 | 73.80 | 73.46 | 74.27 | 74.33 | 77.66 | 76.57 | 76.64 | 76.69 | 75.06 | 72.21 | 75.19 | 73.84 | 77.52 | 73.56 | 76.69 | 76.44 | 76.62 | 76.50 | 74.84 | 73.11 | 76.94 | 72.86 | 74.42 | 73.82 | 79.27 | 68.55 | 76.00 | 75.44 |
| SU011248 | 73.80 | 69.35 | 75.05 | 72.06 | 76.23 | 72.33 | 77.46 | 75.15 | 79.83 | 75.13 | 78.83 | 76.81 | 79.39 | 76.09 | 81.34 | 77.53 | 80.08 | 76.24 | 79.18 | 76.44 | 79.72 | 76.81 | 80.84 | 76.71 | 80.59 | 77.22 | 80.39 | 76.53 | 80.50 | 76.51 | 79.85 | 75.51 | 80.74 | 77.10 | 80.40 | 77.76 | 81.47 | 77.05 | 81.10 | 76.85 |
EQ-5D Health State Index: a brief, self-administered generic health status instrument. Respondents were asked to describe their current health state on each of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety or depression) on a three-level scale (1=no problem, 2=some problem, and 3=extreme problem). A maximum score of 1 can be derived from these 5 dimensions by score conversion; range: -0.39 (worst health state)to 1.00 (best health state). This descriptive system classifies respondents into one of 243 possible distinct health states (EQ-5D descriptive system). (NCT00083889)
Timeframe: Day 1 & 28 of each cycle: duration of treatment phase
| Intervention | scores on scale (Mean) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=363, 352) | Cycle 1 Day 28 (346, 315) | Cycle 2 Day 1 (326, 244) | Cycle 2 Day 28 (311, 233) | Cycle 3 Day 1 (287, 200) | Cycle 3 Day 28 (283, 195) | Cycle 4 Day 1 (269, 150) | Cycle 4 Day 28 (261, 142) | Cycle 5 Day 1 (247, 120) | Cycle 5 Day 28 (240, 106) | Cycle 6 Day 1 (240, 98) | Cycle 6 Day 28 (224, 100) | Cycle 7 Day 1 (205, 79) | Cycle 7 Day 28 (204, 74) | Cycle 8 Day 1 (192, 68) | Cycle 8 Day 28 (190, 61) | Cycle 9 Day 1 (170, 51) | Cycle 9 Day 28 (168, 45) | Cycle 10 Day 1 (161, 50) | Cycle 10 Day 28 (153, 46) | Cycle 11 Day 1 (138, 34) | Cycle 11 Day 28 (138, 32) | Cycle 12 Day 1 (132, 31) | Cycle 12 Day 28 (127, 31) | Cycle 13 Day 1 (114, 26) | Cycle 13 Day 28 (115, 27) | Cycle 14 Day 1 (114, 25) | Cycle 14 Day 28 (107, 24) | Cycle 15 Day 1 (100, 21) | Cycle 15 Day 28 (95, 20) | Cycle 16 Day 1 (96, 19) | Cycle 16 Day 28 (93, 18) | Cycle 17 Day 1 (84, 15) | Cycle 17 Day 28 (82, 14) | Cycle 18 Day 1 (80, 12) | Cycle 18 Day 28 (71, 10) | Cycle 19 Day 1 (69, 11) | Cycle 19 Day 28 (62, 11) | Cycle 20 Day 1 (63, 8) | Cycle 20 Day 28 (54, 9) | |
| IFN-α | 0.76 | 0.70 | 0.75 | 0.74 | 0.76 | 0.75 | 0.80 | 0.79 | 0.79 | 0.78 | 0.80 | 0.80 | 0.80 | 0.81 | 0.82 | 0.81 | 0.84 | 0.84 | 0.85 | 0.82 | 0.85 | 0.84 | 0.82 | 0.85 | 0.83 | 0.82 | 0.86 | 0.87 | 0.88 | 0.88 | 0.84 | 0.83 | 0.88 | 0.83 | 0.86 | 0.84 | 0.88 | 0.72 | 0.85 | 0.86 |
| SU011248 | 0.76 | 0.72 | 0.78 | 0.73 | 0.78 | 0.75 | 0.80 | 0.76 | 0.80 | 0.76 | 0.80 | 0.77 | 0.81 | 0.77 | 0.82 | 0.77 | 0.80 | 0.78 | 0.81 | 0.78 | 0.80 | 0.75 | 0.81 | 0.77 | 0.81 | 0.77 | 0.81 | 0.75 | 0.80 | 0.75 | 0.79 | 0.76 | 0.79 | 0.77 | 0.81 | 0.76 | 0.81 | 0.78 | 0.81 | 0.77 |
FACT-Kidney Symptom Index (FKSI) subscale designed to be a stand-alone instrument to measure symptoms and quality of life in patients with advanced kidney cancer. Contains 15 questions; some questions overlap with the FACT-G questions. Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Total FKSI score = sum score of the 15 item scores; total range: 0 - 60; 0 (most severe symptoms and concerns) to 60 (no symptoms or concerns). (NCT00083889)
Timeframe: Day 1 & 28 of each cycle: duration of treatment phase
| Intervention | scores on scale (Mean) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=369, 351) | Cycle 1 Day 28 (n=348, 317) | Cycle 2 Day 1 (n=327, 246) | Cycle 2 Day 28 (n=315, 238) | Cycle 3 Day 1 (n=294, 198) | Cycle 3 Day 28 (n=285, 195) | Cycle 4 Day 1 (n=272, 151) | Cycle 4 Day 28 (n=264, 142) | Cycle 5 Day 1 (n=248, 119) | Cycle 5 Day 28 (n=242, 109) | Cycle 6 Day 1 (n=240, 99) | Cycle 6 Day 28 (n=223, 99) | Cycle 7 Day 1 (n=208, 79) | Cycle 7 Day 28 (n=203, 75) | Cycle 8 Day 1 (n=192, 68) | Cycle 8 Day 28 (n=190, 62) | Cycle 9 Day 1 (n=172, 51) | Cycle 9 Day 28 (n=166, 46) | Cycle 10 Day 1 (n=161, 50) | Cycle 10 Day 28 (n=155, 46) | Cycle 11 Day 1 (n=138, 35) | Cycle 11 Day 28 (n=141, 33) | Cycle 12 Day 1 (n=132, 31) | Cycle 12 Day 28 (n=128, 31) | Cycle 13 Day 1 (n=113, 27) | Cycle 13 Day 28 (n=114, 27) | Cycle 14 Day 1 (n=114, 26) | Cycle 14 Day 28 (n=105, 25) | Cycle 15 Day 1 (n=100, 22) | Cycle 15 Day 28 (n=94, 20) | Cycle 16 Day 1 (n=96, 19) | Cycle 16 Day 28 (n=90, 18) | Cycle 17 Day 1 (n=85, 17) | Cycle 17 Day 28 (n=81, 14) | Cycle 18 Day 1 (n=80, 12) | Cycle 18 Day 28 (n=70, 11) | Cycle 19 Day 1 (n=71, 11) | Cycle 19 Day 28 (n=61, 10) | Cycle 20 Day 1 (n=65, 9) | Cycle 20 Day 28 (n=53, 9) | |
| IFN-α | 46.09 | 40.93 | 42.33 | 42.01 | 43.64 | 43.13 | 44.78 | 44.03 | 44.82 | 44.41 | 45.38 | 44.07 | 45.09 | 44.65 | 45.38 | 45.10 | 46.88 | 46.16 | 46.22 | 45.16 | 46.26 | 45.46 | 46.08 | 46.00 | 46.25 | 45.84 | 46.08 | 46.10 | 45.62 | 45.30 | 43.64 | 43.46 | 45.59 | 43.64 | 44.92 | 45.27 | 46.64 | 44.47 | 45.00 | 46.00 |
| SU011248 | 46.45 | 42.71 | 45.98 | 43.75 | 46.60 | 44.01 | 46.99 | 45.08 | 47.99 | 44.99 | 47.61 | 45.40 | 47.84 | 45.39 | 48.24 | 45.83 | 48.31 | 45.79 | 47.90 | 45.70 | 47.90 | 45.28 | 47.90 | 45.67 | 48.02 | 45.65 | 47.90 | 45.10 | 48.26 | 45.37 | 47.75 | 45.95 | 48.07 | 46.27 | 47.47 | 45.36 | 47.70 | 46.07 | 48.88 | 46.26 |
FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) subscale of the FKSI to measure advanced kidney cancer disease related symptoms. Includes 9 items: lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, and hematuria. Each question was answered on a five-point Likert-type scale ranging from 0 (not at all) to 4 (very much). Score = the sum score of the item scores in the subscale; total range: 0 to 36. A score greater than 0 indicates the difference favored sunitinib. (NCT00083889)
Timeframe: Day 1 & 28 of each cycle: duration of treatment phase
| Intervention | scores on scale (Mean) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=368, 351) | Cycle 1 Day 28 (n=348, 317) | Cycle 2 Day 1 (n=327, 246) | Cycle 2 Day 28 (n= 315, 237) | Cycle 3 Day 1 (n=294, 198) | Cycle 3 Day 28 (n=285, 195) | Cycle 4 Day 1 (n=272, 151) | Cycle 4 Day 28 (n=264, 142) | Cycle 5 Day 1 (n=248, 119 ) | Cycle 5 Day 28 (n=242, 109) | Cycle 6 Day 1 (n=240, 99) | Cycle 6 Day 28 (n=223, 99) | Cycle 7 Day 1 (n=208, 79) | Cycle 7 Day 28 (n=203, 75 ) | Cycle 8 Day 1 (n=192, 68) | Cycle 8 Day 28 (n=190, 62) | Cycle 9 Day 1 (n=172, 51) | Cycle 9 Day 28 (n=166, 46) | Cycle 10 Day 1 (n=161, 50) | Cycle 10 Day 28 (n=155, 46) | Cycle 11 Day 1 (n=138, 35) | Cycle 11 Day 28 (n=141, 33) | Cycle 12 Day 1 (n=132, 31) | Cycle 12 Day 28 (n=128, 31) | Cycle 13 Day 1 (113, 27) | Cycle 13 Day 28 (n=114, 27) | Cycle 14 Day 1 (n=114, 26) | Cycle 14 Day 28 (n=105, 25) | Cycle 15 Day 1 (n=100, 22) | Cycle 15 Day 28 (n=94, 20) | Cycle 16 Day 1 (n=96, 19) | Cycle 16 Day 28 (n=90, 18) | Cycle 17 Day 1 (n=85, 17) | Cycle 17 Day 28 (n=81, 14) | Cycle 18 Day 1 (n=80, 12) | Cycle 18 Day 28 (n=70, 11) | Cycle 19 Day 1 (n=71, 11) | Cycle 19 Day 28 (n=61, 10) | Cycle 20 Day 1 (n=65, 9) | Cycle 20 Day 28 (n=53, 9) | |
| IFN-α | 29.55 | 26.68 | 27.59 | 27.22 | 28.20 | 27.81 | 28.85 | 28.30 | 28.57 | 28.37 | 29.12 | 28.44 | 28.99 | 28.50 | 28.76 | 28.67 | 29.86 | 29.36 | 29.43 | 29.03 | 29.89 | 29.24 | 29.54 | 29.48 | 29.81 | 29.63 | 29.35 | 29.23 | 29.18 | 28.89 | 27.79 | 28.28 | 29.26 | 27.94 | 28.83 | 28.73 | 29.64 | 28.65 | 28.44 | 29.22 |
| SU011248 | 29.74 | 27.73 | 29.66 | 28.49 | 29.93 | 28.72 | 30.25 | 29.43 | 30.87 | 29.43 | 30.80 | 29.62 | 30.93 | 29.73 | 31.03 | 29.76 | 31.24 | 29.72 | 30.73 | 29.78 | 30.72 | 29.34 | 30.76 | 29.63 | 30.58 | 29.30 | 30.58 | 28.94 | 30.87 | 29.26 | 30.63 | 29.51 | 30.69 | 29.73 | 30.24 | 29.15 | 30.11 | 29.48 | 31.07 | 29.44 |
Functional Assessment of Cancer Therapy-General (FACT-G): core questionnaire of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system that has been validated in a variety of cancer populations. 27 questions grouped into 4 domains that measure a patient's physical, functional, social and family, and emotional well-being. Five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = sum score of item scores in the subscale; total range: 0 to 108 with higher score indicating better quality of life. (NCT00083889)
Timeframe: Day 1 & 28 of each cycle: duration of treatment phase
| Intervention | scores on scale (Mean) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=368, 346) | Cycle 1 Day 28 (n=345, 316) | Cycle 2 Day 1 (n=328, 247) | Cycle 2 Day 28 (n=314, 237) | Cycle 3 Day 1 (n=293, 199) | Cycle 3 Day 28 (n=285, 193) | Cycle 4 Day 1 (n=269, 149) | Cycle 4 Day 28 (n=263, 142) | Cycle 5 Day 1 (n=247, 119) | Cycle 5 Day 28 (n=240, 106) | Cycle 6 Day 1 (n=238, 98) | Cycle 6 Day 28 (n=222, 97) | Cycle 7 Day 1 (n=206, 78) | Cycle 7 Day 28 (n=200, 75) | Cycle 8 Day 1 (n=192, 66) | Cycle 8 Day 28 (n=189, 61) | Cycle 9 Day 1 (n=170, 51) | Cycle 9 Day 28 (n=166, 46) | Cycle 10 Day 1 (n=158, 49) | Cycle 10 Day 28 (n=150, 45) | Cycle 11 Day 1 (n=134, 35) | Cycle 11 Day 28 (n=139, 32) | Cycle 12 Day 1 (n=130, 29) | Cycle 12 Day 28 (n=126, 31) | Cycle 13 Day 1 (n=113, 27) | Cycle 13 Day 28 (n=114, 27) | Cycle 14 Day 1 (n=112, 26) | Cycle 14 Day 28 (n=107, 24) | Cycle 15 Day 1 (n=101, 20) | Cycle 15 Day 28 (n=96, 20) | Cycle 16 Day 1 (n=94, 19) | Cycle 16 Day 28 (n=89, 18) | Cycle 17 Day 1 (n=84, 16) | Cycle 17 Day 28 (n=80, 14) | Cycle 18 Day 1 (n=79, 12) | Cycle 18 Day 28 (n=70, 11) | Cycle 19 Day 1 (n=71, 11) | Cycle 19 Day 28 (n=61, 10) | Cycle 20 Day 1 (n=63, 9) | Cycle 20 Day 28 (n=52, 8) | |
| IFN-α | 81.22 | 74.91 | 77.02 | 77.05 | 79.35 | 78.42 | 80.86 | 80.46 | 81.96 | 80.60 | 81.97 | 79.70 | 80.39 | 81.06 | 81.25 | 81.31 | 84.50 | 83.14 | 84.03 | 81.79 | 81.60 | 80.20 | 80.99 | 81.73 | 81.18 | 80.67 | 81.22 | 81.57 | 81.66 | 80.88 | 78.20 | 78.38 | 81.80 | 78.96 | 82.24 | 82.27 | 82.48 | 79.63 | 81.70 | 79.54 |
| SU011248 | 82.30 | 78.75 | 82.88 | 80.51 | 84.24 | 80.59 | 85.32 | 82.08 | 86.40 | 82.23 | 84.90 | 82.54 | 85.01 | 82.16 | 86.83 | 83.05 | 85.81 | 82.71 | 85.32 | 82.14 | 84.75 | 81.91 | 85.31 | 82.43 | 85.50 | 83.61 | 85.24 | 82.34 | 86.24 | 82.64 | 84.77 | 83.38 | 86.78 | 84.42 | 85.74 | 83.51 | 87.16 | 84.54 | 87.96 | 84.62 |
Emotional well-being (EWB)subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 24; lower score indicates better emotional well-being. (NCT00083889)
Timeframe: Day 1 & 28 of each cycle: duration of treatment phase
| Intervention | scores on scale (Mean) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (370, 352) | Cycle 1 Day 28 (n=347, 318) | Cycle 2 Day 1 (n=328, 249) | Cycle 2 Day 28 (n=316, 237) | Cycle 3 Day 1 (n=294, 200) | Cycle 3 Day 28 (n=287, 196) | Cycle 4 Day 1 (n=272, 152) | Cycle 4 Day 28 (n=265, 142) | Cycle 5 Day 1 (n=249, 120) | Cycle 5 Day 28 (n=241, 109) | Cycle 6 Day 1 (n=240, 99) | Cycle 6 Day 28 (n=222, 99) | Cycle 7 Day 1 (n=208, 77) | Cycle 7 Day 28 (n=204, 75) | Cycle 8 Day 1 (n=192, 67) | Cycle 8 Day 28 (n=189, 62) | Cycle 9 Day 1 (n=171, 51) | Cycle 9 Day 28 (n=167, 46) | Cycle 10 Day 1 (n=161, 50) | Cycle 10 Day 28 (n=154, 45) | Cycle 11 Day 1 (n=138, 35) | Cycle 11 Day 28 (n=141, 33) | Cycle 12 Day 1 (n=132, 30) | Cycle 12 Day 28 (n=128, 31) | Cycle 13 Day 1 (n=114, 27) | Cycle 13 Day 28 (n=114, 27) | Cycle 14 Day 1 (n=114, 26) | Cycle 14 Day 28 (n=107, 25) | Cycle 15 Day 1 (n=101, 21) | Cycle 15 Day 28 (n=96, 20) | Cycle 16 Day 1 (n=96, 19) | Cycle 16 Day 28 (n=91, 18) | Cycle 17 Day 1 (n=84, 17) | Cycle 17 Day 28 (n=81, 14) | Cycle 18 Day 1 (n=80, 12) | Cycle 18 Day 28 (n=71, 11) | Cycle 19 Day 1 (n=71, 11) | Cycle 19 Day 28 (n=61, 10) | Cycle 20 Day 1 (n=65, 9) | Cycle 20 Day 28 (n=53, 9) | |
| IFN-α | 17.06 | 17.40 | 17.52 | 17.73 | 18.13 | 18.17 | 18.80 | 18.39 | 19.00 | 18.70 | 18.60 | 18.14 | 18.08 | 18.55 | 18.54 | 18.55 | 18.98 | 18.76 | 18.92 | 18.36 | 18.97 | 18.52 | 18.87 | 19.45 | 18.63 | 18.97 | 18.05 | 18.76 | 18.24 | 18.75 | 17.26 | 16.83 | 18.28 | 18.00 | 19.62 | 19.55 | 19.09 | 18.20 | 18.67 | 18.67 |
| SU011248 | 17.15 | 17.76 | 18.46 | 18.46 | 18.82 | 18.53 | 19.04 | 18.76 | 19.18 | 18.63 | 18.99 | 18.73 | 19.08 | 18.69 | 19.33 | 18.98 | 19.25 | 18.93 | 19.32 | 18.71 | 18.92 | 19.10 | 19.14 | 19.06 | 19.38 | 19.39 | 19.55 | 19.23 | 19.57 | 19.41 | 19.54 | 19.33 | 19.95 | 19.66 | 19.64 | 19.34 | 19.94 | 19.61 | 20.00 | 19.75 |
Functional well-being (FWB) subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; higher score indicates greater functional well-being. (NCT00083889)
Timeframe: Day 1 & 28 of each cycle: duration of treatment phase
| Intervention | scores on scale (Mean) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=371, 353) | Cycle 1 Day 28 (n=347, 318) | Cycle 2 Day 1 (n=328, 249) | Cycle 2 Day 28 (n=315, 238) | Cycle 3 Day 1 (n=294, 200) | Cycle 3 Day 28 (n=287, 195) | Cycle 4 Day 1 (n=272, 152) | Cycle 4 Day 28 (n=265, 142) | Cycle 5 Day 1 (n=249, 120) | Cycle 5 Day 28 (n=241, 109) | Cycle 6 Day 1 (n=239, 99) | Cycle 6 Day 28 (n=222, 99) | Cycle 7 Day 1 (n=208, 79) | Cycle 7 Day 28 (n=204, 75) | Cycle 8 Day 1 (n=192, 67) | Cycle 8 Day 28 (n=190, 62) | Cycle 9 Day 1 (n=170, 51) | Cycle 9 Day 28 (n=167, 46) | Cycle 10 Day 1 (n=161, 50) | Cycle 10 Day 28 (n=154, 46) | Cycle 11 Day 1 (n=137, 35) | Cycle 11 Day 28 (n=140, 33) | Cycle 12 Day 1 (n=132, 30) | Cycle 12 Day 28 (n=128, 31) | Cycle 13 Day 1 (n=114, 27) | Cycle 13 Day 28 (n=114, 27) | Cycle 14 Day 1 (n=114, 26) | Cycle 14 Day 28 (n=107, 25) | Cycle 15 Day 1 (n=101, 21) | Cycle 15 Day 28 (n=96, 20) | Cycle 16 Day 1 (n=96, 19) | Cycle 16 Day 28 (n=91, 18) | Cycle 17 Day 1 (n=85, 17) | Cycle 17 Day 28 (n=81, 14) | Cycle 18 Day 1 (n=80, 12) | Cycle 18 Day 28 (n=71, 11) | Cycle 19 Day 1 (n=71, 11) | Cycle 19 Day 28 (n=61, 10) | Cycle 20 Day 1 (n=65, 9) | Cycle 20 Day 28 (n=53, 9) | |
| IFN-α | 18.51 | 16.37 | 17.08 | 17.18 | 17.92 | 17.56 | 18.40 | 18.37 | 18.81 | 18.47 | 19.02 | 18.24 | 18.45 | 18.76 | 19.22 | 19.10 | 20.20 | 20.04 | 19.88 | 19.40 | 18.89 | 18.81 | 18.80 | 19.13 | 19.63 | 18.59 | 19.62 | 19.72 | 19.86 | 19.83 | 18.89 | 18.61 | 19.35 | 18.71 | 19.08 | 19.00 | 19.64 | 19.10 | 20.00 | 20.22 |
| SU011248 | 18.93 | 17.92 | 18.78 | 18.37 | 19.51 | 18.58 | 19.93 | 18.86 | 20.27 | 19.02 | 19.74 | 19.21 | 19.69 | 19.12 | 20.29 | 19.33 | 19.87 | 19.27 | 19.95 | 19.22 | 19.81 | 19.12 | 19.98 | 19.42 | 20.02 | 19.65 | 20.04 | 19.07 | 20.13 | 19.24 | 19.80 | 19.53 | 20.20 | 19.67 | 19.76 | 19.47 | 20.18 | 19.59 | 20.50 | 20.15 |
Physical well-being (PWB) subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; lower score indicates better physical well-being. (NCT00083889)
Timeframe: Day 1 & 28 of each cycle: duration of treatment phase
| Intervention | scores on scale (Mean) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=369, 348) | Cycle 1 Day 28 (n=348, 318) | Cycle 2 Day 1 (n=329, 247) | Cycle 2 Day 28 (n=316, 239) | Cycle 3 Day 1 (n=294, 200) | Cycle 3 Day 28 (n=286, 195) | Cycle 4 Day 1 (n=270, 150) | Cycle 4 Day 28 (n=264, 142) | Cycle 5 Day 1 (n=248, 120) | Cycle 5 Day 28 (n=241, 106) | Cycle 6 Day 1 (n=239, 99) | Cycle 6 Day 28 (n=224, 97) | Cycle 7 Day 1 (n=207, 79) | Cycle 7 Day 28 (n=201, 75) | Cycle 8 Day 1 (n=193, 67) | Cycle 8 Day 28 (n=189, 61) | Cycle 9 Day 1 (n=172, 51) | Cycle 9 Day 28 (n=166, 46) | Cycle 10 Day 1 (n=159, 49) | Cycle 10 Day 28 (n=151, 46) | Cycle 11 Day 1 (n=135, 35) | Cycle 11 Day 28 (n=140, 32) | Cycle 12 Day 1 (n=131, 30) | Cycle 12 Day 28 (n=127, 31) | Cycle 13 Day 1 (n=114, 27) | Cycle 13 Day 28 (n=114, 27) | Cycle 14 Day 1 (n=112, 26) | Cycle 14 Day 28 (n=107, 24) | Cycle 15 Day 1 (n=101, 21) | Cycle 15 Day 28 (n=96, 20) | Cycle 16 Day 1 (n=94, 19) | Cycle 16 Day 28 (n=90, 18) | Cycle 17 Day 1 (n=85, 16) | Cycle 17 Day 28 (n=80, 14) | Cycle 18 Day 1 (n=79, 12) | Cycle 18 Day 28 (n=70, 11) | Cycle 19 Day 1 (n=71, 11) | Cycle 19 Day 28 (n=61, 10) | Cycle 20 Day 1 (n=63, 9) | Cycle 20 Day 28 (n=52, 9) | |
| IFN-α | 22.70 | 18.85 | 20.05 | 19.84 | 20.87 | 20.63 | 21.56 | 21.31 | 21.84 | 21.23 | 21.70 | 20.96 | 21.67 | 21.66 | 21.94 | 21.40 | 22.58 | 22.38 | 22.60 | 21.83 | 22.23 | 21.88 | 22.60 | 21.90 | 21.99 | 21.80 | 22.05 | 22.75 | 22.33 | 22.07 | 20.63 | 21.42 | 21.81 | 20.50 | 21.83 | 22.45 | 22.45 | 21.60 | 21.78 | 22.33 |
| SU011248 | 23.14 | 19.43 | 22.22 | 20.34 | 22.45 | 20.18 | 22.72 | 21.00 | 23.24 | 20.91 | 22.99 | 21.22 | 23.05 | 21.22 | 23.58 | 21.51 | 23.41 | 21.29 | 22.94 | 21.21 | 23.16 | 20.98 | 23.03 | 20.87 | 23.05 | 21.26 | 23.02 | 20.80 | 23.26 | 20.95 | 22.60 | 21.31 | 22.99 | 21.68 | 22.85 | 20.89 | 23.20 | 21.82 | 23.68 | 21.81 |
Social/family well-being (SWB)subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; lower score indicates less social/family well-being. (NCT00083889)
Timeframe: Day 1 & 28 of each cycle: duration of treatment phase
| Intervention | scores on scale (Mean) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n=370, 349) | Cycle 1 Day 28 (n=348, 319) | Cycle 2 Day 1 (n=328, 247) | Cycle 2 Day 28 (n=315, 238) | Cycle 3 Day 1 (n=292, 200) | Cycle 3 Day 28 (n=284, 194) | Cycle 4 Day 1 (n=269, 150) | Cycle 4 Day 28 (n=263, 142) | Cycle 5 Day 1 (n=247, 120) | Cycle 5 Day 28 (n=241, 107) | Cycle 6 Day 1 (n=238, 98) | Cycle 6 Day 28 (n=224, 97) | Cycle 7 Day 1 (n=207, 79) | Cycle 7 Day 28 (n=200, 75) | Cycle 8 Day 1 (n=193, 67) | Cycle 8 Day 28 (n=189, 61) | Cycle 9 Day 1 (n=172, 51) | Cycle 9 Day 28 (n=166, 46) | Cycle 10 Day 1 (n=158, 49) | Cycle 10 Day 28 (n=151, 46) | Cycle 11 Day 1 (n=135, 35) | Cycle 11 Day 28 (n=140, 32) | Cycle 12 Day 1 (n=131, 30) | Cycle 12 Day 28 (n=127, 31) | Cycle 13 Day 1 (n=114, 27) | Cycle 13 Day 28 (n=114, 27) | Cycle 14 Day 1 (n=112, 26) | Cycle 14 Day 28 (n=107, 24) | Cycle 15 Day 1 (n=101, 21) | Cycle 15 Day 28 (n=96, 20) | Cycle 16 Day 1 (n=94, 19) | Cycle 16 Day 28 (n=89, 18) | Cycle 17 Day 1 (n=85, 16) | Cycle 17 Day 28 (n=80, 14) | Cycle 18 Day 1 (n=79, 12) | Cycle 18 Day 28 (n=70, 11) | Cycle 19 Day 1 (n=71, 11) | Cycle 19 Day 28 (n=61, 10) | Cycle 20 Day 1 (n=63, 9) | Cycle 20 Day 28 (n=52, 8) | |
| IFN-α | 22.94 | 22.20 | 22.31 | 22.22 | 22.42 | 22.12 | 22.26 | 22.38 | 22.35 | 22.36 | 22.56 | 22.33 | 22.46 | 22.10 | 21.95 | 22.17 | 22.74 | 21.96 | 22.45 | 22.06 | 21.51 | 21.09 | 20.79 | 21.25 | 20.93 | 21.30 | 21.51 | 20.32 | 20.35 | 20.23 | 21.41 | 21.52 | 22.25 | 21.75 | 21.71 | 21.27 | 21.30 | 20.73 | 21.26 | 20.67 |
| SU011248 | 23.14 | 23.60 | 23.50 | 23.40 | 23.51 | 23.44 | 23.73 | 23.36 | 23.53 | 23.68 | 23.35 | 23.40 | 23.29 | 23.13 | 23.67 | 23.26 | 23.26 | 23.26 | 23.08 | 23.03 | 23.05 | 22.71 | 23.23 | 23.07 | 23.15 | 23.31 | 22.82 | 23.24 | 23.28 | 23.04 | 23.11 | 23.41 | 23.42 | 23.50 | 23.53 | 23.70 | 23.85 | 23.53 | 23.60 | 22.93 |
Plasma concentrations of soluble proteins that may be associated with tumor proliferation or angiogenesis collected from a subset of patients were analyzed by enzyme-linked immunosorbent assay (ELISA) analysis. Soluble protein values: Baseline concentration (pM) and ratio to Baseline at each timepoint; ratio = plasma concentration of soluble protein (picograms per milliliter [pg/ml]) at timepoint / concentration of soluble protein (pg/ml) at baseline. Samples below the limit of quantitation and samples with insufficient volume available were excluded. (NCT00083889)
Timeframe: Day 1 & Day 28, Cycle 1 to Cycle 4
| Intervention | pg/ml and ratio to Baseline (Mean) | ||||
|---|---|---|---|---|---|
| PLASMA bFGF: C2D28:C1D1 (n=14, 0) | PLASMA bFGF: C3D1:C1D1 (n=12, 0) | PLASMA bFGF: C3D28:C1D1 (n=12, 0) | PLASMA bFGF: C4D1:C1D1 (n=14, 0) | PLASMA bFGF: C4:D28:C1D1 (n=10, 0) | |
| SU011248 | 0.760 | 1.582 | 1.671 | 2.895 | 0.803 |
Plasma concentrations of soluble proteins that may be associated with tumor proliferation or angiogenesis collected from a subset of patients were analyzed by enzyme-linked immunosorbent assay (ELISA) analysis. Soluble protein values: Baseline concentration (pM) and ratio to Baseline at each timepoint; ratio = plasma concentration of soluble protein (picograms per milliliter [pg/ml]) at timepoint / concentration of soluble protein (pg/ml) at baseline. Samples below the limit of quantitation and samples with insufficient volume available were excluded. (NCT00083889)
Timeframe: Day 1 & Day 28, Cycle 1 to Cycle 4
| Intervention | pg/ml and ratio to Baseline (Mean) | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plasma VEGF-A: Baseline (n=33, 31) | Plasma VEGF-A: C1D28: C1D1 (n=31, 26) | Plasma VEGF-A: C2D1: C1D1 (n=32, 21) | Plasma VEGF-A: C2D28: C1D1 (n=31, 20) | Plasma VEGF-A: C3D1: C1D1 (n=27, 15) | Plasma VEGF-A: C3D28: C1D1 (n=28, 15) | Plasma VEGF-A: C4D1: C1D1 (n=27, 12) | Plasma VEGF-A: C4D28: C1D1 (n=25, 11) | Plasma VEGF-C: Baseline (n=35, 31) | Plasma VEGF-C: C1D28: C1D1 (n=31, 26) | Plasma VEGF-C: C2D1:C1D1 (n=30, 21) | Plasma VEGF-C: C2D28:C1D1 (n=31, 19) | Plasma VEGF-C: C3D1:C1D1 (n=28, 15) | Plasma VEGF-C: C3D28:C1D1 (n=28, 15) | Plasma VEGF-C: C4D1:C1D1 (n=28, 12) | Plasma VEGF-C: C4:D28:C1D1 (n=26, 11) | PLASMA sVEGFR-3: Baseline (n=29, 30) | PLASMA sVEGFR-3: C1D28:C1D1 (n=27, 25) | PLASMA sVEGFR-3: C2D1:C1D1 (n=28, 20) | PLASMA sVEGFR-3: C2D28:C1D1 (n=28, 19) | PLASMA sVEGFR-3: C3D1:C1D1 (n=25, 14) | PLASMA sVEGFR-3: C3D28:C1D1 (n=25, 14) | PLASMA sVEGFR-3: C4D1:C1D1 (n=24, 11) | PLASMA sVEGFR-3: C4:D28:C1D1 (n=23, 10) | PLASMA IL-8: Baseline (n=31, 29) | PLASMA IL-8: C1D28:C1D1 (n=29, 25) | PLASMA IL-8: C2D1:C1D1 (n=29, 20) | PLASMA IL-8: C2D28:C1D1 (n=29, 19) | PLASMA IL-8: C3D1:C1D1 (n=26, 15) | PLASMA IL-8: C3D28:C1D1 (n=26, 14) | PLASMA IL-8: C4D1:C1D1 (n=26, 12) | PLASMA IL-8: C4:D28:C1D1 (n=25, 11) | PLASMA bFGF: Baseline (n=21, 2) | PLASMA bFGF: C1D28:C1D1 (n=15, 1) | PLASMA bFGF: C2D1:C1D1 (n=13, 1) | |
| IFN-α | 109.0 | 1.134 | 1.171 | 1.153 | 1.253 | 1.149 | 1.209 | 1.008 | 651.2 | 1.165 | 1.177 | 1.081 | 1.174 | 1.054 | 1.382 | 1.139 | 40317.7 | 1.068 | 1.075 | 1.150 | 1.015 | 1.042 | 1.183 | 1.044 | 18.6 | 2.297 | 1.579 | 1.858 | 1.531 | 1.999 | 1.662 | 2.492 | 13.6 | 0.429 | 0.157 |
| SU011248 | 101.9 | 4.280 | 1.161 | 5.851 | 1.630 | 5.236 | 1.486 | 4.924 | 556.4 | 0.945 | 1.045 | 0.871 | 1.159 | 1.043 | 1.243 | 1.207 | 44049.3 | 0.473 | 0.787 | 0.407 | 0.800 | 0.427 | 0.846 | 0.486 | 10.1 | 2.815 | 1.716 | 2.423 | 2.788 | 2.574 | 1.934 | 2.549 | 13.1 | 2.762 | 1.370 |
DR: Time from first documentation of objective tumor response to first date that recurrence or progressive disease (PD) was objectively documented, taking as a reference for PD, the smallest sum LD recorded since randomization. (NCT00065468)
Timeframe: Baseline, every month until tumor progression or death (up to Month 80)
| Intervention | months (Median) |
|---|---|
| Interferon Alfa | 7.4 |
| Temsirolimus | 11.1 |
| Interferon Alfa and Temsirolimus | 9.3 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. EQ-5D index measured 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Range of EQ-5D index score = -0.594 to 1 where higher scores indicated a better health state. (NCT00065468)
Timeframe: Baseline
| Intervention | units on a scale (Median) |
|---|---|
| Interferon Alfa | 0.656 |
| Temsirolimus | 0.689 |
| Interferon Alfa and Temsirolimus | 0.689 |
Overall survival is the duration from randomization to death. For participants who are alive, overall survival is censored at the last contact. (NCT00065468)
Timeframe: Baseline up to Month 80
| Intervention | months (Median) |
|---|---|
| Interferon Alfa | 7.3 |
| Temsirolimus | 10.9 |
| Interferon Alfa and Temsirolimus | 8.4 |
Clinical benefit: confirmed CR or PR or had stable disease (SD) lasting at least 24 weeks. CR was the disappearance of all target lesions and non target lesions. PR was at least a 30% decrease in sum of the LD of target lesions, taking as reference the baseline sum LD. SD was having neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. (NCT00065468)
Timeframe: Baseline, every 2 months until tumor progression or death (up to Month 80)
| Intervention | percentage of participants (Number) |
|---|---|
| Interferon Alfa | 16.4 |
| Temsirolimus | 34.0 |
| Interferon Alfa and Temsirolimus | 30.0 |
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was the disappearance of all target lesions and non target lesions. PR was at least a 30 percent (%) decrease in sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. (NCT00065468)
Timeframe: Baseline, every 2 months until tumor progression or death (up to Month 80)
| Intervention | percentage of participants (Number) |
|---|---|
| Interferon Alfa | 5.3 |
| Temsirolimus | 9.1 |
| Interferon Alfa and Temsirolimus | 9.5 |
PFS based on Independent Central Review Assessment. The period from randomization until disease progression, death or date of last contact. (NCT00065468)
Timeframe: Baseline, monthly until tumor progression or death (up to Month 80)
| Intervention | months (Median) |
|---|---|
| Interferon Alfa | 3.2 |
| Temsirolimus | 5.6 |
| Interferon Alfa and Temsirolimus | 4.9 |
"The Q-Twist is not a score calculated for each participant but is defined only on a by treatment group basis. For each treatment group, it is the weighted sum of the mean durations of the health states Tox, Twist, and Relapse. Tox is defined as time with severe toxicity related to treatment; Twist: time without symptoms or toxic side effects; and Relapse: time after relapse/progression. The mean duration of each health state is calculated based on the area under the Kaplan Meier curve pertaining to that health state. There is no direct method for calculating the dispersion of Q-Twist, and it is typically done using bootstrap method for purposes of inference (see, e.g., Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med 1990; 9: 1259-76). In practice, as apparently in the case with this study, the intermediate values resulting from the bootstrap exercise were not displayed." (NCT00065468)
Timeframe: Baseline to Month 80
| Intervention | months (Number) |
|---|---|
| Interferon Alfa | 6.9083 |
| Temsirolimus | 8.3707 |
| Interferon Alfa and Temsirolimus | 7.4821 |
TTF is defined as the time from the date of randomization to the date of PD or death, withdrawal from treatment due to an adverse event (AE), withdrawal of voluntary consent, or lost to follow-up, whichever occurred first, censored at the date of the conclusion of treatment phase. (NCT00065468)
Timeframe: Baseline, every month until tumor progression or death (up to Month 80)
| Intervention | months (Median) |
|---|---|
| Interferon Alfa | 1.9 |
| Temsirolimus | 3.7 |
| Interferon Alfa and Temsirolimus | 2.5 |
Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 542 |
| Placebo | 436 |
Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 542 |
| Placebo | 461 |
PFS determined as the time (days) from the date of randomization at start of study to the actual date of disease progression (PD) (radiological or clinical) or death due to any cause, if death occurred before PD. Outcome measure was assessed approximately every 8 weeks using RECIST v1.0 criteria by independent radiologic review. Radiological PD defined as at least 20% increase in sum of longest diameter (LD) of measured lesions taking as reference smallest sum LD recorded since treatment started or appearance of new lesions. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 167 |
| Placebo | 84 |
Best overall response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 by independent radiologic review. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased) and not evaluated. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not Evaluated | |
| Placebo | 0.0 | 0.0 | 55.2 | 30.3 | 14.5 |
| Sorafenib (Nexavar, BAY43-9006) | 0.0 | 2.1 | 77.9 | 8.7 | 11.3 |
"Primary Analysis for FKSI-10 patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FKSI-10 patient responses for each question range from 0=not at all to 4=very much and after reverse coding the range of values for FKSI-10 total score is from 0 to 40; higher score represents better HRQOL." (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.
| Intervention | Scores on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5, Day 1 | Cycles 1-5 (Overall) | |
| Placebo | 27.78 | 27.28 | 26.78 | 26.28 | 27.20 |
| Sorafenib (Nexavar, BAY43-9006) | 27.77 | 27.27 | 26.77 | 26.27 | 27.19 |
"Primary Analysis for FACT-G (using PWB score) patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FACT-G (PWB score) patient responses for each question range from 0=not at all to 4=very much and after reverse coding the total FACT-G (PWB score) range of values is from 0 to 28; higher score represents better HRQOL." (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.
| Intervention | Scores on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5, Day 1 | Cycles 1-5 (Overall) | |
| Placebo | 21.16 | 20.72 | 20.28 | 19.84 | 20.65 |
| Sorafenib (Nexavar, BAY43-9006) | 21.21 | 20.77 | 20.33 | 19.89 | 20.70 |
The FACT-BRM comprises 40 questions within 6 domains (physical well being, social/family well being, emotional well being, additional concern: physical, and additional concern: emotional). Each question was answered on a five point scale from 0 (not at all) to 4 (very much). The total score range is from 0 to 160 with higher scores indicating better QoL. (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib 400 mg in Period 1 | 104 |
| Interferon Therapy in Period 1 | 93 |
The FACT-BRM comprises 40 questions within 6 domains (physical well being, social/family well being, emotional well being, additional concern: physical, and additional concern: emotional). Each question was answered on a five point scale from 0 (not at all) to 4 (very much). The total score range is from 0 to 160 with higher scores indicating better QoL. (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib 600 mg (as Dose Escalation After 400 mg) | 89.7 |
| Sorafenib 400 mg (After Interferon Therapy) | 108.4 |
"The FKSI questionnaire comprises 15 questions dispatched within 4 domains (respiratory, pain, general symptoms and overall Quality of Life (QoL)) plus 2 individual items. Each question was answered on a five point scale from 0 (not at all) to 4 (very much) indicating the severity of symptoms. The total score range was from 0 to 60 with higher scores indicating subjects reported fewer kidney cancer related symptoms and concerns. The respiratory domain of the FKSI comprises 2 questions: I have been short in breath and I have been coughing; its score ranges from 0 to 8." (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib 400 mg in Period 1 | 6.4 |
| Interferon Therapy in Period 1 | 5.1 |
"The FKSI questionnaire comprises 15 questions dispatched within 4 domains (respiratory, pain, general symptoms and overall Quality of Life (QoL)) plus 2 individual items. Each question was answered on a five point scale from 0 (not at all) to 4 (very much) indicating the severity of symptoms. The total score range was from 0 to 60 with higher scores indicating subjects reported fewer kidney cancer related symptoms and concerns. The respiratory domain of the FKSI comprises 2 questions: I have been short in breath and I have been coughing; its score ranges from 0 to 8." (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib 600 mg (as Dose Escalation After 400 mg) | 5.7 |
| Sorafenib 400 mg (After Interferon Therapy) | 6.4 |
The FKSI questionnaire comprises 15 questions dispatched within 4 domains (respiratory, pain, general symptoms and overall Quality of Life (QoL)) plus 2 individual items. Each question was answered on a five point scale from 0 (not at all) to 4 (very much) indicating the severity of symptoms. The total score range was from 0 to 60 with higher scores indicating subjects reported fewer kidney cancer related symptoms and concerns. (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib 400 mg in Period 1 | 40.5 |
| Interferon Therapy in Period 1 | 34.6 |
The FKSI questionnaire comprises 15 questions dispatched within 4 domains (respiratory, pain, general symptoms and overall Quality of Life (QoL)) plus 2 individual items. Each question was answered on a five point scale from 0 (not at all) to 4 (very much) indicating the severity of symptoms. The total score range was from 0 to 60 with higher scores indicating subjects reported fewer kidney cancer related symptoms and concerns. (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib 600 mg (as Dose Escalation After 400 mg) | 34.6 |
| Sorafenib 400 mg (After Interferon Therapy) | 42.3 |
The TSQM comprises 14 questions dispatched within 4 domains (effectiveness, side effects, convenience, and global satisfaction). Each question was answered on either a 5-point or 7-point scale. Each domain score can vary from 0 to 100 with higher scores indicating subject reported higher effectiveness of treatment, less bothered by side-effects, more convenient use of medication and overall greater satisfaction with the treatment. No total score is calculated. (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib 400 mg in Period 1 | 82 |
| Interferon Therapy in Period 1 | 66 |
The TSQM comprises 14 questions dispatched within 4 domains (effectiveness, side effects, convenience, and global satisfaction). Each question was answered on either a 5-point or 7-point scale. Each domain score can vary from 0 to 100 with higher scores indicating subject reported higher effectiveness of treatment, less bothered by side-effects, more convenient use of medication and overall greater satisfaction with the treatment. No total score is calculated. (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib 600 mg (as Dose Escalation After 400 mg) | 86.5 |
| Sorafenib 400 mg (After Interferon Therapy) | 82.5 |
The TSQM comprises 14 questions dispatched within 4 domains (effectiveness, side effects, convenience, and global satisfaction). Each question was answered on either a 5-point or 7-point scale. Each domain score can vary from 0 to 100 with higher scores indicating subject reported higher effectiveness of treatment, less bothered by side-effects, more convenient use of medication and overall greater satisfaction with the treatment. No total score is calculated. (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib 400 mg in Period 1 | 52 |
| Interferon Therapy in Period 1 | 42 |
The TSQM comprises 14 questions dispatched within 4 domains (effectiveness, side effects, convenience, and global satisfaction). Each question was answered on either a 5-point or 7-point scale. Each domain score can vary from 0 to 100 with higher scores indicating subject reported higher effectiveness of treatment, less bothered by side-effects, more convenient use of medication and overall greater satisfaction with the treatment. No total score is calculated. (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib 600 mg (as Dose Escalation After 400 mg) | 56.9 |
| Sorafenib 400 mg (After Interferon Therapy) | 40.3 |
The TSQM comprises 14 questions dispatched within 4 domains (effectiveness, side effects, convenience, and global satisfaction). Each question was answered on either a 5-point or 7-point scale. Each domain score can vary from 0 to 100 with higher scores indicating subject reported higher effectiveness of treatment, less bothered by side-effects, more convenient use of medication and overall greater satisfaction with the treatment. No total score is calculated. (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib 400 mg in Period 1 | 60 |
| Interferon Therapy in Period 1 | 46 |
The TSQM comprises 14 questions dispatched within 4 domains (effectiveness, side effects, convenience, and global satisfaction). Each question was answered on either a 5-point or 7-point scale. Each domain score can vary from 0 to 100 with higher scores indicating subject reported higher effectiveness of treatment, less bothered by side-effects, more convenient use of medication and overall greater satisfaction with the treatment. No total score is calculated. (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib 600 mg (as Dose Escalation After 400 mg) | 39.9 |
| Sorafenib 400 mg (After Interferon Therapy) | 35.4 |
The TSQM comprises 14 questions dispatched within 4 domains (effectiveness, side effects, convenience, and global satisfaction). Each question was answered on either a 5-point or 7-point scale. Each domain score can vary from 0 to 100 with higher scores indicating subject reported higher effectiveness of treatment, less bothered by side-effects, more convenient use of medication and overall greater satisfaction with the treatment. No total score is calculated. (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib 400 mg in Period 1 | 63 |
| Interferon Therapy in Period 1 | 46 |
The TSQM comprises 14 questions dispatched within 4 domains (effectiveness, side effects, convenience, and global satisfaction). Each question was answered on either a 5-point or 7-point scale. Each domain score can vary from 0 to 100 with higher scores indicating subject reported higher effectiveness of treatment, less bothered by side-effects, more convenient use of medication and overall greater satisfaction with the treatment. No total score is calculated. (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib 600 mg (as Dose Escalation After 400 mg) | 61.3 |
| Sorafenib 400 mg (After Interferon Therapy) | 57.6 |
Plasma samples were collected prior to dosing every 4 weeks after the patient reached steady-state (at least 10 days at 400 mg BID). (NCT00117637)
Timeframe: From start of treatment of the first subject until 15 months later assessed every 4 weeks.
| Intervention | 100*mg/L (Geometric Mean) |
|---|---|
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600mg | 93.9 |
Duration of Response was defined as the time from date of first response (Complete Response (CR) or Partial Response (PR)) to the date when Progressive Disease (PD) is first documented or to the date of death, whichever occurs first. Subjects still having CR or PR at the time of analysis were censored at their last date of last contact (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | months (Median) |
|---|---|
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600 mg | 7.5 |
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 7.7 |
Duration of Response was defined as the time from date of first response (Complete Response (CR) or Partial Response (PR)) to the date when Progressive Disease (PD) is first documented or to the date of death, whichever occurs first. Subjects still having CR or PR at the time of analysis were censored at their last date of last contact (NCT00117637)
Timeframe: From randomization of the first subject until 3 years and 9 months later, assessed every 8 weeks
| Intervention | months (Median) |
|---|---|
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600 mg | 4.4 |
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 9.2 |
Duration of Response was defined as the time from date of first response (Complete Response (CR) or Partial Response (PR)) to the date when Progressive Disease (PD) is first documented or to the date of death, whichever occurs first. Subjects still having CR or PR at the time of analysis were censored at their last date of last contact (NCT00117637)
Timeframe: From randomization of the first subject until 3 years and 9 months later, assessed every 8 weeks
| Intervention | months (Median) |
|---|---|
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 5.5 |
Overall Survival was defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact (NCT00117637)
Timeframe: From randomization of the first subject until 3 years and 9 months later, assessed every 8 weeks
| Intervention | months (Median) |
|---|---|
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600 mg | 14.8 |
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 26.9 |
Progression-free Survival (PFS) was defined as the time from date of randomization to disease progression (radiological or clinical or death due to any cause, whichever occurs first). Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation (NCT00117637)
Timeframe: From randomization of the first subject until 3 years and 9 months later, assessed every 8 weeks
| Intervention | months (Median) |
|---|---|
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600 mg | 4.5 |
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 5.5 |
Progression-free Survival (PFS) was defined as the time from date of randomization to disease progression (radiological or clinical or death due to any cause, whichever occurs first). Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | months (Median) |
|---|---|
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600 mg | 5.7 |
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 5.6 |
Progression-free Survival (PFS) was defined as the time from date of randomization to disease progression (radiological or clinical or death due to any cause, whichever occurs first). Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation (NCT00117637)
Timeframe: From randomization of the first subject until 3 years and 9 months later, assessed every 8 weeks
| Intervention | months (Median) |
|---|---|
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600 mg | 5.6 |
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 7.0 |
Plasma samples were collected prior to dosing every 4 weeks after the patient reached steady-state (at least 10 days at 400 mg BID (bis in die, twice daily)) to assess any potential trends in trough concentration over time. (NCT00117637)
Timeframe: From start of treatment of the first subject until 15 months later assessed every 4 weeks.
| Intervention | 100*(mg/L/cycle) (Mean) |
|---|---|
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600mg | -8.3 |
Time to Response (TTR) for subjects who achieved a response (Complete Response (CR) or Partial Response (PR) with confirmation was defined as the time from date of randomization to the earliest date that the response was first documented (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | months (Median) |
|---|---|
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600 mg | 1.8 |
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 5.4 |
Time to Response (TTR) for subjects who achieved a response (Complete Response (CR) or Partial Response (PR) with confirmation was defined as the time from date of randomization to the earliest date that the response was first documented (NCT00117637)
Timeframe: From randomization of the first subject until 3 years and 9 months later, assessed every 4 weeks
| Intervention | months (Median) |
|---|---|
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600 mg | 3.5 |
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 5.4 |
Time to Response (TTR) for subjects who achieved a response (Complete Response (CR) or Partial Response (PR) with confirmation) was defined as the time from date of randomization to the earliest date that the response was first documented (NCT00117637)
Timeframe: From randomization of the first subject until 3 years and 9 months later, assessed every 4 weeks
| Intervention | months (Median) |
|---|---|
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 1.7 |
Eastern Cooperative Oncology Group (ECOG) Performance Status is a scale that measures how cancer affects the daily life of a patient on an ordinal scale from grade 0 (best) to grade 5 (worst). (NCT00117637)
Timeframe: From randomization of the first subject until 3 years and 9 months later, assessed every 4 weeks
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| 0= Fully active without restriction | 1= Restricted in physically strenuous activity | 2= Ambulatory, capable of all selfcare | 3= Capable of limited selfcare | 4= Completely disabled | 5= Dead | |
| Interferon Therapy in Period 1 | 19 | 42 | 21 | 5 | 2 | 0 |
| Sorafenib 400 mg in Period 1 | 20 | 48 | 20 | 5 | 1 | 1 |
Eastern Cooperative Oncology Group (ECOG) Performance Status is a scale that measures how cancer affects the daily life of a patient on an ordinal scale from grade 0 (best) to grade 5 (worst). (NCT00117637)
Timeframe: From randomization of the first subject until 3 years and 9 months later, assessed every 4 weeks
| Intervention | participant s (Number) | |||||
|---|---|---|---|---|---|---|
| 0= Fully active without restriction | 1= Restricted in physically strenuous activity | 2= Ambulatory, capable of all selfcare | 3= Capable of limited selfcare | 4= Completely disabled | 5= Dead | |
| Sorafenib 400 mg (After Interferon Therapy) | 16 | 26 | 10 | 5 | 1 | 0 |
| Sorafenib 600 mg (as Dose Escalation After 400 mg) | 5 | 25 | 10 | 4 | 1 | 0 |
Disease Control (DC) was defined as the total number of subjects whose best response was not Progressive Disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR) + total number of Partial Response (PR) + total number of Stable Disease (SD); CR, PR, or SD had to be maintained for at least 28 days from the first demonstration of that rating). CR: disappearance of tumor lesions (TL); PR: a decrease of at least 30% in the sum of TL sizes; SD: steady state of disease; PD: an increase of at least 20% in the sum of TL sizes. (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| disease control (CR or PR or SD) | no disease control | Unknown | |
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 59 | 24 | 9 |
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600 mg | 77 | 10 | 10 |
Disease Control (DC) was defined as the total number of subjects whose best response was not Progressive Disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR) + total number of Partial Response (PR) + total number of Stable Disease (SD); CR, PR, or SD had to be maintained for at least 28 days from the first demonstration of that rating). CR: disappearance of tumor lesions (TL); PR: a decrease of at least 30% in the sum of TL sizes; SD: steady state of disease; PD: an increase of at least 20% in the sum of TL sizes. (NCT00117637)
Timeframe: From randomization of the first subject until 3 years and 9 months later, assessed every 8 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| disease control (CR or PR or SD) | no disease control | Unknown | |
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 62 | 24 | 6 |
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600 mg | 83 | 7 | 7 |
Disease Control (DC) was defined as the total number of subjects whose best response was not Progressive Disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR) + total number of Partial Response (PR) + total number of Stable Disease (SD); CR, PR, or SD had to be maintained for at least 28 days from the first demonstration of that rating). CR: disappearance of tumor lesions (TL); PR: a decrease of at least 30% in the sum of TL sizes; SD: steady state of disease; PD: an increase of at least 20% in the sum of TL sizes. (NCT00117637)
Timeframe: From randomization of the first subject until 3 years and 9 months later, assessed every 8 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| disease control (CR or PR or SD) | no disease control | Unknown | |
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 49 | 6 | 6 |
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600 mg | 25 | 16 | 8 |
Tumor Response (= Best Overall Response) of a subject was defined as the best tumor response (confirmed Complete Response (CR), confirmed Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes, SD was defined as steady state of disease, PD was defined as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00117637)
Timeframe: From randomization of the first subject until 15 months later, assessed every 8 weeks
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | Not Evaluated | |
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 1 | 7 | 51 | 24 | 9 |
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600 mg | 0 | 5 | 72 | 10 | 10 |
Tumor Response (= Best Overall Response) of a subject was defined as the best tumor response (confirmed Complete Response (CR), confirmed Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes, SD was defined as steady state of disease, PD was defined as an increase of at least 20% in the sum of tumor lesions sizes (NCT00117637)
Timeframe: From randomization of the first subject until 3 years and 9 months later, assessed every 8 weeks
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | Not Evaluated | |
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 1 | 13 | 48 | 24 | 6 |
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600 mg | 0 | 21 | 62 | 7 | 7 |
Tumor Response (= Best Overall Response) of a subject was defined as the best tumor response (confirmed Complete Response (CR), confirmed Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes, SD was defined as steady state of disease, PD was defined as an increase of at least 20% in the sum of tumor lesions sizes (NCT00117637)
Timeframe: From randomization of the first subject until 3 years and 9 months later, assessed every 8 weeks
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | Not Evaluated | |
| First Interferon Then Sorafenib (Nexavar, BAY43-9006) 400 mg | 1 | 11 | 37 | 6 | 6 |
| First Sorafenib (Nexavar, BAY43-9006) 400 mg Then 600 mg | 0 | 0 | 25 | 16 | 8 |
"Best overall response was evaluated using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v 1.0). Response is defined as complete response or partial response.~Complete Response (CR): disappearance of all target lesions Partial Response (PR): >=30% decrease in the sum of the longest diameter of target lesions" (NCT01649180)
Timeframe: Assessed every 12 weeks up to 36 months
| Intervention | proportion of participants (Number) |
|---|---|
| Axitinib | 1.00 |
Progression-free survival is defined as the time from registration to disease progression or death, whichever occurs first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01649180)
Timeframe: Assessed every 12 weeks up to 36 months
| Intervention | months (Median) |
|---|---|
| Axitinib | 16.6 |
"The Caregiver Burden Scale is a standard set of questions which will be used to measure the non-medical impact of TSC on caregivers and how it affects the feasibility of study completion.~The Caregiver's Burden Scale (CBS) is a 22-item scale that assess subjectively experienced burden by caregiver's to chronically disabled persons. maximum scores: 88 & Minumum scores: 22~High values represent a worse outcome" (NCT01929642)
Timeframe: Change from baseline to EOT visit 12 week 53
| Intervention | units on a scale (Mean) |
|---|---|
| Everolimus or Sirolimus | 61 |
"Score range maximum: 100 Score range minimum: 0~High values represent a high cognitive function Below 70 is abnormal. 70-100 is the normal range." (NCT01929642)
Timeframe: 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Everolimus or Sirolimus | 15 |
"Measurements of stress will be administered. Specifically, we will use the Parental Stress Index. Quantifying stress, as well as compliance with the study protocol, will allow investigators to objectively assess the feasibility of a larger clinical trial of sirolimus in patients with TSC.~Parental stress index maximum score: 180 Parental stress index minimum score: 36 higher raw scores indicate higher levels of stress." (NCT01929642)
Timeframe: Change from baseline to EOT visit 12 week 53
| Intervention | units on a scale (Mean) |
|---|---|
| Everolimus or Sirolimus | 111 |
Parents will be asked to document the frequency of their child's seizures using a manual or electronic (seizuretracker.com) seizure diary. The total number of seizures at baseline for all participants. (NCT01929642)
Timeframe: at baseline
| Intervention | seizures (Number) |
|---|---|
| Everolimus or Sirolimus | 0 |
"Repetitive behavior will be assessed using the Repetitive Behavior Scale - revised, a questionnaire to characterize several domains of repetitive behavior including ritualistic behavior, stereotypic behavior, self-injurious behavior, compulsive behavior, and restricted interests.~There are 36 items on the scale. Behaviors are rated on a 4-point scale: 0-Behavior does not occur, 1-Behavior occurs and is a mild problem, 2-Behavior occurs and is a moderate problem, 3-Behavior occurs and is a severe problem.~Maximum score: 108 & minimum score: 0 A high score represents the worse outcome" (NCT01929642)
Timeframe: 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Everolimus or Sirolimus | 69 |
This is the total number of aggressions or self-injuries for all participants. (NCT01929642)
Timeframe: 1 year
| Intervention | Number of aggressions or self-injuries (Number) |
|---|---|
| Everolimus or Sirolimus | 82 |
One outcome measurement of feasibility will include family/patient compliance with the treatment protocol, which will be assessed and documented at every study visit and telephone follow-up call, by the physician and/or study team member. This was calculated by calculating dividing the total number of study visits and study assessments completed by the total number of study visits and study assessments indicated by the treatment protocol. (NCT01929642)
Timeframe: Change from baseline to EOT visit 12 week 53
| Intervention | percentage of completed visits/measures (Number) | ||
|---|---|---|---|
| Participant 002 | Participant 003 | Participant 001 | |
| Everolimus or Sirolimus | 100 | 58 | 58 |
Geometric mean exposure for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | mg/L.h (Geometric Mean) |
|---|---|
| First Stage - Disease Progression | 9.76 |
| Second Stage - Increased Accrual | 18.63 |
Plasma concentration-time profile for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, AND 24 hours post dose
| Intervention | mg/L (Mean) |
|---|---|
| First Stage - Disease Progression | 1.28 |
| Second Stage - Increased Accrual | 2.57 |
Time from treatment start date until date of death or date last known alive. (NCT00090545)
Timeframe: Time from treatment start date until date of death or date last known alive, approximately 18.3 months.
| Intervention | Months (Median) |
|---|---|
| First Stage - Disease Progression | 18 |
| Second Stage - Increased Accrual | 18.3 |
Here is the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module. (NCT00090545)
Timeframe: Date treatment consent signed to date off study, approximately 49 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| First Stage - Disease Progression | 22 |
| Second Stage - Increased Accrual | 23 |
Determine whether BAY 43-9006 when used to treat metastatic prostate cancer is associated with having 50% of Patients Progression Free at 4 Months by clinical, radiographic, and prostatic specific antigen (PSA)criteria. (NCT00090545)
Timeframe: 4 months
| Intervention | months (Median) |
|---|---|
| First Stage - Disease Progression | 1.83 |
| Second Stage - Increased Accrual | 3.7 |
Time to maximum concentration for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | hours (Median) |
|---|---|
| First Stage - Disease Progression | 0.68 |
| Second Stage - Increased Accrual | 8 |
Overall response was evaluated by the RECIST. Complete Response (CR) is the disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00090545)
Timeframe: Every 2 cycles (1 cycle = 28 days)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Progressive Disease | Stable Disease | |
| First Stage - Disease Progression | 0 | 0 | 8 | 0 |
| Second Stage - Increased Accrual | 0 | 1 | 13 | 10 |
Number of subjects who died due to any cause. (NCT00586495)
Timeframe: From start of treatment of the first subject until 45 months later, assessed every 3 months
| Intervention | participants (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 43 |
Subjects who have a best response rating of CR, PR or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started) per RECIST that is maintained for at least 28 days from the first demonstration of that rating. (NCT00586495)
Timeframe: From start of treatment of the first subject until 45 months later, assessed every 8 weeks
| Intervention | participants (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 81 |
Time from the date of first objective response (CR or PR, whichever is first recorded) to the date when progressive disease (PD, at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions) is first documented according to RECIST. (NCT00586495)
Timeframe: From start of treatment of the first subject until 45 months later, assessed every 8 weeks
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 419 |
Time from initiation of treatment to disease progression (radiological or clinical, whichever earlier) or death (if death occurs before progression). (NCT00586495)
Timeframe: From start of treatment of the first subject until 45 months later, assessed every 8 weeks
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 386 |
Time from initiation of treatment to the date when an objective response (CR or PR, whichever is first recorded) is first documented according to RECIST. (NCT00586495)
Timeframe: From start of treatment of the first subject until 45 months later, assessed every 8 weeks
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 84 |
Best tumor response, including Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter) according to the Response Evaluation Criteria in Solid Tumors (RECIST) (NCT00586495)
Timeframe: From start of treatment of the first subject until 45 months later, assessed every 8 weeks
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Disease Progression (radiological or clinical) | Not evaluated | |
| Sorafenib (Nexavar, BAY43-9006) | 0 | 25 | 64 | 4 | 1 |
The size of the coagulation zone was determined on CT imaging obtained after RFA for the single index tumor. (NCT00813293)
Timeframe: Up to day 50 from study enrollment (target 30 days after RFA)
| Intervention | millimeters (Mean) |
|---|---|
| Sorafenib | 42.4 |
| Placebo | 44.1 |
The size of the coagulation zone was determined on CT imaging obtained after RFA for the single index tumor. (NCT00813293)
Timeframe: Up to day 50 from study enrollment (target 30 days after RFA)
| Intervention | millimeters (Mean) |
|---|---|
| Sorafenib | 36.0 |
| Placebo | 35.1 |
The size of the coagulation zone was determined on CT imaging obtained after RFA for the single index tumor. (NCT00813293)
Timeframe: Up to day 50 from study enrollment (target 30 days after RFA)
| Intervention | centimeters^3 (Mean) |
|---|---|
| Sorafenib | 30.7 |
| Placebo | 30.5 |
Feasibility rate is defined as the percentage of participants completing radiofrequency ablation following 9 days of sorafenib or placebo therapy. (NCT00813293)
Timeframe: Up to day 14 since enrollment
| Intervention | percentage of particpants (Number) |
|---|---|
| Sorafenib | 90 |
| Placebo | 90 |
AEs were assessed based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v3.0). The number of Grade 1-4 AEs with treatment attribution possibly, probably or definitely related up to day 9 of study drug treatment were counted for this outcome. Worst grade by patient within AE type was calculated. Participants could have multiple different AE types within a grade. (NCT00813293)
Timeframe: Day 9
| Intervention | adverse events (Number) |
|---|---|
| Sorafenib | 8 |
| Placebo | 4 |
AEs were assessed based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v3.0). The number of Grade 1-4 AEs with treatment attribution possibly, probably or definitely related on day of RFA treatment were counted for this outcome. Worst grade by patient within AE type was calculated. Participants could have multiple AE types within a grade. (NCT00813293)
Timeframe: Up to day 14 (target day 10 RFA)
| Intervention | adverse events (Number) |
|---|---|
| Sorafenib | 5 |
| Placebo | 4 |
AEs were assessed based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v3.0). The number of Grade 1-4 AEs with treatment attribution possibly, probably or definitely related one month after RFA treatment were counted for this outcome. Worst grade by patient within AE type was calculated. Participants could have multiple AE types within a grade. (NCT00813293)
Timeframe: Up to day 40 post RFA (target 30 days)
| Intervention | adverse events (Number) |
|---|---|
| Sorafenib | 8 |
| Placebo | 4 |
175 reviews available for niacinamide and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Indoles; | 2017 |
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; | 2017 |
Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; In | 2017 |
A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Molecular Targe | 2017 |
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group.
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamid | 2019 |
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell | 2013 |
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Re | 2013 |
Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Renal Cell; Disease Progr | 2013 |
Molecular markers to predict response to therapy.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Bevacizumab; Biomarkers, Tumor; Carbonic Anhy | 2013 |
Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.
Topics: Antineoplastic Agents; Axitinib; Bayes Theorem; Carcinoma, Renal Cell; Everolimus; Humans; Imidazole | 2013 |
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Clin | 2014 |
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; | 2014 |
[Medical treatment of renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carc | 2013 |
Advanced kidney cancer: treating the elderly.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carc | 2013 |
Axitinib for the treatment of advanced renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imid | 2014 |
Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; | 2014 |
Kidney cancer: Temsirolimus fails to expand its role in patients with mRCC.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fema | 2014 |
Sorafenib in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Ni | 2014 |
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Incidence; Indazoles; Indoles; Kidn | 2015 |
Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Therapy; Humans; Hypertension; Incidence; K | 2014 |
Comparing comparators: a look at control arms in kidney cancer studies over the years.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Interferon-alpha; Kidney Neoplasms; Niacinamid | 2015 |
A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.
Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Approval; Humans; Kidney Neoplasms; Niacinamid | 2015 |
Sorafenib: 10 years after the first pivotal trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Liver Neoplasms; Ni | 2015 |
Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasm | 2015 |
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Diseas | 2015 |
Clinical management of metastatic kidney cancer: the role of new molecular drugs.
Topics: Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Molecular Targeted Therapy; | 2016 |
Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Indoles; | 2016 |
Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzimidazoles; Carcinoma, Renal Cell; Hum | 2016 |
Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Prote | 2016 |
A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Renal Cell; Gene Expression; Humans; | 2016 |
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcin | 2016 |
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Rela | 2016 |
Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dise | 2016 |
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibi | 2016 |
Systemic therapy in metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Decision Trees; Ever | 2017 |
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Bevacizumab; Biomarkers, Tumor; C | 2016 |
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Compa | 2017 |
Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: Methodology of clinical trials and clinical benefit.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Molecular Targe | 2017 |
Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Humans | 2017 |
Targeted Therapy for Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everol | 2016 |
Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature.
Topics: Adult; Age of Onset; Antineoplastic Agents; Axitinib; Basic Helix-Loop-Helix Leucine Zipper Transcri | 2017 |
Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Dise | 2017 |
Renal cell carcinoma.
Topics: Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney | 2017 |
[Value of targeted therapies for renal cell cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2008 |
Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2008 |
An update on the medical therapy of advanced metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Ther | 2008 |
Targeted therapy in renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2008 |
New therapies in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2007 |
[Molecular basis of targeted therapy in metastatic renal cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic | 2008 |
[Molecular targeted therapy for renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Gene Targ | 2008 |
Exploring the role of novel agents in the treatment of renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2008 |
Novel drugs for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; | 2008 |
Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2008 |
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Systemic therapy for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2008 |
Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
Recent advances in the systemic treatment of metastatic papillary renal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2009 |
Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; | 2009 |
Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Case-Control Studies; Female; | 2009 |
Targeted therapies in metastatic renal cancer in 2009.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenes | 2009 |
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzen | 2009 |
Prognostic markers and new, innovative treatments in renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cancer Vaccines; Carcinoma, Renal Cell; | 2009 |
Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug-Rela | 2009 |
Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Del | 2009 |
[Sorafenib(Nexavar)].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Nia | 2009 |
[Interferon alpha and half-dose sorafenib is an effective treatment modality for interferon alpha-resistant metastatic renal cell carcinoma: a case report].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Dr | 2009 |
Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Health Status | 2009 |
Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical T | 2009 |
Metastatic renal cell carcinoma: current standards of care.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Everolim | 2009 |
Management of vascular endothelial growth factor and multikinase inhibitor side effects.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Heart Diseases; Human | 2010 |
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2009 |
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; | 2010 |
Toxicity of sorafenib: clinical and molecular aspects.
Topics: Animals; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Exanthema; Humans; Kidn | 2010 |
Progress in the management of advanced renal cell carcinoma (RCC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
[Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinom | 2010 |
Update on systemic therapies of metastatic renal cell carcinoma.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzen | 2010 |
[Use of sorafenib in patients with hepatocellular or renal carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical | 2010 |
Experience with sorafenib and adverse event management.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypertension; Niacinamide; | 2011 |
[Treatment of locally advanced renal tumors].
Topics: Adrenalectomy; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; A | 2010 |
[Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2010 |
Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2010 |
Treatment of metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinami | 2010 |
Present state of target therapy for disseminated renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2010 |
Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Female | 2010 |
[Molecular targeted therapy for renal cell carcinoma and other urological cancers].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; | 2010 |
A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Designer Drugs; Humans; Kidney Neop | 2011 |
The therapy of kidney cancer with biomolecular drugs.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma | 2011 |
Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2011 |
Sorafenib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney; Kidney Neo | 2011 |
[Novelties in the treatment for advanced renal-cell cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2011 |
Treatment of metastatic renal cell carcinoma and renal pelvic cancer.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Everolimus; Gemcitabine; Humans; | 2011 |
[Treatment of metastatic renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2011 |
Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Molecular T | 2011 |
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical | 2012 |
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney | 2011 |
Sorafenib for the management of advanced renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Kidn | 2011 |
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinom | 2011 |
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Indoles; Kidn | 2011 |
[Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2011 |
Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Disease M | 2012 |
[Systemic treatment of renal cell carcinoma - recent update].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Mo | 2011 |
[Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma].
Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrase IX; Carbonic Anhydr | 2012 |
Tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs | 2011 |
[Myocardial metastasis from renal cell carcinoma treated with sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Heart Neoplasms; Humans; Kidney Neo | 2011 |
VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carc | 2011 |
Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Topics: Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2012 |
Sorafenib for the treatment of renal cancer.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Targeted therapeutic strategies for the management of renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-F | 2012 |
[First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; In | 2012 |
Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans | 2012 |
Hypothyroidism during treatment with tyrosine kinase inhibitors.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Indoles | 2012 |
[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; In | 2012 |
Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation.
Topics: Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylur | 2013 |
Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bayes Theo | 2013 |
Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevaciz | 2014 |
Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor.
Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea C | 2013 |
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2005 |
Raf kinase as a target for anticancer therapeutics.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumo | 2005 |
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2005 |
Promising systemic therapy for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2005 |
Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, | 2005 |
Targeted therapy for metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma | 2006 |
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2005 |
[Progress in therapeutic strategy for renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; | 2006 |
Sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; | 2006 |
VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Molecule of the month. Sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinami | 2006 |
Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, | 2006 |
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II | 2006 |
Molecular targeting therapy for renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenes | 2006 |
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Transformation, Neopl | 2006 |
New treatment approaches in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Deliv | 2006 |
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; | 2006 |
[Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Female; Ga | 2006 |
Molecular biology of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
New weapons to snuff out kidney cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunotherapy; Indoles; Kid | 2006 |
Targeted therapy for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Targeting von Hippel-Lindau pathway in renal cell carcinoma.
Topics: Benzenesulfonates; Biomedical Research; Carcinoma, Renal Cell; Enzyme Inhibitors; Everolimus; Humans | 2006 |
Sorafenib for the treatment of advanced renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; | 2006 |
Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; | 2006 |
Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; I | 2006 |
Sorafenib in renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease P | 2007 |
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2007 |
Sorafenib: in advanced renal cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Humans; Kidney | 2007 |
[Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, | 2007 |
Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidne | 2007 |
Sorafenib: delivering a targeted drug to the right targets.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical | 2007 |
[Clinical results of Nexavar for the treatment of kidney cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; K | 2007 |
Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; Drug Evaluatio | 2007 |
CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; | 2007 |
The role of targeted therapy in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Deli | 2007 |
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Deli | 2007 |
[Effect of angiogenesis inhibitors on renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2007 |
Treatment options in renal cell carcinoma: past, present and future.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma | 2007 |
[Angiogenesis and renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2007 |
Managing side effects of angiogenesis inhibitors in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; In | 2007 |
Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Kidney Neopla | 2007 |
Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistanc | 2007 |
Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Dru | 2007 |
[Angiogenesis targeting in renal carcinomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2007 |
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; D | 2008 |
Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Niacinami | 2008 |
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Eruptions | 2008 |
[Molecular targeted therapy for renal cell carcinoma].
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzenesulfonates; Carcinoma, Renal Cell; Drug | 2008 |
[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2008 |
Renal cell carcinoma.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzen | 2008 |
Treatment options for metastatic renal cell carcinoma: a review.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2008 |
115 trials available for niacinamide and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans | 2022 |
Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypoal | 2017 |
Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Disease-F | 2017 |
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; He | 2017 |
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Huma | 2013 |
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; | 2013 |
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; | 2013 |
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; | 2013 |
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; | 2013 |
Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 2013 |
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Axitinib; Carcinoma, Renal Cell; Diarrhea; Disease-Fre | 2013 |
"Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.
Topics: Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Everolimus; Female; Humans; Indoles; K | 2013 |
Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Kidney Neop | 2014 |
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; | 2013 |
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; | 2013 |
Efficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment.
Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Dr | 2014 |
Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; | 2014 |
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Confounding Factors, Epidemiolo | 2013 |
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Confounding Factors, Epidemiolo | 2013 |
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Confounding Factors, Epidemiolo | 2013 |
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Confounding Factors, Epidemiolo | 2013 |
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; | 2014 |
A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; | 2014 |
A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Bandages, Hydrocolloid; Carcinoma, Renal Cell; Ceramides; Female; Hand- | 2014 |
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2014 |
Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
Topics: Aged; Antibodies, Monoclonal; Carcinoma, Renal Cell; Drug Synergism; Female; Humans; Immunohistochem | 2014 |
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal | 2014 |
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal | 2014 |
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal | 2014 |
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal | 2014 |
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Hypertension; Imidazoles; In | 2015 |
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; | 2014 |
Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cognition; Cognition Disorders; Cross-Section | 2014 |
Neoadjuvant sorafenib treatment of clear cell renal cell carcinoma and release of circulating tumor fragments.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kaplan-Meier Estimate; Kidney; K | 2014 |
[First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of pat
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2014 |
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Humans; Im | 2014 |
A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease- | 2014 |
Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; | 2015 |
[Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Feasibility | 2015 |
Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carcinoma, Renal Cell; Dise | 2015 |
Comparison of volumetric and linear serial CT assessments of lung metastases in renal cell carcinoma patients in a clinical phase IIB study.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Kidney Neoplasms; Lu | 2015 |
Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Axitinib; Blood Pressure; Carcinoma, Renal Cell; Disease-Free Surviva | 2015 |
The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ren | 2015 |
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brai | 2015 |
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Chemotherapy, Ad | 2015 |
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN C
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2015 |
Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2015 |
Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Fema | 2015 |
Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; | 2015 |
The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Ha | 2016 |
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease- | 2016 |
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease- | 2016 |
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease- | 2016 |
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease- | 2016 |
Comparison of central and local serial CT assessments of metastatic renal cell carcinoma patients in a clinical phase IIB study.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Data Interpretation, Statistical; Humans; Interferon a | 2017 |
Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.
Topics: Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidne | 2017 |
Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; | 2017 |
Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Double-Blind Method; Female; Hepatectomy; | 2017 |
Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; In | 2017 |
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; D | 2017 |
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; | 2008 |
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Biomarke | 2008 |
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Fr | 2008 |
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Ren | 2009 |
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cross-Over Studies; Diarrhea; | 2009 |
Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Male; Middle | 2009 |
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indole | 2009 |
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Huma | 2009 |
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; | 2010 |
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Re | 2010 |
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarke | 2010 |
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; F | 2010 |
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; F | 2010 |
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; F | 2010 |
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; F | 2010 |
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Body Mass Index; Carcinoma, Renal Cell; Dose-Respons | 2010 |
Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Fea | 2010 |
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2010 |
Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; F | 2010 |
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal | 2010 |
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Topics: Aged; Antigens, Neoplasm; Benzenesulfonates; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhy | 2010 |
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Ren | 2010 |
Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2010 |
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfo | 2010 |
A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonat | 2010 |
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabin | 2011 |
Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Be | 2012 |
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; C | 2011 |
A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Ever | 2011 |
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.
Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Rena | 2011 |
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Cluster Analysis | 2012 |
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neopl | 2011 |
Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cyt | 2011 |
Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cyt | 2011 |
Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cyt | 2011 |
Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cyt | 2011 |
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2011 |
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney | 2011 |
Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Immuni | 2011 |
Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Fem | 2012 |
[Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiang
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Carcinoma, | 2011 |
Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benz | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesul | 2011 |
Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; CD3 Complex; CD4 Antig | 2012 |
Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Ever | 2012 |
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Diarrhe | 2012 |
Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.
Topics: Adenocarcinoma, Clear Cell; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Age | 2012 |
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 2013 |
A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; | 2012 |
[First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; In | 2012 |
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Diarrhea; Disease | 2013 |
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2012 |
Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Biological Transport; Carcinoma, Renal Cell; Feas | 2012 |
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2013 |
Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dise | 2012 |
Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Bindin | 2013 |
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; C | 2013 |
[Phase II clinical trial of sorafenib plus local chemotherapy in the treatment of metastatic renal cell carcinoma with pleural effusion].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; | 2012 |
Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
Topics: Adult; Aged; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Disease-Free Survival; Ev | 2013 |
Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles | 2013 |
Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progressio | 2013 |
Kinase inhibition with BAY 43-9006 in renal cell carcinoma.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Enzyme Inhibitors; Humans; Kidney Neoplasms; Niacinamide; | 2004 |
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; | 2005 |
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; | 2006 |
Randomized discontinuation trial of sorafenib (BAY 43-9006).
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Double-Blind M | 2006 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2007 |
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarke | 2007 |
Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carc | 2007 |
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2007 |
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; B | 2007 |
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Di | 2007 |
Sorafenib TARGET trial results in Spanish patients.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female | 2007 |
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; | 2008 |
501 other studies available for niacinamide and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Kidney; Kidney Neop | 2022 |
Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain.
Topics: Adult; Brain; Carcinoma, Renal Cell; Gallium Radioisotopes; Humans; Kidney Neoplasms; Male; Niacinam | 2022 |
Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Deoxyglucose; Glucose; Glutamine; Humans; Kidney Neoplasms; Niacinamide; Tumo | 2022 |
18F-PSMA 1007 in Suspected Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Fluorine Radioisotopes; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinam | 2020 |
Lactate Increases Renal Cell Carcinoma Aggressiveness through Sirtuin 1-Dependent Epithelial Mesenchymal Transition Axis Regulation.
Topics: Acetylation; Animals; Biological Transport; Cadherins; Carcinoma, Renal Cell; Cell Line, Tumor; Cell | 2020 |
18F-PSMA-1007 PET/CT for Initial Staging of Renal Cell Carcinoma in an End-Stage Renal Disease Patient.
Topics: Carcinoma, Renal Cell; Female; Fluorine Radioisotopes; Humans; Kidney Failure, Chronic; Kidney Neopl | 2021 |
Utility of 18F-Prostate-Specific Membrane Antigen 1007 in Imaging of Tumor Thrombus of Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Fluorine Radioisotopes; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinam | 2021 |
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Coh | 2017 |
In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Chromatography, High Pressure | 2017 |
Korean Red Ginseng Extract Enhances the Anticancer Effects of Sorafenib through Abrogation of CREB and c-Jun Activation in Renal Cell Carcinoma.
Topics: Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cyclic AMP Response Element-Binding Protein; Hum | 2017 |
Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Deubiquitina | 2017 |
Evaluation of First-Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Single-Center Experience With Four Cases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Kidney Transplantation | 2017 |
The significance of TIMD4 expression in clear cell renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Disease-Fr | 2017 |
Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
Topics: Aged; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase II | 2017 |
Combination of sorafenib and cytokine-induced killer cells in metastatic renal cell carcinoma: a potential regimen.
Topics: Carcinoma, Renal Cell; Cytokine-Induced Killer Cells; Humans; Immunotherapy; Kidney Neoplasms; Male; | 2017 |
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Renal Cell; Disease | 2017 |
Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cohort Studies; Dat | 2017 |
Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; China; Disease-Free Survival; Drug-Related Si | 2017 |
Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival | 2017 |
Leg ulcers associated with cutaneous vascular degeneration in a patient receiving pazopanib chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Leg Ulcer; | 2017 |
Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Indo | 2017 |
Ethanol extract of Patrinia scabiosaefolia induces the death of human renal cell carcinoma 786-O cells via SIRT-1 and mTOR signaling-mediated metabolic disruptions.
Topics: Antineoplastic Agents; Calcium; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Dose-Respons | 2018 |
CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney N | 2018 |
Skull Base Metastasis From Occult Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Thera | 2018 |
Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Stu | 2018 |
Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells.
Topics: Carcinoma, Renal Cell; Cell Cycle; Drug Synergism; Gene Expression Regulation, Enzymologic; Gene Exp | 2018 |
[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Disease-Free Survival; | 2018 |
Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Renal Cell; | 2018 |
Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; Heart Diseases; H | 2018 |
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, P | 2013 |
[Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocel | 2013 |
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; | 2013 |
Model-based drug development in oncology: what's next?
Topics: Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Kidney Neoplasms; M | 2013 |
Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Male; | 2013 |
Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Fr | 2012 |
New options for second-line therapy of advanced renal cancer.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidne | 2013 |
Case of sorafenib-induced thyroid storm.
Topics: Adrenal Gland Neoplasms; Aged; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Atrial Fib | 2013 |
Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female | 2013 |
Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Comorbidity; D | 2014 |
Urological cancer: second-line option for metastatic RCC.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasm | 2013 |
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Beva | 2013 |
[Drug now immediately available in Germany].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Approval; Germany; Humans; | 2006 |
Kidney cancer: AXIS trial data confirm axitinib as second-line option for mRCC.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasm | 2013 |
Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Humans; Kidney Neoplasms; Male; Neoplasms, Se | 2013 |
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Carcinoma, | 2013 |
A wife asks for futile therapy for her husband, a "fighter": how to respond?
Topics: Carcinoma, Renal Cell; Ethics, Medical; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacina | 2013 |
Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
Topics: Aged; Antineoplastic Agents; Body Composition; Carcinoma, Renal Cell; Clinical Trials as Topic; Dise | 2013 |
First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Asymptomatic Diseases; Blood Cell Count; C-Reactive Protein; Car | 2013 |
[A case of metastatic renal cell carcinoma with no evidence of disease for a long term after a favorable response to molecular-targeted therapy followed by metastasectomy].
Topics: Adrenalectomy; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targete | 2013 |
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Antineoplastic Agents; Antineoplastic Combine | 2013 |
Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Car | 2013 |
Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
Topics: Aged; Betamethasone; Carcinoma, Renal Cell; Fatal Outcome; Humans; Kidney Neoplasms; Male; Neoplasm | 2013 |
[Treatment of hemodialyzed patient by targeted therapy in metastatic renal cell carcinoma: a case report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Molecular Target | 2013 |
[Complete remission by sorafenib for local reccurence of renal cell carcinoma with a tempraly elevation of C-reactive protein: a case report].
Topics: Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Ma | 2013 |
[A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents].
Topics: Animals; Antineoplastic Agents; Birt-Hogg-Dube Syndrome; Carcinoma, Renal Cell; Everolimus; Humans; | 2013 |
[Extracorporeal partial nephrectomy and auto-transplantation after presurgical targeted therapy with tyrosine kinase inhibitors for renal cell cancer].
Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Nephrecto | 2013 |
Kidney cancer: predicting survival after targeted therapy for mRCC.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Live | 2013 |
Slow and steady wins the race: practical (and philosophical) considerations of treatment activity evaluation when novel anticancer agents just slow neoplastic progression.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Kidney Neoplasms; Niacinamide; Phe | 2014 |
Sorafenib induced eruptive melanocytic lesions.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Renal Cell; Drug Eruptions; Fatal Outcome; Humans; | 2013 |
Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Neoadjuvant Th | 2013 |
Sorafenib and sunitinib for elderly patients with renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Disease-Free Surviv | 2013 |
Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up.
Topics: Adult; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Human | 2013 |
Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Carc | 2014 |
Axitinib in advanced renal-cell carcinoma.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidne | 2013 |
Kidney cancer: Axitinib destined for second place?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasm | 2013 |
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Asia; Be | 2014 |
Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles | 2014 |
Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium; Carcinoma, Renal Cell; Disease-Free | 2014 |
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cytokines; Disea | 2014 |
Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; | 2014 |
Targeted therapies: Juggling combinations--not the way forward.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fema | 2014 |
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2014 |
Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Pro | 2014 |
Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cost-Benefit Analysis; Cyprus; Decision Support Techni | 2014 |
Treatment of collecting duct carcinoma: current status and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cel | 2014 |
Treatment of collecting duct carcinoma: current status and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cel | 2014 |
Treatment of collecting duct carcinoma: current status and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cel | 2014 |
Treatment of collecting duct carcinoma: current status and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cel | 2014 |
Maturing of renal cancer therapeutics.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fema | 2014 |
Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
Topics: Aged; Algorithms; Carcinoma, Renal Cell; Combined Modality Therapy; Denmark; Enzyme Inhibitors; Fema | 2014 |
[Systemic treatment of metastatic renal cell carcinoma: change of paradigms after introduction of targeted therapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Ther | 2014 |
Third-line dovitinib in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male | 2014 |
Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.
Topics: Adult; Aged; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Female; Humans; Indoles; K | 2014 |
Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasm | 2014 |
Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Human | 2014 |
Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; CD8-Positive | 2014 |
Management of sorafenib-related adverse events: a clinician's perspective.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue | 2014 |
Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue | 2014 |
Kidney cancer: targeting FGF for third-line treatment of mRCC.
Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male | 2014 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Dens | 2014 |
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Follow-Up Stud | 2014 |
The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Trans | 2014 |
[Metastasized renal cell carcinoma - research subjects needed!].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; | 2014 |
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant | 2014 |
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cohort Studies; | 2014 |
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc | 2014 |
Safety and efficacy of preoperative sorafenib therapy in facilitating cytoreductive surgery in renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Cytoreduction Surgical Procedures; Humans; Niacinamide; Phenylurea Compounds; | 2014 |
Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agent | 2014 |
Metastatic involvement of the maxillary antrum from an uncommon source.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; | 2014 |
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevaciz | 2014 |
Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Diseas | 2014 |
Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor.
Topics: Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dise | 2015 |
Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.
Topics: Adult; Aged; Bone Marrow Cells; Carcinoma, Renal Cell; Humans; Indoles; Leukemia, Myelogenous, Chron | 2015 |
[Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; | 2014 |
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2015 |
Delayed onset perforating folliculitis associated with sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Folliculitis; Humans; Kidney Neoplasms | 2014 |
Survival trends among patients with advanced renal cell carcinoma in the United States.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; M | 2015 |
MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Renal Cell; Cell Line, Tumor; DNA Methylation; Heme Ox | 2014 |
Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Czech Republic; Databa | 2015 |
Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Everolimus; Humans; Indoles; Kidney | 2015 |
Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Antineoplastic Agents; Carci | 2015 |
Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiogenesis Inhibitors; Antineoplastic Agents; Bev | 2015 |
Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; | 2015 |
Cyclophilin D-mediated apoptosis attributes to sorafenib-induced cytotoxicity in clear cell-renal cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Cell Survival; | 2015 |
[Five-year therapeutic experience of sorafenib for patients with advanced renal cell carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Fatigue; Female; Humans; Kidney Neoplasms; M | 2014 |
Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middl | 2015 |
MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
Topics: Aged; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related | 2015 |
Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; D | 2015 |
Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma.
Topics: Asia; Asian People; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Inda | 2015 |
Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Dose-Response | 2015 |
Cost-effectiveness analysis of axitinib through a probabilistic decision model.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; | 2015 |
Kidney cancer: SWITCHing inconsequential.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Ce | 2015 |
Results of the first trial assessing adjuvant tyrosine kinase inhibitors in renal cell carcinoma do not reASSURE.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Early T | 2015 |
Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 2015 |
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System.
Topics: Aged; Antineoplastic Agents; Arteries; Blood Pressure; Carcinoma, Renal Cell; Female; Heart; Humans; | 2016 |
Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, | 2015 |
Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Renal Cell; Contrast Media; Diffusion Magnetic Resonance Imag | 2015 |
Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Fema | 2016 |
Sorafenib-Sunitinib Sequence: The Jury Is Out.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Ce | 2015 |
A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side | 2015 |
Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; China; Disease-Free Survival; Dose-Response Relationsh | 2015 |
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Indazo | 2015 |
Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Surviva | 2016 |
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Huma | 2016 |
Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Laparoscopy; Male; Middle Aged; Neoad | 2015 |
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Ca | 2016 |
[Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; | 2016 |
Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; | 2015 |
Growth inhibitory effect of an injectable hyaluronic acid-tyramine hydrogels incorporating human natural interferon-α and sorafenib on renal cell carcinoma cells.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Humans; Hyaluronic Acid; Hydrogels; Interferon-alp | 2016 |
[Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Middle Aged; Mol | 2015 |
Kidney cancer: TKIs associated with stroke risk.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Card | 2015 |
Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Ren | 2016 |
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databa | 2016 |
Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; | 2016 |
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comorbidity; Disease-Free Survival; Do | 2016 |
The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; China; Disease Progres | 2015 |
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Surviva | 2016 |
Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer.
Topics: Axitinib; Carcinoma, Renal Cell; Cell Communication; Cell Hypoxia; Cell Line, Tumor; Cell Proliferat | 2016 |
[Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Fatigue; Humans; Kidn | 2015 |
A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neopla | 2015 |
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
Topics: Aged; Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comparative Effectiveness Res | 2016 |
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Huma | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC).
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axit | 2015 |
Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses.
Topics: Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Models, Mole | 2016 |
Tyrosine receptor kinase B silencing inhibits anoikis‑resistance and improves anticancer efficiency of sorafenib in human renal cancer cells.
Topics: Anoikis; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene | 2016 |
Combined Treatment of Tyrosine Kinase Inhibitor-Labeled Gold Nanorod Encapsulated Albumin With Laser Thermal Ablation in a Renal Cell Carcinoma Model.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Coumarins; Drug Compo | 2016 |
Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Fatigue; Female; Huma | 2016 |
Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; | 2017 |
Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Renal Cell; Cell Lin | 2016 |
Adjuvant therapy for renal-cell carcinoma: settled for now.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niaci | 2016 |
Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazo | 2016 |
Kidney cancer: No advantage of adjuvant sunitinib or sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenyl | 2016 |
Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kaplan-Me | 2016 |
Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Eye Hemorrhage; Fundus Oculi; Humans; Liver Neo | 2016 |
Little Impact on Renal Function in Advanced Renal Cell Carcinoma Patients Treated with Sorafenib--Analyses of Postmarketing Surveillance in Japan in over 3,200 Consecutive Cases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Glomerular Filtration Rate; Humans; Kidn | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; | 2016 |
Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Gene E | 2016 |
Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lung Neoplasms; Male; | 2016 |
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Inj | 2016 |
Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Developing C | 2016 |
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical | 2016 |
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles | 2016 |
Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carbo | 2016 |
Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Female | 2016 |
Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; | 2017 |
Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Enzyme Inhibitors; Eos | 2016 |
Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Erythrocyte Indices; Erythroc | 2016 |
Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.
Topics: Adenine; Animals; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Dose-Response Relationship, Dr | 2016 |
Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcino | 2017 |
Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma.
Topics: Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expressi | 2017 |
Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease Progression | 2017 |
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease- | 2017 |
Adjuvant Treatment of High-risk Renal Cell Carcinoma: Leaving the Desert?
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Indoles; Kidney Neopla | 2017 |
Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Fo | 2017 |
Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles | 2017 |
Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neopl | 2017 |
Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Carcinoma, Renal | 2017 |
Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; | 2017 |
MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Car | 2017 |
Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Renal Cel | 2017 |
Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Demography; Disease-Free Survival; Female; Humans; Kaplan-Mei | 2017 |
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Glycolysis; H | 2017 |
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinom | 2008 |
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous C | 2008 |
Sorafenib-induced eruptive melanocytic lesions.
Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Diagn | 2008 |
Sorafenib-induced palmoplantar hyperkeratosis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Keratoderma, Palmop | 2008 |
Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemoth | 2008 |
Comment on Di Silverio et al.: Neodajuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 2008;80:451-453.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; | 2008 |
Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Sur | 2009 |
[Regression of vena cava tumour thrombus in response to sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Follow-Up Studies; Humans; Kidney; | 2008 |
Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Dose-Response Relatio | 2008 |
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antineoplastic Agents; Ben | 2008 |
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2008 |
A Kaposi's sarcoma complete clinical response after sorafenib administration.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Follow-Up Studies; Humans; K | 2008 |
[Targeted therapy - point blank or single shot].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indo | 2008 |
Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Kidney Ne | 2008 |
Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Therapy, Combinat | 2008 |
[New therapeutic regimes in metastasic renal-cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; I | 2008 |
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, R | 2008 |
Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Cor | 2009 |
Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Female; Hu | 2008 |
Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lu | 2008 |
Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms | 2008 |
Major treatment improvements encourage kidney cancer researchers to seek further gains.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2008 |
[Renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2008 |
[Systemic therapy of metastasizing renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2008 |
[Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2008 |
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Biomarkers; Carcinoma, Renal Cell; Cardiovascular Diseas | 2008 |
Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Fol | 2009 |
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dose- | 2009 |
Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; K | 2008 |
Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Failure, Chron | 2009 |
Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cel | 2009 |
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dermatitis, Exfoliative; Drug Erupt | 2008 |
Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferatio | 2008 |
Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell | 2009 |
[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinom | 2009 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain; Brain Edema; Brain Neoplasms; Breast Neoplasm | 2009 |
Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lymphatic | 2009 |
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Foot Diseases; Hand Dermatoses; Humans; In | 2009 |
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Drug Eruptions; Female; Hu | 2009 |
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, R | 2009 |
Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2009 |
A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; | 2009 |
Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma.
Topics: Angiogenesis Inhibitors; Antihypertensive Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; | 2009 |
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2009 |
Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cost-Bene | 2009 |
Sequential sorafenib and sunitinib for renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2009 |
Targeting renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic | 2009 |
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidn | 2009 |
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Image Processing, Computer | 2009 |
Erythema multiforme induced by sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema Mul | 2009 |
A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hemoglobin | 2009 |
Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; E | 2009 |
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfon | 2009 |
Surgical resection of renal cell carcinoma after targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2009 |
Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; China; Female; Follow-Up Stud | 2009 |
Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney; | 2009 |
The histologic spectrum of epithelial neoplasms induced by sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous C | 2009 |
Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carc | 2010 |
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates | 2010 |
Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcitonin; Carcinoma, Rena | 2010 |
Everolimus: in advanced renal cell carcinoma.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Clinical Trials, Phase III as Topic; D | 2009 |
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfo | 2009 |
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfo | 2009 |
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfo | 2009 |
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfo | 2009 |
Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Density Conservation Agents; | 2009 |
Acute aortic dissection during sorafenib-containing therapy.
Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm; Aort | 2010 |
Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms | 2010 |
Therapy for metastatic RCC--questions remain.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; I | 2009 |
Where does the combination of sorafenib and interferon in renal cell carcinoma stand?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical T | 2010 |
Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Foot Dermatoses; Hand Dermatoses; H | 2009 |
Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.
Topics: Antineoplastic Agents; Asian People; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Human | 2010 |
Successful treatment of a brain-metastasized renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Follow-Up Studies; | 2009 |
Evidence-based urology in practice: when to believe a subgroup analysis?
Topics: Age Factors; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Evidence-Based M | 2010 |
Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Ren | 2009 |
The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neo | 2010 |
[Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; | 2010 |
Sorafenib-induced acute myocardial infarction due to coronary artery spasm.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Coronary Vasospasm; Humans; K | 2009 |
VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Drug | 2010 |
Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Hum | 2010 |
Health policy: The UK 'postcode lottery' in renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Health Care Rationing; Humans; Indo | 2009 |
[Sorafenib-induced multiple eruptive keratoacanthomas].
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunosuppr | 2009 |
[Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, | 2009 |
Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, | 2010 |
Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment.
Topics: Adrenal Gland Neoplasms; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; | 2010 |
Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
Topics: Adult; Aged; Analysis of Variance; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease | 2010 |
Experience with sorafenib and the elderly patient.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical T | 2010 |
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Ren | 2010 |
Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidn | 2010 |
Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; C | 2010 |
[Renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; | 2010 |
Choroidal metastasis of renal cell carcinoma: a case report.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Choroid Neoplasms; Eye Enucleation; | 2010 |
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
Topics: Adolescent; Adult; Antineoplastic Agents; Antiviral Agents; Basic Helix-Loop-Helix Leucine Zipper Tr | 2010 |
Sorafenib-associated remission of psoriasis in hypernephroma: case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neopl | 2010 |
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrase IX; Carbonic | 2010 |
Painless acute pancreatitis associated with sorafenib treatment: a case report.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Huma | 2011 |
Highlights from the Eigth International Kidney Cancer Symposium.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Li | 2009 |
Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study.
Topics: Antineoplastic Agents; Benzenesulfonates; Biotransformation; Carcinoma, Renal Cell; Drug Administrat | 2010 |
Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrases; Carc | 2011 |
Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Ce | 2010 |
Prognostic factors in patients treated with VEGF-targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma | 2010 |
Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modalit | 2010 |
[Renal cell carcinoma management and therapies in 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2010 |
[Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2010 |
[Advanced renal carcinomas with special situations. How to treat them?].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesul | 2010 |
Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Carcinoma, Ren | 2010 |
Editorial comment.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; | 2010 |
Editorial comment.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; | 2010 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antine | 2010 |
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Dise | 2010 |
[Diagnosis and treatment of bone metastasis of renal cancer: an expert consensus statement (2008 version)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neopl | 2010 |
Non-pigmenting fixed drug eruption induced by sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Drug Eruptions; Eryth | 2010 |
Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Mal | 2011 |
Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemothera | 2010 |
Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Ery | 2010 |
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carc | 2011 |
Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chromosomes, Human, X; Disease-Free | 2010 |
Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cyt | 2010 |
Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Ma | 2010 |
Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant | 2010 |
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2010 |
Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Disease Progression; Hum | 2010 |
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Ethnicity; Female; Humans; Ka | 2010 |
[Nexavar clinical registry].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplas | 2010 |
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chro | 2010 |
Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lymphocyt | 2011 |
Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug | 2011 |
Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dis | 2011 |
Transient perforating folliculitis induced by sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Folliculitis; Humans; Kidney | 2010 |
Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Erythema; Humans; Kidney Neoplasms; Male; Middle Aged; Nia | 2010 |
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfona | 2010 |
High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid.
Topics: Antineoplastic Agents; Ascitic Fluid; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal | 2011 |
Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Graft vs | 2010 |
[Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug | 2010 |
Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery.
Topics: Adenoviridae; Animals; Apoptosis; bcl-X Protein; Benzenesulfonates; Blotting, Western; Carcinoma, Re | 2010 |
Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma | 2010 |
111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma | 2010 |
Mechanism of synergistic antitumor effect of sorafenib and interferon-α on treatment of renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Syn | 2010 |
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2011 |
Kidney cancer: Does hypothyroidism predict clinical outcome?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Ki | 2011 |
Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-β1 mRNA expression in peripheral blood mononuclear cells.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; CD4-Positive T-Lymphocytes; Disease-Free Surv | 2011 |
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Fem | 2011 |
Prolonged survival in renal transplant recipient with advanced renal cell carcinoma by everolimus and sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Fr | 2011 |
More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Fr | 2010 |
Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Female; Hum | 2011 |
Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female | 2011 |
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2011 |
Biomarkers in renal cell carcinoma: what next?
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort | 2011 |
Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; In | 2011 |
Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2012 |
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell ca
Topics: Academic Medical Centers; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, H | 2011 |
Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Com | 2011 |
[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
Topics: Adult; Benzamides; Benzenesulfonates; Carcinoma, Renal Cell; Choristoma; Female; Gastrointestinal St | 2011 |
[Squamous cell carcinoma in a patient receiving sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; C | 2011 |
Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2011 |
[Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cel | 2010 |
Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).
Topics: Aged; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Female; Humans; Indoles; Kid | 2013 |
Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug A | 2011 |
Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette | 2011 |
Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcin | 2011 |
Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, | 2013 |
Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship | 2011 |
Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administr | 2011 |
Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Cancer Care Facilities; | 2012 |
Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Blood Sedimentation; Carcinoma, R | 2011 |
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasm | 2011 |
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
Topics: Adult; Aged; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; | 2013 |
Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cel | 2012 |
Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Com | 2011 |
One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Fr | 2011 |
Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizuma | 2011 |
Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Lung Neopla | 2011 |
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; C | 2011 |
[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Data Collection; Disea | 2011 |
Editorial comment to erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Blood Sedimentation; Carcinoma, Renal Cell; Humans; Kidney | 2011 |
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2011 |
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Proto | 2011 |
cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.
Topics: Animals; Benzenesulfonates; Bucladesine; Carcinoma, Renal Cell; Cell Line; Cyclin D1; Cyclin-Depende | 2011 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, | 2011 |
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neopl | 2011 |
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; C | 2011 |
Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2011 |
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.
Topics: Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Databases, | 2011 |
Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; | 2012 |
Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kaplan-Meier Esti | 2012 |
Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinom | 2012 |
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; In | 2013 |
Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzenesulfonates; Carcinoma, R | 2011 |
Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulato | 2013 |
Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Tri | 2011 |
Role of sorafenib in renal cell carcinoma: focus on elderly patients.
Topics: Age Factors; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Sur | 2011 |
Chloracne-like drug eruption associated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chloracne; Drug Eruptions; Humans; | 2011 |
Tilting the AXIS towards therapeutic limits in renal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; | 2011 |
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates | 2012 |
Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidn | 2011 |
Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects | 2013 |
Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.
Topics: Angiogenesis Inhibitors; Antiviral Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials | 2011 |
Downsizing a thrombus of advanced renal cell carcinoma in a presurgical setting with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Kid | 2012 |
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Pro | 2011 |
Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Huma | 2012 |
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; F | 2012 |
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenes | 2012 |
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; | 2012 |
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; | 2012 |
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; | 2012 |
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; | 2012 |
Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.
Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazo | 2012 |
Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinom | 2012 |
Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Hu | 2012 |
Sorafenib rechalenge in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; M | 2012 |
Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Databases as Topic; | 2012 |
Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VE
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Enzyme Inhibitors; Erb | 2012 |
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose | 2012 |
Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hyperthyroidism; Kidney Neoplasms; Male; Middl | 2012 |
Painful leg mass.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hospice Care; Humans; Kidney Neopla | 2012 |
Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.
Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; | 2012 |
Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns.
Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topi | 2012 |
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Huma | 2012 |
Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; | 2012 |
Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcin | 2012 |
A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Fr | 2012 |
Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; | 2012 |
GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2012 |
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Coronary Angiography; Coronary Sten | 2012 |
Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Comorbidity; Dis | 2012 |
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; | 2012 |
Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Co | 2013 |
Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 2012 |
Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant | 2012 |
Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Diagnosis, Differential; Female; Humans; Kidney | 2012 |
HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferatio | 2012 |
Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; C-Reactive Protein; Carcinoma | 2012 |
Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; C-Reactive Protein; Carcinoma, Renal Ce | 2013 |
The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Comorbid | 2012 |
Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Intestinal Perforation; Kidney Neo | 2012 |
Editorial comment from Dr Saito to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male | 2012 |
Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Humans; | 2012 |
Editorial comment from Dr Vázquez-Alonso and Dr Puche-Sanz to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male | 2012 |
Sorafenib-induced tuberculosis reactivation.
Topics: Aged; Antineoplastic Agents; Antitubercular Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; | 2012 |
Thyroid dysfunction in patients treated with sunitinib or sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyro | 2012 |
Tyrosine kinase inhibitor induced pancreatitis.
Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Pa | 2013 |
[A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma].
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Glucose Intole | 2012 |
c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; N | 2013 |
Effects of antiangiogenic therapy.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cystoscopy; Embolization, Therapeutic; Female; | 2012 |
Conditional survival of patients with metastatic renal-cell carcinoma.
Topics: Carcinoma, Renal Cell; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prog | 2012 |
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Ca | 2012 |
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbon | 2013 |
Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Chemical and Drug Induc | 2013 |
Durable spontaneous regression of lung metastases from renal cell carcinoma after incomplete use of multiple kinase inhibitor sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Lung; Lung Neo | 2013 |
Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antibodies, Monoclona | 2012 |
Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Dietary Supplements; Disease Models, | 2013 |
Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Fatal Out | 2012 |
Pituitary metastasis from a renal cell carcinoma progressed after sorafenib treatment.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinami | 2013 |
[Side effects of sorafenib and countermeasures].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Molecular Targeted Therapy; | 2012 |
Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Sc | 2013 |
Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding | 2013 |
Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoplasm Metasta | 2013 |
Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carc | 2013 |
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevaciz | 2013 |
Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Ne | 2013 |
Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA; Female; Humans; Kidney N | 2013 |
[Two cases of bowel perforation in patients with metastatic renal cancer treated with a molecularly targeted drug].
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Intestinal Perfora | 2012 |
Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis.
Topics: Aneuploidy; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; | 2013 |
Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community.
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers; Carcinoma, Renal Cell; Community Health Servic | 2006 |
Trials probe new agents for kidney cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2006 |
Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; | 2006 |
Renal cell carcinoma: today's targeted therapies improving tomorrow's outcomes.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Fr | 2006 |
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog | 2006 |
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog | 2006 |
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog | 2006 |
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog | 2006 |
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog | 2006 |
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog | 2006 |
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog | 2006 |
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog | 2006 |
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Prog | 2006 |
New therapeutic options for renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, | 2006 |
Problems with the randomized discontinuation design.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Data Interpretation, Statistical | 2006 |
Speeding up cancer-drug development.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials, Phase II as To | 2006 |
Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferat | 2006 |
Renal-cell carcinoma--molecular pathways and therapies.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Gene Silencing; Humans; Hypoxia-I | 2007 |
Hand-foot and stump syndrome to sorafenib.
Topics: Amputation Stumps; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; | 2007 |
[Therapy sequence for renal cell carcinoma--new aspects!].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Combined M | 2007 |
Two new drugs for renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Drug Interactions; Huma | 2007 |
Newly approved therapies for RCC and their effect on the standard of care.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma | 2007 |
ASCO 2006 highlights: targeted therapy for renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; I | 2007 |
Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
Topics: Acrodermatitis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythema; Humans; K | 2007 |
Sorafenib-induced pancreatitis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; M | 2007 |
Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Combined Moda | 2007 |
Do the results of the new trials change the standard treatment of metastatic renal cell cancer?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical T | 2007 |
Interstitial nephritis in a patient taking sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Disease-Free Survival | 2007 |
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma | 2007 |
Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Fe | 2007 |
Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunologic Factors; Indole | 2007 |
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
Sorafenib [corrected] in kidney cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; | 2007 |
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.
Topics: Analysis of Variance; Animals; Benzenesulfonates; Carcinoma, Renal Cell; Catheter Ablation; Combined | 2007 |
[Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Controlled Clinical Trials as Topic | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesu | 2007 |
[Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinami | 2007 |
Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neoplasm | 2007 |
ASCO 2007: plenary top 5.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinom | 2007 |
High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
Topics: Adult; Aged; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Hemorrhage; Female; | 2008 |
Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Men | 2007 |
Acute pancreatitis associated with sorafenib.
Topics: Acute Disease; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; E | 2007 |
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Chem | 2008 |
Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Hu | 2007 |
Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Colonic Diseases; Colonoscop | 2009 |
Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
Topics: Aged; Atrial Fibrillation; Benzenesulfonates; Carcinoma, Renal Cell; Cardiovascular Diseases; Chest | 2007 |
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cel | 2008 |
Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Blister; Carcinoma, Renal Cell; Drug Eruptions; Female; | 2008 |
Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;
Topics: Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Hemorrhage; France; Humans; Inci | 2008 |
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2008 |
[New drugs; sunitinib and sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; | 2007 |
Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Facial Neoplasms; Humans; Interleuk | 2007 |
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kid | 2008 |
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2007 |
Bowel perforation after radiotherapy in a patient receiving sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; | 2008 |
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2008 |
Contractile properties of human renal cell carcinoma recruited arteries and their response to nicotinamide.
Topics: Adrenergic alpha-Agonists; Arteries; Blood Flow Velocity; Carcinoma, Renal Cell; Humans; Kidney Neop | 2000 |